id	sid	tid	token	lemma	pos
chd-214	1	1	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	AUX
chd-214	1	2	e1	e1	NOUN
chd-214	1	3	cancer	cancer	NOUN
chd-214	1	4	health	health	NOUN
chd-214	1	5	disparities	disparity	NOUN
chd-214	1	6	research	research	VERB
chd-214	1	7	racial	racial	ADJ
chd-214	1	8	differences	difference	NOUN
chd-214	1	9	in	in	ADP
chd-214	1	10	prostate	prostate	NOUN
chd-214	1	11	tumor	tumor	NOUN
chd-214	1	12	microenvironment	microenvironment	NOUN
chd-214	1	13	:	:	PUNCT
chd-214	1	14	implications	implication	NOUN
chd-214	1	15	for	for	ADP
chd-214	1	16	disparate	disparate	ADJ
chd-214	1	17	clinical	clinical	ADJ
chd-214	1	18	outcomes	outcome	NOUN
chd-214	1	19	and	and	CCONJ
chd-214	1	20	potential	potential	ADJ
chd-214	1	21	opportunities	opportunity	NOUN
chd-214	1	22	sandeep	sandeep	VERB
chd-214	1	23	goswami	goswami	PROPN
chd-214	1	24	1,2	1,2	NUM
chd-214	1	25	chandrani	chandrani	NOUN
chd-214	1	26	sarkar	sarkar	NOUN
chd-214	1	27	1	1	NUM
chd-214	1	28	,	,	PUNCT
chd-214	1	29	2,3	2,3	NUM
chd-214	1	30	,	,	PUNCT
chd-214	1	31	seema	seema	PROPN
chd-214	1	32	singh	singh	PROPN
chd-214	1	33	1	1	NUM
chd-214	1	34	,	,	PUNCT
chd-214	1	35	2,3	2,3	NUM
chd-214	1	36	ajay	ajay	NOUN
chd-214	1	37	pratap	pratap	PROPN
chd-214	1	38	singh	singh	PROPN
chd-214	1	39	1,2,3	1,2,3	NUM
chd-214	1	40	debanjan	debanjan	NOUN
chd-214	1	41	chakroborty	chakroborty	NOUN
chd-214	1	42	1,2,3	1,2,3	NUM
chd-214	1	43	1	1	NUM
chd-214	1	44	department	department	NOUN
chd-214	1	45	of	of	ADP
chd-214	1	46	pathology	pathology	PROPN
chd-214	1	47	,	,	PUNCT
chd-214	1	48	university	university	PROPN
chd-214	1	49	of	of	ADP
chd-214	1	50	south	south	PROPN
chd-214	1	51	alabama	alabama	PROPN
chd-214	1	52	,	,	PUNCT
chd-214	1	53	mobile	mobile	NOUN
chd-214	1	54	,	,	PUNCT
chd-214	1	55	alabama	alabama	PROPN
chd-214	1	56	,	,	PUNCT
chd-214	1	57	usa	usa	PROPN
chd-214	1	58	.	.	PROPN
chd-214	1	59	2	2	NUM
chd-214	1	60	cancer	cancer	NOUN
chd-214	1	61	biology	biology	NOUN
chd-214	1	62	program	program	NOUN
chd-214	1	63	,	,	PUNCT
chd-214	1	64	mitchell	mitchell	PROPN
chd-214	1	65	cancer	cancer	PROPN
chd-214	1	66	institute	institute	PROPN
chd-214	1	67	,	,	PUNCT
chd-214	1	68	university	university	PROPN
chd-214	1	69	of	of	ADP
chd-214	1	70	south	south	PROPN
chd-214	1	71	alabama	alabama	PROPN
chd-214	1	72	,	,	PUNCT
chd-214	1	73	mobile	mobile	NOUN
chd-214	1	74	,	,	PUNCT
chd-214	1	75	alabama	alabama	PROPN
chd-214	1	76	,	,	PUNCT
chd-214	1	77	usa	usa	PROPN
chd-214	1	78	.	.	PROPN
chd-214	1	79	3	3	NUM
chd-214	1	80	department	department	NOUN
chd-214	1	81	of	of	ADP
chd-214	1	82	biochemistry	biochemistry	NOUN
chd-214	1	83	and	and	CCONJ
chd-214	1	84	molecular	molecular	ADJ
chd-214	1	85	biology	biology	NOUN
chd-214	1	86	,	,	PUNCT
chd-214	1	87	university	university	NOUN
chd-214	1	88	of	of	ADP
chd-214	1	89	south	south	PROPN
chd-214	1	90	alabama	alabama	PROPN
chd-214	1	91	,	,	PUNCT
chd-214	1	92	mobile	mobile	NOUN
chd-214	1	93	,	,	PUNCT
chd-214	1	94	alabama	alabama	PROPN
chd-214	1	95	,	,	PUNCT
chd-214	1	96	usa	usa	PROPN
chd-214	1	97	.	.	PROPN
chd-214	2	1	*	*	PUNCT
chd-214	2	2	corresponding	correspond	VERB
chd-214	2	3	author	author	NOUN
chd-214	2	4	:	:	PUNCT
chd-214	2	5	debanjan	debanjan	PROPN
chd-214	2	6	chakroborty	chakroborty	PROPN
chd-214	2	7	,	,	PUNCT
chd-214	2	8	email	email	NOUN
chd-214	2	9	:	:	PUNCT
chd-214	2	10	dchakroborty@southalabama.edu	dchakroborty@southalabama.edu	NOUN
chd-214	2	11	,	,	PUNCT
chd-214	2	12	abstract	abstract	ADJ
chd-214	2	13	disparities	disparity	NOUN
chd-214	2	14	in	in	ADP
chd-214	2	15	cancer	cancer	NOUN
chd-214	2	16	incidence	incidence	NOUN
chd-214	2	17	and	and	CCONJ
chd-214	2	18	outcome	outcome	NOUN
chd-214	2	19	are	be	AUX
chd-214	2	20	common	common	ADJ
chd-214	2	21	among	among	ADP
chd-214	2	22	the	the	DET
chd-214	2	23	racial	racial	ADJ
chd-214	2	24	and	and	CCONJ
chd-214	2	25	ethnical	ethnical	ADJ
chd-214	2	26	minorities	minority	NOUN
chd-214	2	27	in	in	ADP
chd-214	2	28	the	the	DET
chd-214	2	29	united	united	PROPN
chd-214	2	30	states	states	PROPN
chd-214	2	31	and	and	CCONJ
chd-214	2	32	are	be	AUX
chd-214	2	33	of	of	ADP
chd-214	2	34	significant	significant	ADJ
chd-214	2	35	social	social	ADJ
chd-214	2	36	and	and	CCONJ
chd-214	2	37	clinical	clinical	ADJ
chd-214	2	38	concern	concern	NOUN
chd-214	2	39	.	.	PUNCT
chd-214	3	1	prostate	prostate	NOUN
chd-214	3	2	cancer	cancer	NOUN
chd-214	3	3	is	be	AUX
chd-214	3	4	the	the	DET
chd-214	3	5	most	most	ADV
chd-214	3	6	commonly	commonly	ADV
chd-214	3	7	diagnosed	diagnose	VERB
chd-214	3	8	non	non	ADJ
chd-214	3	9	-	-	ADJ
chd-214	3	10	cutaneous	cutaneous	ADJ
chd-214	3	11	malignancy	malignancy	NOUN
chd-214	3	12	in	in	ADP
chd-214	3	13	american	american	ADJ
chd-214	3	14	men	man	NOUN
chd-214	3	15	and	and	CCONJ
chd-214	3	16	exhibits	exhibit	VERB
chd-214	3	17	substantial	substantial	ADJ
chd-214	3	18	racial	racial	ADJ
chd-214	3	19	disparities	disparity	NOUN
chd-214	3	20	with	with	ADP
chd-214	3	21	african	african	ADJ
chd-214	3	22	american	american	ADJ
chd-214	3	23	men	man	NOUN
chd-214	3	24	bearing	bear	VERB
chd-214	3	25	the	the	DET
chd-214	3	26	highest	high	ADJ
chd-214	3	27	burden	burden	NOUN
chd-214	3	28	in	in	ADP
chd-214	3	29	terms	term	NOUN
chd-214	3	30	of	of	ADP
chd-214	3	31	incidence	incidence	NOUN
chd-214	3	32	and	and	CCONJ
chd-214	3	33	mortality	mortality	NOUN
chd-214	3	34	.	.	PUNCT
chd-214	4	1	a	a	DET
chd-214	4	2	multitude	multitude	NOUN
chd-214	4	3	of	of	ADP
chd-214	4	4	factors	factor	NOUN
chd-214	4	5	,	,	PUNCT
chd-214	4	6	including	include	VERB
chd-214	4	7	socioeconomic	socioeconomic	ADJ
chd-214	4	8	,	,	PUNCT
chd-214	4	9	behavioral	behavioral	ADJ
chd-214	4	10	,	,	PUNCT
chd-214	4	11	and	and	CCONJ
chd-214	4	12	access	access	NOUN
chd-214	4	13	to	to	ADP
chd-214	4	14	healthcare	healthcare	PROPN
chd-214	4	15	,	,	PUNCT
chd-214	4	16	have	have	AUX
chd-214	4	17	been	be	AUX
chd-214	4	18	implicated	implicate	VERB
chd-214	4	19	as	as	ADP
chd-214	4	20	the	the	DET
chd-214	4	21	underlying	underlying	ADJ
chd-214	4	22	causes	cause	NOUN
chd-214	4	23	of	of	ADP
chd-214	4	24	such	such	ADJ
chd-214	4	25	disparities	disparity	NOUN
chd-214	4	26	.	.	PUNCT
chd-214	5	1	more	more	ADJ
chd-214	5	2	recent	recent	ADJ
chd-214	5	3	data	datum	NOUN
chd-214	5	4	also	also	ADV
chd-214	5	5	suggest	suggest	VERB
chd-214	5	6	that	that	SCONJ
chd-214	5	7	there	there	PRON
chd-214	5	8	are	be	VERB
chd-214	5	9	inherent	inherent	ADJ
chd-214	5	10	molecular	molecular	ADJ
chd-214	5	11	and	and	CCONJ
chd-214	5	12	biological	biological	ADJ
chd-214	5	13	differences	difference	NOUN
chd-214	5	14	in	in	ADP
chd-214	5	15	prostate	prostate	NOUN
chd-214	5	16	tumors	tumor	NOUN
chd-214	5	17	of	of	ADP
chd-214	5	18	patients	patient	NOUN
chd-214	5	19	having	have	VERB
chd-214	5	20	distinct	distinct	ADJ
chd-214	5	21	racial	racial	ADJ
chd-214	5	22	backgrounds	background	NOUN
chd-214	5	23	.	.	PUNCT
chd-214	6	1	tumor	tumor	NOUN
chd-214	6	2	microenvironment	microenvironment	NOUN
chd-214	6	3	has	have	VERB
chd-214	6	4	tremendous	tremendous	ADJ
chd-214	6	5	impact	impact	NOUN
chd-214	6	6	on	on	ADP
chd-214	6	7	the	the	DET
chd-214	6	8	course	course	NOUN
chd-214	6	9	of	of	ADP
chd-214	6	10	cancer	cancer	NOUN
chd-214	6	11	progression	progression	NOUN
chd-214	6	12	and	and	CCONJ
chd-214	6	13	clinical	clinical	ADJ
chd-214	6	14	outcome	outcome	NOUN
chd-214	6	15	and	and	CCONJ
chd-214	6	16	may	may	AUX
chd-214	6	17	also	also	ADV
chd-214	6	18	contribute	contribute	VERB
chd-214	6	19	to	to	ADP
chd-214	6	20	the	the	DET
chd-214	6	21	racial	racial	ADJ
chd-214	6	22	disparities	disparity	NOUN
chd-214	6	23	observed	observe	VERB
chd-214	6	24	in	in	ADP
chd-214	6	25	prostate	prostate	NOUN
chd-214	6	26	cancer	cancer	NOUN
chd-214	6	27	.	.	PUNCT
chd-214	7	1	therefore	therefore	ADV
chd-214	7	2	,	,	PUNCT
chd-214	7	3	a	a	DET
chd-214	7	4	better	well	ADJ
chd-214	7	5	understanding	understanding	NOUN
chd-214	7	6	of	of	ADP
chd-214	7	7	critical	critical	ADJ
chd-214	7	8	differences	difference	NOUN
chd-214	7	9	in	in	ADP
chd-214	7	10	the	the	DET
chd-214	7	11	tumor	tumor	NOUN
chd-214	7	12	microenvironment	microenvironment	ADJ
chd-214	7	13	components	component	NOUN
chd-214	7	14	may	may	AUX
chd-214	7	15	provide	provide	VERB
chd-214	7	16	newer	new	ADJ
chd-214	7	17	directions	direction	NOUN
chd-214	7	18	to	to	PART
chd-214	7	19	study	study	VERB
chd-214	7	20	the	the	DET
chd-214	7	21	biological	biological	ADJ
chd-214	7	22	causes	cause	NOUN
chd-214	7	23	of	of	ADP
chd-214	7	24	prostate	prostate	NOUN
chd-214	7	25	cancer	cancer	NOUN
chd-214	7	26	health	health	NOUN
chd-214	7	27	disparities	disparity	NOUN
chd-214	7	28	and	and	CCONJ
chd-214	7	29	may	may	AUX
chd-214	7	30	identify	identify	VERB
chd-214	7	31	novel	novel	ADJ
chd-214	7	32	therapeutic	therapeutic	ADJ
chd-214	7	33	targets	target	NOUN
chd-214	7	34	.	.	PUNCT
chd-214	8	1	this	this	DET
chd-214	8	2	review	review	NOUN
chd-214	8	3	discusses	discuss	VERB
chd-214	8	4	the	the	DET
chd-214	8	5	findings	finding	NOUN
chd-214	8	6	related	relate	VERB
chd-214	8	7	to	to	ADP
chd-214	8	8	the	the	DET
chd-214	8	9	tumor	tumor	NOUN
chd-214	8	10	microenvironment	microenvironment	NOUN
chd-214	8	11	differences	difference	NOUN
chd-214	8	12	between	between	ADP
chd-214	8	13	african	african	ADJ
chd-214	8	14	american	american	ADJ
chd-214	8	15	and	and	CCONJ
chd-214	8	16	caucasian	caucasian	ADJ
chd-214	8	17	american	american	ADJ
chd-214	8	18	prostate	prostate	NOUN
chd-214	8	19	cancer	cancer	NOUN
chd-214	8	20	patients	patient	NOUN
chd-214	8	21	and	and	CCONJ
chd-214	8	22	makes	make	VERB
chd-214	8	23	suggestion	suggestion	NOUN
chd-214	8	24	regarding	regard	VERB
chd-214	8	25	their	their	PRON
chd-214	8	26	potential	potential	ADJ
chd-214	8	27	significance	significance	NOUN
chd-214	8	28	in	in	ADP
chd-214	8	29	prostate	prostate	NOUN
chd-214	8	30	cancer	cancer	NOUN
chd-214	8	31	disparities	disparity	NOUN
chd-214	8	32	.	.	PUNCT
chd-214	9	1	keywords	keyword	NOUN
chd-214	9	2	:	:	PUNCT
chd-214	9	3	prostate	prostate	NOUN
chd-214	9	4	cancer	cancer	NOUN
chd-214	9	5	,	,	PUNCT
chd-214	9	6	racial	racial	ADJ
chd-214	9	7	disparity	disparity	NOUN
chd-214	9	8	,	,	PUNCT
chd-214	9	9	tumor	tumor	NOUN
chd-214	9	10	microenvironment	microenvironment	ADJ
chd-214	9	11	citation	citation	NOUN
chd-214	9	12	:	:	PUNCT
chd-214	10	1	goswami	goswami	PROPN
chd-214	10	2	s	s	VERB
chd-214	10	3	et	et	PROPN
chd-214	10	4	al	al	PROPN
chd-214	10	5	(	(	PUNCT
chd-214	10	6	2022	2022	NUM
chd-214	10	7	)	)	PUNCT
chd-214	10	8	racial	racial	ADJ
chd-214	10	9	differences	difference	NOUN
chd-214	10	10	in	in	ADP
chd-214	10	11	prostate	prostate	NOUN
chd-214	10	12	tumor	tumor	NOUN
chd-214	10	13	microenvironment	microenvironment	NOUN
chd-214	10	14	:	:	PUNCT
chd-214	10	15	implications	implication	NOUN
chd-214	10	16	for	for	ADP
chd-214	10	17	disparate	disparate	ADJ
chd-214	10	18	clinical	clinical	ADJ
chd-214	10	19	outcomes	outcome	NOUN
chd-214	10	20	and	and	CCONJ
chd-214	10	21	potential	potential	ADJ
chd-214	10	22	opportunities	opportunity	NOUN
chd-214	10	23	.	.	PUNCT
chd-214	11	1	cancer	cancer	NOUN
chd-214	11	2	health	health	NOUN
chd-214	11	3	disparities	disparity	NOUN
chd-214	11	4	.	.	PUNCT
chd-214	12	1	6	6	NUM
chd-214	12	2	:	:	PUNCT
chd-214	12	3	e1	e1	NOUN
chd-214	12	4	-	-	PUNCT
chd-214	12	5	e14	e14	NOUN
chd-214	12	6	.	.	PUNCT
chd-214	13	1	doi:10.9777	doi:10.9777	PROPN
chd-214	13	2	/	/	SYM
chd-214	13	3	chd.2022.1003	chd.2022.1003	PROPN
chd-214	13	4	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	PROPN
chd-214	13	5	e2	e2	PROPN
chd-214	13	6	cancer	cancer	NOUN
chd-214	13	7	health	health	NOUN
chd-214	13	8	disparities	disparity	NOUN
chd-214	13	9	research	research	VERB
chd-214	13	10	1.0	1.0	NUM
chd-214	13	11	.	.	PUNCT
chd-214	14	1	introduction	introduction	NOUN
chd-214	14	2	prostate	prostate	NOUN
chd-214	14	3	cancer	cancer	NOUN
chd-214	14	4	(	(	PUNCT
chd-214	14	5	pca	pca	PROPN
chd-214	14	6	)	)	PUNCT
chd-214	14	7	is	be	AUX
chd-214	14	8	the	the	DET
chd-214	14	9	most	most	ADV
chd-214	14	10	commonly	commonly	ADV
chd-214	14	11	diagnosed	diagnose	VERB
chd-214	14	12	non	non	ADJ
chd-214	14	13	-	-	ADJ
chd-214	14	14	cutaneous	cutaneous	ADJ
chd-214	14	15	malignancy	malignancy	NOUN
chd-214	14	16	and	and	CCONJ
chd-214	14	17	the	the	DET
chd-214	14	18	second	second	ADJ
chd-214	14	19	leading	leading	ADJ
chd-214	14	20	cause	cause	NOUN
chd-214	14	21	of	of	ADP
chd-214	14	22	cancer	cancer	NOUN
chd-214	14	23	-	-	PUNCT
chd-214	14	24	related	relate	VERB
chd-214	14	25	death	death	NOUN
chd-214	14	26	in	in	ADP
chd-214	14	27	american	american	ADJ
chd-214	14	28	men	man	NOUN
chd-214	15	1	[	[	X
chd-214	15	2	1	1	NUM
chd-214	15	3	,	,	PUNCT
chd-214	15	4	2	2	NUM
chd-214	15	5	]	]	PUNCT
chd-214	15	6	.	.	PUNCT
chd-214	16	1	among	among	ADP
chd-214	16	2	all	all	DET
chd-214	16	3	the	the	DET
chd-214	16	4	cancers	cancer	NOUN
chd-214	16	5	,	,	PUNCT
chd-214	16	6	pca	pca	NOUN
chd-214	16	7	not	not	PART
chd-214	16	8	only	only	ADV
chd-214	16	9	shows	show	VERB
chd-214	16	10	extreme	extreme	ADJ
chd-214	16	11	variations	variation	NOUN
chd-214	16	12	in	in	ADP
chd-214	16	13	its	its	PRON
chd-214	16	14	potential	potential	NOUN
chd-214	16	15	to	to	PART
chd-214	16	16	cause	cause	VERB
chd-214	16	17	morbidity	morbidity	NOUN
chd-214	16	18	and	and	CCONJ
chd-214	16	19	death	death	NOUN
chd-214	16	20	in	in	ADP
chd-214	16	21	men	man	NOUN
chd-214	16	22	but	but	CCONJ
chd-214	16	23	also	also	ADV
chd-214	16	24	displays	display	VERB
chd-214	16	25	great	great	ADJ
chd-214	16	26	variations	variation	NOUN
chd-214	16	27	in	in	ADP
chd-214	16	28	geographic	geographic	ADJ
chd-214	16	29	and	and	CCONJ
chd-214	16	30	racial	racial	ADJ
chd-214	16	31	distribution	distribution	NOUN
chd-214	16	32	[	[	X
chd-214	16	33	1	1	NUM
chd-214	16	34	,	,	PUNCT
chd-214	16	35	2	2	NUM
chd-214	16	36	,	,	PUNCT
chd-214	16	37	3	3	NUM
chd-214	16	38	,	,	PUNCT
chd-214	16	39	4	4	NUM
chd-214	16	40	]	]	PUNCT
chd-214	16	41	.	.	PUNCT
chd-214	17	1	in	in	ADP
chd-214	17	2	the	the	DET
chd-214	17	3	united	united	PROPN
chd-214	17	4	states	states	PROPN
chd-214	17	5	,	,	PUNCT
chd-214	17	6	despite	despite	SCONJ
chd-214	17	7	significant	significant	ADJ
chd-214	17	8	improvements	improvement	NOUN
chd-214	17	9	in	in	ADP
chd-214	17	10	cancer	cancer	NOUN
chd-214	17	11	diagnosis	diagnosis	NOUN
chd-214	17	12	and	and	CCONJ
chd-214	17	13	treatment	treatment	NOUN
chd-214	17	14	strategies	strategy	NOUN
chd-214	17	15	,	,	PUNCT
chd-214	17	16	african	african	ADJ
chd-214	17	17	american	american	PROPN
chd-214	17	18	(	(	PUNCT
chd-214	17	19	aa	aa	NOUN
chd-214	17	20	)	)	PUNCT
chd-214	17	21	men	man	NOUN
chd-214	17	22	suffer	suffer	VERB
chd-214	17	23	disproportionately	disproportionately	ADV
chd-214	17	24	from	from	ADP
chd-214	17	25	pca	pca	NOUN
chd-214	17	26	with	with	ADP
chd-214	17	27	over	over	ADP
chd-214	17	28	80	80	NUM
chd-214	17	29	%	%	NOUN
chd-214	17	30	higher	high	ADJ
chd-214	17	31	incidence	incidence	NOUN
chd-214	17	32	rates	rate	NOUN
chd-214	17	33	than	than	ADP
chd-214	17	34	men	man	NOUN
chd-214	17	35	of	of	ADP
chd-214	17	36	european	european	PROPN
chd-214	17	37	american	american	PROPN
chd-214	17	38	(	(	PUNCT
chd-214	17	39	ca	ca	PROPN
chd-214	17	40	,	,	PUNCT
chd-214	17	41	caucasian	caucasian	ADJ
chd-214	17	42	american	american	PROPN
chd-214	17	43	)	)	PUNCT
chd-214	17	44	origin	origin	NOUN
chd-214	17	45	[	[	X
chd-214	17	46	5	5	NUM
chd-214	17	47	,	,	PUNCT
chd-214	17	48	6	6	NUM
chd-214	17	49	,	,	PUNCT
chd-214	17	50	7	7	NUM
chd-214	17	51	,	,	PUNCT
chd-214	17	52	8	8	NUM
chd-214	17	53	]	]	PUNCT
chd-214	17	54	.	.	PUNCT
chd-214	18	1	aa	aa	PROPN
chd-214	18	2	men	man	NOUN
chd-214	18	3	are	be	AUX
chd-214	18	4	also	also	ADV
chd-214	18	5	more	more	ADV
chd-214	18	6	likely	likely	ADJ
chd-214	18	7	to	to	PART
chd-214	18	8	be	be	AUX
chd-214	18	9	diagnosed	diagnose	VERB
chd-214	18	10	at	at	ADP
chd-214	18	11	a	a	DET
chd-214	18	12	younger	young	ADJ
chd-214	18	13	age	age	NOUN
chd-214	18	14	and	and	CCONJ
chd-214	18	15	present	present	ADJ
chd-214	18	16	with	with	ADP
chd-214	18	17	more	more	ADV
chd-214	18	18	advanced	advanced	ADJ
chd-214	18	19	and	and	CCONJ
chd-214	18	20	aggressive	aggressive	ADJ
chd-214	18	21	disease	disease	NOUN
chd-214	18	22	stages	stage	NOUN
chd-214	18	23	[	[	X
chd-214	18	24	8	8	NUM
chd-214	18	25	-	-	SYM
chd-214	18	26	12	12	NUM
chd-214	18	27	]	]	PUNCT
chd-214	18	28	compared	compare	VERB
chd-214	18	29	to	to	ADP
chd-214	18	30	men	man	NOUN
chd-214	18	31	with	with	ADP
chd-214	18	32	ca	ca	NOUN
chd-214	18	33	ancestry	ancestry	NOUN
chd-214	18	34	.	.	PUNCT
chd-214	19	1	accordingly	accordingly	ADV
chd-214	19	2	,	,	PUNCT
chd-214	19	3	for	for	ADP
chd-214	19	4	aa	aa	PROPN
chd-214	19	5	men	man	NOUN
chd-214	19	6	,	,	PUNCT
chd-214	19	7	the	the	DET
chd-214	19	8	lifetime	lifetime	NOUN
chd-214	19	9	risk	risk	NOUN
chd-214	19	10	of	of	ADP
chd-214	19	11	developing	develop	VERB
chd-214	19	12	pca	pca	NOUN
chd-214	19	13	is	be	AUX
chd-214	19	14	1	1	NUM
chd-214	19	15	in	in	ADP
chd-214	19	16	6	6	NUM
chd-214	19	17	,	,	PUNCT
chd-214	19	18	while	while	SCONJ
chd-214	19	19	that	that	PRON
chd-214	19	20	for	for	ADP
chd-214	19	21	ca	ca	NOUN
chd-214	19	22	men	man	NOUN
chd-214	19	23	is	be	AUX
chd-214	19	24	1	1	NUM
chd-214	19	25	in	in	ADP
chd-214	19	26	8	8	NUM
chd-214	19	27	.	.	PUNCT
chd-214	20	1	aa	aa	NOUN
chd-214	20	2	men	man	NOUN
chd-214	20	3	are	be	AUX
chd-214	20	4	also	also	ADV
chd-214	20	5	greater	great	ADJ
chd-214	20	6	than	than	ADP
chd-214	20	7	twice	twice	ADV
chd-214	20	8	as	as	ADV
chd-214	20	9	likely	likely	ADJ
chd-214	20	10	to	to	PART
chd-214	20	11	succumb	succumb	VERB
chd-214	20	12	to	to	ADP
chd-214	20	13	the	the	DET
chd-214	20	14	disease	disease	NOUN
chd-214	20	15	compared	compare	VERB
chd-214	20	16	with	with	ADP
chd-214	20	17	ca	ca	NOUN
chd-214	20	18	men	man	NOUN
chd-214	20	19	as	as	ADP
chd-214	20	20	the	the	DET
chd-214	20	21	pca	pca	NOUN
chd-214	20	22	specific	specific	ADJ
chd-214	20	23	mortality	mortality	NOUN
chd-214	20	24	in	in	ADP
chd-214	20	25	aa	aa	PROPN
chd-214	20	26	men	man	NOUN
chd-214	20	27	is	be	AUX
chd-214	20	28	1	1	NUM
chd-214	20	29	in	in	ADP
chd-214	20	30	23	23	NUM
chd-214	20	31	whereas	whereas	SCONJ
chd-214	20	32	it	it	PRON
chd-214	20	33	is	be	AUX
chd-214	20	34	1	1	NUM
chd-214	20	35	in	in	ADP
chd-214	20	36	42	42	NUM
chd-214	20	37	in	in	ADP
chd-214	20	38	ca	ca	NOUN
chd-214	20	39	men	man	NOUN
chd-214	21	1	[	[	X
chd-214	21	2	1	1	NUM
chd-214	21	3	,	,	PUNCT
chd-214	21	4	2	2	NUM
chd-214	21	5	,	,	PUNCT
chd-214	21	6	7	7	NUM
chd-214	21	7	]	]	PUNCT
chd-214	21	8	.	.	PUNCT
chd-214	22	1	in	in	ADP
chd-214	22	2	order	order	NOUN
chd-214	22	3	to	to	PART
chd-214	22	4	overcome	overcome	VERB
chd-214	22	5	the	the	DET
chd-214	22	6	disparity	disparity	NOUN
chd-214	22	7	that	that	PRON
chd-214	22	8	affects	affect	VERB
chd-214	22	9	aa	aa	PROPN
chd-214	22	10	population	population	NOUN
chd-214	22	11	negatively	negatively	ADV
chd-214	22	12	and	and	CCONJ
chd-214	22	13	to	to	PART
chd-214	22	14	develop	develop	VERB
chd-214	22	15	personalized	personalize	VERB
chd-214	22	16	therapeutic	therapeutic	ADJ
chd-214	22	17	approaches	approach	NOUN
chd-214	22	18	,	,	PUNCT
chd-214	22	19	we	we	PRON
chd-214	22	20	need	need	VERB
chd-214	22	21	to	to	PART
chd-214	22	22	identify	identify	VERB
chd-214	22	23	and	and	CCONJ
chd-214	22	24	understand	understand	VERB
chd-214	22	25	the	the	DET
chd-214	22	26	factors	factor	NOUN
chd-214	22	27	that	that	PRON
chd-214	22	28	drive	drive	VERB
chd-214	22	29	pca	pca	PROPN
chd-214	22	30	tumor	tumor	NOUN
chd-214	22	31	progression	progression	NOUN
chd-214	22	32	and	and	CCONJ
chd-214	22	33	metastasis	metastasis	NOUN
chd-214	22	34	in	in	ADP
chd-214	22	35	aa	aa	PROPN
chd-214	22	36	men	man	NOUN
chd-214	22	37	.	.	PUNCT
chd-214	23	1	over	over	ADP
chd-214	23	2	the	the	DET
chd-214	23	3	years	year	NOUN
chd-214	23	4	,	,	PUNCT
chd-214	23	5	a	a	DET
chd-214	23	6	number	number	NOUN
chd-214	23	7	of	of	ADP
chd-214	23	8	such	such	ADJ
chd-214	23	9	interconnected	interconnected	ADJ
chd-214	23	10	factors	factor	NOUN
chd-214	23	11	including	include	VERB
chd-214	23	12	socioeconomic	socioeconomic	ADJ
chd-214	23	13	status	status	NOUN
chd-214	23	14	,	,	PUNCT
chd-214	23	15	lifestyle	lifestyle	NOUN
chd-214	23	16	and	and	CCONJ
chd-214	23	17	dietary	dietary	ADJ
chd-214	23	18	issues	issue	NOUN
chd-214	23	19	,	,	PUNCT
chd-214	23	20	problems	problem	NOUN
chd-214	23	21	with	with	ADP
chd-214	23	22	accessing	access	VERB
chd-214	23	23	healthcare	healthcare	NOUN
chd-214	23	24	have	have	AUX
chd-214	23	25	been	be	AUX
chd-214	23	26	identified	identify	VERB
chd-214	23	27	as	as	ADP
chd-214	23	28	probable	probable	ADJ
chd-214	23	29	causes	cause	NOUN
chd-214	23	30	of	of	ADP
chd-214	23	31	this	this	DET
chd-214	23	32	epidemiological	epidemiological	ADJ
chd-214	23	33	disparity	disparity	NOUN
chd-214	23	34	in	in	ADP
chd-214	23	35	pca	pca	NOUN
chd-214	23	36	incidence	incidence	NOUN
chd-214	23	37	and	and	CCONJ
chd-214	23	38	mortality	mortality	NOUN
chd-214	23	39	[	[	X
chd-214	23	40	1	1	NUM
chd-214	23	41	,	,	PUNCT
chd-214	23	42	2	2	NUM
chd-214	23	43	,	,	PUNCT
chd-214	23	44	8	8	NUM
chd-214	23	45	]	]	PUNCT
chd-214	23	46	.	.	PUNCT
chd-214	24	1	interestingly	interestingly	ADV
chd-214	24	2	,	,	PUNCT
chd-214	24	3	several	several	ADJ
chd-214	24	4	newer	new	ADJ
chd-214	24	5	lines	line	NOUN
chd-214	24	6	of	of	ADP
chd-214	24	7	evidence	evidence	NOUN
chd-214	24	8	have	have	AUX
chd-214	24	9	also	also	ADV
chd-214	24	10	demonstrated	demonstrate	VERB
chd-214	24	11	genetic	genetic	ADJ
chd-214	24	12	and	and	CCONJ
chd-214	24	13	biological	biological	ADJ
chd-214	24	14	variations	variation	NOUN
chd-214	24	15	among	among	ADP
chd-214	24	16	patients	patient	NOUN
chd-214	24	17	of	of	ADP
chd-214	24	18	different	different	ADJ
chd-214	24	19	racial	racial	ADJ
chd-214	24	20	backgrounds	background	NOUN
chd-214	24	21	.	.	PUNCT
chd-214	25	1	the	the	DET
chd-214	25	2	androgen	androgen	NOUN
chd-214	25	3	hormonal	hormonal	ADJ
chd-214	25	4	axis	axis	NOUN
chd-214	25	5	,	,	PUNCT
chd-214	25	6	the	the	DET
chd-214	25	7	androgen	androgen	NOUN
chd-214	25	8	receptor	receptor	NOUN
chd-214	25	9	(	(	PUNCT
chd-214	25	10	ar	ar	NOUN
chd-214	25	11	)	)	PUNCT
chd-214	25	12	,	,	PUNCT
chd-214	25	13	and	and	CCONJ
chd-214	25	14	its	its	PRON
chd-214	25	15	signaling	signal	VERB
chd-214	25	16	pathway	pathway	NOUN
chd-214	25	17	play	play	VERB
chd-214	25	18	critical	critical	ADJ
chd-214	25	19	roles	role	NOUN
chd-214	25	20	in	in	ADP
chd-214	25	21	pca	pca	NOUN
chd-214	25	22	progression	progression	NOUN
chd-214	26	1	[	[	X
chd-214	26	2	13].several	13].several	ADJ
chd-214	26	3	aspects	aspect	NOUN
chd-214	26	4	of	of	ADP
chd-214	26	5	the	the	DET
chd-214	26	6	ar	ar	NOUN
chd-214	26	7	pathway	pathway	NOUN
chd-214	26	8	have	have	AUX
chd-214	26	9	also	also	ADV
chd-214	26	10	been	be	AUX
chd-214	26	11	implicated	implicate	VERB
chd-214	26	12	in	in	ADP
chd-214	26	13	pca	pca	PROPN
chd-214	26	14	associated	associate	VERB
chd-214	26	15	racial	racial	ADJ
chd-214	26	16	differences	difference	NOUN
chd-214	26	17	[	[	X
chd-214	26	18	14	14	NUM
chd-214	26	19	-	-	SYM
chd-214	26	20	16	16	NUM
chd-214	26	21	]	]	PUNCT
chd-214	26	22	.	.	PUNCT
chd-214	27	1	however	however	ADV
chd-214	27	2	,	,	PUNCT
chd-214	27	3	in	in	ADP
chd-214	27	4	addition	addition	NOUN
chd-214	27	5	to	to	ADP
chd-214	27	6	androgens	androgens	NOUN
chd-214	27	7	and	and	CCONJ
chd-214	27	8	ar	ar	NOUN
chd-214	27	9	signaling	signal	VERB
chd-214	27	10	,	,	PUNCT
chd-214	27	11	the	the	DET
chd-214	27	12	crosstalk	crosstalk	NOUN
chd-214	27	13	between	between	ADP
chd-214	27	14	epithelial	epithelial	ADJ
chd-214	27	15	cells	cell	NOUN
chd-214	27	16	and	and	CCONJ
chd-214	27	17	cellular	cellular	ADJ
chd-214	27	18	components	component	NOUN
chd-214	27	19	of	of	ADP
chd-214	27	20	the	the	DET
chd-214	27	21	tumor	tumor	NOUN
chd-214	27	22	microenvironment	microenvironment	NOUN
chd-214	27	23	(	(	PUNCT
chd-214	27	24	tme	tme	NOUN
chd-214	27	25	)	)	PUNCT
chd-214	27	26	,	,	PUNCT
chd-214	27	27	such	such	ADJ
chd-214	27	28	as	as	ADP
chd-214	27	29	mesenchymal	mesenchymal	ADJ
chd-214	27	30	stem	stem	NOUN
chd-214	27	31	cells	cell	NOUN
chd-214	27	32	,	,	PUNCT
chd-214	27	33	endothelial	endothelial	ADJ
chd-214	27	34	cells	cell	NOUN
chd-214	27	35	,	,	PUNCT
chd-214	27	36	fibroblasts	fibroblast	NOUN
chd-214	27	37	/	/	SYM
chd-214	27	38	myofibroblasts	myofibroblast	NOUN
chd-214	27	39	,	,	PUNCT
chd-214	27	40	and	and	CCONJ
chd-214	27	41	immune	immune	ADJ
chd-214	27	42	cells	cell	NOUN
chd-214	27	43	also	also	ADV
chd-214	27	44	plays	play	VERB
chd-214	27	45	an	an	DET
chd-214	27	46	integral	integral	ADJ
chd-214	27	47	role	role	NOUN
chd-214	27	48	in	in	ADP
chd-214	27	49	pca	pca	NOUN
chd-214	27	50	progression	progression	NOUN
chd-214	27	51	and	and	CCONJ
chd-214	27	52	metastasis	metastasis	PRON
chd-214	27	53	[	[	X
chd-214	27	54	2,17	2,17	X
chd-214	27	55	]	]	PUNCT
chd-214	27	56	.	.	PUNCT
chd-214	28	1	the	the	DET
chd-214	28	2	immune	immune	ADJ
chd-214	28	3	cells	cell	NOUN
chd-214	28	4	as	as	ADV
chd-214	28	5	well	well	ADV
chd-214	28	6	as	as	ADP
chd-214	28	7	the	the	DET
chd-214	28	8	endothelial	endothelial	ADJ
chd-214	28	9	cells	cell	NOUN
chd-214	28	10	forming	form	VERB
chd-214	28	11	the	the	DET
chd-214	28	12	blood	blood	NOUN
chd-214	28	13	vessels	vessel	NOUN
chd-214	28	14	in	in	ADP
chd-214	28	15	the	the	DET
chd-214	28	16	pca	pca	PROPN
chd-214	28	17	tme	tme	PROPN
chd-214	28	18	,	,	PUNCT
chd-214	28	19	secrete	secrete	ADJ
chd-214	28	20	growth	growth	NOUN
chd-214	28	21	factors	factor	NOUN
chd-214	28	22	and	and	CCONJ
chd-214	28	23	cytokines	cytokine	NOUN
chd-214	28	24	to	to	PART
chd-214	28	25	induce	induce	VERB
chd-214	28	26	pca	pca	NOUN
chd-214	28	27	cell	cell	NOUN
chd-214	28	28	proliferation	proliferation	NOUN
chd-214	28	29	and	and	CCONJ
chd-214	28	30	spread	spread	VERB
chd-214	28	31	[	[	X
chd-214	28	32	2	2	NUM
chd-214	28	33	,	,	PUNCT
chd-214	28	34	17	17	NUM
chd-214	28	35	]	]	PUNCT
chd-214	28	36	.	.	PUNCT
chd-214	29	1	increasing	increase	VERB
chd-214	29	2	evidences	evidence	NOUN
chd-214	29	3	now	now	ADV
chd-214	29	4	indicate	indicate	VERB
chd-214	29	5	that	that	SCONJ
chd-214	29	6	the	the	DET
chd-214	29	7	tme	tme	PROPN
chd-214	29	8	components	component	NOUN
chd-214	29	9	may	may	AUX
chd-214	29	10	also	also	ADV
chd-214	29	11	be	be	AUX
chd-214	29	12	a	a	DET
chd-214	29	13	significant	significant	ADJ
chd-214	29	14	contributor	contributor	NOUN
chd-214	29	15	to	to	ADP
chd-214	29	16	the	the	DET
chd-214	29	17	racial	racial	ADJ
chd-214	29	18	disparity	disparity	NOUN
chd-214	29	19	observed	observe	VERB
chd-214	29	20	in	in	ADP
chd-214	29	21	pca	pca	NOUN
chd-214	29	22	incidence	incidence	NOUN
chd-214	29	23	,	,	PUNCT
chd-214	29	24	aggressiveness	aggressiveness	NOUN
chd-214	29	25	and	and	CCONJ
chd-214	29	26	clinical	clinical	ADJ
chd-214	29	27	outcomes	outcome	NOUN
chd-214	29	28	between	between	ADP
chd-214	29	29	aa	aa	PROPN
chd-214	29	30	and	and	CCONJ
chd-214	29	31	ca	ca	NOUN
chd-214	29	32	populations	population	NOUN
chd-214	29	33	[	[	X
chd-214	29	34	2	2	NUM
chd-214	29	35	,	,	PUNCT
chd-214	29	36	18	18	NUM
chd-214	29	37	-	-	SYM
chd-214	29	38	20	20	NUM
chd-214	29	39	]	]	PUNCT
chd-214	29	40	.	.	PUNCT
chd-214	30	1	therefore	therefore	ADV
chd-214	30	2	,	,	PUNCT
chd-214	30	3	we	we	PRON
chd-214	30	4	have	have	AUX
chd-214	30	5	reviewed	review	VERB
chd-214	30	6	the	the	DET
chd-214	30	7	pertinent	pertinent	ADJ
chd-214	30	8	data	datum	NOUN
chd-214	30	9	to	to	PART
chd-214	30	10	discuss	discuss	VERB
chd-214	30	11	the	the	DET
chd-214	30	12	potential	potential	ADJ
chd-214	30	13	contribution	contribution	NOUN
chd-214	30	14	of	of	ADP
chd-214	30	15	the	the	DET
chd-214	30	16	tme	tme	NOUN
chd-214	30	17	to	to	ADP
chd-214	30	18	the	the	DET
chd-214	30	19	observed	observe	VERB
chd-214	30	20	racial	racial	ADJ
chd-214	30	21	disparity	disparity	NOUN
chd-214	30	22	associated	associate	VERB
chd-214	30	23	with	with	ADP
chd-214	30	24	pca	pca	PROPN
chd-214	30	25	(	(	PUNCT
chd-214	30	26	table	table	NOUN
chd-214	30	27	1	1	NUM
chd-214	30	28	)	)	PUNCT
chd-214	30	29	.	.	PUNCT
chd-214	31	1	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	AUX
chd-214	31	2	e3	e3	NOUN
chd-214	31	3	cancer	cancer	NOUN
chd-214	31	4	health	health	NOUN
chd-214	31	5	disparities	disparity	NOUN
chd-214	31	6	research	research	NOUN
chd-214	31	7	table	table	NOUN
chd-214	31	8	1	1	NUM
chd-214	31	9	.	.	PUNCT
chd-214	32	1	role	role	NOUN
chd-214	32	2	of	of	ADP
chd-214	32	3	stromal	stromal	ADJ
chd-214	32	4	cells	cell	NOUN
chd-214	32	5	in	in	ADP
chd-214	32	6	aa	aa	PROPN
chd-214	32	7	and	and	CCONJ
chd-214	32	8	ca	ca	PROPN
chd-214	32	9	pca	pca	PROPN
chd-214	32	10	.	.	PROPN
chd-214	33	1	cell	cell	NOUN
chd-214	33	2	type	type	NOUN
chd-214	33	3	role	role	NOUN
chd-214	33	4	in	in	ADP
chd-214	33	5	pca	pca	NOUN
chd-214	33	6	differences	difference	NOUN
chd-214	33	7	in	in	ADP
chd-214	33	8	aa	aa	NOUN
chd-214	33	9	and	and	CCONJ
chd-214	33	10	ca	ca	PROPN
chd-214	33	11	pca	pca	NOUN
chd-214	33	12	references	reference	NOUN
chd-214	33	13	fibroblasts	fibroblast	VERB
chd-214	33	14	•	•	NUM
chd-214	33	15	secrete	secrete	NOUN
chd-214	33	16	chemokines	chemokine	NOUN
chd-214	33	17	,	,	PUNCT
chd-214	33	18	cytokines	cytokine	NOUN
chd-214	33	19	,	,	PUNCT
chd-214	33	20	growth	growth	NOUN
chd-214	33	21	factors	factor	NOUN
chd-214	33	22	(	(	PUNCT
chd-214	33	23	brain	brain	NOUN
chd-214	33	24	derived	derive	VERB
chd-214	33	25	neurotrophic	neurotrophic	ADJ
chd-214	33	26	factor	factor	NOUN
chd-214	33	27	and	and	CCONJ
chd-214	33	28	chemokines	chemokine	NOUN
chd-214	33	29	like	like	ADP
chd-214	33	30	ccl5	ccl5	PROPN
chd-214	33	31	,	,	PUNCT
chd-214	33	32	cxcl5	cxcl5	PROPN
chd-214	33	33	,	,	PUNCT
chd-214	33	34	sdf1	sdf1	PROPN
chd-214	33	35	-	-	PUNCT
chd-214	33	36	alpha	alpha	NOUN
chd-214	33	37	and	and	CCONJ
chd-214	33	38	soluble	soluble	ADJ
chd-214	33	39	factors	factor	NOUN
chd-214	33	40	such	such	ADJ
chd-214	33	41	as	as	ADP
chd-214	33	42	vegf	vegf	PROPN
chd-214	33	43	,	,	PUNCT
chd-214	33	44	bfgf	bfgf	NOUN
chd-214	33	45	,	,	PUNCT
chd-214	33	46	hgf	hgf	NOUN
chd-214	33	47	)	)	PUNCT
chd-214	33	48	•	•	X
chd-214	33	49	promote	promote	VERB
chd-214	33	50	tumor	tumor	NOUN
chd-214	33	51	growth	growth	NOUN
chd-214	33	52	and	and	CCONJ
chd-214	33	53	metastasis	metastasis	PRON
chd-214	33	54	•	•	NOUN
chd-214	33	55	pro	pro	ADJ
chd-214	33	56	-	-	ADJ
chd-214	33	57	inflammatory	inflammatory	ADJ
chd-214	33	58	cytokines	cytokine	NOUN
chd-214	33	59	and	and	CCONJ
chd-214	33	60	growth	growth	NOUN
chd-214	33	61	factors	factor	NOUN
chd-214	33	62	[	[	X
chd-214	33	63	brain	brain	NOUN
chd-214	33	64	-	-	PUNCT
chd-214	33	65	derived	derive	VERB
chd-214	33	66	neurotrophic	neurotrophic	ADJ
chd-214	33	67	factor	factor	NOUN
chd-214	33	68	(	(	PUNCT
chd-214	33	69	bdnf	bdnf	PROPN
chd-214	33	70	)	)	PUNCT
chd-214	33	71	,	,	PUNCT
chd-214	33	72	vegf	vegf	PROPN
chd-214	33	73	,	,	PUNCT
chd-214	33	74	and	and	CCONJ
chd-214	33	75	fibroblast	fibroblast	ADJ
chd-214	33	76	growth	growth	NOUN
chd-214	33	77	factor	factor	NOUN
chd-214	33	78	7	7	NUM
chd-214	33	79	(	(	PUNCT
chd-214	33	80	fgf7	fgf7	PROPN
chd-214	33	81	)	)	PUNCT
chd-214	33	82	]	]	PUNCT
chd-214	33	83	are	be	AUX
chd-214	33	84	significantly	significantly	ADV
chd-214	33	85	elevated	elevate	VERB
chd-214	33	86	in	in	ADP
chd-214	33	87	aa	aa	PROPN
chd-214	33	88	pca	pca	PROPN
chd-214	33	89	•	•	ADP
chd-214	33	90	higher	high	ADJ
chd-214	33	91	expressions	expression	NOUN
chd-214	33	92	of	of	ADP
chd-214	33	93	myofibroblast	myofibroblast	NOUN
chd-214	33	94	activating	activate	VERB
chd-214	33	95	markers	marker	NOUN
chd-214	34	1	[	[	X
chd-214	34	2	αsma	αsma	NOUN
chd-214	34	3	,	,	PUNCT
chd-214	34	4	vimentin	vimentin	NOUN
chd-214	34	5	,	,	PUNCT
chd-214	34	6	and	and	CCONJ
chd-214	34	7	fap1	fap1	PROPN
chd-214	34	8	]	]	PUNCT
chd-214	34	9	and	and	CCONJ
chd-214	34	10	mesenchymal	mesenchymal	NOUN
chd-214	34	11	stem	stem	NOUN
chd-214	34	12	cell	cell	NOUN
chd-214	34	13	marker	marker	NOUN
chd-214	34	14	,	,	PUNCT
chd-214	34	15	cd90	cd90	PROPN
chd-214	34	16	,	,	PUNCT
chd-214	34	17	in	in	ADP
chd-214	34	18	cancer	cancer	NOUN
chd-214	34	19	associated	associate	VERB
chd-214	34	20	fibroblasts	fibroblast	NOUN
chd-214	34	21	(	(	PUNCT
chd-214	34	22	cafs	cafs	NOUN
chd-214	34	23	)	)	PUNCT
chd-214	34	24	of	of	ADP
chd-214	34	25	aa	aa	PROPN
chd-214	34	26	pca	pca	PROPN
chd-214	34	27	2,19	2,19	PROPN
chd-214	34	28	immune	immune	ADJ
chd-214	34	29	cells	cell	NOUN
chd-214	34	30	•	•	ADP
chd-214	34	31	inflammation	inflammation	NOUN
chd-214	34	32	promotes	promote	VERB
chd-214	34	33	initiation	initiation	NOUN
chd-214	34	34	and	and	CCONJ
chd-214	34	35	progression	progression	NOUN
chd-214	34	36	•	•	ADP
chd-214	34	37	increased	increase	VERB
chd-214	34	38	lymphocytic	lymphocytic	ADJ
chd-214	34	39	infiltration	infiltration	NOUN
chd-214	34	40	in	in	ADP
chd-214	34	41	aa	aa	PROPN
chd-214	34	42	pca	pca	PROPN
chd-214	34	43	tissues	tissue	NOUN
chd-214	34	44	•	•	CCONJ
chd-214	34	45	pro	pro	ADJ
chd-214	34	46	-	-	ADJ
chd-214	34	47	inflammatory	inflammatory	ADJ
chd-214	34	48	cytokines	cytokine	NOUN
chd-214	34	49	(	(	PUNCT
chd-214	34	50	interferon	interferon	ADJ
chd-214	34	51	-	-	PUNCT
chd-214	34	52	alpha	alpha	NOUN
chd-214	34	53	(	(	PUNCT
chd-214	34	54	ifnα	ifnα	NOUN
chd-214	34	55	)	)	PUNCT
chd-214	34	56	,	,	PUNCT
chd-214	34	57	ifnγ	ifnγ	NOUN
chd-214	34	58	,	,	PUNCT
chd-214	34	59	tumor	tumor	NOUN
chd-214	34	60	necrosis	necrosis	NOUN
chd-214	34	61	factor	factor	NOUN
chd-214	34	62	-	-	PUNCT
chd-214	34	63	alpha	alpha	NOUN
chd-214	34	64	(	(	PUNCT
chd-214	34	65	tnfα	tnfα	NOUN
chd-214	34	66	)	)	PUNCT
chd-214	34	67	,	,	PUNCT
chd-214	34	68	and	and	CCONJ
chd-214	34	69	interleukin	interleukin	NOUN
chd-214	34	70	4	4	NUM
chd-214	34	71	and	and	CCONJ
chd-214	34	72	interleukin	interleukin	NOUN
chd-214	34	73	13	13	NUM
chd-214	34	74	)	)	PUNCT
chd-214	34	75	are	be	AUX
chd-214	34	76	upregulated	upregulate	VERB
chd-214	34	77	in	in	ADP
chd-214	34	78	pca	pca	PROPN
chd-214	34	79	of	of	ADP
chd-214	34	80	aa	aa	PROPN
chd-214	34	81	men	man	NOUN
chd-214	34	82	•	•	ADV
chd-214	34	83	increased	increase	VERB
chd-214	34	84	nk	nk	PROPN
chd-214	34	85	cell	cell	NOUN
chd-214	34	86	activity	activity	NOUN
chd-214	34	87	in	in	ADP
chd-214	34	88	aa	aa	PROPN
chd-214	34	89	pca	pca	PROPN
chd-214	34	90	2	2	NUM
chd-214	34	91	,	,	PUNCT
chd-214	34	92	28	28	NUM
chd-214	34	93	,	,	PUNCT
chd-214	34	94	34	34	NUM
chd-214	34	95	-	-	SYM
chd-214	34	96	36	36	NUM
chd-214	34	97	endothelial	endothelial	ADJ
chd-214	34	98	cells	cell	NOUN
chd-214	34	99	•	•	ADP
chd-214	34	100	form	form	NOUN
chd-214	34	101	neovesels	neovesel	NOUN
chd-214	34	102	to	to	PART
chd-214	34	103	support	support	VERB
chd-214	34	104	tumor	tumor	NOUN
chd-214	34	105	growth	growth	NOUN
chd-214	34	106	and	and	CCONJ
chd-214	34	107	metastatic	metastatic	ADJ
chd-214	34	108	progression	progression	NOUN
chd-214	34	109	•	•	ADP
chd-214	34	110	increased	increase	VERB
chd-214	34	111	vegf	vegf	PROPN
chd-214	34	112	secretion	secretion	NOUN
chd-214	34	113	in	in	ADP
chd-214	34	114	aa	aa	PROPN
chd-214	34	115	pca	pca	PROPN
chd-214	34	116	•	•	ADV
chd-214	34	117	higher	high	ADJ
chd-214	34	118	mvd	mvd	PROPN
chd-214	34	119	in	in	ADP
chd-214	34	120	aa	aa	PROPN
chd-214	34	121	pca	pca	PROPN
chd-214	34	122	tissues	tissue	NOUN
chd-214	34	123	2,19	2,19	NUM
chd-214	34	124	,	,	PUNCT
chd-214	34	125	44	44	NUM
chd-214	34	126	,	,	PUNCT
chd-214	34	127	50	50	NUM
chd-214	34	128	2.0	2.0	NUM
chd-214	34	129	.	.	PUNCT
chd-214	35	1	prostate	prostate	NOUN
chd-214	35	2	cancer	cancer	NOUN
chd-214	35	3	microenvironment	microenvironment	NOUN
chd-214	35	4	prostate	prostate	NOUN
chd-214	35	5	,	,	PUNCT
chd-214	35	6	a	a	DET
chd-214	35	7	tubule	tubule	ADJ
chd-214	35	8	-	-	PUNCT
chd-214	35	9	alveolar	alveolar	ADJ
chd-214	35	10	gland	gland	NOUN
chd-214	35	11	is	be	AUX
chd-214	35	12	primarily	primarily	ADV
chd-214	35	13	composed	compose	VERB
chd-214	35	14	of	of	ADP
chd-214	35	15	prostatic	prostatic	ADJ
chd-214	35	16	epithelial	epithelial	ADJ
chd-214	35	17	cells	cell	NOUN
chd-214	35	18	surrounded	surround	VERB
chd-214	35	19	by	by	ADP
chd-214	35	20	the	the	DET
chd-214	35	21	stromal	stromal	ADJ
chd-214	35	22	components	component	NOUN
chd-214	35	23	[	[	X
chd-214	35	24	17	17	NUM
chd-214	35	25	,	,	PUNCT
chd-214	35	26	21	21	NUM
chd-214	35	27	]	]	PUNCT
chd-214	35	28	.	.	PUNCT
chd-214	36	1	the	the	DET
chd-214	36	2	gland	gland	NOUN
chd-214	36	3	has	have	VERB
chd-214	36	4	three	three	NUM
chd-214	36	5	distinct	distinct	ADJ
chd-214	36	6	zones	zone	NOUN
chd-214	36	7	;	;	PUNCT
chd-214	36	8	peripheral	peripheral	ADJ
chd-214	36	9	,	,	PUNCT
chd-214	36	10	central	central	ADJ
chd-214	36	11	,	,	PUNCT
chd-214	36	12	transition	transition	NOUN
chd-214	36	13	,	,	PUNCT
chd-214	36	14	and	and	CCONJ
chd-214	36	15	a	a	DET
chd-214	36	16	mixed	mixed	ADJ
chd-214	36	17	zone	zone	NOUN
chd-214	36	18	called	call	VERB
chd-214	36	19	the	the	DET
chd-214	36	20	anterior	anterior	ADJ
chd-214	36	21	fibro	fibro	PROPN
chd-214	36	22	-	-	PUNCT
chd-214	36	23	muscular	muscular	ADJ
chd-214	36	24	zone	zone	NOUN
chd-214	36	25	or	or	CCONJ
chd-214	36	26	stromal	stromal	ADJ
chd-214	36	27	zone	zone	NOUN
chd-214	36	28	[	[	X
chd-214	36	29	17	17	NUM
chd-214	36	30	,	,	PUNCT
chd-214	36	31	21	21	NUM
chd-214	36	32	,	,	PUNCT
chd-214	36	33	22	22	NUM
chd-214	36	34	]	]	PUNCT
chd-214	36	35	.	.	PUNCT
chd-214	37	1	it	it	PRON
chd-214	37	2	is	be	AUX
chd-214	37	3	mainly	mainly	ADV
chd-214	37	4	composed	compose	VERB
chd-214	37	5	of	of	ADP
chd-214	37	6	four	four	NUM
chd-214	37	7	major	major	ADJ
chd-214	37	8	epithelial	epithelial	ADJ
chd-214	37	9	cell	cell	NOUN
chd-214	37	10	typesbasal	typesbasal	NOUN
chd-214	37	11	cells	cell	NOUN
chd-214	37	12	,	,	PUNCT
chd-214	37	13	neuroendocrine	neuroendocrine	ADJ
chd-214	37	14	cells	cell	NOUN
chd-214	37	15	,	,	PUNCT
chd-214	37	16	epithelial	epithelial	ADJ
chd-214	37	17	stem	stem	NOUN
chd-214	37	18	/	/	SYM
chd-214	37	19	progenitor	progenitor	NOUN
chd-214	37	20	cells	cell	NOUN
chd-214	37	21	,	,	PUNCT
chd-214	37	22	and	and	CCONJ
chd-214	37	23	secretory	secretory	ADJ
chd-214	37	24	luminal	luminal	ADJ
chd-214	37	25	cells	cell	NOUN
chd-214	37	26	[	[	X
chd-214	37	27	17	17	NUM
chd-214	37	28	,	,	PUNCT
chd-214	37	29	22	22	NUM
chd-214	37	30	]	]	PUNCT
chd-214	37	31	.	.	PUNCT
chd-214	38	1	the	the	DET
chd-214	38	2	stroma	stroma	NOUN
chd-214	38	3	consists	consist	VERB
chd-214	38	4	primarily	primarily	ADV
chd-214	38	5	of	of	ADP
chd-214	38	6	fibroblasts	fibroblast	NOUN
chd-214	38	7	,	,	PUNCT
chd-214	38	8	myofibroblasts	myofibroblast	NOUN
chd-214	38	9	,	,	PUNCT
chd-214	38	10	endothelial	endothelial	ADJ
chd-214	38	11	cells	cell	NOUN
chd-214	38	12	,	,	PUNCT
chd-214	38	13	immune	immune	ADJ
chd-214	38	14	cells	cell	NOUN
chd-214	38	15	,	,	PUNCT
chd-214	38	16	nerve	nerve	NOUN
chd-214	38	17	cells	cell	NOUN
chd-214	38	18	and	and	CCONJ
chd-214	38	19	smooth	smooth	ADJ
chd-214	38	20	muscle	muscle	NOUN
chd-214	38	21	cells	cell	NOUN
chd-214	38	22	[	[	X
chd-214	38	23	17	17	NUM
chd-214	38	24	,	,	PUNCT
chd-214	38	25	22	22	NUM
chd-214	38	26	]	]	PUNCT
chd-214	38	27	.	.	PUNCT
chd-214	39	1	the	the	DET
chd-214	39	2	development	development	NOUN
chd-214	39	3	and	and	CCONJ
chd-214	39	4	progression	progression	NOUN
chd-214	39	5	of	of	ADP
chd-214	39	6	pca	pca	PROPN
chd-214	39	7	is	be	AUX
chd-214	39	8	a	a	DET
chd-214	39	9	complex	complex	ADJ
chd-214	39	10	process	process	NOUN
chd-214	39	11	and	and	CCONJ
chd-214	39	12	the	the	DET
chd-214	39	13	disease	disease	NOUN
chd-214	39	14	is	be	AUX
chd-214	39	15	extremely	extremely	ADV
chd-214	39	16	heterogeneous	heterogeneous	ADJ
chd-214	39	17	from	from	ADP
chd-214	39	18	molecular	molecular	ADJ
chd-214	39	19	,	,	PUNCT
chd-214	39	20	cellular	cellular	ADJ
chd-214	39	21	and	and	CCONJ
chd-214	39	22	clinical	clinical	ADJ
chd-214	39	23	standpoints	standpoint	NOUN
chd-214	39	24	[	[	X
chd-214	39	25	23	23	NUM
chd-214	39	26	]	]	PUNCT
chd-214	39	27	.	.	PUNCT
chd-214	40	1	in	in	ADP
chd-214	40	2	most	most	ADJ
chd-214	40	3	cases	case	NOUN
chd-214	40	4	,	,	PUNCT
chd-214	40	5	pca	pca	NOUN
chd-214	40	6	originates	originate	NOUN
chd-214	40	7	in	in	ADP
chd-214	40	8	prostatic	prostatic	ADJ
chd-214	40	9	epithelial	epithelial	ADJ
chd-214	40	10	cells	cell	NOUN
chd-214	40	11	.	.	PUNCT
chd-214	41	1	therefore	therefore	ADV
chd-214	41	2	,	,	PUNCT
chd-214	41	3	studies	study	NOUN
chd-214	41	4	on	on	ADP
chd-214	41	5	pca	pca	PROPN
chd-214	41	6	development	development	NOUN
chd-214	41	7	and	and	CCONJ
chd-214	41	8	progression	progression	NOUN
chd-214	41	9	have	have	AUX
chd-214	41	10	mainly	mainly	ADV
chd-214	41	11	focused	focus	VERB
chd-214	41	12	on	on	ADP
chd-214	41	13	these	these	DET
chd-214	41	14	cells	cell	NOUN
chd-214	41	15	[	[	X
chd-214	41	16	22	22	NUM
chd-214	41	17	,	,	PUNCT
chd-214	41	18	23	23	NUM
chd-214	41	19	]	]	PUNCT
chd-214	41	20	.	.	PUNCT
chd-214	42	1	however	however	ADV
chd-214	42	2	,	,	PUNCT
chd-214	42	3	epithelial	epithelial	ADJ
chd-214	42	4	cells	cell	NOUN
chd-214	42	5	are	be	AUX
chd-214	42	6	not	not	PART
chd-214	42	7	sole	sole	ADJ
chd-214	42	8	players	player	NOUN
chd-214	42	9	contributing	contribute	VERB
chd-214	42	10	to	to	ADP
chd-214	42	11	pca	pca	NOUN
chd-214	42	12	tumorigenesis	tumorigenesis	NOUN
chd-214	42	13	;	;	PUNCT
chd-214	42	14	the	the	DET
chd-214	42	15	stromal	stromal	ADJ
chd-214	42	16	cells	cell	NOUN
chd-214	42	17	in	in	ADP
chd-214	42	18	the	the	DET
chd-214	42	19	tme	tme	NOUN
chd-214	42	20	also	also	ADV
chd-214	42	21	play	play	VERB
chd-214	42	22	critical	critical	ADJ
chd-214	42	23	roles	role	NOUN
chd-214	42	24	in	in	ADP
chd-214	42	25	pca	pca	PROPN
chd-214	42	26	development	development	NOUN
chd-214	42	27	and	and	CCONJ
chd-214	42	28	progression	progression	NOUN
chd-214	42	29	[	[	X
chd-214	42	30	2	2	NUM
chd-214	42	31	,	,	PUNCT
chd-214	42	32	17	17	NUM
chd-214	42	33	,	,	PUNCT
chd-214	42	34	24	24	NUM
chd-214	42	35	]	]	PUNCT
chd-214	42	36	.	.	PUNCT
chd-214	43	1	the	the	DET
chd-214	43	2	crosstalk	crosstalk	NOUN
chd-214	43	3	between	between	ADP
chd-214	43	4	the	the	DET
chd-214	43	5	stroma	stroma	NOUN
chd-214	43	6	and	and	CCONJ
chd-214	43	7	the	the	DET
chd-214	43	8	epithelium	epithelium	NOUN
chd-214	43	9	is	be	AUX
chd-214	43	10	a	a	DET
chd-214	43	11	major	major	ADJ
chd-214	43	12	driver	driver	NOUN
chd-214	43	13	of	of	ADP
chd-214	43	14	pca	pca	PROPN
chd-214	43	15	pathogenesis	pathogenesis	NOUN
chd-214	43	16	and	and	CCONJ
chd-214	43	17	disease	disease	NOUN
chd-214	43	18	progression	progression	NOUN
chd-214	43	19	[	[	X
chd-214	43	20	24	24	NUM
chd-214	43	21	,	,	PUNCT
chd-214	43	22	25	25	NUM
chd-214	43	23	]	]	PUNCT
chd-214	43	24	.	.	PUNCT
chd-214	44	1	the	the	DET
chd-214	44	2	interaction	interaction	NOUN
chd-214	44	3	between	between	ADP
chd-214	44	4	the	the	DET
chd-214	44	5	epithelial	epithelial	ADJ
chd-214	44	6	or	or	CCONJ
chd-214	44	7	cancer	cancer	NOUN
chd-214	44	8	cells	cell	NOUN
chd-214	44	9	and	and	CCONJ
chd-214	44	10	the	the	DET
chd-214	44	11	non	non	ADJ
chd-214	44	12	-	-	ADJ
chd-214	44	13	epithelial	epithelial	ADJ
chd-214	44	14	or	or	CCONJ
chd-214	44	15	stromal	stromal	ADJ
chd-214	44	16	cells	cell	NOUN
chd-214	44	17	in	in	ADP
chd-214	44	18	pca	pca	PROPN
chd-214	44	19	is	be	AUX
chd-214	44	20	mediated	mediate	VERB
chd-214	44	21	by	by	ADP
chd-214	44	22	a	a	DET
chd-214	44	23	variety	variety	NOUN
chd-214	44	24	of	of	ADP
chd-214	44	25	paracrine	paracrine	NOUN
chd-214	44	26	factors	factor	NOUN
chd-214	44	27	secreted	secrete	VERB
chd-214	44	28	both	both	CCONJ
chd-214	44	29	by	by	ADP
chd-214	44	30	cancer	cancer	NOUN
chd-214	44	31	cells	cell	NOUN
chd-214	44	32	as	as	ADV
chd-214	44	33	well	well	ADV
chd-214	44	34	as	as	ADP
chd-214	44	35	by	by	ADP
chd-214	44	36	the	the	DET
chd-214	44	37	stromal	stromal	ADJ
chd-214	44	38	cells	cell	NOUN
chd-214	44	39	[	[	X
chd-214	44	40	2	2	NUM
chd-214	44	41	,	,	PUNCT
chd-214	44	42	25	25	NUM
chd-214	44	43	]	]	PUNCT
chd-214	44	44	(	(	PUNCT
chd-214	44	45	figure	figure	NOUN
chd-214	44	46	1	1	NUM
chd-214	44	47	)	)	PUNCT
chd-214	44	48	.	.	PUNCT
chd-214	45	1	several	several	ADJ
chd-214	45	2	studies	study	NOUN
chd-214	45	3	have	have	AUX
chd-214	45	4	emphasized	emphasize	VERB
chd-214	45	5	the	the	DET
chd-214	45	6	contribution	contribution	NOUN
chd-214	45	7	of	of	ADP
chd-214	45	8	altered	altered	ADJ
chd-214	45	9	/	/	SYM
chd-214	45	10	reactive	reactive	ADJ
chd-214	45	11	stromal	stromal	ADJ
chd-214	45	12	microenvironment	microenvironment	NOUN
chd-214	45	13	characterized	characterize	VERB
chd-214	45	14	by	by	ADP
chd-214	45	15	increase	increase	NOUN
chd-214	45	16	in	in	ADP
chd-214	45	17	the	the	DET
chd-214	45	18	numbers	number	NOUN
chd-214	45	19	of	of	ADP
chd-214	45	20	myofibroblasts	myofibroblast	NOUN
chd-214	45	21	and	and	CCONJ
chd-214	45	22	fibroblasts	fibroblast	NOUN
chd-214	45	23	and	and	CCONJ
chd-214	45	24	significant	significant	ADJ
chd-214	45	25	decrease	decrease	NOUN
chd-214	45	26	in	in	ADP
chd-214	45	27	the	the	DET
chd-214	45	28	numbers	number	NOUN
chd-214	45	29	of	of	ADP
chd-214	45	30	smooth	smooth	ADJ
chd-214	45	31	muscle	muscle	NOUN
chd-214	45	32	cells	cell	NOUN
chd-214	45	33	in	in	ADP
chd-214	45	34	tumorigenesis	tumorigenesis	NOUN
chd-214	45	35	and	and	CCONJ
chd-214	45	36	progression	progression	NOUN
chd-214	45	37	of	of	ADP
chd-214	45	38	pca	pca	PROPN
chd-214	45	39	[	[	X
chd-214	45	40	17	17	NUM
chd-214	45	41	,	,	PUNCT
chd-214	45	42	25	25	NUM
chd-214	45	43	]	]	PUNCT
chd-214	45	44	.	.	PUNCT
chd-214	46	1	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	PROPN
chd-214	46	2	e4	e4	PROPN
chd-214	46	3	cancer	cancer	NOUN
chd-214	46	4	health	health	NOUN
chd-214	46	5	disparities	disparity	NOUN
chd-214	46	6	research	research	NOUN
chd-214	46	7	figure	figure	NOUN
chd-214	46	8	1	1	NUM
chd-214	46	9	:	:	PUNCT
chd-214	46	10	interaction	interaction	NOUN
chd-214	46	11	between	between	ADP
chd-214	46	12	pca	pca	NOUN
chd-214	46	13	cells	cell	NOUN
chd-214	46	14	and	and	CCONJ
chd-214	46	15	the	the	DET
chd-214	46	16	stroma	stroma	NOUN
chd-214	46	17	(	(	PUNCT
chd-214	46	18	created	create	VERB
chd-214	46	19	by	by	ADP
chd-214	46	20	biorender	biorender	NOUN
chd-214	46	21	)	)	PUNCT
chd-214	46	22	regarding	regard	VERB
chd-214	46	23	the	the	DET
chd-214	46	24	disproportionate	disproportionate	ADJ
chd-214	46	25	burdens	burden	NOUN
chd-214	46	26	of	of	ADP
chd-214	46	27	pca	pca	NOUN
chd-214	46	28	between	between	ADP
chd-214	46	29	aa	aa	PROPN
chd-214	46	30	and	and	CCONJ
chd-214	46	31	ca	ca	NOUN
chd-214	46	32	populations	population	NOUN
chd-214	46	33	,	,	PUNCT
chd-214	46	34	while	while	SCONJ
chd-214	46	35	most	most	ADJ
chd-214	46	36	studies	study	NOUN
chd-214	46	37	have	have	AUX
chd-214	46	38	focused	focus	VERB
chd-214	46	39	on	on	ADP
chd-214	46	40	genetic	genetic	ADJ
chd-214	46	41	differences	difference	NOUN
chd-214	46	42	within	within	ADP
chd-214	46	43	different	different	ADJ
chd-214	46	44	prostate	prostate	NOUN
chd-214	46	45	tumor	tumor	NOUN
chd-214	46	46	subtypes	subtype	NOUN
chd-214	46	47	,	,	PUNCT
chd-214	46	48	emphasizing	emphasize	VERB
chd-214	46	49	mostly	mostly	ADV
chd-214	46	50	on	on	ADP
chd-214	46	51	pca	pca	NOUN
chd-214	46	52	cells	cell	NOUN
chd-214	46	53	,	,	PUNCT
chd-214	46	54	a	a	DET
chd-214	46	55	handful	handful	NOUN
chd-214	46	56	of	of	ADP
chd-214	46	57	studies	study	NOUN
chd-214	46	58	have	have	AUX
chd-214	46	59	also	also	ADV
chd-214	46	60	indicated	indicate	VERB
chd-214	46	61	how	how	SCONJ
chd-214	46	62	differences	difference	NOUN
chd-214	46	63	in	in	ADP
chd-214	46	64	pca	pca	PROPN
chd-214	46	65	tme	tme	X
chd-214	46	66	can	can	AUX
chd-214	46	67	affect	affect	VERB
chd-214	46	68	tumor	tumor	NOUN
chd-214	46	69	progression	progression	NOUN
chd-214	46	70	among	among	ADP
chd-214	46	71	men	man	NOUN
chd-214	46	72	with	with	ADP
chd-214	46	73	different	different	ADJ
chd-214	46	74	racial	racial	ADJ
chd-214	46	75	and	and	CCONJ
chd-214	46	76	ethnic	ethnic	ADJ
chd-214	46	77	backgrounds	background	NOUN
chd-214	46	78	[	[	X
chd-214	46	79	18	18	NUM
chd-214	46	80	,	,	PUNCT
chd-214	46	81	19	19	NUM
chd-214	46	82	]	]	PUNCT
chd-214	46	83	.	.	PUNCT
chd-214	47	1	altered	alter	VERB
chd-214	47	2	gene	gene	NOUN
chd-214	47	3	expression	expression	NOUN
chd-214	47	4	profiles	profile	NOUN
chd-214	47	5	of	of	ADP
chd-214	47	6	fibroblasts	fibroblast	NOUN
chd-214	47	7	,	,	PUNCT
chd-214	47	8	immune	immune	ADJ
chd-214	47	9	cells	cell	NOUN
chd-214	47	10	and	and	CCONJ
chd-214	47	11	angiogenic	angiogenic	ADJ
chd-214	47	12	components	component	NOUN
chd-214	47	13	was	be	AUX
chd-214	47	14	noted	note	VERB
chd-214	47	15	between	between	ADP
chd-214	47	16	the	the	DET
chd-214	47	17	tme	tme	NOUN
chd-214	47	18	of	of	ADP
chd-214	47	19	aa	aa	PROPN
chd-214	47	20	and	and	CCONJ
chd-214	47	21	ca	can	AUX
chd-214	47	22	men	man	NOUN
chd-214	47	23	with	with	ADP
chd-214	47	24	pca	pca	PROPN
chd-214	47	25	[	[	X
chd-214	47	26	18	18	NUM
chd-214	47	27	-	-	SYM
chd-214	47	28	20	20	NUM
chd-214	47	29	,	,	PUNCT
chd-214	47	30	26	26	NUM
chd-214	47	31	-	-	SYM
chd-214	47	32	27	27	NUM
chd-214	47	33	]	]	PUNCT
chd-214	47	34	.	.	PUNCT
chd-214	48	1	in	in	ADP
chd-214	48	2	a	a	DET
chd-214	48	3	study	study	NOUN
chd-214	48	4	involving	involve	VERB
chd-214	48	5	pca	pca	NOUN
chd-214	48	6	samples	sample	NOUN
chd-214	48	7	from	from	ADP
chd-214	48	8	patients	patient	NOUN
chd-214	48	9	of	of	ADP
chd-214	48	10	aa	aa	NOUN
chd-214	48	11	and	and	CCONJ
chd-214	48	12	ca	ca	NOUN
chd-214	48	13	backgrounds	background	NOUN
chd-214	48	14	,	,	PUNCT
chd-214	48	15	a	a	DET
chd-214	48	16	total	total	NOUN
chd-214	48	17	of	of	ADP
chd-214	48	18	677	677	NUM
chd-214	48	19	genes	gene	NOUN
chd-214	48	20	associated	associate	VERB
chd-214	48	21	with	with	ADP
chd-214	48	22	103	103	NUM
chd-214	48	23	pathways	pathway	NOUN
chd-214	48	24	were	be	AUX
chd-214	48	25	identified	identify	VERB
chd-214	48	26	to	to	PART
chd-214	48	27	be	be	AUX
chd-214	48	28	differentially	differentially	ADV
chd-214	48	29	expressed	express	VERB
chd-214	48	30	in	in	ADP
chd-214	48	31	the	the	DET
chd-214	48	32	pca	pca	PROPN
chd-214	48	33	tme	tme	NOUN
chd-214	49	1	[	[	X
chd-214	49	2	20	20	NUM
chd-214	49	3	]	]	PUNCT
chd-214	49	4	.	.	PUNCT
chd-214	50	1	furthermore	furthermore	ADV
chd-214	50	2	,	,	PUNCT
chd-214	50	3	pathway	pathway	NOUN
chd-214	50	4	analysis	analysis	NOUN
chd-214	50	5	and	and	CCONJ
chd-214	50	6	disease	disease	NOUN
chd-214	50	7	association	association	NOUN
chd-214	50	8	studies	study	NOUN
chd-214	50	9	have	have	AUX
chd-214	50	10	revealed	reveal	VERB
chd-214	50	11	a	a	DET
chd-214	50	12	significant	significant	ADJ
chd-214	50	13	difference	difference	NOUN
chd-214	50	14	in	in	ADP
chd-214	50	15	tumor	tumor	NOUN
chd-214	50	16	inflammatory	inflammatory	ADJ
chd-214	50	17	response	response	NOUN
chd-214	50	18	and	and	CCONJ
chd-214	50	19	cytokine	cytokine	ADJ
chd-214	50	20	secretion	secretion	NOUN
chd-214	50	21	between	between	ADP
chd-214	50	22	aa	aa	NOUN
chd-214	50	23	and	and	CCONJ
chd-214	50	24	ca	can	AUX
chd-214	50	25	patient	patient	VERB
chd-214	50	26	samples	sample	NOUN
chd-214	50	27	[	[	X
chd-214	50	28	18	18	NUM
chd-214	50	29	,	,	PUNCT
chd-214	50	30	20	20	NUM
chd-214	50	31	,	,	PUNCT
chd-214	50	32	21	21	NUM
chd-214	50	33	,	,	PUNCT
chd-214	50	34	28	28	NUM
chd-214	50	35	,	,	PUNCT
chd-214	50	36	29].the	29].the	DET
chd-214	50	37	differences	difference	NOUN
chd-214	50	38	in	in	ADP
chd-214	50	39	tme	tme	NOUN
chd-214	50	40	of	of	ADP
chd-214	50	41	aa	aa	PROPN
chd-214	50	42	and	and	CCONJ
chd-214	50	43	ca	ca	PROPN
chd-214	50	44	pca	pca	NOUN
chd-214	50	45	patients	patient	NOUN
chd-214	50	46	may	may	AUX
chd-214	50	47	account	account	VERB
chd-214	50	48	for	for	ADP
chd-214	50	49	the	the	DET
chd-214	50	50	differences	difference	NOUN
chd-214	50	51	observed	observe	VERB
chd-214	50	52	in	in	ADP
chd-214	50	53	tumor	tumor	NOUN
chd-214	50	54	growth	growth	NOUN
chd-214	50	55	,	,	PUNCT
chd-214	50	56	progression	progression	NOUN
chd-214	50	57	and	and	CCONJ
chd-214	50	58	therapeutic	therapeutic	ADJ
chd-214	50	59	response	response	NOUN
chd-214	50	60	.	.	PUNCT
chd-214	51	1	in	in	ADP
chd-214	51	2	the	the	DET
chd-214	51	3	following	follow	VERB
chd-214	51	4	sections	section	NOUN
chd-214	51	5	,	,	PUNCT
chd-214	51	6	we	we	PRON
chd-214	51	7	will	will	AUX
chd-214	51	8	therefore	therefore	ADV
chd-214	51	9	discuss	discuss	VERB
chd-214	51	10	the	the	DET
chd-214	51	11	racial	racial	ADJ
chd-214	51	12	differences	difference	NOUN
chd-214	51	13	observed	observe	VERB
chd-214	51	14	in	in	ADP
chd-214	51	15	three	three	NUM
chd-214	51	16	important	important	ADJ
chd-214	51	17	cellular	cellular	ADJ
chd-214	51	18	components	component	NOUN
chd-214	51	19	of	of	ADP
chd-214	51	20	the	the	DET
chd-214	51	21	tme	tme	NOUN
chd-214	51	22	in	in	ADP
chd-214	51	23	pca	pca	PROPN
chd-214	51	24	:	:	PUNCT
chd-214	51	25	cancer	cancer	NOUN
chd-214	51	26	associated	associate	VERB
chd-214	51	27	fibroblasts	fibroblast	NOUN
chd-214	51	28	(	(	PUNCT
chd-214	51	29	cafs	cafs	NOUN
chd-214	51	30	)	)	PUNCT
chd-214	51	31	,	,	PUNCT
chd-214	51	32	immune	immune	ADJ
chd-214	51	33	cells	cell	NOUN
chd-214	51	34	and	and	CCONJ
chd-214	51	35	endothelial	endothelial	ADJ
chd-214	51	36	cells	cell	NOUN
chd-214	51	37	.	.	PUNCT
chd-214	52	1	2.1	2.1	NUM
chd-214	52	2	.	.	PUNCT
chd-214	52	3	fibroblasts	fibroblast	VERB
chd-214	52	4	the	the	DET
chd-214	52	5	stromal	stromal	ADJ
chd-214	52	6	fibroblasts	fibroblast	NOUN
chd-214	52	7	play	play	VERB
chd-214	52	8	a	a	DET
chd-214	52	9	major	major	ADJ
chd-214	52	10	role	role	NOUN
chd-214	52	11	in	in	ADP
chd-214	52	12	normal	normal	ADJ
chd-214	52	13	prostate	prostate	NOUN
chd-214	52	14	development	development	NOUN
chd-214	52	15	as	as	ADV
chd-214	52	16	well	well	ADV
chd-214	52	17	as	as	ADP
chd-214	52	18	in	in	ADP
chd-214	52	19	pca	pca	NOUN
chd-214	52	20	progression	progression	NOUN
chd-214	53	1	[	[	X
chd-214	53	2	2	2	NUM
chd-214	53	3	,	,	PUNCT
chd-214	53	4	17	17	NUM
chd-214	53	5	,	,	PUNCT
chd-214	53	6	25	25	NUM
chd-214	53	7	]	]	PUNCT
chd-214	53	8	.	.	PUNCT
chd-214	54	1	cancer	cancer	NOUN
chd-214	54	2	associated	associate	VERB
chd-214	54	3	fibroblasts	fibroblast	NOUN
chd-214	54	4	(	(	PUNCT
chd-214	54	5	cafs	cafs	NOUN
chd-214	54	6	)	)	PUNCT
chd-214	54	7	form	form	VERB
chd-214	54	8	a	a	DET
chd-214	54	9	major	major	ADJ
chd-214	54	10	component	component	NOUN
chd-214	54	11	of	of	ADP
chd-214	54	12	tme	tme	NOUN
chd-214	54	13	and	and	CCONJ
chd-214	54	14	they	they	PRON
chd-214	54	15	actively	actively	ADV
chd-214	54	16	communicate	communicate	VERB
chd-214	54	17	with	with	ADP
chd-214	54	18	pca	pca	NOUN
chd-214	54	19	cells	cell	NOUN
chd-214	54	20	both	both	CCONJ
chd-214	54	21	via	via	ADP
chd-214	54	22	direct	direct	ADJ
chd-214	54	23	contact	contact	NOUN
chd-214	54	24	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	NUM
chd-214	54	25	e5	e5	PROPN
chd-214	54	26	cancer	cancer	NOUN
chd-214	54	27	health	health	NOUN
chd-214	54	28	disparities	disparity	NOUN
chd-214	54	29	research	research	NOUN
chd-214	54	30	and	and	CCONJ
chd-214	54	31	via	via	ADP
chd-214	54	32	soluble	soluble	ADJ
chd-214	54	33	mediators	mediator	NOUN
chd-214	54	34	such	such	ADJ
chd-214	54	35	as	as	ADP
chd-214	54	36	chemokines	chemokine	NOUN
chd-214	54	37	,	,	PUNCT
chd-214	54	38	cytokines	cytokine	NOUN
chd-214	54	39	,	,	PUNCT
chd-214	54	40	growth	growth	NOUN
chd-214	54	41	factors	factor	NOUN
chd-214	54	42	secreted	secrete	VERB
chd-214	54	43	by	by	ADP
chd-214	54	44	both	both	PRON
chd-214	54	45	of	of	ADP
chd-214	54	46	the	the	DET
chd-214	54	47	cell	cell	NOUN
chd-214	54	48	types	type	NOUN
chd-214	55	1	[	[	X
chd-214	55	2	2	2	NUM
chd-214	55	3	,	,	PUNCT
chd-214	55	4	17	17	NUM
chd-214	55	5	,	,	PUNCT
chd-214	55	6	25	25	NUM
chd-214	55	7	,	,	PUNCT
chd-214	55	8	30	30	NUM
chd-214	55	9	,	,	PUNCT
chd-214	55	10	31	31	NUM
chd-214	55	11	]	]	PUNCT
chd-214	55	12	.	.	PUNCT
chd-214	56	1	this	this	DET
chd-214	56	2	bidirectional	bidirectional	ADJ
chd-214	56	3	communication	communication	NOUN
chd-214	56	4	between	between	ADP
chd-214	56	5	pca	pca	NOUN
chd-214	56	6	cells	cell	NOUN
chd-214	56	7	and	and	CCONJ
chd-214	56	8	cafs	cafs	NOUN
chd-214	56	9	is	be	AUX
chd-214	56	10	crucial	crucial	ADJ
chd-214	56	11	for	for	ADP
chd-214	56	12	tumor	tumor	NOUN
chd-214	56	13	progression	progression	NOUN
chd-214	56	14	and	and	CCONJ
chd-214	56	15	metastasis	metastasis	NOUN
chd-214	56	16	.	.	PUNCT
chd-214	57	1	cafs	cafs	PROPN
chd-214	57	2	secrete	secrete	NOUN
chd-214	57	3	growth	growth	NOUN
chd-214	57	4	factors	factor	NOUN
chd-214	57	5	like	like	ADP
chd-214	57	6	brain	brain	NOUN
chd-214	57	7	derived	derive	VERB
chd-214	57	8	neurotrophic	neurotrophic	ADJ
chd-214	57	9	factor	factor	NOUN
chd-214	57	10	and	and	CCONJ
chd-214	57	11	chemokines	chemokine	NOUN
chd-214	57	12	like	like	ADP
chd-214	57	13	ccl5	ccl5	PROPN
chd-214	57	14	,	,	PUNCT
chd-214	57	15	cxcl5	cxcl5	PROPN
chd-214	57	16	,	,	PUNCT
chd-214	57	17	sdf1	sdf1	PROPN
chd-214	57	18	-	-	PUNCT
chd-214	57	19	alpha	alpha	NOUN
chd-214	57	20	and	and	CCONJ
chd-214	57	21	soluble	soluble	ADJ
chd-214	57	22	factors	factor	NOUN
chd-214	57	23	such	such	ADJ
chd-214	57	24	as	as	ADP
chd-214	57	25	vegf	vegf	PROPN
chd-214	57	26	,	,	PUNCT
chd-214	57	27	bfgf	bfgf	PROPN
chd-214	57	28	,	,	PUNCT
chd-214	57	29	hgf	hgf	NOUN
chd-214	57	30	that	that	PRON
chd-214	57	31	promote	promote	VERB
chd-214	57	32	pca	pca	NOUN
chd-214	57	33	growth	growth	NOUN
chd-214	57	34	and	and	CCONJ
chd-214	57	35	progression	progression	NOUN
chd-214	57	36	[	[	X
chd-214	57	37	2	2	NUM
chd-214	57	38	,	,	PUNCT
chd-214	57	39	19	19	NUM
chd-214	57	40	]	]	PUNCT
chd-214	57	41	.	.	PUNCT
chd-214	58	1	studies	study	NOUN
chd-214	58	2	have	have	AUX
chd-214	58	3	shown	show	VERB
chd-214	58	4	cafs	cafs	NOUN
chd-214	58	5	can	can	AUX
chd-214	58	6	differentially	differentially	ADV
chd-214	58	7	impact	impact	VERB
chd-214	58	8	pca	pca	NOUN
chd-214	58	9	progression	progression	NOUN
chd-214	58	10	in	in	ADP
chd-214	58	11	aa	aa	PROPN
chd-214	58	12	and	and	CCONJ
chd-214	58	13	ca	ca	NOUN
chd-214	58	14	patients	patient	NOUN
chd-214	58	15	.	.	PUNCT
chd-214	59	1	in	in	ADP
chd-214	59	2	a	a	DET
chd-214	59	3	study	study	NOUN
chd-214	59	4	where	where	SCONJ
chd-214	59	5	prostate	prostate	NOUN
chd-214	59	6	fibroblasts	fibroblast	NOUN
chd-214	59	7	from	from	ADP
chd-214	59	8	pca	pca	PROPN
chd-214	59	9	specimens	specimen	NOUN
chd-214	59	10	of	of	ADP
chd-214	59	11	aa	aa	NOUN
chd-214	59	12	and	and	CCONJ
chd-214	59	13	ca	can	AUX
chd-214	59	14	patients	patient	NOUN
chd-214	59	15	with	with	ADP
chd-214	59	16	similar	similar	ADJ
chd-214	59	17	clinicopathologic	clinicopathologic	ADJ
chd-214	59	18	characteristics	characteristic	NOUN
chd-214	59	19	were	be	AUX
chd-214	59	20	isolated	isolate	VERB
chd-214	59	21	,	,	PUNCT
chd-214	59	22	it	it	PRON
chd-214	59	23	was	be	AUX
chd-214	59	24	noted	note	VERB
chd-214	59	25	that	that	SCONJ
chd-214	59	26	pro	pro	ADJ
chd-214	59	27	-	-	ADJ
chd-214	59	28	inflammatory	inflammatory	ADJ
chd-214	59	29	cytokines	cytokine	NOUN
chd-214	59	30	and	and	CCONJ
chd-214	59	31	growth	growth	NOUN
chd-214	59	32	factors	factor	NOUN
chd-214	59	33	[	[	X
chd-214	59	34	brain	brain	NOUN
chd-214	59	35	-	-	PUNCT
chd-214	59	36	derived	derive	VERB
chd-214	59	37	neurotrophic	neurotrophic	ADJ
chd-214	59	38	factor	factor	NOUN
chd-214	59	39	(	(	PUNCT
chd-214	59	40	bdnf	bdnf	PROPN
chd-214	59	41	)	)	PUNCT
chd-214	59	42	,	,	PUNCT
chd-214	59	43	vegf	vegf	PROPN
chd-214	59	44	,	,	PUNCT
chd-214	59	45	and	and	CCONJ
chd-214	59	46	fibroblast	fibroblast	ADJ
chd-214	59	47	growth	growth	NOUN
chd-214	59	48	factor	factor	NOUN
chd-214	59	49	7	7	NUM
chd-214	59	50	(	(	PUNCT
chd-214	59	51	fgf7	fgf7	PROPN
chd-214	59	52	)	)	PUNCT
chd-214	59	53	]	]	PUNCT
chd-214	59	54	were	be	AUX
chd-214	59	55	significantly	significantly	ADV
chd-214	59	56	elevated	elevate	VERB
chd-214	59	57	in	in	ADP
chd-214	59	58	caf	caf	NOUN
chd-214	59	59	isolated	isolate	VERB
chd-214	59	60	from	from	ADP
chd-214	59	61	aa	aa	PROPN
chd-214	59	62	pca	pca	NOUN
chd-214	59	63	samples	sample	NOUN
chd-214	59	64	compared	compare	VERB
chd-214	59	65	to	to	ADP
chd-214	59	66	ca	ca	PROPN
chd-214	59	67	pca	pca	PROPN
chd-214	60	1	[	[	X
chd-214	60	2	19	19	NUM
chd-214	60	3	]	]	PUNCT
chd-214	60	4	.	.	PUNCT
chd-214	61	1	in	in	ADP
chd-214	61	2	addition	addition	NOUN
chd-214	61	3	,	,	PUNCT
chd-214	61	4	myofibroblast	myofibroblast	NOUN
chd-214	61	5	activating	activate	VERB
chd-214	61	6	markers	marker	NOUN
chd-214	61	7	[	[	X
chd-214	61	8	αsma	αsma	NOUN
chd-214	61	9	,	,	PUNCT
chd-214	61	10	vimentin	vimentin	NOUN
chd-214	61	11	,	,	PUNCT
chd-214	61	12	and	and	CCONJ
chd-214	61	13	fap1	fap1	PROPN
chd-214	61	14	]	]	PUNCT
chd-214	61	15	and	and	CCONJ
chd-214	61	16	mesenchymal	mesenchymal	NOUN
chd-214	61	17	stem	stem	NOUN
chd-214	61	18	cell	cell	NOUN
chd-214	61	19	marker	marker	NOUN
chd-214	61	20	,	,	PUNCT
chd-214	61	21	cd90	cd90	PROPN
chd-214	61	22	,	,	PUNCT
chd-214	61	23	showed	show	VERB
chd-214	61	24	significantly	significantly	ADV
chd-214	61	25	higher	high	ADJ
chd-214	61	26	expressions	expression	NOUN
chd-214	61	27	in	in	ADP
chd-214	61	28	aa	aa	PROPN
chd-214	61	29	cafs	cafs	NOUN
chd-214	61	30	compared	compare	VERB
chd-214	61	31	with	with	ADP
chd-214	61	32	ca	ca	NOUN
chd-214	61	33	cafs	cafs	NOUN
chd-214	61	34	[	[	X
chd-214	61	35	19	19	NUM
chd-214	61	36	]	]	PUNCT
chd-214	61	37	.	.	PUNCT
chd-214	62	1	with	with	ADP
chd-214	62	2	increased	increase	VERB
chd-214	62	3	myofibroblastic	myofibroblastic	ADJ
chd-214	62	4	components	component	NOUN
chd-214	62	5	and	and	CCONJ
chd-214	62	6	presence	presence	NOUN
chd-214	62	7	of	of	ADP
chd-214	62	8	a	a	DET
chd-214	62	9	population	population	NOUN
chd-214	62	10	of	of	ADP
chd-214	62	11	mesenchymal	mesenchymal	NOUN
chd-214	62	12	-	-	PUNCT
chd-214	62	13	like	like	ADJ
chd-214	62	14	cells	cell	NOUN
chd-214	62	15	(	(	PUNCT
chd-214	62	16	cd90	cd90	PROPN
chd-214	62	17	+	+	PROPN
chd-214	62	18	)	)	PUNCT
chd-214	62	19	it	it	PRON
chd-214	62	20	was	be	AUX
chd-214	62	21	inferred	infer	VERB
chd-214	62	22	that	that	SCONJ
chd-214	62	23	aa	aa	NOUN
chd-214	62	24	-	-	PUNCT
chd-214	62	25	derived	derive	VERB
chd-214	62	26	cells	cell	NOUN
chd-214	62	27	would	would	AUX
chd-214	62	28	show	show	VERB
chd-214	62	29	increased	increase	VERB
chd-214	62	30	response	response	NOUN
chd-214	62	31	to	to	ADP
chd-214	62	32	growth	growth	NOUN
chd-214	62	33	factors	factor	NOUN
chd-214	62	34	compared	compare	VERB
chd-214	62	35	with	with	ADP
chd-214	62	36	ca	ca	NOUN
chd-214	62	37	-	-	PUNCT
chd-214	62	38	derived	derive	VERB
chd-214	62	39	cells	cell	NOUN
chd-214	62	40	[	[	X
chd-214	62	41	19	19	NUM
chd-214	62	42	]	]	PUNCT
chd-214	62	43	.	.	PUNCT
chd-214	63	1	on	on	ADP
chd-214	63	2	the	the	DET
chd-214	63	3	other	other	ADJ
chd-214	63	4	hand	hand	NOUN
chd-214	63	5	,	,	PUNCT
chd-214	63	6	the	the	DET
chd-214	63	7	expression	expression	NOUN
chd-214	63	8	of	of	ADP
chd-214	63	9	caveolin1	caveolin1	NOUN
chd-214	63	10	(	(	PUNCT
chd-214	63	11	cav1	cav1	PROPN
chd-214	63	12	)	)	PUNCT
chd-214	63	13	that	that	PRON
chd-214	63	14	is	be	AUX
chd-214	63	15	a	a	DET
chd-214	63	16	membrane	membrane	NOUN
chd-214	63	17	-	-	PUNCT
chd-214	63	18	associated	associate	VERB
chd-214	63	19	protein	protein	NOUN
chd-214	63	20	,	,	PUNCT
chd-214	63	21	whose	whose	DET
chd-214	63	22	expression	expression	NOUN
chd-214	63	23	in	in	ADP
chd-214	63	24	cancer	cancer	NOUN
chd-214	63	25	cells	cell	NOUN
chd-214	63	26	increases	increase	VERB
chd-214	63	27	with	with	ADP
chd-214	63	28	progression	progression	NOUN
chd-214	63	29	but	but	CCONJ
chd-214	63	30	loss	loss	NOUN
chd-214	63	31	in	in	ADP
chd-214	63	32	pca	pca	PROPN
chd-214	63	33	stroma	stroma	NOUN
chd-214	63	34	correlates	correlate	VERB
chd-214	63	35	with	with	ADP
chd-214	63	36	reduced	reduced	ADJ
chd-214	63	37	relapse	relapse	NOUN
chd-214	63	38	-	-	PUNCT
chd-214	63	39	free	free	ADJ
chd-214	63	40	survival	survival	NOUN
chd-214	63	41	[	[	X
chd-214	63	42	19	19	NUM
chd-214	63	43	,	,	PUNCT
chd-214	63	44	32	32	NUM
chd-214	63	45	,	,	PUNCT
chd-214	63	46	33	33	NUM
chd-214	63	47	]	]	PUNCT
chd-214	63	48	,	,	PUNCT
chd-214	63	49	was	be	AUX
chd-214	63	50	found	find	VERB
chd-214	63	51	to	to	PART
chd-214	63	52	be	be	AUX
chd-214	63	53	lower	low	ADJ
chd-214	63	54	in	in	ADP
chd-214	63	55	aa	aa	PROPN
chd-214	63	56	cafs	cafs	NOUN
chd-214	63	57	compared	compare	VERB
chd-214	63	58	with	with	ADP
chd-214	63	59	ca	ca	NOUN
chd-214	63	60	cafs	cafs	NOUN
chd-214	63	61	.	.	PUNCT
chd-214	64	1	upon	upon	SCONJ
chd-214	64	2	exposure	exposure	NOUN
chd-214	64	3	of	of	ADP
chd-214	64	4	pca	pca	NOUN
chd-214	64	5	cells	cell	NOUN
chd-214	64	6	to	to	ADP
chd-214	64	7	conditioned	condition	VERB
chd-214	64	8	media	medium	NOUN
chd-214	64	9	from	from	ADP
chd-214	64	10	fibroblasts	fibroblast	NOUN
chd-214	64	11	isolated	isolate	VERB
chd-214	64	12	from	from	ADP
chd-214	64	13	aa	aa	NOUN
chd-214	64	14	and	and	CCONJ
chd-214	64	15	ca	ca	NOUN
chd-214	64	16	pca	pca	NOUN
chd-214	64	17	patients	patient	NOUN
chd-214	64	18	,	,	PUNCT
chd-214	64	19	it	it	PRON
chd-214	64	20	was	be	AUX
chd-214	64	21	seen	see	VERB
chd-214	64	22	that	that	SCONJ
chd-214	64	23	there	there	PRON
chd-214	64	24	was	be	VERB
chd-214	64	25	increased	increase	VERB
chd-214	64	26	proliferation	proliferation	NOUN
chd-214	64	27	and	and	CCONJ
chd-214	64	28	migration	migration	NOUN
chd-214	64	29	in	in	ADP
chd-214	64	30	vitro	vitro	X
chd-214	64	31	when	when	SCONJ
chd-214	64	32	pca	pca	NOUN
chd-214	64	33	cells	cell	NOUN
chd-214	64	34	were	be	AUX
chd-214	64	35	exposed	expose	VERB
chd-214	64	36	to	to	ADP
chd-214	64	37	conditioned	condition	VERB
chd-214	64	38	media	medium	NOUN
chd-214	64	39	from	from	ADP
chd-214	64	40	aa	aa	ADJ
chd-214	64	41	prostate	prostate	NOUN
chd-214	64	42	fibroblasts	fibroblast	NOUN
chd-214	64	43	compared	compare	VERB
chd-214	64	44	to	to	ADP
chd-214	64	45	ca	ca	AUX
chd-214	64	46	prostate	prostate	VERB
chd-214	64	47	fibroblasts	fibroblast	NOUN
chd-214	64	48	[	[	X
chd-214	64	49	19	19	NUM
chd-214	64	50	]	]	PUNCT
chd-214	64	51	.	.	PUNCT
chd-214	65	1	furthermore	furthermore	ADV
chd-214	65	2	,	,	PUNCT
chd-214	65	3	this	this	DET
chd-214	65	4	study	study	NOUN
chd-214	65	5	demonstrated	demonstrate	VERB
chd-214	65	6	that	that	SCONJ
chd-214	65	7	regardless	regardless	ADV
chd-214	65	8	of	of	ADP
chd-214	65	9	the	the	DET
chd-214	65	10	racial	racial	ADJ
chd-214	65	11	background	background	NOUN
chd-214	65	12	of	of	ADP
chd-214	65	13	pca	pca	NOUN
chd-214	65	14	cells	cell	NOUN
chd-214	65	15	,	,	PUNCT
chd-214	65	16	growth	growth	NOUN
chd-214	65	17	and/or	and/or	CCONJ
chd-214	65	18	proliferation	proliferation	NOUN
chd-214	65	19	of	of	ADP
chd-214	65	20	pca	pca	NOUN
chd-214	65	21	cells	cell	NOUN
chd-214	65	22	was	be	AUX
chd-214	65	23	significantly	significantly	ADV
chd-214	65	24	increased	increase	VERB
chd-214	65	25	when	when	SCONJ
chd-214	65	26	conditioned	condition	VERB
chd-214	65	27	media	medium	NOUN
chd-214	65	28	from	from	ADP
chd-214	65	29	aa	aa	PROPN
chd-214	65	30	patients	patient	NOUN
chd-214	65	31	’	'	PUNCT
chd-214	65	32	fibroblasts	fibroblast	NOUN
chd-214	65	33	was	be	AUX
chd-214	65	34	used	use	VERB
chd-214	65	35	(	(	PUNCT
chd-214	65	36	19	19	NUM
chd-214	65	37	)	)	PUNCT
chd-214	65	38	.	.	PUNCT
chd-214	66	1	in	in	ADP
chd-214	66	2	addition	addition	NOUN
chd-214	66	3	,	,	PUNCT
chd-214	66	4	the	the	DET
chd-214	66	5	study	study	NOUN
chd-214	66	6	also	also	ADV
chd-214	66	7	reported	report	VERB
chd-214	66	8	an	an	DET
chd-214	66	9	increased	increase	VERB
chd-214	66	10	collagen	collagen	NOUN
chd-214	66	11	deposition	deposition	NOUN
chd-214	66	12	and	and	CCONJ
chd-214	66	13	myofibroblasts	myofibroblast	NOUN
chd-214	66	14	forming	form	VERB
chd-214	66	15	the	the	DET
chd-214	66	16	‘	'	PUNCT
chd-214	66	17	reactive	reactive	ADJ
chd-214	66	18	stroma	stroma	NOUN
chd-214	66	19	’	'	PUNCT
chd-214	66	20	and	and	CCONJ
chd-214	66	21	elevated	elevated	ADJ
chd-214	66	22	expression	expression	NOUN
chd-214	66	23	of	of	ADP
chd-214	66	24	fibroblast	fibroblast	ADJ
chd-214	66	25	specific	specific	ADJ
chd-214	66	26	marker	marker	NOUN
chd-214	66	27	,	,	PUNCT
chd-214	66	28	tenascin	tenascin	PROPN
chd-214	66	29	-	-	PUNCT
chd-214	66	30	c	c	NOUN
chd-214	66	31	,	,	PUNCT
chd-214	66	32	in	in	ADP
chd-214	66	33	the	the	DET
chd-214	66	34	extracellular	extracellular	ADJ
chd-214	66	35	matrix	matrix	NOUN
chd-214	66	36	(	(	PUNCT
chd-214	66	37	ecm	ecm	PROPN
chd-214	66	38	)	)	PUNCT
chd-214	66	39	of	of	ADP
chd-214	66	40	aa	aa	PROPN
chd-214	66	41	pca	pca	PROPN
chd-214	66	42	patients	patient	NOUN
chd-214	66	43	[	[	X
chd-214	66	44	19	19	NUM
chd-214	66	45	]	]	PUNCT
chd-214	66	46	.	.	PUNCT
chd-214	67	1	high	high	ADJ
chd-214	67	2	expression	expression	NOUN
chd-214	67	3	of	of	ADP
chd-214	67	4	tenascin	tenascin	PROPN
chd-214	67	5	-	-	PUNCT
chd-214	67	6	c	c	NOUN
chd-214	67	7	in	in	ADP
chd-214	67	8	cafs	cafs	NOUN
chd-214	67	9	is	be	AUX
chd-214	67	10	associated	associate	VERB
chd-214	67	11	with	with	ADP
chd-214	67	12	poor	poor	ADJ
chd-214	67	13	prognosis	prognosis	NOUN
chd-214	67	14	in	in	ADP
chd-214	67	15	pca	pca	PROPN
chd-214	67	16	[	[	X
chd-214	67	17	34].taken	34].taken	PROPN
chd-214	67	18	together	together	ADV
chd-214	67	19	;	;	PUNCT
chd-214	67	20	these	these	DET
chd-214	67	21	data	datum	NOUN
chd-214	67	22	suggest	suggest	VERB
chd-214	67	23	that	that	SCONJ
chd-214	67	24	cafs	cafs	NOUN
chd-214	67	25	in	in	ADP
chd-214	67	26	aa	aa	PROPN
chd-214	67	27	pca	pca	PROPN
chd-214	67	28	patients	patient	NOUN
chd-214	67	29	produce	produce	VERB
chd-214	67	30	significantly	significantly	ADV
chd-214	67	31	higher	high	ADJ
chd-214	67	32	levels	level	NOUN
chd-214	67	33	of	of	ADP
chd-214	67	34	growth	growth	NOUN
chd-214	67	35	factors	factor	NOUN
chd-214	67	36	that	that	PRON
chd-214	67	37	enhance	enhance	VERB
chd-214	67	38	the	the	DET
chd-214	67	39	tumorigenicity	tumorigenicity	NOUN
chd-214	67	40	of	of	ADP
chd-214	67	41	pca	pca	NOUN
chd-214	67	42	cells	cell	NOUN
chd-214	67	43	compared	compare	VERB
chd-214	67	44	with	with	ADP
chd-214	67	45	cafs	cafs	NOUN
chd-214	67	46	in	in	ADP
chd-214	67	47	ca	ca	PROPN
chd-214	67	48	pca	pca	NOUN
chd-214	67	49	patients	patient	NOUN
chd-214	67	50	.	.	PUNCT
chd-214	68	1	2.2	2.2	NUM
chd-214	68	2	.	.	NOUN
chd-214	68	3	immune	immune	ADJ
chd-214	68	4	cells	cell	NOUN
chd-214	68	5	although	although	SCONJ
chd-214	68	6	pca	pca	PROPN
chd-214	68	7	is	be	AUX
chd-214	68	8	considered	consider	VERB
chd-214	68	9	as	as	ADP
chd-214	68	10	a	a	DET
chd-214	68	11	poorly	poorly	ADV
chd-214	68	12	immunogenic	immunogenic	ADJ
chd-214	68	13	tumor	tumor	NOUN
chd-214	68	14	,	,	PUNCT
chd-214	68	15	chronic	chronic	ADJ
chd-214	68	16	inflammation	inflammation	NOUN
chd-214	68	17	has	have	AUX
chd-214	68	18	been	be	AUX
chd-214	68	19	consistently	consistently	ADV
chd-214	68	20	shown	show	VERB
chd-214	68	21	to	to	PART
chd-214	68	22	be	be	AUX
chd-214	68	23	associated	associate	VERB
chd-214	68	24	with	with	ADP
chd-214	68	25	the	the	DET
chd-214	68	26	development	development	NOUN
chd-214	68	27	and	and	CCONJ
chd-214	68	28	progression	progression	NOUN
chd-214	68	29	of	of	ADP
chd-214	68	30	the	the	DET
chd-214	68	31	disease	disease	NOUN
chd-214	68	32	[	[	X
chd-214	68	33	35	35	NUM
chd-214	68	34	]	]	SYM
chd-214	68	35	.	.	PUNCT
chd-214	69	1	immune	immune	ADJ
chd-214	69	2	cells	cell	NOUN
chd-214	69	3	form	form	VERB
chd-214	69	4	the	the	DET
chd-214	69	5	cellular	cellular	ADJ
chd-214	69	6	arm	arm	NOUN
chd-214	69	7	of	of	ADP
chd-214	69	8	inflammatory	inflammatory	ADJ
chd-214	69	9	responses	response	NOUN
chd-214	69	10	and	and	CCONJ
chd-214	69	11	presence	presence	NOUN
chd-214	69	12	of	of	ADP
chd-214	69	13	inflammatory	inflammatory	ADJ
chd-214	69	14	cells	cell	NOUN
chd-214	69	15	in	in	ADP
chd-214	69	16	pca	pca	PROPN
chd-214	69	17	tme	tme	PROPN
chd-214	69	18	is	be	AUX
chd-214	69	19	well	well	ADV
chd-214	69	20	documented.only	documented.only	ADV
chd-214	69	21	a	a	DET
chd-214	69	22	few	few	ADJ
chd-214	69	23	studies	study	NOUN
chd-214	69	24	however	however	ADV
chd-214	69	25	have	have	AUX
chd-214	69	26	explored	explore	VERB
chd-214	69	27	the	the	DET
chd-214	69	28	immunological	immunological	ADJ
chd-214	69	29	differences	difference	NOUN
chd-214	69	30	observed	observe	VERB
chd-214	69	31	in	in	ADP
chd-214	69	32	the	the	DET
chd-214	69	33	tme	tme	NOUN
chd-214	69	34	of	of	ADP
chd-214	69	35	aa	aa	PROPN
chd-214	69	36	and	and	CCONJ
chd-214	69	37	ca	ca	NOUN
chd-214	69	38	pca.[36	pca.[36	NOUN
chd-214	69	39	]	]	X
chd-214	69	40	.	.	PUNCT
chd-214	70	1	very	very	ADV
chd-214	70	2	recently	recently	ADV
chd-214	70	3	,	,	PUNCT
chd-214	70	4	it	it	PRON
chd-214	70	5	was	be	AUX
chd-214	70	6	reported	report	VERB
chd-214	70	7	that	that	SCONJ
chd-214	70	8	there	there	PRON
chd-214	70	9	is	be	VERB
chd-214	70	10	over	over	ADP
chd-214	70	11	-	-	PUNCT
chd-214	70	12	representation	representation	NOUN
chd-214	70	13	of	of	ADP
chd-214	70	14	immunogenic	immunogenic	ADJ
chd-214	70	15	tme	tme	NOUN
chd-214	70	16	in	in	ADP
chd-214	70	17	aa	aa	PROPN
chd-214	70	18	pca	pca	PROPN
chd-214	70	19	patients	patient	NOUN
chd-214	70	20	,	,	PUNCT
chd-214	70	21	with	with	ADP
chd-214	70	22	significantly	significantly	ADV
chd-214	70	23	higher	high	ADJ
chd-214	70	24	inflammatory	inflammatory	ADJ
chd-214	70	25	cytokines	cytokine	NOUN
chd-214	70	26	and	and	CCONJ
chd-214	70	27	lymphocytic	lymphocytic	ADJ
chd-214	70	28	infiltrates	infiltrate	NOUN
chd-214	70	29	which	which	PRON
chd-214	70	30	increases	increase	VERB
chd-214	70	31	the	the	DET
chd-214	70	32	potential	potential	NOUN
chd-214	70	33	for	for	ADP
chd-214	70	34	better	well	ADJ
chd-214	70	35	response	response	NOUN
chd-214	70	36	to	to	ADP
chd-214	70	37	immunotherapy	immunotherapy	NOUN
chd-214	70	38	in	in	ADP
chd-214	70	39	these	these	DET
chd-214	70	40	patients	patient	NOUN
chd-214	70	41	[	[	X
chd-214	70	42	37	37	NUM
chd-214	70	43	]	]	PUNCT
chd-214	70	44	.	.	PUNCT
chd-214	71	1	studies	study	NOUN
chd-214	71	2	have	have	AUX
chd-214	71	3	reported	report	VERB
chd-214	71	4	a	a	DET
chd-214	71	5	significant	significant	ADJ
chd-214	71	6	difference	difference	NOUN
chd-214	71	7	in	in	ADP
chd-214	71	8	both	both	CCONJ
chd-214	71	9	the	the	DET
chd-214	71	10	numbers	number	NOUN
chd-214	71	11	and	and	CCONJ
chd-214	71	12	types	type	NOUN
chd-214	71	13	of	of	ADP
chd-214	71	14	inflammatory	inflammatory	ADJ
chd-214	71	15	cells	cell	NOUN
chd-214	71	16	and	and	CCONJ
chd-214	71	17	inflammatory	inflammatory	ADJ
chd-214	71	18	responses	response	NOUN
chd-214	71	19	between	between	ADP
chd-214	71	20	aa	aa	NOUN
chd-214	71	21	and	and	CCONJ
chd-214	71	22	ca	ca	NOUN
chd-214	71	23	pca	pca	NOUN
chd-214	71	24	populations	population	NOUN
chd-214	71	25	.	.	PUNCT
chd-214	72	1	differences	difference	NOUN
chd-214	72	2	were	be	AUX
chd-214	72	3	noted	note	VERB
chd-214	72	4	between	between	ADP
chd-214	72	5	aa	aa	PROPN
chd-214	72	6	and	and	CCONJ
chd-214	72	7	ca	ca	PROPN
chd-214	72	8	pca	pca	NOUN
chd-214	72	9	patients	patient	NOUN
chd-214	72	10	in	in	ADP
chd-214	72	11	expression	expression	NOUN
chd-214	72	12	of	of	ADP
chd-214	72	13	chronic	chronic	ADJ
chd-214	72	14	inflammatory	inflammatory	ADJ
chd-214	72	15	cytokines	cytokine	NOUN
chd-214	72	16	,	,	PUNCT
chd-214	72	17	such	such	ADJ
chd-214	72	18	as	as	ADP
chd-214	72	19	interferon	interferon	ADJ
chd-214	72	20	-	-	PUNCT
chd-214	72	21	alpha	alpha	NOUN
chd-214	72	22	(	(	PUNCT
chd-214	72	23	ifnα	ifnα	NOUN
chd-214	72	24	)	)	PUNCT
chd-214	72	25	,	,	PUNCT
chd-214	72	26	ifnγ	ifnγ	NOUN
chd-214	72	27	,	,	PUNCT
chd-214	72	28	tumor	tumor	NOUN
chd-214	72	29	necrosis	necrosis	NOUN
chd-214	72	30	factor	factor	NOUN
chd-214	72	31	-	-	PUNCT
chd-214	72	32	alpha	alpha	NOUN
chd-214	72	33	(	(	PUNCT
chd-214	72	34	tnfα	tnfα	NOUN
chd-214	72	35	)	)	PUNCT
chd-214	72	36	,	,	PUNCT
chd-214	72	37	interleukin	interleukin	NOUN
chd-214	72	38	(	(	PUNCT
chd-214	72	39	il	il	PROPN
chd-214	72	40	)	)	PUNCT
chd-214	72	41	il-1β	il-1β	PROPN
chd-214	72	42	,	,	PUNCT
chd-214	72	43	il	il	PROPN
chd-214	72	44	4	4	NUM
chd-214	72	45	,	,	PUNCT
chd-214	72	46	il	il	PROPN
chd-214	72	47	6	6	NUM
chd-214	72	48	,	,	PUNCT
chd-214	72	49	il	il	PROPN
chd-214	72	50	8	8	NUM
chd-214	72	51	and	and	CCONJ
chd-214	72	52	il	il	PROPN
chd-214	72	53	13	13	NUM
chd-214	72	54	.	.	PUNCT
chd-214	73	1	these	these	DET
chd-214	73	2	pro	pro	ADJ
chd-214	73	3	-	-	ADJ
chd-214	73	4	inflammatory	inflammatory	ADJ
chd-214	73	5	cytokines	cytokine	NOUN
chd-214	73	6	show	show	VERB
chd-214	73	7	significant	significant	ADJ
chd-214	73	8	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	PUNCT
chd-214	73	9	e6	e6	VERB
chd-214	73	10	cancer	cancer	NOUN
chd-214	73	11	health	health	NOUN
chd-214	73	12	disparities	disparity	NOUN
chd-214	73	13	research	research	NOUN
chd-214	73	14	upregulation	upregulation	NOUN
chd-214	73	15	in	in	ADP
chd-214	73	16	pca	pca	PROPN
chd-214	73	17	of	of	ADP
chd-214	73	18	aa	aa	PROPN
chd-214	73	19	men	man	NOUN
chd-214	74	1	[	[	X
chd-214	74	2	20	20	NUM
chd-214	74	3	,	,	PUNCT
chd-214	74	4	38	38	NUM
chd-214	74	5	]	]	PUNCT
chd-214	74	6	.	.	PUNCT
chd-214	75	1	il-6	il-6	NOUN
chd-214	75	2	promotes	promote	VERB
chd-214	75	3	migration	migration	NOUN
chd-214	75	4	of	of	ADP
chd-214	75	5	cells	cell	NOUN
chd-214	75	6	and	and	CCONJ
chd-214	75	7	helps	help	VERB
chd-214	75	8	to	to	PART
chd-214	75	9	evade	evade	VERB
chd-214	75	10	apoptosis	apoptosis	NOUN
chd-214	75	11	through	through	ADP
chd-214	75	12	stat	stat	NOUN
chd-214	75	13	and	and	CCONJ
chd-214	75	14	pi3k	pi3k	PROPN
chd-214	75	15	pathways	pathway	NOUN
chd-214	75	16	and	and	CCONJ
chd-214	75	17	is	be	AUX
chd-214	75	18	considered	consider	VERB
chd-214	75	19	immunosuppressive	immunosuppressive	ADJ
chd-214	75	20	as	as	SCONJ
chd-214	75	21	it	it	PRON
chd-214	75	22	helps	help	VERB
chd-214	75	23	to	to	PART
chd-214	75	24	recruit	recruit	VERB
chd-214	75	25	myeloid	myeloid	ADJ
chd-214	75	26	derived	derive	VERB
chd-214	75	27	suppressor	suppressor	NOUN
chd-214	75	28	cells	cell	NOUN
chd-214	75	29	(	(	PUNCT
chd-214	75	30	mdsc	mdsc	NOUN
chd-214	75	31	)	)	PUNCT
chd-214	75	32	to	to	ADP
chd-214	75	33	the	the	DET
chd-214	75	34	tme	tme	NOUN
chd-214	76	1	[	[	X
chd-214	76	2	37	37	NUM
chd-214	76	3	,	,	PUNCT
chd-214	76	4	39	39	NUM
chd-214	76	5	]	]	PUNCT
chd-214	76	6	.	.	PUNCT
chd-214	76	7	il-8	il-8	PROPN
chd-214	76	8	activates	activate	VERB
chd-214	76	9	neutrophil	neutrophil	ADJ
chd-214	76	10	and	and	CCONJ
chd-214	76	11	plays	play	VERB
chd-214	76	12	a	a	DET
chd-214	76	13	role	role	NOUN
chd-214	76	14	in	in	ADP
chd-214	76	15	cell	cell	NOUN
chd-214	76	16	proliferation	proliferation	NOUN
chd-214	76	17	and	and	CCONJ
chd-214	76	18	invasion	invasion	NOUN
chd-214	76	19	.	.	PUNCT
chd-214	77	1	higher	high	ADJ
chd-214	77	2	levels	level	NOUN
chd-214	77	3	of	of	ADP
chd-214	77	4	il-8	il-8	NOUN
chd-214	77	5	expression	expression	NOUN
chd-214	77	6	in	in	ADP
chd-214	77	7	pca	pca	PROPN
chd-214	77	8	was	be	AUX
chd-214	77	9	associated	associate	VERB
chd-214	77	10	with	with	ADP
chd-214	77	11	higher	high	ADJ
chd-214	77	12	tumor	tumor	NOUN
chd-214	77	13	grade	grade	NOUN
chd-214	77	14	but	but	CCONJ
chd-214	77	15	this	this	DET
chd-214	77	16	association	association	NOUN
chd-214	77	17	was	be	AUX
chd-214	77	18	comparable	comparable	ADJ
chd-214	77	19	in	in	ADP
chd-214	77	20	aa	aa	NOUN
chd-214	77	21	and	and	CCONJ
chd-214	77	22	ca	ca	AUX
chd-214	77	23	pca	pca	PROPN
chd-214	78	1	[	[	X
chd-214	78	2	37	37	NUM
chd-214	78	3	,	,	PUNCT
chd-214	78	4	40	40	NUM
chd-214	78	5	]	]	PUNCT
chd-214	78	6	.	.	PUNCT
chd-214	79	1	a	a	DET
chd-214	79	2	recent	recent	ADJ
chd-214	79	3	study	study	NOUN
chd-214	79	4	that	that	PRON
chd-214	79	5	was	be	AUX
chd-214	79	6	conducted	conduct	VERB
chd-214	79	7	using	use	VERB
chd-214	79	8	grade	grade	NOUN
chd-214	79	9	,	,	PUNCT
chd-214	79	10	stage	stage	NOUN
chd-214	79	11	matched	match	VERB
chd-214	79	12	aa	aa	NOUN
chd-214	79	13	and	and	CCONJ
chd-214	79	14	ca	ca	PROPN
chd-214	79	15	pca	pca	PROPN
chd-214	79	16	,	,	PUNCT
chd-214	79	17	has	have	AUX
chd-214	79	18	reported	report	VERB
chd-214	79	19	an	an	DET
chd-214	79	20	increased	increase	VERB
chd-214	79	21	lymphocytic	lymphocytic	ADJ
chd-214	79	22	infiltration	infiltration	NOUN
chd-214	79	23	in	in	ADP
chd-214	79	24	aa	aa	PROPN
chd-214	79	25	pca	pca	PROPN
chd-214	79	26	tissues	tissue	NOUN
chd-214	79	27	compared	compare	VERB
chd-214	79	28	to	to	ADP
chd-214	79	29	pca	pca	NOUN
chd-214	79	30	tissues	tissue	NOUN
chd-214	79	31	of	of	ADP
chd-214	79	32	ca	can	AUX
chd-214	79	33	origin	origin	VERB
chd-214	80	1	[	[	X
chd-214	80	2	28	28	NUM
chd-214	80	3	]	]	PUNCT
chd-214	80	4	.	.	PUNCT
chd-214	81	1	upon	upon	SCONJ
chd-214	81	2	further	further	ADJ
chd-214	81	3	analysis	analysis	NOUN
chd-214	81	4	of	of	ADP
chd-214	81	5	the	the	DET
chd-214	81	6	lymphocytic	lymphocytic	ADJ
chd-214	81	7	population	population	NOUN
chd-214	81	8	,	,	PUNCT
chd-214	81	9	the	the	DET
chd-214	81	10	study	study	NOUN
chd-214	81	11	reported	report	VERB
chd-214	81	12	a	a	DET
chd-214	81	13	higher	high	ADJ
chd-214	81	14	presence	presence	NOUN
chd-214	81	15	of	of	ADP
chd-214	81	16	plasma	plasma	NOUN
chd-214	81	17	cells	cell	NOUN
chd-214	81	18	in	in	ADP
chd-214	81	19	tme	tme	NOUN
chd-214	81	20	of	of	ADP
chd-214	81	21	aa	aa	PROPN
chd-214	81	22	pca	pca	PROPN
chd-214	81	23	that	that	PRON
chd-214	81	24	correlated	correlate	VERB
chd-214	81	25	with	with	ADP
chd-214	81	26	ifnγ	ifnγ	NOUN
chd-214	81	27	expression	expression	NOUN
chd-214	81	28	and	and	CCONJ
chd-214	81	29	increased	increase	VERB
chd-214	81	30	inflammation	inflammation	NOUN
chd-214	81	31	observed	observe	VERB
chd-214	81	32	in	in	ADP
chd-214	81	33	these	these	DET
chd-214	81	34	tissues	tissue	NOUN
chd-214	81	35	[	[	X
chd-214	81	36	28	28	NUM
chd-214	81	37	]	]	PUNCT
chd-214	81	38	.	.	PUNCT
chd-214	82	1	high	high	ADJ
chd-214	82	2	expression	expression	NOUN
chd-214	82	3	of	of	ADP
chd-214	82	4	igg	igg	PROPN
chd-214	82	5	was	be	AUX
chd-214	82	6	also	also	ADV
chd-214	82	7	noted	note	VERB
chd-214	82	8	in	in	ADP
chd-214	82	9	these	these	DET
chd-214	82	10	aa	aa	PROPN
chd-214	82	11	pca	pca	PROPN
chd-214	82	12	samples	sample	NOUN
chd-214	82	13	,	,	PUNCT
chd-214	82	14	which	which	PRON
chd-214	82	15	suggested	suggest	VERB
chd-214	82	16	more	more	ADJ
chd-214	82	17	antibody	antibody	NOUN
chd-214	82	18	secretion	secretion	NOUN
chd-214	82	19	by	by	ADP
chd-214	82	20	these	these	DET
chd-214	82	21	cells	cell	NOUN
chd-214	82	22	[	[	X
chd-214	82	23	28	28	NUM
chd-214	82	24	]	]	PUNCT
chd-214	82	25	.	.	PUNCT
chd-214	83	1	in	in	ADP
chd-214	83	2	addition	addition	NOUN
chd-214	83	3	,	,	PUNCT
chd-214	83	4	increased	increase	VERB
chd-214	83	5	activity	activity	NOUN
chd-214	83	6	of	of	ADP
chd-214	83	7	nk	nk	PROPN
chd-214	83	8	cells	cell	NOUN
chd-214	83	9	,	,	PUNCT
chd-214	83	10	which	which	PRON
chd-214	83	11	primarily	primarily	ADV
chd-214	83	12	drives	drive	VERB
chd-214	83	13	antibody	antibody	NOUN
chd-214	83	14	dependent	dependent	ADJ
chd-214	83	15	cellular	cellular	ADJ
chd-214	83	16	toxicity	toxicity	NOUN
chd-214	83	17	,	,	PUNCT
chd-214	83	18	have	have	AUX
chd-214	83	19	been	be	AUX
chd-214	83	20	reported	report	VERB
chd-214	83	21	in	in	ADP
chd-214	83	22	aa	aa	PROPN
chd-214	83	23	pca	pca	PROPN
chd-214	83	24	tissues	tissue	NOUN
chd-214	83	25	compared	compare	VERB
chd-214	83	26	to	to	ADP
chd-214	83	27	tissues	tissue	NOUN
chd-214	83	28	from	from	ADP
chd-214	83	29	ca	can	AUX
chd-214	83	30	patient	patient	VERB
chd-214	84	1	[	[	X
chd-214	84	2	28	28	NUM
chd-214	84	3	]	]	PUNCT
chd-214	84	4	.	.	PUNCT
chd-214	85	1	a	a	DET
chd-214	85	2	different	different	ADJ
chd-214	85	3	study	study	NOUN
chd-214	85	4	also	also	ADV
chd-214	85	5	reported	report	VERB
chd-214	85	6	that	that	SCONJ
chd-214	85	7	aa	aa	PROPN
chd-214	85	8	pca	pca	PROPN
chd-214	85	9	had	have	VERB
chd-214	85	10	higher	high	ADJ
chd-214	85	11	expression	expression	NOUN
chd-214	85	12	of	of	ADP
chd-214	85	13	cd4	cd4	PROPN
chd-214	85	14	+	+	PROPN
chd-214	85	15	 	 	SPACE
chd-214	85	16	and	and	CCONJ
chd-214	85	17	cd8	cd8	PROPN
chd-214	85	18	+	+	PROPN
chd-214	85	19	 	 	SPACE
chd-214	85	20	t	t	NOUN
chd-214	85	21	-	-	PUNCT
chd-214	85	22	cell	cell	NOUN
chd-214	85	23	markers	marker	NOUN
chd-214	85	24	in	in	ADP
chd-214	85	25	tme	tme	NOUN
chd-214	86	1	[	[	X
chd-214	86	2	38	38	NUM
chd-214	86	3	]	]	PUNCT
chd-214	86	4	.	.	PUNCT
chd-214	87	1	in	in	ADP
chd-214	87	2	contrast	contrast	NOUN
chd-214	87	3	,	,	PUNCT
chd-214	87	4	there	there	PRON
chd-214	87	5	is	be	VERB
chd-214	87	6	also	also	ADV
chd-214	87	7	a	a	DET
chd-214	87	8	report	report	NOUN
chd-214	87	9	that	that	PRON
chd-214	87	10	indicated	indicate	VERB
chd-214	87	11	no	no	DET
chd-214	87	12	difference	difference	NOUN
chd-214	87	13	in	in	ADP
chd-214	87	14	t	t	NOUN
chd-214	87	15	-	-	PUNCT
chd-214	87	16	cell	cell	NOUN
chd-214	87	17	infiltration	infiltration	NOUN
chd-214	87	18	between	between	ADP
chd-214	87	19	aa	aa	PROPN
chd-214	87	20	and	and	CCONJ
chd-214	87	21	ca	ca	NOUN
chd-214	87	22	pca	pca	PROPN
chd-214	87	23	but	but	CCONJ
chd-214	87	24	increased	increase	VERB
chd-214	87	25	regulatory	regulatory	ADJ
chd-214	87	26	t	t	PROPN
chd-214	87	27	-	-	PUNCT
chd-214	87	28	cells	cell	NOUN
chd-214	87	29	in	in	ADP
chd-214	87	30	aa	aa	PROPN
chd-214	87	31	pca	pca	PROPN
chd-214	87	32	that	that	PRON
chd-214	87	33	correlated	correlate	VERB
chd-214	87	34	with	with	ADP
chd-214	87	35	disease	disease	NOUN
chd-214	87	36	recurrence	recurrence	NOUN
chd-214	87	37	[	[	X
chd-214	87	38	41	41	NUM
chd-214	87	39	]	]	PUNCT
chd-214	87	40	.	.	PUNCT
chd-214	88	1	poor	poor	ADJ
chd-214	88	2	disease	disease	NOUN
chd-214	88	3	prognosis	prognosis	NOUN
chd-214	88	4	associated	associate	VERB
chd-214	88	5	with	with	ADP
chd-214	88	6	lymphocytic	lymphocytic	ADJ
chd-214	88	7	tme	tme	NOUN
chd-214	88	8	infiltrates	infiltrate	NOUN
chd-214	88	9	may	may	AUX
chd-214	88	10	be	be	AUX
chd-214	88	11	due	due	ADJ
chd-214	88	12	to	to	ADP
chd-214	88	13	their	their	PRON
chd-214	88	14	association	association	NOUN
chd-214	88	15	with	with	ADP
chd-214	88	16	more	more	ADV
chd-214	88	17	aggressive	aggressive	ADJ
chd-214	88	18	tumors	tumor	NOUN
chd-214	88	19	,	,	PUNCT
chd-214	88	20	or	or	CCONJ
chd-214	88	21	as	as	SCONJ
chd-214	88	22	the	the	DET
chd-214	88	23	infiltrating	infiltrating	ADJ
chd-214	88	24	t	t	PROPN
chd-214	88	25	-	-	PUNCT
chd-214	88	26	cells	cell	NOUN
chd-214	88	27	were	be	AUX
chd-214	88	28	dysfunctional	dysfunctional	ADJ
chd-214	88	29	,	,	PUNCT
chd-214	88	30	or	or	CCONJ
chd-214	88	31	as	as	SCONJ
chd-214	88	32	were	be	AUX
chd-214	88	33	immunosuppressive	immunosuppressive	ADJ
chd-214	88	34	regulatory	regulatory	ADJ
chd-214	88	35	t	t	PROPN
chd-214	88	36	-	-	PUNCT
chd-214	88	37	cells	cell	NOUN
chd-214	88	38	[	[	X
chd-214	88	39	37	37	NUM
chd-214	88	40	,	,	PUNCT
chd-214	88	41	42	42	NUM
chd-214	88	42	]	]	PUNCT
chd-214	88	43	.	.	PUNCT
chd-214	89	1	macrophages	macrophage	NOUN
chd-214	89	2	comprise	comprise	VERB
chd-214	89	3	a	a	DET
chd-214	89	4	major	major	ADJ
chd-214	89	5	portion	portion	NOUN
chd-214	89	6	of	of	ADP
chd-214	89	7	the	the	DET
chd-214	89	8	immune	immune	ADJ
chd-214	89	9	cells	cell	NOUN
chd-214	89	10	in	in	ADP
chd-214	89	11	the	the	DET
chd-214	89	12	tme	tme	PROPN
chd-214	89	13	.	.	PUNCT
chd-214	90	1	m1	m1	PROPN
chd-214	90	2	type	type	NOUN
chd-214	90	3	or	or	CCONJ
chd-214	90	4	classically	classically	ADV
chd-214	90	5	activated	activate	VERB
chd-214	90	6	macrophages	macrophage	NOUN
chd-214	90	7	which	which	PRON
chd-214	90	8	are	be	AUX
chd-214	90	9	anti	anti	ADJ
chd-214	90	10	-	-	ADJ
chd-214	90	11	tumorigenic	tumorigenic	ADJ
chd-214	90	12	and	and	CCONJ
chd-214	90	13	m2	m2	PROPN
chd-214	90	14	type	type	NOUN
chd-214	90	15	or	or	CCONJ
chd-214	90	16	alternatively	alternatively	ADV
chd-214	90	17	activated	activate	VERB
chd-214	90	18	macrophages	macrophage	NOUN
chd-214	90	19	which	which	PRON
chd-214	90	20	are	be	AUX
chd-214	90	21	pro	pro	ADJ
chd-214	90	22	-	-	ADJ
chd-214	90	23	tumorigenic	tumorigenic	ADJ
chd-214	90	24	have	have	AUX
chd-214	90	25	been	be	AUX
chd-214	90	26	shown	show	VERB
chd-214	90	27	to	to	PART
chd-214	90	28	be	be	AUX
chd-214	90	29	present	present	ADJ
chd-214	90	30	in	in	ADP
chd-214	90	31	the	the	DET
chd-214	90	32	pca	pca	PROPN
chd-214	90	33	tme	tme	PROPN
chd-214	90	34	.	.	PUNCT
chd-214	91	1	in	in	ADP
chd-214	91	2	the	the	DET
chd-214	91	3	tme	tme	NOUN
chd-214	91	4	,	,	PUNCT
chd-214	91	5	the	the	DET
chd-214	91	6	tumor	tumor	NOUN
chd-214	91	7	-	-	PUNCT
chd-214	91	8	associated	associate	VERB
chd-214	91	9	macrophages	macrophage	NOUN
chd-214	91	10	(	(	PUNCT
chd-214	91	11	tams	tam	NOUN
chd-214	91	12	)	)	PUNCT
chd-214	91	13	are	be	AUX
chd-214	91	14	converted	convert	VERB
chd-214	91	15	from	from	ADP
chd-214	91	16	a	a	DET
chd-214	91	17	m1	m1	NOUN
chd-214	91	18	-	-	PUNCT
chd-214	91	19	type	type	NOUN
chd-214	91	20	to	to	ADP
chd-214	91	21	the	the	DET
chd-214	91	22	m2	m2	PROPN
chd-214	91	23	-	-	PUNCT
chd-214	91	24	type	type	NOUN
chd-214	91	25	phenotype	phenotype	NOUN
chd-214	91	26	that	that	PRON
chd-214	91	27	secrete	secrete	VERB
chd-214	91	28	numerous	numerous	ADJ
chd-214	91	29	growth	growth	NOUN
chd-214	91	30	factors	factor	NOUN
chd-214	91	31	,	,	PUNCT
chd-214	91	32	which	which	PRON
chd-214	91	33	influence	influence	VERB
chd-214	91	34	diverse	diverse	ADJ
chd-214	91	35	processes	process	NOUN
chd-214	91	36	during	during	ADP
chd-214	91	37	pca	pca	PROPN
chd-214	91	38	progression.the	progression.the	DET
chd-214	91	39	density	density	NOUN
chd-214	91	40	and	and	CCONJ
chd-214	91	41	type	type	NOUN
chd-214	91	42	of	of	ADP
chd-214	91	43	tams	tam	NOUN
chd-214	91	44	present	present	ADJ
chd-214	91	45	in	in	ADP
chd-214	91	46	pca	pca	NOUN
chd-214	91	47	thus	thus	ADV
chd-214	91	48	provide	provide	VERB
chd-214	91	49	prognostic	prognostic	ADJ
chd-214	91	50	information	information	NOUN
chd-214	92	1	[	[	X
chd-214	92	2	2	2	NUM
chd-214	92	3	,	,	PUNCT
chd-214	92	4	43	43	NUM
chd-214	92	5	]	]	PUNCT
chd-214	92	6	.	.	PUNCT
chd-214	93	1	aa	aa	PROPN
chd-214	93	2	pca	pca	PROPN
chd-214	93	3	patients	patient	NOUN
chd-214	93	4	show	show	VERB
chd-214	93	5	increased	increase	VERB
chd-214	93	6	tam	tam	NOUN
chd-214	93	7	numbers	number	NOUN
chd-214	93	8	compared	compare	VERB
chd-214	93	9	to	to	ADP
chd-214	93	10	ca	ca	PROPN
chd-214	93	11	pca	pca	NOUN
chd-214	93	12	patients	patient	NOUN
chd-214	93	13	as	as	ADP
chd-214	93	14	both	both	PRON
chd-214	93	15	cd68	cd68	PROPN
chd-214	93	16	+	+	PROPN
chd-214	93	17	(	(	PUNCT
chd-214	93	18	m1	m1	NOUN
chd-214	93	19	)	)	PUNCT
chd-214	93	20	,	,	PUNCT
chd-214	93	21	and	and	CCONJ
chd-214	93	22	cd163	cd163	PROPN
chd-214	93	23	+	+	CCONJ
chd-214	93	24	(	(	PUNCT
chd-214	93	25	m2	m2	PROPN
chd-214	93	26	)	)	PUNCT
chd-214	93	27	cells	cell	NOUN
chd-214	93	28	were	be	AUX
chd-214	93	29	significantly	significantly	ADV
chd-214	93	30	higher	high	ADJ
chd-214	93	31	in	in	ADP
chd-214	93	32	aa	aa	PROPN
chd-214	93	33	pca	pca	PROPN
chd-214	93	34	tissues	tissue	NOUN
chd-214	93	35	[	[	X
chd-214	93	36	2	2	NUM
chd-214	93	37	]	]	PUNCT
chd-214	93	38	.	.	PUNCT
chd-214	94	1	a	a	DET
chd-214	94	2	study	study	NOUN
chd-214	94	3	investigating	investigate	VERB
chd-214	94	4	the	the	DET
chd-214	94	5	role	role	NOUN
chd-214	94	6	of	of	ADP
chd-214	94	7	inflammation	inflammation	NOUN
chd-214	94	8	and	and	CCONJ
chd-214	94	9	immune	immune	ADJ
chd-214	94	10	genes	gene	NOUN
chd-214	94	11	in	in	ADP
chd-214	94	12	aa	aa	PROPN
chd-214	94	13	pca	pca	PROPN
chd-214	94	14	characterized	characterize	VERB
chd-214	94	15	124	124	NUM
chd-214	94	16	tme	tme	NOUN
chd-214	94	17	and	and	CCONJ
chd-214	94	18	immune	immune	ADJ
chd-214	94	19	response	response	NOUN
chd-214	94	20	genes	gene	NOUN
chd-214	94	21	in	in	ADP
chd-214	94	22	aa	aa	PROPN
chd-214	94	23	pca	pca	PROPN
chd-214	94	24	patients	patient	NOUN
chd-214	94	25	[	[	X
chd-214	94	26	44	44	NUM
chd-214	94	27	]	]	PUNCT
chd-214	94	28	.	.	PUNCT
chd-214	95	1	it	it	PRON
chd-214	95	2	was	be	AUX
chd-214	95	3	reported	report	VERB
chd-214	95	4	that	that	SCONJ
chd-214	95	5	22	22	NUM
chd-214	95	6	%	%	NOUN
chd-214	95	7	of	of	ADP
chd-214	95	8	total	total	ADJ
chd-214	95	9	aam	aam	PROPN
chd-214	95	10	patients	patient	NOUN
chd-214	95	11	showed	show	VERB
chd-214	95	12	adverse	adverse	ADJ
chd-214	95	13	pathology	pathology	NOUN
chd-214	95	14	features	feature	NOUN
chd-214	95	15	,	,	PUNCT
chd-214	95	16	high	high	ADJ
chd-214	95	17	genomic	genomic	ADJ
chd-214	95	18	risk	risk	NOUN
chd-214	95	19	(	(	PUNCT
chd-214	95	20	53	53	NUM
chd-214	95	21	%	%	NOUN
chd-214	95	22	)	)	PUNCT
chd-214	95	23	and	and	CCONJ
chd-214	95	24	higher	high	ADJ
chd-214	95	25	expressions	expression	NOUN
chd-214	95	26	of	of	ADP
chd-214	95	27	immuneresponse	immuneresponse	NOUN
chd-214	95	28	genes	gene	NOUN
chd-214	95	29	some	some	PRON
chd-214	95	30	of	of	ADP
chd-214	95	31	which	which	PRON
chd-214	95	32	along	along	ADP
chd-214	95	33	with	with	ADP
chd-214	95	34	their	their	PRON
chd-214	95	35	functions	function	NOUN
chd-214	95	36	have	have	AUX
chd-214	95	37	been	be	AUX
chd-214	95	38	included	include	VERB
chd-214	95	39	in	in	ADP
chd-214	95	40	table	table	NOUN
chd-214	95	41	2	2	NUM
chd-214	95	42	.	.	PUNCT
chd-214	95	43	table	table	NOUN
chd-214	95	44	2	2	NUM
chd-214	95	45	:	:	PUNCT
chd-214	95	46	immune	immune	ADJ
chd-214	95	47	response	response	NOUN
chd-214	95	48	genes	gene	NOUN
chd-214	95	49	elevated	elevate	VERB
chd-214	95	50	in	in	ADP
chd-214	95	51	aa	aa	PROPN
chd-214	95	52	pca	pca	PROPN
chd-214	95	53	patients	patient	NOUN
chd-214	95	54	compared	compare	VERB
chd-214	95	55	to	to	ADP
chd-214	95	56	ca	ca	PROPN
chd-214	95	57	pca	pca	PROPN
chd-214	95	58	patients	patient	NOUN
chd-214	95	59	.	.	PUNCT
chd-214	96	1	gene	gene	NOUN
chd-214	96	2	name	name	NOUN
chd-214	96	3	expression	expression	NOUN
chd-214	96	4	in	in	ADP
chd-214	96	5	aa	aa	PROPN
chd-214	96	6	pca	pca	PROPN
chd-214	96	7	patients	patient	NOUN
chd-214	96	8	role	role	NOUN
chd-214	96	9	in	in	ADP
chd-214	96	10	cancer	cancer	NOUN
chd-214	96	11	references	reference	NOUN
chd-214	96	12	cluster	cluster	NOUN
chd-214	96	13	of	of	ADP
chd-214	96	14	differentiation	differentiation	NOUN
chd-214	96	15	2	2	NUM
chd-214	96	16	(	(	PUNCT
chd-214	96	17	cd2	cd2	PROPN
chd-214	96	18	)	)	PUNCT
chd-214	96	19	immunomodulatory	immunomodulatory	NOUN
chd-214	96	20	in	in	ADP
chd-214	96	21	the	the	DET
chd-214	96	22	tme	tme	NOUN
chd-214	96	23	;	;	PUNCT
chd-214	96	24	associated	associate	VERB
chd-214	96	25	with	with	ADP
chd-214	96	26	delayed	delay	VERB
chd-214	96	27	disease	disease	NOUN
chd-214	96	28	progression	progression	NOUN
chd-214	96	29	;	;	PUNCT
chd-214	96	30	enhances	enhance	VERB
chd-214	96	31	tumor	tumor	NOUN
chd-214	96	32	immunogenicity	immunogenicity	NOUN
chd-214	96	33	and	and	CCONJ
chd-214	96	34	may	may	AUX
chd-214	96	35	improve	improve	VERB
chd-214	96	36	response	response	NOUN
chd-214	96	37	to	to	ADP
chd-214	96	38	immunotherapy	immunotherapy	NOUN
chd-214	96	39	.	.	PUNCT
chd-214	97	1	44	44	NUM
chd-214	97	2	,	,	PUNCT
chd-214	97	3	45	45	NUM
chd-214	97	4	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	NUM
chd-214	97	5	e7	e7	PROPN
chd-214	97	6	cancer	cancer	NOUN
chd-214	97	7	health	health	NOUN
chd-214	97	8	disparities	disparity	NOUN
chd-214	97	9	research	research	NOUN
chd-214	97	10	cluster	cluster	NOUN
chd-214	97	11	of	of	ADP
chd-214	97	12	differentiation	differentiation	NOUN
chd-214	97	13	3	3	NUM
chd-214	97	14	(	(	PUNCT
chd-214	97	15	cd3	cd3	PROPN
chd-214	97	16	)	)	PUNCT
chd-214	97	17	activates	activate	VERB
chd-214	97	18	cytotoxic	cytotoxic	ADJ
chd-214	97	19	t	t	NOUN
chd-214	97	20	cells	cell	NOUN
chd-214	97	21	(	(	PUNCT
chd-214	97	22	cd8	cd8	PROPN
chd-214	97	23	+	+	PROPN
chd-214	97	24	naive	naive	ADJ
chd-214	97	25	t	t	NOUN
chd-214	97	26	cells	cell	NOUN
chd-214	97	27	)	)	PUNCT
chd-214	97	28	and	and	CCONJ
chd-214	97	29	t	t	PROPN
chd-214	97	30	helper	helper	NOUN
chd-214	97	31	cells	cell	NOUN
chd-214	97	32	(	(	PUNCT
chd-214	97	33	cd4	cd4	PROPN
chd-214	97	34	+	+	PROPN
chd-214	97	35	naive	naive	ADJ
chd-214	97	36	t	t	NOUN
chd-214	97	37	cells	cell	NOUN
chd-214	97	38	)	)	PUNCT
chd-214	97	39	.	.	PUNCT
chd-214	98	1	44	44	NUM
chd-214	98	2	,	,	PUNCT
chd-214	98	3	46	46	NUM
chd-214	98	4	cluster	cluster	NOUN
chd-214	98	5	of	of	ADP
chd-214	98	6	differentiation	differentiation	NOUN
chd-214	98	7	4	4	NUM
chd-214	98	8	(	(	PUNCT
chd-214	98	9	cd4	cd4	PROPN
chd-214	98	10	)	)	PUNCT
chd-214	98	11	immunosuppressive	immunosuppressive	ADJ
chd-214	98	12	;	;	PUNCT
chd-214	98	13	may	may	AUX
chd-214	98	14	help	help	VERB
chd-214	98	15	in	in	ADP
chd-214	98	16	identifying	identify	VERB
chd-214	98	17	patient	patient	NOUN
chd-214	98	18	subset	subset	NOUN
chd-214	98	19	that	that	PRON
chd-214	98	20	would	would	AUX
chd-214	98	21	benefit	benefit	VERB
chd-214	98	22	from	from	ADP
chd-214	98	23	immunotherapy	immunotherapy	NOUN
chd-214	98	24	.	.	PUNCT
chd-214	99	1	44	44	NUM
chd-214	99	2	,	,	PUNCT
chd-214	99	3	47	47	NUM
chd-214	99	4	,	,	PUNCT
chd-214	99	5	48	48	NUM
chd-214	99	6	cluster	cluster	NOUN
chd-214	99	7	of	of	ADP
chd-214	99	8	differentiation	differentiation	NOUN
chd-214	99	9	45	45	NUM
chd-214	99	10	(	(	PUNCT
chd-214	99	11	cd45	cd45	PROPN
chd-214	99	12	)	)	PUNCT
chd-214	99	13	regulates	regulate	VERB
chd-214	99	14	lymphocyte	lymphocyte	ADJ
chd-214	99	15	survival	survival	NOUN
chd-214	99	16	,	,	PUNCT
chd-214	99	17	cytokine	cytokine	ADJ
chd-214	99	18	responses	response	NOUN
chd-214	99	19	,	,	PUNCT
chd-214	99	20	and	and	CCONJ
chd-214	99	21	tcr	tcr	PROPN
chd-214	99	22	signaling	signal	VERB
chd-214	99	23	;	;	PUNCT
chd-214	99	24	altered	alter	VERB
chd-214	99	25	cd45	cd45	PROPN
chd-214	99	26	could	could	AUX
chd-214	99	27	result	result	VERB
chd-214	99	28	in	in	ADP
chd-214	99	29	severe	severe	ADJ
chd-214	99	30	combined	combine	VERB
chd-214	99	31	immunodeficiency	immunodeficiency	NOUN
chd-214	99	32	.	.	PUNCT
chd-214	100	1	44	44	NUM
chd-214	100	2	,	,	PUNCT
chd-214	100	3	49	49	NUM
chd-214	100	4	cluster	cluster	NOUN
chd-214	100	5	of	of	ADP
chd-214	100	6	differentiation	differentiation	NOUN
chd-214	100	7	96	96	NUM
chd-214	100	8	(	(	PUNCT
chd-214	100	9	cd96	cd96	PROPN
chd-214	100	10	)	)	PUNCT
chd-214	100	11	inhibits	inhibit	VERB
chd-214	100	12	function	function	NOUN
chd-214	100	13	of	of	ADP
chd-214	100	14	cd8	cd8	PROPN
chd-214	100	15	+	+	PROPN
chd-214	100	16	t	t	NOUN
chd-214	100	17	cells	cell	NOUN
chd-214	100	18	;	;	PUNCT
chd-214	100	19	regulates	regulate	VERB
chd-214	100	20	nk	nk	PROPN
chd-214	100	21	cell	cell	NOUN
chd-214	100	22	effector	effector	NOUN
chd-214	100	23	function	function	NOUN
chd-214	100	24	and	and	CCONJ
chd-214	100	25	cellular	cellular	ADJ
chd-214	100	26	metastasis	metastasis	NOUN
chd-214	100	27	.	.	PUNCT
chd-214	101	1	44	44	NUM
chd-214	101	2	,	,	PUNCT
chd-214	101	3	50	50	NUM
chd-214	101	4	c	c	NOUN
chd-214	101	5	-	-	PUNCT
chd-214	101	6	c	c	NOUN
chd-214	101	7	motif	motif	NOUN
chd-214	101	8	chemokine	chemokine	ADJ
chd-214	101	9	ligand	ligand	NOUN
chd-214	101	10	5	5	NUM
chd-214	101	11	(	(	PUNCT
chd-214	101	12	ccl5	ccl5	PROPN
chd-214	101	13	)	)	PUNCT
chd-214	101	14	promotes	promote	VERB
chd-214	101	15	angiogenesis	angiogenesis	NOUN
chd-214	101	16	and	and	CCONJ
chd-214	101	17	metastasis	metastasis	NOUN
chd-214	101	18	;	;	PUNCT
chd-214	101	19	increases	increase	VERB
chd-214	101	20	drug	drug	NOUN
chd-214	101	21	resistance	resistance	NOUN
chd-214	101	22	;	;	PUNCT
chd-214	101	23	promotes	promote	VERB
chd-214	101	24	self	self	NOUN
chd-214	101	25	-	-	PUNCT
chd-214	101	26	renewal	renewal	NOUN
chd-214	101	27	of	of	ADP
chd-214	101	28	pca	pca	NOUN
chd-214	101	29	cells	cell	NOUN
chd-214	101	30	.	.	PUNCT
chd-214	102	1	44	44	NUM
chd-214	102	2	,	,	PUNCT
chd-214	102	3	51	51	NUM
chd-214	102	4	c	c	NOUN
chd-214	102	5	-	-	PUNCT
chd-214	102	6	x	x	NOUN
chd-214	102	7	-	-	NOUN
chd-214	102	8	c	c	ADJ
chd-214	102	9	motif	motif	NOUN
chd-214	102	10	chemokine	chemokine	ADJ
chd-214	102	11	ligand	ligand	NOUN
chd-214	102	12	9	9	NUM
chd-214	102	13	(	(	PUNCT
chd-214	102	14	cxcl9	cxcl9	PROPN
chd-214	102	15	)	)	PUNCT
chd-214	102	16	inhibits	inhibit	VERB
chd-214	102	17	cytokine	cytokine	ADJ
chd-214	102	18	secretion	secretion	NOUN
chd-214	102	19	from	from	ADP
chd-214	102	20	t	t	NOUN
chd-214	102	21	cells	cell	NOUN
chd-214	102	22	;	;	PUNCT
chd-214	102	23	promotes	promote	VERB
chd-214	102	24	pca	pca	NOUN
chd-214	102	25	progression	progression	NOUN
chd-214	102	26	.	.	PUNCT
chd-214	103	1	44	44	NUM
chd-214	103	2	,	,	PUNCT
chd-214	103	3	52	52	NUM
chd-214	103	4	c	c	NOUN
chd-214	103	5	-	-	PUNCT
chd-214	103	6	x	x	NOUN
chd-214	103	7	-	-	NOUN
chd-214	103	8	c	c	ADJ
chd-214	103	9	motif	motif	NOUN
chd-214	103	10	chemokine	chemokine	ADJ
chd-214	103	11	ligand	ligand	NOUN
chd-214	103	12	10	10	NUM
chd-214	103	13	(	(	PUNCT
chd-214	103	14	cxcl10	cxcl10	NOUN
chd-214	103	15	)	)	PUNCT
chd-214	103	16	increase	increase	VERB
chd-214	103	17	infiltration	infiltration	NOUN
chd-214	103	18	of	of	ADP
chd-214	103	19	pre	pre	ADJ
chd-214	103	20	-	-	NOUN
chd-214	103	21	adipocytes	adipocyte	NOUN
chd-214	103	22	and	and	CCONJ
chd-214	103	23	tams	tam	NOUN
chd-214	103	24	in	in	ADP
chd-214	103	25	pca	pca	PROPN
chd-214	103	26	tme	tme	PROPN
chd-214	103	27	;	;	PUNCT
chd-214	103	28	promotes	promote	VERB
chd-214	103	29	migration	migration	NOUN
chd-214	103	30	and	and	CCONJ
chd-214	103	31	invasion	invasion	NOUN
chd-214	103	32	of	of	ADP
chd-214	103	33	pca	pca	NOUN
chd-214	103	34	cells	cell	NOUN
chd-214	103	35	.	.	PUNCT
chd-214	104	1	44	44	NUM
chd-214	104	2	,	,	PUNCT
chd-214	104	3	53	53	NUM
chd-214	104	4	c	c	NOUN
chd-214	104	5	-	-	PUNCT
chd-214	104	6	x	x	NOUN
chd-214	104	7	-	-	NOUN
chd-214	104	8	c	c	ADJ
chd-214	104	9	motif	motif	NOUN
chd-214	104	10	chemokine	chemokine	ADJ
chd-214	104	11	ligand	ligand	NOUN
chd-214	104	12	11	11	NUM
chd-214	104	13	(	(	PUNCT
chd-214	104	14	cxcl11	cxcl11	NOUN
chd-214	104	15	)	)	PUNCT
chd-214	104	16	promotes	promote	VERB
chd-214	104	17	pca	pca	NOUN
chd-214	104	18	cell	cell	NOUN
chd-214	104	19	migration	migration	NOUN
chd-214	104	20	and	and	CCONJ
chd-214	104	21	invasion	invasion	NOUN
chd-214	104	22	.	.	PUNCT
chd-214	105	1	44	44	NUM
chd-214	105	2	,	,	PUNCT
chd-214	105	3	54	54	NUM
chd-214	105	4	signal	signal	NOUN
chd-214	105	5	transducer	transducer	NOUN
chd-214	105	6	and	and	CCONJ
chd-214	105	7	activator	activator	NOUN
chd-214	105	8	of	of	ADP
chd-214	105	9	transcription	transcription	NOUN
chd-214	105	10	1	1	NUM
chd-214	105	11	(	(	PUNCT
chd-214	105	12	stat1	stat1	X
chd-214	105	13	)	)	PUNCT
chd-214	105	14	tumor	tumor	NOUN
chd-214	105	15	suppressor	suppressor	NOUN
chd-214	105	16	in	in	ADP
chd-214	105	17	early	early	ADJ
chd-214	105	18	pca	pca	NOUN
chd-214	105	19	stages	stage	NOUN
chd-214	105	20	;	;	PUNCT
chd-214	105	21	promotes	promote	VERB
chd-214	105	22	drug	drug	NOUN
chd-214	105	23	resistance	resistance	NOUN
chd-214	105	24	.	.	PUNCT
chd-214	106	1	44	44	NUM
chd-214	106	2	,	,	PUNCT
chd-214	106	3	55	55	NUM
chd-214	106	4	indoleamine	indoleamine	NOUN
chd-214	106	5	2,3dioxygenase	2,3dioxygenase	NUM
chd-214	106	6	1(ido1	1(ido1	NUM
chd-214	106	7	)	)	PUNCT
chd-214	106	8	mediates	mediate	NOUN
chd-214	106	9	immunosuppression	immunosuppression	NOUN
chd-214	106	10	;	;	PUNCT
chd-214	106	11	associated	associate	VERB
chd-214	106	12	with	with	ADP
chd-214	106	13	significantly	significantly	ADV
chd-214	106	14	worse	bad	ADJ
chd-214	106	15	clinical	clinical	ADJ
chd-214	106	16	outcomes	outcome	NOUN
chd-214	106	17	.	.	PUNCT
chd-214	107	1	44,56	44,56	NOUN
chd-214	107	2	matrix	matrix	NOUN
chd-214	107	3	metallopeptidase	metallopeptidase	NOUN
chd-214	107	4	9	9	NUM
chd-214	107	5	(	(	PUNCT
chd-214	107	6	mmp9	mmp9	PROPN
chd-214	107	7	)	)	PUNCT
chd-214	107	8	promotes	promote	VERB
chd-214	107	9	angiogenesis	angiogenesis	NOUN
chd-214	107	10	.	.	PUNCT
chd-214	108	1	18	18	NUM
chd-214	108	2	,	,	PUNCT
chd-214	108	3	57	57	NUM
chd-214	108	4	autocrine	autocrine	NOUN
chd-214	108	5	motility	motility	NOUN
chd-214	108	6	factor	factor	NOUN
chd-214	108	7	receptor	receptor	NOUN
chd-214	108	8	(	(	PUNCT
chd-214	108	9	amfr	amfr	NOUN
chd-214	108	10	)	)	PUNCT
chd-214	108	11	mediates	mediate	VERB
chd-214	108	12	amf	amf	PROPN
chd-214	108	13	-	-	PUNCT
chd-214	108	14	mediated	mediate	VERB
chd-214	108	15	cell	cell	NOUN
chd-214	108	16	migration	migration	NOUN
chd-214	108	17	and	and	CCONJ
chd-214	108	18	metastasis	metastasis	NOUN
chd-214	108	19	.	.	PUNCT
chd-214	109	1	18	18	NUM
chd-214	109	2	,	,	PUNCT
chd-214	109	3	58	58	NUM
chd-214	109	4	taken	take	VERB
chd-214	109	5	together	together	ADV
chd-214	109	6	,	,	PUNCT
chd-214	109	7	the	the	DET
chd-214	109	8	tme	tme	NOUN
chd-214	109	9	in	in	ADP
chd-214	109	10	pca	pca	PROPN
chd-214	109	11	exhibits	exhibit	VERB
chd-214	109	12	an	an	DET
chd-214	109	13	immunosuppressive	immunosuppressive	ADJ
chd-214	109	14	microenvironment	microenvironment	NOUN
chd-214	109	15	and	and	CCONJ
chd-214	109	16	manifests	manifest	VERB
chd-214	109	17	a	a	DET
chd-214	109	18	unique	unique	ADJ
chd-214	109	19	immune	immune	ADJ
chd-214	109	20	repertoire	repertoire	NOUN
chd-214	109	21	in	in	ADP
chd-214	109	22	aa	aa	ADJ
chd-214	109	23	population	population	NOUN
chd-214	109	24	characterized	characterize	VERB
chd-214	109	25	by	by	ADP
chd-214	109	26	increased	increase	VERB
chd-214	109	27	inflammatory	inflammatory	ADJ
chd-214	109	28	mediators	mediator	NOUN
chd-214	109	29	and	and	CCONJ
chd-214	109	30	significant	significant	ADJ
chd-214	109	31	enrichment	enrichment	NOUN
chd-214	109	32	of	of	ADP
chd-214	109	33	proinflammatory	proinflammatory	ADJ
chd-214	109	34	immune	immune	ADJ
chd-214	109	35	pathways	pathway	NOUN
chd-214	109	36	creating	create	VERB
chd-214	109	37	a	a	DET
chd-214	109	38	tumor	tumor	NOUN
chd-214	109	39	supportive	supportive	ADJ
chd-214	109	40	environment	environment	NOUN
chd-214	109	41	that	that	PRON
chd-214	109	42	negatively	negatively	ADV
chd-214	109	43	associates	associate	VERB
chd-214	109	44	with	with	ADP
chd-214	109	45	disease	disease	NOUN
chd-214	109	46	outcomes	outcome	NOUN
chd-214	109	47	.	.	PUNCT
chd-214	110	1	however	however	ADV
chd-214	110	2	,	,	PUNCT
chd-214	110	3	a	a	DET
chd-214	110	4	study	study	NOUN
chd-214	110	5	also	also	ADV
chd-214	110	6	indicates	indicate	VERB
chd-214	110	7	that	that	SCONJ
chd-214	110	8	there	there	PRON
chd-214	110	9	is	be	VERB
chd-214	110	10	no	no	DET
chd-214	110	11	significant	significant	ADJ
chd-214	110	12	association	association	NOUN
chd-214	110	13	between	between	ADP
chd-214	110	14	inflammatory	inflammatory	ADJ
chd-214	110	15	infiltrate	infiltrate	ADJ
chd-214	110	16	and	and	CCONJ
chd-214	110	17	inflammation	inflammation	NOUN
chd-214	110	18	and	and	CCONJ
chd-214	110	19	the	the	DET
chd-214	110	20	difference	difference	NOUN
chd-214	110	21	in	in	ADP
chd-214	110	22	pca	pca	NOUN
chd-214	110	23	incidence	incidence	NOUN
chd-214	110	24	and	and	CCONJ
chd-214	110	25	outcomes	outcome	NOUN
chd-214	110	26	in	in	ADP
chd-214	110	27	different	different	ADJ
chd-214	110	28	racial	racial	ADJ
chd-214	110	29	groups	group	NOUN
chd-214	110	30	[	[	X
chd-214	110	31	59	59	NUM
chd-214	110	32	,	,	PUNCT
chd-214	110	33	60].therefore	60].therefore	NUM
chd-214	110	34	,	,	PUNCT
chd-214	110	35	more	more	ADJ
chd-214	110	36	studies	study	NOUN
chd-214	110	37	are	be	AUX
chd-214	110	38	needed	need	VERB
chd-214	110	39	to	to	PART
chd-214	110	40	draw	draw	VERB
chd-214	110	41	a	a	DET
chd-214	110	42	conclusion	conclusion	NOUN
chd-214	110	43	regarding	regard	VERB
chd-214	110	44	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	PROPN
chd-214	110	45	e8	e8	PROPN
chd-214	110	46	cancer	cancer	NOUN
chd-214	110	47	health	health	NOUN
chd-214	110	48	disparities	disparity	NOUN
chd-214	110	49	research	research	NOUN
chd-214	110	50	contribution	contribution	NOUN
chd-214	110	51	of	of	ADP
chd-214	110	52	immune	immune	ADJ
chd-214	110	53	microenvironment	microenvironment	NOUN
chd-214	110	54	to	to	ADP
chd-214	110	55	pca	pca	PROPN
chd-214	110	56	associated	associate	VERB
chd-214	110	57	racial	racial	ADJ
chd-214	110	58	disparity	disparity	NOUN
chd-214	110	59	.	.	PUNCT
chd-214	111	1	2.3	2.3	NUM
chd-214	111	2	.	.	PUNCT
chd-214	111	3	endothelial	endothelial	ADJ
chd-214	111	4	cells	cell	NOUN
chd-214	111	5	in	in	ADP
chd-214	111	6	addition	addition	NOUN
chd-214	111	7	to	to	ADP
chd-214	111	8	the	the	DET
chd-214	111	9	fibroblasts	fibroblast	NOUN
chd-214	111	10	and	and	CCONJ
chd-214	111	11	immune	immune	ADJ
chd-214	111	12	cells	cell	NOUN
chd-214	111	13	,	,	PUNCT
chd-214	111	14	endothelial	endothelial	ADJ
chd-214	111	15	cells	cell	NOUN
chd-214	111	16	form	form	VERB
chd-214	111	17	a	a	DET
chd-214	111	18	major	major	ADJ
chd-214	111	19	cellular	cellular	ADJ
chd-214	111	20	component	component	NOUN
chd-214	111	21	of	of	ADP
chd-214	111	22	the	the	DET
chd-214	111	23	tme	tme	PROPN
chd-214	111	24	.	.	PUNCT
chd-214	112	1	endothelial	endothelial	ADJ
chd-214	112	2	cells	cell	NOUN
chd-214	112	3	form	form	VERB
chd-214	112	4	new	new	ADJ
chd-214	112	5	blood	blood	NOUN
chd-214	112	6	vessels	vessel	NOUN
chd-214	112	7	from	from	ADP
chd-214	112	8	existing	exist	VERB
chd-214	112	9	vasculature	vasculature	NOUN
chd-214	112	10	by	by	ADP
chd-214	112	11	a	a	DET
chd-214	112	12	process	process	NOUN
chd-214	112	13	termed	term	VERB
chd-214	112	14	angiogenesis	angiogenesis	NOUN
chd-214	112	15	to	to	PART
chd-214	112	16	meet	meet	VERB
chd-214	112	17	the	the	DET
chd-214	112	18	nutrient	nutrient	NOUN
chd-214	112	19	and	and	CCONJ
chd-214	112	20	oxygen	oxygen	NOUN
chd-214	112	21	requirements	requirement	NOUN
chd-214	112	22	of	of	ADP
chd-214	112	23	the	the	DET
chd-214	112	24	rapidly	rapidly	ADV
chd-214	112	25	dividing	divide	VERB
chd-214	112	26	cancer	cancer	NOUN
chd-214	112	27	cells	cell	NOUN
chd-214	112	28	.	.	PUNCT
chd-214	113	1	additionally	additionally	ADV
chd-214	113	2	,	,	PUNCT
chd-214	113	3	these	these	DET
chd-214	113	4	cells	cell	NOUN
chd-214	113	5	by	by	ADP
chd-214	113	6	forming	form	VERB
chd-214	113	7	neovessels	neovessel	NOUN
chd-214	113	8	provide	provide	VERB
chd-214	113	9	routes	route	NOUN
chd-214	113	10	for	for	ADP
chd-214	113	11	dissemination	dissemination	NOUN
chd-214	113	12	of	of	ADP
chd-214	113	13	cancer	cancer	NOUN
chd-214	113	14	cells	cell	NOUN
chd-214	113	15	to	to	ADP
chd-214	113	16	other	other	ADJ
chd-214	113	17	parts	part	NOUN
chd-214	113	18	of	of	ADP
chd-214	113	19	the	the	DET
chd-214	113	20	body	body	NOUN
chd-214	113	21	[	[	X
chd-214	113	22	61	61	NUM
chd-214	113	23	-	-	SYM
chd-214	113	24	67	67	NUM
chd-214	113	25	]	]	PUNCT
chd-214	113	26	.	.	PUNCT
chd-214	114	1	in	in	ADP
chd-214	114	2	order	order	NOUN
chd-214	114	3	to	to	PART
chd-214	114	4	propagate	propagate	VERB
chd-214	114	5	and	and	CCONJ
chd-214	114	6	form	form	VERB
chd-214	114	7	new	new	ADJ
chd-214	114	8	blood	blood	NOUN
chd-214	114	9	vessels	vessel	VERB
chd-214	114	10	the	the	DET
chd-214	114	11	endothelial	endothelial	ADJ
chd-214	114	12	cells	cell	NOUN
chd-214	114	13	in	in	ADP
chd-214	114	14	tme	tme	PROPN
chd-214	114	15	respond	respond	NOUN
chd-214	114	16	to	to	ADP
chd-214	114	17	growth	growth	NOUN
chd-214	114	18	factors	factor	NOUN
chd-214	114	19	secreted	secrete	VERB
chd-214	114	20	by	by	ADP
chd-214	114	21	cancer	cancer	NOUN
chd-214	114	22	cells	cell	NOUN
chd-214	114	23	and	and	CCONJ
chd-214	114	24	cells	cell	NOUN
chd-214	114	25	in	in	ADP
chd-214	114	26	tme	tme	NOUN
chd-214	114	27	including	include	VERB
chd-214	114	28	endothelial	endothelial	ADJ
chd-214	114	29	cells	cell	NOUN
chd-214	114	30	themselves	themselves	PRON
chd-214	114	31	,	,	PUNCT
chd-214	114	32	such	such	ADJ
chd-214	114	33	as	as	ADP
chd-214	114	34	vascular	vascular	ADJ
chd-214	114	35	endothelial	endothelial	ADJ
chd-214	114	36	growth	growth	NOUN
chd-214	114	37	factor	factor	NOUN
chd-214	114	38	(	(	PUNCT
chd-214	114	39	vegf	vegf	PROPN
chd-214	114	40	)	)	PUNCT
chd-214	114	41	and	and	CCONJ
chd-214	114	42	fibroblast	fibroblast	ADJ
chd-214	114	43	growth	growth	NOUN
chd-214	114	44	factor	factor	NOUN
chd-214	114	45	(	(	PUNCT
chd-214	114	46	fgf	fgf	PROPN
chd-214	114	47	)	)	PUNCT
chd-214	114	48	.	.	PUNCT
chd-214	115	1	pca	pca	PROPN
chd-214	115	2	,	,	PUNCT
chd-214	115	3	like	like	ADP
chd-214	115	4	other	other	ADJ
chd-214	115	5	solid	solid	ADJ
chd-214	115	6	tumors	tumor	NOUN
chd-214	115	7	depends	depend	VERB
chd-214	115	8	on	on	ADP
chd-214	115	9	angiogenesis	angiogenesis	NOUN
chd-214	115	10	and	and	CCONJ
chd-214	115	11	overexpression	overexpression	NOUN
chd-214	115	12	of	of	ADP
chd-214	115	13	proangiogenic	proangiogenic	ADJ
chd-214	115	14	factors	factor	NOUN
chd-214	115	15	like	like	ADP
chd-214	115	16	vegf	vegf	PROPN
chd-214	115	17	and	and	CCONJ
chd-214	115	18	fgf	fgf	PROPN
chd-214	115	19	have	have	AUX
chd-214	115	20	been	be	AUX
chd-214	115	21	shown	show	VERB
chd-214	115	22	to	to	PART
chd-214	115	23	be	be	AUX
chd-214	115	24	associated	associate	VERB
chd-214	115	25	with	with	ADP
chd-214	115	26	poor	poor	ADJ
chd-214	115	27	pca	pca	NOUN
chd-214	115	28	prognosis	prognosis	NOUN
chd-214	115	29	[	[	X
chd-214	115	30	65	65	NUM
chd-214	115	31	,	,	PUNCT
chd-214	115	32	68	68	NUM
chd-214	115	33	-	-	SYM
chd-214	115	34	71	71	NUM
chd-214	115	35	]	]	PUNCT
chd-214	115	36	.	.	PUNCT
chd-214	116	1	vegf	vegf	PROPN
chd-214	116	2	is	be	AUX
chd-214	116	3	the	the	DET
chd-214	116	4	most	most	ADV
chd-214	116	5	prominent	prominent	ADJ
chd-214	116	6	cytokine	cytokine	NOUN
chd-214	116	7	regulating	regulate	VERB
chd-214	116	8	the	the	DET
chd-214	116	9	process	process	NOUN
chd-214	116	10	of	of	ADP
chd-214	116	11	angiogenesis	angiogenesis	NOUN
chd-214	116	12	[	[	X
chd-214	116	13	65	65	NUM
chd-214	116	14	,	,	PUNCT
chd-214	116	15	70	70	NUM
chd-214	116	16	,	,	PUNCT
chd-214	116	17	72	72	NUM
chd-214	116	18	,	,	PUNCT
chd-214	116	19	73	73	NUM
chd-214	116	20	]	]	PUNCT
chd-214	116	21	.	.	PUNCT
chd-214	117	1	in	in	ADP
chd-214	117	2	pca	pca	PROPN
chd-214	117	3	,	,	PUNCT
chd-214	117	4	the	the	DET
chd-214	117	5	expressions	expression	NOUN
chd-214	117	6	of	of	ADP
chd-214	117	7	vegf	vegf	PROPN
chd-214	117	8	and/or	and/or	CCONJ
chd-214	117	9	its	its	PRON
chd-214	117	10	receptor	receptor	NOUN
chd-214	117	11	vegfr-2	vegfr-2	PRON
chd-214	117	12	are	be	AUX
chd-214	117	13	directly	directly	ADV
chd-214	117	14	correlated	correlate	VERB
chd-214	117	15	to	to	ADP
chd-214	117	16	tumor	tumor	PROPN
chd-214	117	17	gleason	gleason	PROPN
chd-214	117	18	grade	grade	PROPN
chd-214	117	19	,	,	PUNCT
chd-214	117	20	metastatic	metastatic	ADJ
chd-214	117	21	potential	potential	NOUN
chd-214	117	22	,	,	PUNCT
chd-214	117	23	and	and	CCONJ
chd-214	117	24	progression	progression	NOUN
chd-214	117	25	-	-	PUNCT
chd-214	117	26	free	free	ADJ
chd-214	117	27	survival	survival	NOUN
chd-214	117	28	(	(	PUNCT
chd-214	117	29	pfs	pfs	PROPN
chd-214	117	30	)	)	PUNCT
chd-214	117	31	.	.	PUNCT
chd-214	118	1	in	in	ADP
chd-214	118	2	aa	aa	PROPN
chd-214	118	3	pca	pca	PROPN
chd-214	118	4	tme	tme	PROPN
chd-214	118	5	increased	increase	VERB
chd-214	118	6	vegf	vegf	PROPN
chd-214	118	7	secretion	secretion	NOUN
chd-214	118	8	by	by	ADP
chd-214	118	9	fibroblasts	fibroblast	NOUN
chd-214	118	10	may	may	AUX
chd-214	118	11	impact	impact	VERB
chd-214	118	12	tumor	tumor	NOUN
chd-214	118	13	angiogenesis	angiogenesis	NOUN
chd-214	119	1	[	[	X
chd-214	119	2	71	71	NUM
chd-214	119	3	]	]	SYM
chd-214	119	4	.	.	PUNCT
chd-214	120	1	microvessel	microvessel	NOUN
chd-214	120	2	density	density	PROPN
chd-214	120	3	(	(	PUNCT
chd-214	120	4	mvd	mvd	PROPN
chd-214	120	5	)	)	PUNCT
chd-214	120	6	a	a	DET
chd-214	120	7	surrogate	surrogate	ADJ
chd-214	120	8	marker	marker	NOUN
chd-214	120	9	assessing	assess	VERB
chd-214	120	10	angiogenic	angiogenic	ADJ
chd-214	120	11	response	response	NOUN
chd-214	120	12	in	in	ADP
chd-214	120	13	tissues	tissue	NOUN
chd-214	120	14	has	have	AUX
chd-214	120	15	been	be	AUX
chd-214	120	16	shown	show	VERB
chd-214	120	17	be	be	AUX
chd-214	120	18	higher	high	ADJ
chd-214	120	19	in	in	ADP
chd-214	120	20	pca	pca	NOUN
chd-214	120	21	tissues	tissue	NOUN
chd-214	120	22	collected	collect	VERB
chd-214	120	23	from	from	ADP
chd-214	120	24	aa	aa	PROPN
chd-214	120	25	patients	patient	NOUN
chd-214	120	26	compared	compare	VERB
chd-214	120	27	to	to	ADP
chd-214	120	28	patients	patient	NOUN
chd-214	120	29	with	with	ADP
chd-214	120	30	ca	ca	NOUN
chd-214	120	31	background	background	NOUN
chd-214	120	32	.	.	PUNCT
chd-214	121	1	[	[	X
chd-214	121	2	2	2	NUM
chd-214	121	3	,	,	PUNCT
chd-214	121	4	19	19	NUM
chd-214	121	5	]	]	PUNCT
chd-214	121	6	.	.	PUNCT
chd-214	122	1	these	these	DET
chd-214	122	2	differences	difference	NOUN
chd-214	122	3	in	in	ADP
chd-214	122	4	expression	expression	NOUN
chd-214	122	5	of	of	ADP
chd-214	122	6	angiogenic	angiogenic	ADJ
chd-214	122	7	factors	factor	NOUN
chd-214	122	8	and	and	CCONJ
chd-214	122	9	angiogenic	angiogenic	ADJ
chd-214	122	10	response	response	NOUN
chd-214	122	11	observed	observe	VERB
chd-214	122	12	between	between	ADP
chd-214	122	13	pca	pca	NOUN
chd-214	122	14	of	of	ADP
chd-214	122	15	aa	aa	NOUN
chd-214	122	16	and	and	CCONJ
chd-214	122	17	ca	can	AUX
chd-214	122	18	men	man	NOUN
chd-214	122	19	could	could	AUX
chd-214	122	20	differentially	differentially	ADV
chd-214	122	21	influence	influence	VERB
chd-214	122	22	pca	pca	NOUN
chd-214	122	23	growth	growth	NOUN
chd-214	122	24	,	,	PUNCT
chd-214	122	25	metastasis	metastasis	NOUN
chd-214	122	26	and	and	CCONJ
chd-214	122	27	clinical	clinical	ADJ
chd-214	122	28	outcomes	outcome	NOUN
chd-214	122	29	in	in	ADP
chd-214	122	30	these	these	DET
chd-214	122	31	two	two	NUM
chd-214	122	32	populations	population	NOUN
chd-214	122	33	.	.	PUNCT
chd-214	123	1	3.0	3.0	NUM
chd-214	123	2	.	.	PUNCT
chd-214	124	1	clinical	clinical	ADJ
chd-214	124	2	implications	implication	NOUN
chd-214	124	3	of	of	ADP
chd-214	124	4	the	the	DET
chd-214	124	5	racially	racially	ADV
chd-214	124	6	different	different	ADJ
chd-214	124	7	tumor	tumor	NOUN
chd-214	124	8	microenvironment	microenvironment	ADJ
chd-214	124	9	composition	composition	NOUN
chd-214	124	10	in	in	ADP
chd-214	124	11	prostate	prostate	NOUN
chd-214	124	12	cancer	cancer	NOUN
chd-214	124	13	tme	tme	NOUN
chd-214	124	14	in	in	ADP
chd-214	124	15	pca	pca	NOUN
chd-214	124	16	patients	patient	NOUN
chd-214	124	17	with	with	ADP
chd-214	124	18	different	different	ADJ
chd-214	124	19	racial	racial	ADJ
chd-214	124	20	backgrounds	background	NOUN
chd-214	124	21	show	show	VERB
chd-214	124	22	prominent	prominent	ADJ
chd-214	124	23	genetic	genetic	ADJ
chd-214	124	24	variability	variability	NOUN
chd-214	124	25	which	which	PRON
chd-214	124	26	influences	influence	VERB
chd-214	124	27	their	their	PRON
chd-214	124	28	ability	ability	NOUN
chd-214	124	29	to	to	PART
chd-214	124	30	synthesize	synthesize	VERB
chd-214	124	31	,	,	PUNCT
chd-214	124	32	secrete	secrete	NOUN
chd-214	124	33	and	and	CCONJ
chd-214	124	34	,	,	PUNCT
chd-214	124	35	respond	respond	VERB
chd-214	124	36	to	to	ADP
chd-214	124	37	growth	growth	NOUN
chd-214	124	38	factors	factor	NOUN
chd-214	124	39	which	which	PRON
chd-214	124	40	results	result	VERB
chd-214	124	41	in	in	ADP
chd-214	124	42	differential	differential	ADJ
chd-214	124	43	growth	growth	NOUN
chd-214	124	44	,	,	PUNCT
chd-214	124	45	progression	progression	NOUN
chd-214	124	46	and	and	CCONJ
chd-214	124	47	therapeutic	therapeutic	ADJ
chd-214	124	48	responses	response	NOUN
chd-214	124	49	[	[	X
chd-214	124	50	2	2	NUM
chd-214	124	51	,	,	PUNCT
chd-214	124	52	17	17	NUM
chd-214	124	53	,	,	PUNCT
chd-214	124	54	19	19	NUM
chd-214	124	55	,	,	PUNCT
chd-214	124	56	20	20	NUM
chd-214	124	57	,	,	PUNCT
chd-214	124	58	24	24	NUM
chd-214	124	59	]	]	PUNCT
chd-214	124	60	.	.	PUNCT
chd-214	125	1	with	with	ADP
chd-214	125	2	the	the	DET
chd-214	125	3	differences	difference	NOUN
chd-214	125	4	observed	observe	VERB
chd-214	125	5	in	in	ADP
chd-214	125	6	tme	tme	PROPN
chd-214	125	7	,	,	PUNCT
chd-214	125	8	it	it	PRON
chd-214	125	9	is	be	AUX
chd-214	125	10	more	more	ADV
chd-214	125	11	likely	likely	ADJ
chd-214	125	12	that	that	SCONJ
chd-214	125	13	aa	aa	PROPN
chd-214	125	14	pca	pca	PROPN
chd-214	125	15	patients	patient	NOUN
chd-214	125	16	may	may	AUX
chd-214	125	17	respond	respond	VERB
chd-214	125	18	differently	differently	ADV
chd-214	125	19	to	to	ADP
chd-214	125	20	different	different	ADJ
chd-214	125	21	therapeutic	therapeutic	ADJ
chd-214	125	22	strategies	strategy	NOUN
chd-214	125	23	.	.	PUNCT
chd-214	126	1	recent	recent	ADJ
chd-214	126	2	evidence	evidence	NOUN
chd-214	126	3	indicates	indicate	VERB
chd-214	126	4	that	that	SCONJ
chd-214	126	5	even	even	ADV
chd-214	126	6	though	though	SCONJ
chd-214	126	7	immunotherapy	immunotherapy	NOUN
chd-214	126	8	has	have	AUX
chd-214	126	9	not	not	PART
chd-214	126	10	been	be	AUX
chd-214	126	11	very	very	ADV
chd-214	126	12	successful	successful	ADJ
chd-214	126	13	in	in	ADP
chd-214	126	14	pca	pca	PROPN
chd-214	126	15	,	,	PUNCT
chd-214	126	16	aa	aa	PROPN
chd-214	126	17	patients	patient	NOUN
chd-214	126	18	might	might	AUX
chd-214	126	19	benefit	benefit	VERB
chd-214	126	20	from	from	ADP
chd-214	126	21	it	it	PRON
chd-214	126	22	due	due	ADP
chd-214	126	23	to	to	ADP
chd-214	126	24	the	the	DET
chd-214	126	25	differences	difference	NOUN
chd-214	126	26	in	in	ADP
chd-214	126	27	the	the	DET
chd-214	126	28	immune	immune	ADJ
chd-214	126	29	landscape	landscape	NOUN
chd-214	126	30	.	.	PUNCT
chd-214	127	1	in	in	ADP
chd-214	127	2	the	the	DET
chd-214	127	3	proceed	proceed	NOUN
chd-214	127	4	(	(	PUNCT
chd-214	127	5	nct01306890	nct01306890	ADJ
chd-214	127	6	)	)	PUNCT
chd-214	127	7	trial	trial	NOUN
chd-214	127	8	for	for	ADP
chd-214	127	9	receiving	receive	VERB
chd-214	127	10	immunotherapy	immunotherapy	NOUN
chd-214	127	11	with	with	ADP
chd-214	127	12	sipuleucel	sipuleucel	NOUN
chd-214	127	13	-	-	PUNCT
chd-214	127	14	t	t	NOUN
chd-214	127	15	for	for	ADP
chd-214	127	16	metastatic	metastatic	ADJ
chd-214	127	17	castration	castration	NOUN
chd-214	127	18	resistant	resistant	ADJ
chd-214	127	19	prostate	prostate	NOUN
chd-214	127	20	cancer	cancer	NOUN
chd-214	127	21	(	(	PUNCT
chd-214	127	22	mcrpc	mcrpc	PROPN
chd-214	127	23	)	)	PUNCT
chd-214	127	24	,	,	PUNCT
chd-214	127	25	aa	aa	PROPN
chd-214	127	26	pca	pca	PROPN
chd-214	127	27	patients	patient	NOUN
chd-214	127	28	showed	show	VERB
chd-214	127	29	a	a	DET
chd-214	127	30	higher	high	ADJ
chd-214	127	31	survival	survival	NOUN
chd-214	127	32	advantage	advantage	NOUN
chd-214	127	33	than	than	ADP
chd-214	127	34	ca	can	AUX
chd-214	127	35	pca	pca	NOUN
chd-214	127	36	patients	patient	NOUN
chd-214	127	37	[	[	X
chd-214	127	38	74	74	NUM
chd-214	127	39	]	]	PUNCT
chd-214	127	40	.	.	PUNCT
chd-214	128	1	in	in	ADP
chd-214	128	2	the	the	DET
chd-214	128	3	psamatched	psamatched	NOUN
chd-214	128	4	set	set	NOUN
chd-214	128	5	,	,	PUNCT
chd-214	128	6	median	median	ADJ
chd-214	128	7	overall	overall	ADJ
chd-214	128	8	survival	survival	NOUN
chd-214	128	9	(	(	PUNCT
chd-214	128	10	os	os	NOUN
chd-214	128	11	)	)	PUNCT
chd-214	128	12	for	for	ADP
chd-214	128	13	aa	aa	PROPN
chd-214	128	14	patients	patient	NOUN
chd-214	128	15	was	be	AUX
chd-214	128	16	35.3	35.3	NUM
chd-214	128	17	and	and	CCONJ
chd-214	128	18	that	that	SCONJ
chd-214	128	19	for	for	ADP
chd-214	128	20	ca	ca	NOUN
chd-214	128	21	patients	patient	NOUN
chd-214	128	22	was	be	AUX
chd-214	128	23	25.8	25.8	NUM
chd-214	128	24	months	month	NOUN
chd-214	128	25	and	and	CCONJ
chd-214	128	26	in	in	ADP
chd-214	128	27	the	the	DET
chd-214	128	28	all	all	DET
chd-214	128	29	patient	patient	NOUN
chd-214	128	30	set	set	NOUN
chd-214	128	31	,	,	PUNCT
chd-214	128	32	os	os	NOUN
chd-214	128	33	of	of	ADP
chd-214	128	34	aa	aa	PROPN
chd-214	128	35	patients	patient	NOUN
chd-214	128	36	was	be	AUX
chd-214	128	37	35.2	35.2	NUM
chd-214	128	38	monthsas	monthsa	NOUN
chd-214	128	39	compared	compare	VERB
chd-214	128	40	to	to	ADP
chd-214	128	41	29.9	29.9	NUM
chd-214	128	42	months	month	NOUN
chd-214	128	43	for	for	ADP
chd-214	128	44	ca	ca	NOUN
chd-214	128	45	patients	patient	NOUN
chd-214	128	46	.	.	PUNCT
chd-214	129	1	mcrpc	mcrpc	PROPN
chd-214	129	2	aa	aa	PROPN
chd-214	129	3	patients	patient	NOUN
chd-214	129	4	with	with	ADP
chd-214	129	5	lower	low	ADJ
chd-214	129	6	baseline	baseline	NOUN
chd-214	129	7	psa	psa	NOUN
chd-214	129	8	showed	show	VERB
chd-214	129	9	even	even	ADV
chd-214	129	10	longer	long	ADV
chd-214	129	11	os	os	ADV
chd-214	129	12	of	of	ADP
chd-214	129	13	over	over	ADP
chd-214	129	14	4.5	4.5	NUM
chd-214	129	15	years	year	NOUN
chd-214	129	16	compared	compare	VERB
chd-214	129	17	to	to	ADP
chd-214	129	18	2.8	2.8	NUM
chd-214	129	19	years	year	NOUN
chd-214	129	20	for	for	ADP
chd-214	129	21	ca	ca	NOUN
chd-214	129	22	patients	patient	NOUN
chd-214	129	23	.	.	PUNCT
chd-214	130	1	the	the	DET
chd-214	130	2	better	well	ADJ
chd-214	130	3	response	response	NOUN
chd-214	130	4	to	to	ADP
chd-214	130	5	immunotherapy	immunotherapy	NOUN
chd-214	130	6	shown	show	VERB
chd-214	130	7	by	by	ADP
chd-214	130	8	aa	aa	PROPN
chd-214	130	9	pca	pca	PROPN
chd-214	130	10	patients	patient	NOUN
chd-214	130	11	proves	prove	VERB
chd-214	130	12	the	the	DET
chd-214	130	13	differences	difference	NOUN
chd-214	130	14	in	in	ADP
chd-214	130	15	immune	immune	ADJ
chd-214	130	16	response	response	NOUN
chd-214	130	17	in	in	ADP
chd-214	130	18	aa	aa	PROPN
chd-214	130	19	and	and	CCONJ
chd-214	130	20	ca	ca	NOUN
chd-214	130	21	pca	pca	NOUN
chd-214	130	22	patients	patient	NOUN
chd-214	130	23	[	[	X
chd-214	130	24	35	35	NUM
chd-214	130	25	]	]	PUNCT
chd-214	130	26	.	.	PUNCT
chd-214	131	1	aa	aa	PROPN
chd-214	131	2	pca	pca	PROPN
chd-214	131	3	patients	patient	NOUN
chd-214	131	4	have	have	AUX
chd-214	131	5	been	be	AUX
chd-214	131	6	predicted	predict	VERB
chd-214	131	7	to	to	PART
chd-214	131	8	have	have	VERB
chd-214	131	9	higher	high	ADJ
chd-214	131	10	response	response	NOUN
chd-214	131	11	score	score	NOUN
chd-214	131	12	to	to	ADP
chd-214	131	13	dna	dna	NOUN
chd-214	131	14	damage	damage	NOUN
chd-214	131	15	and	and	CCONJ
chd-214	131	16	alkylating	alkylate	VERB
chd-214	131	17	agent	agent	NOUN
chd-214	131	18	-	-	PUNCT
chd-214	131	19	based	base	VERB
chd-214	131	20	chemotherapy	chemotherapy	NOUN
chd-214	131	21	whereas	whereas	SCONJ
chd-214	131	22	ca	can	AUX
chd-214	131	23	pca	pca	PROPN
chd-214	131	24	has	have	VERB
chd-214	131	25	a	a	DET
chd-214	131	26	higher	high	ADJ
chd-214	131	27	response	response	NOUN
chd-214	131	28	score	score	NOUN
chd-214	131	29	to	to	ADP
chd-214	131	30	microtubule	microtubule	NOUN
chd-214	131	31	-	-	PUNCT
chd-214	131	32	based	base	VERB
chd-214	131	33	chemotherapy	chemotherapy	NOUN
chd-214	132	1	[	[	X
chd-214	132	2	44	44	NUM
chd-214	132	3	]	]	PUNCT
chd-214	132	4	.	.	PUNCT
chd-214	133	1	other	other	ADJ
chd-214	133	2	studies	study	NOUN
chd-214	133	3	have	have	AUX
chd-214	133	4	reported	report	VERB
chd-214	133	5	that	that	SCONJ
chd-214	133	6	the	the	DET
chd-214	133	7	regular	regular	ADJ
chd-214	133	8	use	use	NOUN
chd-214	133	9	of	of	ADP
chd-214	133	10	aspirin	aspirin	NOUN
chd-214	133	11	can	can	AUX
chd-214	133	12	significantly	significantly	ADV
chd-214	133	13	reduce	reduce	VERB
chd-214	133	14	both	both	DET
chd-214	133	15	the	the	DET
chd-214	133	16	risk	risk	NOUN
chd-214	133	17	of	of	ADP
chd-214	133	18	developing	develop	VERB
chd-214	133	19	metastatic	metastatic	ADJ
chd-214	133	20	pca	pca	NOUN
chd-214	133	21	and	and	CCONJ
chd-214	133	22	disease	disease	NOUN
chd-214	133	23	recurrence	recurrence	NOUN
chd-214	133	24	in	in	ADP
chd-214	133	25	aam	aam	PROPN
chd-214	134	1	[	[	X
chd-214	134	2	75	75	NUM
chd-214	134	3	,	,	PUNCT
chd-214	134	4	76	76	NUM
chd-214	134	5	]	]	PUNCT
chd-214	134	6	by	by	ADP
chd-214	134	7	targeting	target	VERB
chd-214	134	8	the	the	DET
chd-214	134	9	pro	pro	ADJ
chd-214	134	10	-	-	ADJ
chd-214	134	11	inflammatory	inflammatory	ADJ
chd-214	134	12	cyclooxygenase/	cyclooxygenase/	NUM
chd-214	134	13	thromboxane	thromboxane	NOUN
chd-214	134	14	a2	a2	PROPN
chd-214	134	15	pathway	pathway	NOUN
chd-214	135	1	[	[	X
chd-214	135	2	77	77	NUM
chd-214	135	3	]	]	PUNCT
chd-214	135	4	.	.	PUNCT
chd-214	136	1	evidence	evidence	NOUN
chd-214	136	2	also	also	ADV
chd-214	136	3	suggests	suggest	VERB
chd-214	136	4	reduced	reduced	ADJ
chd-214	136	5	mortality	mortality	NOUN
chd-214	136	6	due	due	ADP
chd-214	136	7	to	to	ADP
chd-214	136	8	pca	pca	PROPN
chd-214	136	9	in	in	ADP
chd-214	136	10	aam	aam	PROPN
chd-214	136	11	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	PROPN
chd-214	136	12	e9	e9	PROPN
chd-214	136	13	cancer	cancer	NOUN
chd-214	136	14	health	health	NOUN
chd-214	136	15	disparities	disparity	NOUN
chd-214	136	16	research	research	NOUN
chd-214	136	17	using	use	VERB
chd-214	136	18	aspirin	aspirin	NOUN
chd-214	137	1	[	[	X
chd-214	137	2	78].furthermore	78].furthermore	PROPN
chd-214	137	3	,	,	PUNCT
chd-214	137	4	tme	tme	X
chd-214	137	5	facilitates	facilitate	VERB
chd-214	137	6	therapeutic	therapeutic	ADJ
chd-214	137	7	resistance	resistance	NOUN
chd-214	137	8	by	by	ADP
chd-214	137	9	modification	modification	NOUN
chd-214	137	10	of	of	ADP
chd-214	137	11	stromal	stromal	ADJ
chd-214	137	12	components	component	NOUN
chd-214	137	13	to	to	PART
chd-214	137	14	promote	promote	VERB
chd-214	137	15	invasion	invasion	NOUN
chd-214	137	16	,	,	PUNCT
chd-214	137	17	angiogenesis	angiogenesis	NOUN
chd-214	137	18	,	,	PUNCT
chd-214	137	19	and	and	CCONJ
chd-214	137	20	metastases	metastasis	NOUN
chd-214	137	21	.	.	PUNCT
chd-214	138	1	patient	patient	ADJ
chd-214	138	2	response	response	NOUN
chd-214	138	3	to	to	ADP
chd-214	138	4	therapy	therapy	NOUN
chd-214	138	5	depends	depend	VERB
chd-214	138	6	strongly	strongly	ADV
chd-214	138	7	on	on	ADP
chd-214	138	8	activation	activation	NOUN
chd-214	138	9	of	of	ADP
chd-214	138	10	tumor	tumor	NOUN
chd-214	138	11	stroma	stroma	NOUN
chd-214	138	12	.	.	PUNCT
chd-214	139	1	the	the	DET
chd-214	139	2	presence	presence	NOUN
chd-214	139	3	of	of	ADP
chd-214	139	4	myofibroblasts	myofibroblast	NOUN
chd-214	139	5	,	,	PUNCT
chd-214	139	6	that	that	PRON
chd-214	139	7	show	show	VERB
chd-214	139	8	higher	high	ADJ
chd-214	139	9	expressions	expression	NOUN
chd-214	139	10	in	in	ADP
chd-214	139	11	aa	aa	NOUN
chd-214	139	12	patients	patient	NOUN
chd-214	139	13	than	than	ADP
chd-214	139	14	ca	ca	NOUN
chd-214	139	15	patients	patient	NOUN
chd-214	139	16	,	,	PUNCT
chd-214	139	17	predicts	predict	VERB
chd-214	139	18	biochemical	biochemical	ADJ
chd-214	139	19	recurrence	recurrence	NOUN
chd-214	139	20	in	in	ADP
chd-214	139	21	pca	pca	NOUN
chd-214	139	22	patients	patient	NOUN
chd-214	139	23	[	[	X
chd-214	139	24	79	79	NUM
chd-214	139	25	]	]	PUNCT
chd-214	139	26	.	.	PUNCT
chd-214	140	1	cafs	cafs	PROPN
chd-214	140	2	were	be	AUX
chd-214	140	3	also	also	ADV
chd-214	140	4	shown	show	VERB
chd-214	140	5	to	to	PART
chd-214	140	6	induce	induce	VERB
chd-214	140	7	chemoresistance	chemoresistance	NOUN
chd-214	140	8	through	through	ADP
chd-214	140	9	induction	induction	NOUN
chd-214	140	10	of	of	ADP
chd-214	140	11	emt	emt	PROPN
chd-214	140	12	[	[	X
chd-214	140	13	80	80	NUM
chd-214	140	14	]	]	PUNCT
chd-214	140	15	.	.	PUNCT
chd-214	141	1	interaction	interaction	NOUN
chd-214	141	2	of	of	ADP
chd-214	141	3	tams	tam	NOUN
chd-214	141	4	and	and	CCONJ
chd-214	141	5	cancer	cancer	NOUN
chd-214	141	6	stem	stem	NOUN
chd-214	141	7	cells	cell	NOUN
chd-214	141	8	(	(	PUNCT
chd-214	141	9	cscs	cscs	PROPN
chd-214	141	10	)	)	PUNCT
chd-214	141	11	can	can	AUX
chd-214	141	12	result	result	VERB
chd-214	141	13	in	in	ADP
chd-214	141	14	resistance	resistance	NOUN
chd-214	141	15	to	to	ADP
chd-214	141	16	adt	adt	NOUN
chd-214	141	17	therapy	therapy	NOUN
chd-214	141	18	.	.	PUNCT
chd-214	142	1	cscs	cscs	PROPN
chd-214	142	2	help	help	VERB
chd-214	142	3	in	in	ADP
chd-214	142	4	tam	tam	NOUN
chd-214	142	5	remodeling	remodel	VERB
chd-214	142	6	and	and	CCONJ
chd-214	142	7	tams	tam	NOUN
chd-214	142	8	promote	promote	VERB
chd-214	142	9	the	the	DET
chd-214	142	10	stemlike	stemlike	ADJ
chd-214	142	11	properties	property	NOUN
chd-214	142	12	of	of	ADP
chd-214	142	13	cscs	cscs	PROPN
chd-214	142	14	and	and	CCONJ
chd-214	142	15	drug	drug	NOUN
chd-214	142	16	resistance	resistance	NOUN
chd-214	142	17	by	by	ADP
chd-214	142	18	acting	act	VERB
chd-214	142	19	through	through	ADP
chd-214	142	20	the	the	DET
chd-214	142	21	il-6	il-6	NOUN
chd-214	142	22	/	/	SYM
chd-214	142	23	stat3	stat3	NOUN
chd-214	142	24	signaling	signal	VERB
chd-214	142	25	pathway	pathway	NOUN
chd-214	142	26	[	[	X
chd-214	142	27	81	81	NUM
chd-214	142	28	]	]	PUNCT
chd-214	142	29	.	.	PUNCT
chd-214	143	1	4.0	4.0	NUM
chd-214	143	2	.	.	PUNCT
chd-214	143	3	conclusion	conclusion	NOUN
chd-214	143	4	and	and	CCONJ
chd-214	143	5	future	future	ADJ
chd-214	143	6	perspective	perspective	NOUN
chd-214	143	7	the	the	DET
chd-214	143	8	tme	tme	PROPN
chd-214	143	9	is	be	AUX
chd-214	143	10	a	a	DET
chd-214	143	11	key	key	ADJ
chd-214	143	12	contributor	contributor	NOUN
chd-214	143	13	to	to	ADP
chd-214	143	14	pca	pca	NOUN
chd-214	143	15	progression	progression	NOUN
chd-214	143	16	and	and	CCONJ
chd-214	143	17	determinant	determinant	ADJ
chd-214	143	18	of	of	ADP
chd-214	143	19	clinical	clinical	ADJ
chd-214	143	20	outcomes	outcome	NOUN
chd-214	143	21	.	.	PUNCT
chd-214	144	1	the	the	DET
chd-214	144	2	stromal	stromal	ADJ
chd-214	144	3	cells	cell	NOUN
chd-214	144	4	and	and	CCONJ
chd-214	144	5	the	the	DET
chd-214	144	6	extracellular	extracellular	ADJ
chd-214	144	7	milieu	milieu	NOUN
chd-214	144	8	of	of	ADP
chd-214	144	9	the	the	DET
chd-214	144	10	tme	tme	PROPN
chd-214	144	11	regulate	regulate	VERB
chd-214	144	12	the	the	DET
chd-214	144	13	plasticity	plasticity	NOUN
chd-214	144	14	of	of	ADP
chd-214	144	15	the	the	DET
chd-214	144	16	phenotypic	phenotypic	ADJ
chd-214	144	17	traits	trait	NOUN
chd-214	144	18	of	of	ADP
chd-214	144	19	pca	pca	NOUN
chd-214	144	20	cells	cell	NOUN
chd-214	144	21	.	.	PUNCT
chd-214	145	1	the	the	DET
chd-214	145	2	interaction	interaction	NOUN
chd-214	145	3	between	between	ADP
chd-214	145	4	pca	pca	NOUN
chd-214	145	5	cells	cell	NOUN
chd-214	145	6	and	and	CCONJ
chd-214	145	7	surrounding	surround	VERB
chd-214	145	8	tme	tme	NOUN
chd-214	145	9	components	component	NOUN
chd-214	145	10	(	(	PUNCT
chd-214	145	11	immune	immune	ADJ
chd-214	145	12	,	,	PUNCT
chd-214	145	13	vascular	vascular	ADJ
chd-214	145	14	,	,	PUNCT
chd-214	145	15	and	and	CCONJ
chd-214	145	16	stromal	stromal	ADJ
chd-214	145	17	)	)	PUNCT
chd-214	145	18	are	be	AUX
chd-214	145	19	therefore	therefore	ADV
chd-214	145	20	being	be	AUX
chd-214	145	21	studied	study	VERB
chd-214	145	22	extensively	extensively	ADV
chd-214	145	23	to	to	PART
chd-214	145	24	understand	understand	VERB
chd-214	145	25	its	its	PRON
chd-214	145	26	broader	broad	ADJ
chd-214	145	27	role	role	NOUN
chd-214	145	28	in	in	ADP
chd-214	145	29	pathobiology	pathobiology	NOUN
chd-214	145	30	and	and	CCONJ
chd-214	145	31	disease	disease	NOUN
chd-214	145	32	outcomes	outcome	NOUN
chd-214	145	33	[	[	X
chd-214	145	34	2	2	NUM
chd-214	145	35	,	,	PUNCT
chd-214	145	36	17	17	NUM
chd-214	145	37	,	,	PUNCT
chd-214	145	38	19	19	NUM
chd-214	145	39	,	,	PUNCT
chd-214	145	40	20	20	NUM
chd-214	145	41	,	,	PUNCT
chd-214	145	42	24	24	NUM
chd-214	145	43	]	]	PUNCT
chd-214	145	44	using	use	VERB
chd-214	145	45	traditional	traditional	ADJ
chd-214	145	46	in	in	ADP
chd-214	145	47	vitro	vitro	X
chd-214	145	48	and	and	CCONJ
chd-214	145	49	in	in	ADP
chd-214	145	50	vivo	vivo	ADJ
chd-214	145	51	experiments	experiment	NOUN
chd-214	145	52	and	and	CCONJ
chd-214	145	53	recently	recently	ADV
chd-214	145	54	by	by	ADP
chd-214	145	55	fluorescence	fluorescence	ADJ
chd-214	145	56	-	-	PUNCT
chd-214	145	57	activated	activate	VERB
chd-214	145	58	cell	cell	NOUN
chd-214	145	59	sorting	sorting	NOUN
chd-214	145	60	or	or	CCONJ
chd-214	145	61	laser	laser	NOUN
chd-214	145	62	microdissection	microdissection	NOUN
chd-214	145	63	with	with	ADP
chd-214	145	64	rna	rna	NOUN
chd-214	145	65	sequencing	sequencing	NOUN
chd-214	145	66	and	and	CCONJ
chd-214	145	67	spatial	spatial	ADJ
chd-214	145	68	transcriptomics	transcriptomic	NOUN
chd-214	145	69	[	[	X
chd-214	145	70	82	82	NUM
chd-214	145	71	,	,	PUNCT
chd-214	145	72	83	83	NUM
chd-214	145	73	,	,	PUNCT
chd-214	145	74	84	84	NUM
chd-214	145	75	]	]	PUNCT
chd-214	145	76	.	.	PUNCT
chd-214	146	1	the	the	DET
chd-214	146	2	recent	recent	ADJ
chd-214	146	3	technique	technique	NOUN
chd-214	146	4	of	of	ADP
chd-214	146	5	multiplex	multiplex	PROPN
chd-214	146	6	immunofluorescence	immunofluorescence	NOUN
chd-214	146	7	(	(	PUNCT
chd-214	146	8	mif	mif	PROPN
chd-214	146	9	)	)	PUNCT
chd-214	146	10	with	with	ADP
chd-214	146	11	tyramide	tyramide	NOUN
chd-214	146	12	signal	signal	NOUN
chd-214	146	13	amplification	amplification	NOUN
chd-214	146	14	helps	help	VERB
chd-214	146	15	to	to	PART
chd-214	146	16	gather	gather	VERB
chd-214	146	17	maximum	maximum	ADJ
chd-214	146	18	information	information	NOUN
chd-214	146	19	from	from	ADP
chd-214	146	20	a	a	DET
chd-214	146	21	single	single	ADJ
chd-214	146	22	tissue	tissue	NOUN
chd-214	146	23	section	section	NOUN
chd-214	146	24	with	with	ADP
chd-214	146	25	accurate	accurate	ADJ
chd-214	146	26	classification	classification	NOUN
chd-214	146	27	of	of	ADP
chd-214	146	28	the	the	DET
chd-214	146	29	tme	tme	PROPN
chd-214	146	30	cell	cell	NOUN
chd-214	146	31	population	population	NOUN
chd-214	146	32	[	[	X
chd-214	146	33	85	85	NUM
chd-214	146	34	]	]	PUNCT
chd-214	146	35	.	.	PUNCT
chd-214	147	1	use	use	NOUN
chd-214	147	2	of	of	ADP
chd-214	147	3	single	single	ADJ
chd-214	147	4	-	-	PUNCT
chd-214	147	5	cell	cell	NOUN
chd-214	147	6	rna	rna	NOUN
chd-214	147	7	transcriptome	transcriptome	NOUN
chd-214	147	8	sequencing	sequence	VERB
chd-214	147	9	(	(	PUNCT
chd-214	147	10	scrna	scrna	NOUN
chd-214	147	11	-	-	PUNCT
chd-214	147	12	seq	seq	NOUN
chd-214	147	13	)	)	PUNCT
chd-214	147	14	can	can	AUX
chd-214	147	15	indicate	indicate	VERB
chd-214	147	16	the	the	DET
chd-214	147	17	cell	cell	NOUN
chd-214	147	18	heterogeneity	heterogeneity	NOUN
chd-214	147	19	and	and	CCONJ
chd-214	147	20	help	help	VERB
chd-214	147	21	to	to	PART
chd-214	147	22	analyze	analyze	VERB
chd-214	147	23	cellular	cellular	ADJ
chd-214	147	24	interactions	interaction	NOUN
chd-214	147	25	[	[	X
chd-214	147	26	82	82	NUM
chd-214	147	27	]	]	PUNCT
chd-214	147	28	.	.	PUNCT
chd-214	148	1	the	the	DET
chd-214	148	2	use	use	NOUN
chd-214	148	3	of	of	ADP
chd-214	148	4	these	these	DET
chd-214	148	5	techniques	technique	NOUN
chd-214	148	6	will	will	AUX
chd-214	148	7	further	far	ADV
chd-214	148	8	help	help	VERB
chd-214	148	9	to	to	PART
chd-214	148	10	identify	identify	VERB
chd-214	148	11	the	the	DET
chd-214	148	12	role	role	NOUN
chd-214	148	13	of	of	ADP
chd-214	148	14	the	the	DET
chd-214	148	15	modulated	modulate	VERB
chd-214	148	16	genes	gene	NOUN
chd-214	148	17	in	in	ADP
chd-214	148	18	individual	individual	ADJ
chd-214	148	19	tme	tme	PROPN
chd-214	148	20	components	component	NOUN
chd-214	148	21	of	of	ADP
chd-214	148	22	aa	aa	PROPN
chd-214	148	23	and	and	CCONJ
chd-214	148	24	ca	ca	PROPN
chd-214	148	25	pca	pca	PROPN
chd-214	148	26	.	.	PUNCT
chd-214	149	1	data	datum	NOUN
chd-214	149	2	related	relate	VERB
chd-214	149	3	to	to	ADP
chd-214	149	4	the	the	DET
chd-214	149	5	role	role	NOUN
chd-214	149	6	of	of	ADP
chd-214	149	7	tme	tme	NOUN
chd-214	149	8	in	in	ADP
chd-214	149	9	race	race	NOUN
chd-214	149	10	-	-	PUNCT
chd-214	149	11	associated	associate	VERB
chd-214	149	12	cancer	cancer	NOUN
chd-214	149	13	health	health	NOUN
chd-214	149	14	disparity	disparity	NOUN
chd-214	149	15	has	have	AUX
chd-214	149	16	only	only	ADV
chd-214	149	17	recently	recently	ADV
chd-214	149	18	begun	begin	VERB
chd-214	149	19	to	to	PART
chd-214	149	20	emerge	emerge	VERB
chd-214	149	21	in	in	ADP
chd-214	149	22	prostate	prostate	NOUN
chd-214	149	23	and	and	CCONJ
chd-214	149	24	other	other	ADJ
chd-214	149	25	cancers	cancer	NOUN
chd-214	149	26	.	.	PUNCT
chd-214	150	1	further	further	ADJ
chd-214	150	2	studies	study	NOUN
chd-214	150	3	involving	involve	VERB
chd-214	150	4	larger	large	ADJ
chd-214	150	5	datasets	dataset	NOUN
chd-214	150	6	from	from	ADP
chd-214	150	7	diverse	diverse	ADJ
chd-214	150	8	patient	patient	NOUN
chd-214	150	9	populations	population	NOUN
chd-214	150	10	would	would	AUX
chd-214	150	11	provide	provide	VERB
chd-214	150	12	more	more	ADJ
chd-214	150	13	strengths	strength	NOUN
chd-214	150	14	to	to	PART
chd-214	150	15	tme	tme	VERB
chd-214	150	16	differences	difference	NOUN
chd-214	150	17	and	and	CCONJ
chd-214	150	18	their	their	PRON
chd-214	150	19	association	association	NOUN
chd-214	150	20	with	with	ADP
chd-214	150	21	clinical	clinical	ADJ
chd-214	150	22	outcomes	outcome	NOUN
chd-214	150	23	and	and	CCONJ
chd-214	150	24	clinicopathologic	clinicopathologic	ADJ
chd-214	150	25	progression	progression	NOUN
chd-214	150	26	of	of	ADP
chd-214	150	27	cancer	cancer	NOUN
chd-214	150	28	.	.	PUNCT
chd-214	151	1	similarly	similarly	ADV
chd-214	151	2	,	,	PUNCT
chd-214	151	3	more	more	ADJ
chd-214	151	4	efforts	effort	NOUN
chd-214	151	5	should	should	AUX
chd-214	151	6	also	also	ADV
chd-214	151	7	be	be	AUX
chd-214	151	8	made	make	VERB
chd-214	151	9	to	to	PART
chd-214	151	10	determine	determine	VERB
chd-214	151	11	the	the	DET
chd-214	151	12	exact	exact	ADJ
chd-214	151	13	contribution	contribution	NOUN
chd-214	151	14	of	of	ADP
chd-214	151	15	tme	tme	NOUN
chd-214	151	16	to	to	PART
chd-214	151	17	differential	differential	VERB
chd-214	151	18	pca	pca	NOUN
chd-214	151	19	progression	progression	NOUN
chd-214	151	20	using	use	VERB
chd-214	151	21	appropriate	appropriate	ADJ
chd-214	151	22	experimental	experimental	ADJ
chd-214	151	23	models	model	NOUN
chd-214	151	24	and	and	CCONJ
chd-214	151	25	delineate	delineate	VERB
chd-214	151	26	the	the	DET
chd-214	151	27	underlying	underlying	ADJ
chd-214	151	28	molecular	molecular	ADJ
chd-214	151	29	mechanisms	mechanism	NOUN
chd-214	151	30	.	.	PUNCT
chd-214	152	1	unlike	unlike	ADP
chd-214	152	2	the	the	DET
chd-214	152	3	cancer	cancer	NOUN
chd-214	152	4	cells	cell	NOUN
chd-214	152	5	,	,	PUNCT
chd-214	152	6	cells	cell	NOUN
chd-214	152	7	of	of	ADP
chd-214	152	8	the	the	DET
chd-214	152	9	tme	tme	NOUN
chd-214	152	10	are	be	AUX
chd-214	152	11	genetically	genetically	ADV
chd-214	152	12	stable	stable	ADJ
chd-214	152	13	,	,	PUNCT
chd-214	152	14	which	which	PRON
chd-214	152	15	make	make	VERB
chd-214	152	16	them	they	PRON
chd-214	152	17	attractive	attractive	ADJ
chd-214	152	18	targets	target	NOUN
chd-214	152	19	for	for	ADP
chd-214	152	20	cancer	cancer	NOUN
chd-214	152	21	management	management	NOUN
chd-214	152	22	(	(	PUNCT
chd-214	152	23	prevention	prevention	NOUN
chd-214	152	24	and	and	CCONJ
chd-214	152	25	treatment	treatment	NOUN
chd-214	152	26	)	)	PUNCT
chd-214	152	27	and	and	CCONJ
chd-214	152	28	to	to	PART
chd-214	152	29	reduce	reduce	VERB
chd-214	152	30	the	the	DET
chd-214	152	31	risk	risk	NOUN
chd-214	152	32	of	of	ADP
chd-214	152	33	acquiring	acquire	VERB
chd-214	152	34	therapy	therapy	NOUN
chd-214	152	35	resistance	resistance	NOUN
chd-214	152	36	leading	lead	VERB
chd-214	152	37	to	to	ADP
chd-214	152	38	treatment	treatment	NOUN
chd-214	152	39	failure	failure	NOUN
chd-214	152	40	and	and	CCONJ
chd-214	152	41	recurrence	recurrence	NOUN
chd-214	152	42	.	.	PUNCT
chd-214	153	1	a	a	DET
chd-214	153	2	better	well	ADJ
chd-214	153	3	understanding	understanding	NOUN
chd-214	153	4	of	of	ADP
chd-214	153	5	the	the	DET
chd-214	153	6	role	role	NOUN
chd-214	153	7	of	of	ADP
chd-214	153	8	the	the	DET
chd-214	153	9	tme	tme	NOUN
chd-214	153	10	will	will	AUX
chd-214	153	11	also	also	ADV
chd-214	153	12	help	help	VERB
chd-214	153	13	in	in	ADP
chd-214	153	14	the	the	DET
chd-214	153	15	development	development	NOUN
chd-214	153	16	of	of	ADP
chd-214	153	17	race	race	NOUN
chd-214	153	18	-	-	PUNCT
chd-214	153	19	specific	specific	ADJ
chd-214	153	20	biomarkers	biomarker	NOUN
chd-214	153	21	and	and	CCONJ
chd-214	153	22	therapeutic	therapeutic	ADJ
chd-214	153	23	targets	target	NOUN
chd-214	153	24	leading	lead	VERB
chd-214	153	25	to	to	ADP
chd-214	153	26	personalized	personalized	ADJ
chd-214	153	27	approaches	approach	NOUN
chd-214	153	28	for	for	ADP
chd-214	153	29	risk	risk	NOUN
chd-214	153	30	prediction	prediction	NOUN
chd-214	153	31	,	,	PUNCT
chd-214	153	32	diagnosis	diagnosis	NOUN
chd-214	153	33	,	,	PUNCT
chd-214	153	34	monitoring	monitoring	NOUN
chd-214	153	35	,	,	PUNCT
chd-214	153	36	and	and	CCONJ
chd-214	153	37	management	management	NOUN
chd-214	153	38	of	of	ADP
chd-214	153	39	pca	pca	PROPN
chd-214	153	40	.	.	PUNCT
chd-214	154	1	acknowledgments	acknowledgment	NOUN
chd-214	154	2	authors	author	NOUN
chd-214	154	3	are	be	AUX
chd-214	154	4	supported	support	VERB
chd-214	154	5	by	by	ADP
chd-214	154	6	funding	funding	NOUN
chd-214	154	7	from	from	ADP
chd-214	154	8	nih	nih	PROPN
chd-214	154	9	/	/	SYM
chd-214	154	10	nci	nci	PROPN
chd-214	154	11	(	(	PUNCT
chd-214	154	12	r01ca231925	r01ca231925	NOUN
chd-214	154	13	to	to	PART
chd-214	154	14	ss	ss	VERB
chd-214	154	15	)	)	PUNCT
chd-214	154	16	and	and	CCONJ
chd-214	154	17	usa	usa	PROPN
chd-214	154	18	health	health	PROPN
chd-214	154	19	mitchell	mitchell	PROPN
chd-214	154	20	cancer	cancer	PROPN
chd-214	154	21	institute	institute	PROPN
chd-214	154	22	,	,	PUNCT
chd-214	154	23	university	university	PROPN
chd-214	154	24	of	of	ADP
chd-214	154	25	south	south	PROPN
chd-214	154	26	alabama	alabama	PROPN
chd-214	154	27	.	.	PUNCT
chd-214	155	1	conflicts	conflict	NOUN
chd-214	155	2	of	of	ADP
chd-214	155	3	interest	interest	NOUN
chd-214	155	4	the	the	DET
chd-214	155	5	authors	author	NOUN
chd-214	155	6	declare	declare	VERB
chd-214	155	7	that	that	SCONJ
chd-214	155	8	they	they	PRON
chd-214	155	9	have	have	VERB
chd-214	155	10	no	no	DET
chd-214	155	11	conflicts	conflict	NOUN
chd-214	155	12	of	of	ADP
chd-214	155	13	interest	interest	NOUN
chd-214	155	14	with	with	ADP
chd-214	155	15	the	the	DET
chd-214	155	16	contents	content	NOUN
chd-214	155	17	of	of	ADP
chd-214	155	18	this	this	DET
chd-214	155	19	article	article	NOUN
chd-214	155	20	.	.	PUNCT
chd-214	156	1	authors	author	NOUN
chd-214	156	2	’	’	PART
chd-214	156	3	contributions	contribution	NOUN
chd-214	156	4	conception	conception	NOUN
chd-214	156	5	and	and	CCONJ
chd-214	156	6	design	design	NOUN
chd-214	156	7	:	:	PUNCT
chd-214	156	8	dc	dc	PROPN
chd-214	156	9	.	.	PUNCT
chd-214	157	1	initial	initial	ADJ
chd-214	157	2	manuscript	manuscript	NOUN
chd-214	157	3	writing	writing	NOUN
chd-214	157	4	:	:	PUNCT
chd-214	157	5	sg	sg	PROPN
chd-214	157	6	,	,	PUNCT
chd-214	157	7	cs	cs	X
chd-214	157	8	,	,	PUNCT
chd-214	157	9	and	and	CCONJ
chd-214	157	10	dc	dc	PROPN
chd-214	157	11	.	.	PROPN
chd-214	158	1	review	review	NOUN
chd-214	158	2	and	and	CCONJ
chd-214	158	3	revision	revision	NOUN
chd-214	158	4	of	of	ADP
chd-214	158	5	the	the	DET
chd-214	158	6	manuscript	manuscript	NOUN
chd-214	158	7	:	:	PUNCT
chd-214	158	8	sg	sg	PROPN
chd-214	158	9	,	,	PUNCT
chd-214	158	10	cs	cs	PROPN
chd-214	158	11	,	,	PUNCT
chd-214	158	12	ss	ss	PROPN
chd-214	158	13	,	,	PUNCT
chd-214	158	14	aps	aps	PROPN
chd-214	158	15	and	and	CCONJ
chd-214	158	16	dc	dc	PROPN
chd-214	158	17	.	.	PROPN
chd-214	159	1	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	PROPN
chd-214	159	2	e10	e10	NUM
chd-214	159	3	cancer	cancer	NOUN
chd-214	159	4	health	health	NOUN
chd-214	159	5	disparities	disparity	NOUN
chd-214	159	6	research	research	NOUN
chd-214	159	7	references	reference	NOUN
chd-214	159	8	1	1	NUM
chd-214	159	9	.	.	PUNCT
chd-214	160	1	siegel	siegel	PROPN
chd-214	160	2	,	,	PUNCT
chd-214	160	3	r.l	r.l	PROPN
chd-214	160	4	.	.	PROPN
chd-214	160	5	,	,	PUNCT
chd-214	160	6	miller	miller	PROPN
chd-214	160	7	,	,	PUNCT
chd-214	160	8	k.d	k.d	PROPN
chd-214	160	9	.	.	PROPN
chd-214	160	10	,	,	PUNCT
chd-214	160	11	fuchs	fuchs	PROPN
chd-214	160	12	,	,	PUNCT
chd-214	160	13	h.e	h.e	PROPN
chd-214	160	14	.	.	PROPN
chd-214	160	15	,	,	PUNCT
chd-214	160	16	and	and	CCONJ
chd-214	160	17	jemal	jemal	ADJ
chd-214	160	18	,	,	PUNCT
chd-214	160	19	a.	a.	NOUN
chd-214	160	20	(	(	PUNCT
chd-214	160	21	2021	2021	NUM
chd-214	160	22	)	)	PUNCT
chd-214	160	23	.	.	PUNCT
chd-214	161	1	cancer	cancer	NOUN
chd-214	161	2	statistics	statistic	NOUN
chd-214	161	3	,	,	PUNCT
chd-214	161	4	2021	2021	NUM
chd-214	161	5	.	.	PUNCT
chd-214	162	1	ca	can	AUX
chd-214	162	2	cancer	cancer	PROPN
chd-214	162	3	j	j	PROPN
chd-214	162	4	clin.71(1):7	clin.71(1):7	PROPN
chd-214	162	5	-	-	PUNCT
chd-214	162	6	33	33	NUM
chd-214	162	7	.	.	PUNCT
chd-214	163	1	doi	doi	NOUN
chd-214	163	2	:	:	PUNCT
chd-214	163	3	10.3322	10.3322	NUM
chd-214	163	4	/	/	SYM
chd-214	163	5	caac.21654	caac.21654	PROPN
chd-214	163	6	.	.	PROPN
chd-214	163	7	epub	epub	PROPN
chd-214	163	8	2021	2021	NUM
chd-214	163	9	jan	jan	PROPN
chd-214	163	10	12	12	NUM
chd-214	163	11	.	.	PUNCT
chd-214	164	1	erratum	erratum	PROPN
chd-214	164	2	in	in	ADP
chd-214	164	3	:	:	PUNCT
chd-214	164	4	ca	can	AUX
chd-214	164	5	cancer	cancer	PROPN
chd-214	164	6	j	j	PROPN
chd-214	164	7	clin	clin	PROPN
chd-214	164	8	.	.	PUNCT
chd-214	165	1	71(4):359	71(4):359	VERB
chd-214	165	2	.	.	PUNCT
chd-214	166	1	pmid	pmid	NOUN
chd-214	166	2	:	:	PUNCT
chd-214	166	3	33433946	33433946	NUM
chd-214	166	4	.	.	PUNCT
chd-214	167	1	2	2	X
chd-214	167	2	.	.	X
chd-214	167	3	kakarla	kakarla	NOUN
chd-214	167	4	,	,	PUNCT
chd-214	167	5	m.	m.	NOUN
chd-214	167	6	,	,	PUNCT
chd-214	167	7	challasivakanaka	challasivakanaka	PROPN
chd-214	167	8	,	,	PUNCT
chd-214	167	9	s.	s.	PROPN
chd-214	167	10	,	,	PUNCT
chd-214	167	11	hayward	hayward	PROPN
chd-214	167	12	,	,	PUNCT
chd-214	167	13	s.	s.	PROPN
chd-214	167	14	w.	w.	PROPN
chd-214	167	15	,	,	PUNCT
chd-214	167	16	and	and	CCONJ
chd-214	167	17	franco	franco	NOUN
chd-214	167	18	,	,	PUNCT
chd-214	167	19	o.	o.	PROPN
chd-214	167	20	e.	e.	PROPN
chd-214	167	21	(	(	PUNCT
chd-214	167	22	2021	2021	NUM
chd-214	167	23	)	)	PUNCT
chd-214	167	24	.	.	PUNCT
chd-214	168	1	race	race	NOUN
chd-214	168	2	as	as	ADP
chd-214	168	3	a	a	DET
chd-214	168	4	contributor	contributor	NOUN
chd-214	168	5	to	to	ADP
chd-214	168	6	stromal	stromal	ADJ
chd-214	168	7	modulation	modulation	NOUN
chd-214	168	8	of	of	ADP
chd-214	168	9	tumor	tumor	NOUN
chd-214	168	10	progression	progression	NOUN
chd-214	168	11	.	.	PUNCT
chd-214	169	1	cancers	cancer	NOUN
chd-214	169	2	,	,	PUNCT
chd-214	169	3	13(11	13(11	NUM
chd-214	169	4	)	)	PUNCT
chd-214	169	5	,	,	PUNCT
chd-214	169	6	2656	2656	NUM
chd-214	169	7	.	.	PUNCT
chd-214	170	1	https://doi.org/10.3390/cancers13112656	https://doi.org/10.3390/cancers13112656	NOUN
chd-214	170	2	3	3	NUM
chd-214	170	3	.	.	PUNCT
chd-214	171	1	badal	badal	PROPN
chd-214	171	2	,	,	PUNCT
chd-214	171	3	s.	s.	PROPN
chd-214	171	4	,	,	PUNCT
chd-214	171	5	aiken	aiken	PROPN
chd-214	171	6	,	,	PUNCT
chd-214	171	7	w.	w.	PROPN
chd-214	171	8	,	,	PUNCT
chd-214	171	9	morrison	morrison	PROPN
chd-214	171	10	,	,	PUNCT
chd-214	171	11	b.	b.	PROPN
chd-214	171	12	,	,	PUNCT
chd-214	171	13	valentine	valentine	PROPN
chd-214	171	14	,	,	PUNCT
chd-214	171	15	h.	h.	PROPN
chd-214	171	16	,	,	PUNCT
chd-214	171	17	bryan	bryan	PROPN
chd-214	171	18	,	,	PUNCT
chd-214	171	19	s.	s.	PROPN
chd-214	171	20	,	,	PUNCT
chd-214	171	21	gachii	gachii	PROPN
chd-214	171	22	,	,	PUNCT
chd-214	171	23	a.	a.	NOUN
chd-214	171	24	,	,	PUNCT
chd-214	171	25	and	and	CCONJ
chd-214	171	26	ragin	ragin	ADJ
chd-214	171	27	,	,	PUNCT
chd-214	171	28	c.	c.	NOUN
chd-214	171	29	(	(	PUNCT
chd-214	171	30	2020	2020	NUM
chd-214	171	31	)	)	PUNCT
chd-214	171	32	.	.	PUNCT
chd-214	172	1	disparities	disparity	NOUN
chd-214	172	2	in	in	ADP
chd-214	172	3	prostate	prostate	NOUN
chd-214	172	4	cancer	cancer	NOUN
chd-214	172	5	incidence	incidence	NOUN
chd-214	172	6	and	and	CCONJ
chd-214	172	7	mortality	mortality	NOUN
chd-214	172	8	rates	rate	NOUN
chd-214	172	9	:	:	PUNCT
chd-214	172	10	solvable	solvable	ADJ
chd-214	172	11	or	or	CCONJ
chd-214	172	12	not	not	PART
chd-214	172	13	?	?	PUNCT
chd-214	172	14	.	.	PUNCT
chd-214	173	1	the	the	DET
chd-214	173	2	prostate	prostate	NOUN
chd-214	173	3	,	,	PUNCT
chd-214	173	4	80(1	80(1	NUM
chd-214	173	5	)	)	PUNCT
chd-214	173	6	,	,	PUNCT
chd-214	173	7	3–16	3–16	PROPN
chd-214	173	8	.	.	PUNCT
chd-214	173	9	https://doi.org/10.1002/pros.23923	https://doi.org/10.1002/pros.23923	PROPN
chd-214	173	10	4	4	NUM
chd-214	173	11	.	.	X
chd-214	173	12	johnson	johnson	PROPN
chd-214	173	13	,	,	PUNCT
chd-214	173	14	j.	j.	PROPN
chd-214	173	15	r.	r.	PROPN
chd-214	173	16	,	,	PUNCT
chd-214	173	17	woods	woods	PROPN
chd-214	173	18	-	-	PUNCT
chd-214	173	19	burnham	burnham	PROPN
chd-214	173	20	,	,	PUNCT
chd-214	173	21	l.	l.	PROPN
chd-214	173	22	,	,	PUNCT
chd-214	173	23	hooker	hooker	PROPN
chd-214	173	24	,	,	PUNCT
chd-214	173	25	s.	s.	PROPN
chd-214	173	26	e.	e.	PROPN
chd-214	173	27	,	,	PUNCT
chd-214	173	28	jr	jr	PROPN
chd-214	173	29	,	,	PUNCT
chd-214	173	30	batai	batai	NOUN
chd-214	173	31	,	,	PUNCT
chd-214	173	32	k.	k.	PROPN
chd-214	173	33	,	,	PUNCT
chd-214	173	34	and	and	CCONJ
chd-214	173	35	kittles	kittles	PROPN
chd-214	173	36	,	,	PUNCT
chd-214	173	37	r.	r.	PROPN
chd-214	173	38	a.	a.	PROPN
chd-214	173	39	(	(	PUNCT
chd-214	173	40	2021	2021	NUM
chd-214	173	41	)	)	PUNCT
chd-214	173	42	.	.	PUNCT
chd-214	174	1	genetic	genetic	ADJ
chd-214	174	2	contributions	contribution	NOUN
chd-214	174	3	to	to	ADP
chd-214	174	4	prostate	prostate	NOUN
chd-214	174	5	cancer	cancer	NOUN
chd-214	174	6	disparities	disparity	NOUN
chd-214	174	7	in	in	ADP
chd-214	174	8	men	man	NOUN
chd-214	174	9	of	of	ADP
chd-214	174	10	west	west	ADJ
chd-214	174	11	african	african	ADJ
chd-214	174	12	descent	descent	NOUN
chd-214	174	13	.	.	PUNCT
chd-214	175	1	frontiers	frontier	NOUN
chd-214	175	2	in	in	ADP
chd-214	175	3	oncology	oncology	NOUN
chd-214	175	4	,	,	PUNCT
chd-214	175	5	11	11	NUM
chd-214	175	6	,	,	PUNCT
chd-214	175	7	770500	770500	NUM
chd-214	175	8	.	.	PUNCT
chd-214	176	1	https://doi.org/10.3389/fonc.2021.770500	https://doi.org/10.3389/fonc.2021.770500	PROPN
chd-214	176	2	5	5	NUM
chd-214	176	3	.	.	PUNCT
chd-214	177	1	taitt	taitt	PROPN
chd-214	177	2	h.	h.	PROPN
chd-214	177	3	e.	e.	PROPN
chd-214	177	4	(	(	PUNCT
chd-214	177	5	2018	2018	NUM
chd-214	177	6	)	)	PUNCT
chd-214	177	7	.	.	PUNCT
chd-214	178	1	global	global	ADJ
chd-214	178	2	trends	trend	NOUN
chd-214	178	3	and	and	CCONJ
chd-214	178	4	prostate	prostate	NOUN
chd-214	178	5	cancer	cancer	NOUN
chd-214	178	6	:	:	PUNCT
chd-214	178	7	a	a	DET
chd-214	178	8	review	review	NOUN
chd-214	178	9	of	of	ADP
chd-214	178	10	incidence	incidence	NOUN
chd-214	178	11	,	,	PUNCT
chd-214	178	12	detection	detection	NOUN
chd-214	178	13	,	,	PUNCT
chd-214	178	14	and	and	CCONJ
chd-214	178	15	mortality	mortality	NOUN
chd-214	178	16	as	as	SCONJ
chd-214	178	17	influenced	influence	VERB
chd-214	178	18	by	by	ADP
chd-214	178	19	race	race	NOUN
chd-214	178	20	,	,	PUNCT
chd-214	178	21	ethnicity	ethnicity	NOUN
chd-214	178	22	,	,	PUNCT
chd-214	178	23	and	and	CCONJ
chd-214	178	24	geographic	geographic	ADJ
chd-214	178	25	location	location	NOUN
chd-214	178	26	.	.	PUNCT
chd-214	179	1	american	american	PROPN
chd-214	179	2	journal	journal	PROPN
chd-214	179	3	of	of	ADP
chd-214	179	4	men	man	NOUN
chd-214	179	5	’s	’s	PART
chd-214	179	6	health	health	NOUN
chd-214	179	7	,	,	PUNCT
chd-214	179	8	12(6	12(6	NUM
chd-214	179	9	)	)	PUNCT
chd-214	179	10	,	,	PUNCT
chd-214	179	11	1807	1807	NUM
chd-214	179	12	–	–	PUNCT
chd-214	179	13	1823	1823	NUM
chd-214	179	14	.	.	PUNCT
chd-214	180	1	https://doi.org/10.1177/1557988318798279	https://doi.org/10.1177/1557988318798279	NOUN
chd-214	180	2	6	6	NUM
chd-214	180	3	.	.	PUNCT
chd-214	181	1	marima	marima	PROPN
chd-214	181	2	,	,	PUNCT
chd-214	181	3	r.	r.	PROPN
chd-214	181	4	,	,	PUNCT
chd-214	181	5	hull	hull	NOUN
chd-214	181	6	,	,	PUNCT
chd-214	181	7	r.	r.	PROPN
chd-214	181	8	,	,	PUNCT
chd-214	181	9	mathabe	mathabe	PROPN
chd-214	181	10	,	,	PUNCT
chd-214	181	11	k.	k.	PROPN
chd-214	181	12	,	,	PUNCT
chd-214	181	13	setlai	setlai	PROPN
chd-214	181	14	,	,	PUNCT
chd-214	181	15	b.	b.	PROPN
chd-214	181	16	,	,	PUNCT
chd-214	181	17	batra	batra	PROPN
chd-214	181	18	,	,	PUNCT
chd-214	181	19	j.	j.	PROPN
chd-214	181	20	,	,	PUNCT
chd-214	181	21	sartor	sartor	PROPN
chd-214	181	22	,	,	PUNCT
chd-214	181	23	o.	o.	PROPN
chd-214	181	24	,	,	PUNCT
chd-214	181	25	mehrotra	mehrotra	PROPN
chd-214	181	26	,	,	PUNCT
chd-214	181	27	r.	r.	PROPN
chd-214	181	28	,	,	PUNCT
chd-214	181	29	and	and	CCONJ
chd-214	181	30	dlamini	dlamini	PROPN
chd-214	181	31	,	,	PUNCT
chd-214	181	32	z.	z.	PROPN
chd-214	181	33	(	(	PUNCT
chd-214	181	34	2021	2021	NUM
chd-214	181	35	)	)	PUNCT
chd-214	181	36	.	.	PUNCT
chd-214	182	1	prostate	prostate	NOUN
chd-214	182	2	cancer	cancer	NOUN
chd-214	182	3	racial	racial	ADJ
chd-214	182	4	,	,	PUNCT
chd-214	182	5	socioeconomic	socioeconomic	ADJ
chd-214	182	6	,	,	PUNCT
chd-214	182	7	geographic	geographic	ADJ
chd-214	182	8	disparities	disparity	NOUN
chd-214	182	9	:	:	PUNCT
chd-214	182	10	targeting	target	VERB
chd-214	182	11	the	the	DET
chd-214	182	12	genomic	genomic	ADJ
chd-214	182	13	landscape	landscape	NOUN
chd-214	182	14	and	and	CCONJ
chd-214	182	15	splicing	splicing	NOUN
chd-214	182	16	events	event	NOUN
chd-214	182	17	in	in	ADP
chd-214	182	18	search	search	NOUN
chd-214	182	19	for	for	ADP
chd-214	182	20	diagnostic	diagnostic	ADJ
chd-214	182	21	,	,	PUNCT
chd-214	182	22	prognostic	prognostic	ADJ
chd-214	182	23	and	and	CCONJ
chd-214	182	24	therapeutic	therapeutic	ADJ
chd-214	182	25	targets	target	NOUN
chd-214	182	26	.	.	PUNCT
chd-214	183	1	american	american	ADJ
chd-214	183	2	journal	journal	PROPN
chd-214	183	3	of	of	ADP
chd-214	183	4	cancer	cancer	NOUN
chd-214	183	5	research	research	NOUN
chd-214	183	6	,	,	PUNCT
chd-214	183	7	11(4	11(4	NUM
chd-214	183	8	)	)	PUNCT
chd-214	183	9	,	,	PUNCT
chd-214	183	10	1012–1030	1012–1030	NUM
chd-214	183	11	.	.	PUNCT
chd-214	184	1	7	7	X
chd-214	184	2	.	.	X
chd-214	184	3	siegel	siegel	PROPN
chd-214	184	4	,	,	PUNCT
chd-214	184	5	d.	d.	PROPN
chd-214	184	6	a.	a.	PROPN
chd-214	184	7	,	,	PUNCT
chd-214	184	8	o’neil	o’neil	PROPN
chd-214	184	9	,	,	PUNCT
chd-214	184	10	m.	m.	PROPN
chd-214	184	11	e.	e.	PROPN
chd-214	184	12	,	,	PUNCT
chd-214	184	13	richards	richards	PROPN
chd-214	184	14	,	,	PUNCT
chd-214	184	15	t.	t.	PROPN
chd-214	184	16	b.	b.	PROPN
chd-214	184	17	,	,	PUNCT
chd-214	184	18	dowling	dowling	PROPN
chd-214	184	19	,	,	PUNCT
chd-214	184	20	n.	n.	PROPN
chd-214	184	21	f.	f.	PROPN
chd-214	184	22	,	,	PUNCT
chd-214	184	23	and	and	CCONJ
chd-214	184	24	weir	weir	PROPN
chd-214	184	25	,	,	PUNCT
chd-214	184	26	h.	h.	PROPN
chd-214	184	27	k.	k.	PROPN
chd-214	184	28	(	(	PUNCT
chd-214	184	29	2020	2020	NUM
chd-214	184	30	)	)	PUNCT
chd-214	184	31	.	.	PUNCT
chd-214	185	1	prostate	prostate	NOUN
chd-214	185	2	cancer	cancer	NOUN
chd-214	185	3	incidence	incidence	NOUN
chd-214	185	4	and	and	CCONJ
chd-214	185	5	survival	survival	NOUN
chd-214	185	6	,	,	PUNCT
chd-214	185	7	by	by	ADP
chd-214	185	8	stage	stage	NOUN
chd-214	185	9	and	and	CCONJ
chd-214	185	10	race	race	NOUN
chd-214	185	11	/	/	SYM
chd-214	185	12	ethnicity	ethnicity	NOUN
chd-214	185	13	united	united	PROPN
chd-214	185	14	states	states	PROPN
chd-214	185	15	,	,	PUNCT
chd-214	185	16	20012017	20012017	NUM
chd-214	185	17	.	.	PUNCT
chd-214	186	1	mmwr	mmwr	NOUN
chd-214	186	2	.	.	PUNCT
chd-214	187	1	morbidity	morbidity	NOUN
chd-214	187	2	and	and	CCONJ
chd-214	187	3	mortality	mortality	NOUN
chd-214	187	4	weekly	weekly	ADJ
chd-214	187	5	report	report	NOUN
chd-214	187	6	,	,	PUNCT
chd-214	187	7	69(41	69(41	NOUN
chd-214	187	8	)	)	PUNCT
chd-214	187	9	,	,	PUNCT
chd-214	187	10	1473–1480	1473–1480	NUM
chd-214	187	11	.	.	PUNCT
chd-214	188	1	https://doi.org/10.15585/mmwr.mm6941a1	https://doi.org/10.15585/mmwr.mm6941a1	ADJ
chd-214	188	2	8	8	NUM
chd-214	188	3	.	.	PUNCT
chd-214	189	1	bhardwaj	bhardwaj	PROPN
chd-214	189	2	,	,	PUNCT
chd-214	189	3	a.	a.	PROPN
chd-214	189	4	,	,	PUNCT
chd-214	189	5	srivastava	srivastava	PROPN
chd-214	189	6	,	,	PUNCT
chd-214	189	7	s.	s.	PROPN
chd-214	189	8	k.	k.	PROPN
chd-214	189	9	,	,	PUNCT
chd-214	189	10	khan	khan	PROPN
chd-214	189	11	,	,	PUNCT
chd-214	189	12	m.	m.	NOUN
chd-214	189	13	a.	a.	PROPN
chd-214	189	14	,	,	PUNCT
chd-214	189	15	prajapati	prajapati	PROPN
chd-214	189	16	,	,	PUNCT
chd-214	189	17	v.	v.	PROPN
chd-214	189	18	k.	k.	PROPN
chd-214	189	19	,	,	PUNCT
chd-214	189	20	singh	singh	PROPN
chd-214	189	21	,	,	PUNCT
chd-214	189	22	s.	s.	PROPN
chd-214	189	23	,	,	PUNCT
chd-214	189	24	carter	carter	PROPN
chd-214	189	25	,	,	PUNCT
chd-214	189	26	j.	j.	PROPN
chd-214	189	27	e.	e.	PROPN
chd-214	189	28	,	,	PUNCT
chd-214	189	29	and	and	CCONJ
chd-214	189	30	singh	singh	NOUN
chd-214	189	31	,	,	PUNCT
chd-214	189	32	a.	a.	NOUN
chd-214	189	33	p.	p.	NOUN
chd-214	189	34	(	(	PUNCT
chd-214	189	35	2017	2017	NUM
chd-214	189	36	)	)	PUNCT
chd-214	189	37	.	.	PUNCT
chd-214	190	1	racial	racial	ADJ
chd-214	190	2	disparities	disparity	NOUN
chd-214	190	3	in	in	ADP
chd-214	190	4	prostate	prostate	NOUN
chd-214	190	5	cancer	cancer	NOUN
chd-214	190	6	:	:	PUNCT
chd-214	190	7	a	a	DET
chd-214	190	8	molecular	molecular	ADJ
chd-214	190	9	perspective	perspective	NOUN
chd-214	190	10	.	.	PUNCT
chd-214	191	1	frontiers	frontier	NOUN
chd-214	191	2	in	in	ADP
chd-214	191	3	bioscience	bioscience	PROPN
chd-214	191	4	(	(	PUNCT
chd-214	191	5	landmark	landmark	PROPN
chd-214	191	6	edition	edition	PROPN
chd-214	191	7	)	)	PUNCT
chd-214	191	8	,	,	PUNCT
chd-214	191	9	22	22	NUM
chd-214	191	10	,	,	PUNCT
chd-214	191	11	772–782	772–782	NUM
chd-214	191	12	.	.	PUNCT
chd-214	192	1	https://doi.org/10.2741/4515	https://doi.org/10.2741/4515	NOUN
chd-214	192	2	9	9	NUM
chd-214	192	3	.	.	X
chd-214	192	4	tsodikov	tsodikov	PROPN
chd-214	192	5	,	,	PUNCT
chd-214	192	6	a.	a.	PROPN
chd-214	192	7	,	,	PUNCT
chd-214	192	8	gulati	gulati	PROPN
chd-214	192	9	,	,	PUNCT
chd-214	192	10	r.	r.	PROPN
chd-214	192	11	,	,	PUNCT
chd-214	192	12	de	de	X
chd-214	192	13	carvalho	carvalho	NOUN
chd-214	192	14	,	,	PUNCT
chd-214	192	15	t.	t.	NOUN
chd-214	192	16	m.	m.	NOUN
chd-214	192	17	,	,	PUNCT
chd-214	192	18	heijnsdijk	heijnsdijk	PROPN
chd-214	192	19	,	,	PUNCT
chd-214	192	20	e.	e.	PROPN
chd-214	192	21	,	,	PUNCT
chd-214	192	22	hunter	hunter	NOUN
chd-214	192	23	-	-	PUNCT
chd-214	192	24	merrill	merrill	NOUN
chd-214	192	25	,	,	PUNCT
chd-214	192	26	r.	r.	PROPN
chd-214	192	27	a.	a.	PROPN
chd-214	192	28	,	,	PUNCT
chd-214	192	29	mariotto	mariotto	NOUN
chd-214	192	30	,	,	PUNCT
chd-214	192	31	a.	a.	PROPN
chd-214	192	32	b.	b.	PROPN
chd-214	192	33	,	,	PUNCT
chd-214	192	34	de	de	PROPN
chd-214	192	35	koning	koning	PROPN
chd-214	192	36	,	,	PUNCT
chd-214	192	37	h.	h.	PROPN
chd-214	192	38	j.	j.	PROPN
chd-214	192	39	,	,	PUNCT
chd-214	192	40	and	and	CCONJ
chd-214	192	41	etzioni	etzioni	PROPN
chd-214	192	42	,	,	PUNCT
chd-214	192	43	r.	r.	PROPN
chd-214	192	44	(	(	PUNCT
chd-214	192	45	2017	2017	NUM
chd-214	192	46	)	)	PUNCT
chd-214	192	47	.	.	PUNCT
chd-214	193	1	is	be	AUX
chd-214	193	2	prostate	prostate	NOUN
chd-214	193	3	cancer	cancer	NOUN
chd-214	193	4	different	different	ADJ
chd-214	193	5	in	in	ADP
chd-214	193	6	black	black	ADJ
chd-214	193	7	men	man	NOUN
chd-214	193	8	?	?	PUNCT
chd-214	194	1	answers	answer	NOUN
chd-214	194	2	from	from	ADP
chd-214	194	3	3	3	NUM
chd-214	194	4	natural	natural	ADJ
chd-214	194	5	history	history	NOUN
chd-214	194	6	models	model	NOUN
chd-214	194	7	.	.	PUNCT
chd-214	195	1	cancer	cancer	NOUN
chd-214	195	2	,	,	PUNCT
chd-214	195	3	123(12	123(12	NUM
chd-214	195	4	)	)	PUNCT
chd-214	195	5	,	,	PUNCT
chd-214	195	6	2312–2319	2312–2319	NUM
chd-214	195	7	.	.	PUNCT
chd-214	195	8	https://doi.org/10.1002/cncr.30687	https://doi.org/10.1002/cncr.30687	PROPN
chd-214	195	9	10	10	NUM
chd-214	195	10	.	.	PUNCT
chd-214	196	1	cotter	cotter	NOUN
chd-214	196	2	,	,	PUNCT
chd-214	196	3	m.	m.	NOUN
chd-214	196	4	p.	p.	PROPN
chd-214	196	5	,	,	PUNCT
chd-214	196	6	gern	gern	PROPN
chd-214	196	7	,	,	PUNCT
chd-214	196	8	r.	r.	PROPN
chd-214	196	9	w.	w.	PROPN
chd-214	196	10	,	,	PUNCT
chd-214	196	11	ho	ho	PROPN
chd-214	196	12	,	,	PUNCT
chd-214	196	13	g.	g.	PROPN
chd-214	196	14	y.	y.	PROPN
chd-214	196	15	,	,	PUNCT
chd-214	196	16	chang	chang	PROPN
chd-214	196	17	,	,	PUNCT
chd-214	196	18	r.	r.	PROPN
chd-214	196	19	y.	y.	PROPN
chd-214	196	20	,	,	PUNCT
chd-214	196	21	and	and	CCONJ
chd-214	196	22	burk	burk	PROPN
chd-214	196	23	,	,	PUNCT
chd-214	196	24	r.	r.	PROPN
chd-214	196	25	d.	d.	PROPN
chd-214	196	26	(	(	PUNCT
chd-214	196	27	2002	2002	NUM
chd-214	196	28	)	)	PUNCT
chd-214	196	29	.	.	PUNCT
chd-214	197	1	role	role	NOUN
chd-214	197	2	of	of	ADP
chd-214	197	3	family	family	NOUN
chd-214	197	4	history	history	NOUN
chd-214	197	5	and	and	CCONJ
chd-214	197	6	ethnicity	ethnicity	NOUN
chd-214	197	7	on	on	ADP
chd-214	197	8	the	the	DET
chd-214	197	9	mode	mode	NOUN
chd-214	197	10	and	and	CCONJ
chd-214	197	11	age	age	NOUN
chd-214	197	12	of	of	ADP
chd-214	197	13	prostate	prostate	NOUN
chd-214	197	14	cancer	cancer	NOUN
chd-214	197	15	presentation	presentation	NOUN
chd-214	197	16	.	.	PUNCT
chd-214	198	1	the	the	DET
chd-214	198	2	prostate	prostate	NOUN
chd-214	198	3	,	,	PUNCT
chd-214	198	4	50(4	50(4	NUM
chd-214	198	5	)	)	PUNCT
chd-214	198	6	,	,	PUNCT
chd-214	198	7	216–221	216–221	NUM
chd-214	198	8	.	.	PUNCT
chd-214	198	9	https://doi.org/10.1002/pros.10051	https://doi.org/10.1002/pros.10051	PROPN
chd-214	198	10	11	11	NUM
chd-214	198	11	.	.	PUNCT
chd-214	199	1	lindquist	lindquist	PROPN
chd-214	199	2	,	,	PUNCT
chd-214	199	3	k.	k.	PROPN
chd-214	199	4	j.	j.	PROPN
chd-214	199	5	,	,	PUNCT
chd-214	199	6	paris	paris	PROPN
chd-214	199	7	,	,	PUNCT
chd-214	199	8	p.	p.	PROPN
chd-214	199	9	l.	l.	PROPN
chd-214	199	10	,	,	PUNCT
chd-214	199	11	hoffmann	hoffmann	PROPN
chd-214	199	12	,	,	PUNCT
chd-214	199	13	t.	t.	PROPN
chd-214	199	14	j.	j.	PROPN
chd-214	199	15	,	,	PUNCT
chd-214	199	16	cardin	cardin	PROPN
chd-214	199	17	,	,	PUNCT
chd-214	199	18	n.	n.	PROPN
chd-214	199	19	j.	j.	PROPN
chd-214	199	20	,	,	PUNCT
chd-214	199	21	kazma	kazma	PROPN
chd-214	199	22	,	,	PUNCT
chd-214	199	23	r.	r.	PROPN
chd-214	199	24	,	,	PUNCT
chd-214	199	25	mefford	mefford	PROPN
chd-214	199	26	,	,	PUNCT
chd-214	199	27	j.	j.	PROPN
chd-214	199	28	a.	a.	PROPN
chd-214	199	29	,	,	PUNCT
chd-214	199	30	simko	simko	PROPN
chd-214	199	31	,	,	PUNCT
chd-214	199	32	j.	j.	PROPN
chd-214	199	33	p.	p.	PROPN
chd-214	199	34	,	,	PUNCT
chd-214	199	35	ngo	ngo	PROPN
chd-214	199	36	,	,	PUNCT
chd-214	199	37	v.	v.	PROPN
chd-214	199	38	,	,	PUNCT
chd-214	199	39	chen	chen	PROPN
chd-214	199	40	,	,	PUNCT
chd-214	199	41	y.	y.	PROPN
chd-214	199	42	,	,	PUNCT
chd-214	199	43	levin	levin	PROPN
chd-214	199	44	,	,	PUNCT
chd-214	199	45	a.	a.	NOUN
chd-214	199	46	m.	m.	NOUN
chd-214	199	47	,	,	PUNCT
chd-214	199	48	chitale	chitale	PROPN
chd-214	199	49	,	,	PUNCT
chd-214	199	50	d.	d.	PROPN
chd-214	199	51	,	,	PUNCT
chd-214	199	52	helfand	helfand	ADV
chd-214	199	53	,	,	PUNCT
chd-214	199	54	b.	b.	PROPN
chd-214	199	55	t.	t.	PROPN
chd-214	199	56	,	,	PUNCT
chd-214	199	57	catalona	catalona	PROPN
chd-214	199	58	,	,	PUNCT
chd-214	199	59	w.	w.	PROPN
chd-214	199	60	j.	j.	PROPN
chd-214	199	61	,	,	PUNCT
chd-214	199	62	rybicki	rybicki	PROPN
chd-214	199	63	,	,	PUNCT
chd-214	199	64	b.	b.	PROPN
chd-214	199	65	a.	a.	PROPN
chd-214	199	66	,	,	PUNCT
chd-214	199	67	and	and	CCONJ
chd-214	199	68	witte	witte	NOUN
chd-214	199	69	,	,	PUNCT
chd-214	199	70	j.	j.	PROPN
chd-214	199	71	s.	s.	PROPN
chd-214	199	72	(	(	PUNCT
chd-214	199	73	2016	2016	NUM
chd-214	199	74	)	)	PUNCT
chd-214	199	75	.	.	PUNCT
chd-214	200	1	mutational	mutational	ADJ
chd-214	200	2	landscape	landscape	NOUN
chd-214	200	3	of	of	ADP
chd-214	200	4	aggressive	aggressive	ADJ
chd-214	200	5	prostate	prostate	NOUN
chd-214	200	6	tumors	tumor	NOUN
chd-214	200	7	in	in	ADP
chd-214	200	8	african	african	ADJ
chd-214	200	9	american	american	ADJ
chd-214	200	10	men	man	NOUN
chd-214	200	11	.	.	PUNCT
chd-214	201	1	cancer	cancer	NOUN
chd-214	201	2	research	research	NOUN
chd-214	201	3	,	,	PUNCT
chd-214	201	4	76(7	76(7	NOUN
chd-214	201	5	)	)	PUNCT
chd-214	201	6	,	,	PUNCT
chd-214	201	7	1860–1868	1860–1868	NUM
chd-214	201	8	.	.	PUNCT
chd-214	202	1	https://doi.org/10.1158/0008-5472.can-15-1787	https://doi.org/10.1158/0008-5472.can-15-1787	PROPN
chd-214	202	2	12	12	NUM
chd-214	202	3	.	.	PUNCT
chd-214	203	1	tan	tan	PROPN
chd-214	203	2	,	,	PUNCT
chd-214	203	3	s.	s.	PROPN
chd-214	203	4	h.	h.	PROPN
chd-214	203	5	,	,	PUNCT
chd-214	203	6	petrovics	petrovic	NOUN
chd-214	203	7	,	,	PUNCT
chd-214	203	8	g.	g.	PROPN
chd-214	203	9	,	,	PUNCT
chd-214	203	10	and	and	CCONJ
chd-214	203	11	srivastava	srivastava	PROPN
chd-214	203	12	,	,	PUNCT
chd-214	203	13	s.	s.	PROPN
chd-214	203	14	(	(	PUNCT
chd-214	203	15	2018	2018	NUM
chd-214	203	16	)	)	PUNCT
chd-214	203	17	.	.	PUNCT
chd-214	204	1	prostate	prostate	NOUN
chd-214	204	2	cancer	cancer	NOUN
chd-214	204	3	genomics	genomic	NOUN
chd-214	204	4	:	:	PUNCT
chd-214	204	5	recent	recent	ADJ
chd-214	204	6	advances	advance	NOUN
chd-214	204	7	and	and	CCONJ
chd-214	204	8	the	the	DET
chd-214	204	9	prevailing	prevail	VERB
chd-214	204	10	underrepresentation	underrepresentation	NOUN
chd-214	204	11	from	from	ADP
chd-214	204	12	racial	racial	ADJ
chd-214	204	13	and	and	CCONJ
chd-214	204	14	ethnic	ethnic	ADJ
chd-214	204	15	minorities	minority	NOUN
chd-214	204	16	.	.	PUNCT
chd-214	205	1	international	international	ADJ
chd-214	205	2	journal	journal	NOUN
chd-214	205	3	of	of	ADP
chd-214	205	4	molecular	molecular	ADJ
chd-214	205	5	sciences	science	NOUN
chd-214	205	6	,	,	PUNCT
chd-214	205	7	19(4	19(4	NOUN
chd-214	205	8	)	)	PUNCT
chd-214	205	9	,	,	PUNCT
chd-214	205	10	1255	1255	NUM
chd-214	205	11	.	.	PUNCT
chd-214	206	1	https://doi.org/10.3390/ijms19041255	https://doi.org/10.3390/ijms19041255	PROPN
chd-214	206	2	13	13	NUM
chd-214	206	3	.	.	PUNCT
chd-214	207	1	lonergan	lonergan	PROPN
chd-214	207	2	,	,	PUNCT
chd-214	207	3	p.	p.	PROPN
chd-214	207	4	e.	e.	PROPN
chd-214	207	5	,	,	PUNCT
chd-214	207	6	and	and	CCONJ
chd-214	207	7	tindall	tindall	PROPN
chd-214	207	8	,	,	PUNCT
chd-214	207	9	d.	d.	PROPN
chd-214	207	10	j.	j.	PROPN
chd-214	207	11	(	(	PUNCT
chd-214	207	12	2011	2011	NUM
chd-214	207	13	)	)	PUNCT
chd-214	207	14	.	.	PUNCT
chd-214	208	1	androgen	androgen	NOUN
chd-214	208	2	receptor	receptor	NOUN
chd-214	208	3	signaling	signal	VERB
chd-214	208	4	in	in	ADP
chd-214	208	5	prostate	prostate	NOUN
chd-214	208	6	cancer	cancer	NOUN
chd-214	208	7	development	development	NOUN
chd-214	208	8	and	and	CCONJ
chd-214	208	9	progression	progression	NOUN
chd-214	208	10	.	.	PUNCT
chd-214	209	1	journal	journal	NOUN
chd-214	209	2	of	of	ADP
chd-214	209	3	carcinogenesis	carcinogenesis	NOUN
chd-214	209	4	,	,	PUNCT
chd-214	209	5	10	10	NUM
chd-214	209	6	,	,	PUNCT
chd-214	209	7	20	20	NUM
chd-214	209	8	.	.	PUNCT
chd-214	210	1	https://doi.org/10.4103/1477-3163.83937	https://doi.org/10.4103/1477-3163.83937	PROPN
chd-214	210	2	14	14	NUM
chd-214	210	3	.	.	PUNCT
chd-214	211	1	gaston	gaston	PROPN
chd-214	211	2	,	,	PUNCT
chd-214	211	3	k.	k.	PROPN
chd-214	211	4	e.	e.	PROPN
chd-214	211	5	,	,	PUNCT
chd-214	211	6	kim	kim	PROPN
chd-214	211	7	,	,	PUNCT
chd-214	211	8	d.	d.	PROPN
chd-214	211	9	,	,	PUNCT
chd-214	211	10	singh	singh	PROPN
chd-214	211	11	,	,	PUNCT
chd-214	211	12	s.	s.	PROPN
chd-214	211	13	,	,	PUNCT
chd-214	211	14	ford	ford	PROPN
chd-214	211	15	,	,	PUNCT
chd-214	211	16	o.	o.	PROPN
chd-214	211	17	h.	h.	PROPN
chd-214	211	18	,	,	PUNCT
chd-214	211	19	3rd	3rd	NOUN
chd-214	211	20	,	,	PUNCT
chd-214	211	21	and	and	CCONJ
chd-214	211	22	mohler	mohler	NOUN
chd-214	211	23	,	,	PUNCT
chd-214	211	24	j.	j.	PROPN
chd-214	211	25	l.	l.	PROPN
chd-214	211	26	(	(	PUNCT
chd-214	211	27	2003	2003	NUM
chd-214	211	28	)	)	PUNCT
chd-214	211	29	.	.	PUNCT
chd-214	212	1	racial	racial	ADJ
chd-214	212	2	differences	difference	NOUN
chd-214	212	3	in	in	ADP
chd-214	212	4	androgen	androgen	NOUN
chd-214	212	5	receptor	receptor	NOUN
chd-214	212	6	protein	protein	NOUN
chd-214	212	7	expression	expression	NOUN
chd-214	212	8	in	in	ADP
chd-214	212	9	men	man	NOUN
chd-214	212	10	with	with	ADP
chd-214	212	11	clinically	clinically	ADV
chd-214	212	12	localized	localize	VERB
chd-214	212	13	prostate	prostate	NOUN
chd-214	212	14	cancer	cancer	NOUN
chd-214	212	15	.	.	PUNCT
chd-214	213	1	the	the	DET
chd-214	213	2	journal	journal	NOUN
chd-214	213	3	of	of	ADP
chd-214	213	4	urology	urology	NOUN
chd-214	213	5	,	,	PUNCT
chd-214	213	6	170(3	170(3	NUM
chd-214	213	7	)	)	PUNCT
chd-214	213	8	,	,	PUNCT
chd-214	213	9	990–993	990–993	NUM
chd-214	213	10	.	.	PUNCT
chd-214	213	11	https://doi.org/10.1097/01.ju.000007	https://doi.org/10.1097/01.ju.000007	PUNCT
chd-214	213	12	9761.56154.e5	9761.56154.e5	NUM
chd-214	213	13	15	15	NUM
chd-214	213	14	.	.	PUNCT
chd-214	214	1	crawford	crawford	PROPN
chd-214	214	2	e.	e.	PROPN
chd-214	214	3	d.	d.	PROPN
chd-214	214	4	(	(	PUNCT
chd-214	214	5	2003	2003	NUM
chd-214	214	6	)	)	PUNCT
chd-214	214	7	.	.	PUNCT
chd-214	215	1	epidemiology	epidemiology	NOUN
chd-214	215	2	of	of	ADP
chd-214	215	3	prostate	prostate	NOUN
chd-214	215	4	cancer	cancer	NOUN
chd-214	215	5	.	.	PUNCT
chd-214	216	1	urology	urology	NOUN
chd-214	216	2	,	,	PUNCT
chd-214	216	3	62(6	62(6	NOUN
chd-214	216	4	suppl	suppl	ADJ
chd-214	216	5	1	1	NUM
chd-214	216	6	)	)	PUNCT
chd-214	216	7	,	,	PUNCT
chd-214	216	8	3–12	3–12	PROPN
chd-214	216	9	.	.	PUNCT
chd-214	217	1	https://doi.org/10.1016/j.urology.2003.10.013	https://doi.org/10.1016/j.urology.2003.10.013	PROPN
chd-214	217	2	16	16	NUM
chd-214	217	3	.	.	PUNCT
chd-214	218	1	karakas	karakas	PROPN
chd-214	218	2	,	,	PUNCT
chd-214	218	3	c.	c.	PROPN
chd-214	218	4	,	,	PUNCT
chd-214	218	5	wang	wang	PROPN
chd-214	218	6	,	,	PUNCT
chd-214	218	7	c.	c.	PROPN
chd-214	218	8	,	,	PUNCT
chd-214	218	9	deng	deng	PROPN
chd-214	218	10	,	,	PUNCT
chd-214	218	11	f.	f.	PROPN
chd-214	218	12	,	,	PUNCT
chd-214	218	13	huang	huang	PROPN
chd-214	218	14	,	,	PUNCT
chd-214	218	15	h.	h.	PROPN
chd-214	218	16	,	,	PUNCT
chd-214	218	17	wang	wang	PROPN
chd-214	218	18	,	,	PUNCT
chd-214	218	19	d.	d.	PROPN
chd-214	218	20	,	,	PUNCT
chd-214	218	21	and	and	CCONJ
chd-214	218	22	lee	lee	PROPN
chd-214	218	23	,	,	PUNCT
chd-214	218	24	p.	p.	NOUN
chd-214	218	25	(	(	PUNCT
chd-214	218	26	2017	2017	NUM
chd-214	218	27	)	)	PUNCT
chd-214	218	28	.	.	PUNCT
chd-214	219	1	molecular	molecular	ADJ
chd-214	219	2	mechanisms	mechanism	NOUN
chd-214	219	3	involving	involve	VERB
chd-214	219	4	prostate	prostate	NOUN
chd-214	219	5	cancer	cancer	NOUN
chd-214	219	6	racial	racial	ADJ
chd-214	219	7	disparity	disparity	NOUN
chd-214	219	8	.	.	PUNCT
chd-214	220	1	american	american	ADJ
chd-214	220	2	journal	journal	PROPN
chd-214	220	3	of	of	ADP
chd-214	220	4	clinical	clinical	ADJ
chd-214	220	5	and	and	CCONJ
chd-214	220	6	experimental	experimental	ADJ
chd-214	220	7	urology	urology	NOUN
chd-214	220	8	,	,	PUNCT
chd-214	220	9	5(3	5(3	NUM
chd-214	220	10	)	)	PUNCT
chd-214	220	11	,	,	PUNCT
chd-214	220	12	34–48	34–48	NUM
chd-214	220	13	.	.	PUNCT
chd-214	221	1	17	17	NUM
chd-214	221	2	.	.	PUNCT
chd-214	222	1	josson	josson	PROPN
chd-214	222	2	,	,	PUNCT
chd-214	222	3	s.	s.	PROPN
chd-214	222	4	,	,	PUNCT
chd-214	222	5	matsuoka	matsuoka	VERB
chd-214	222	6	,	,	PUNCT
chd-214	222	7	y.	y.	PROPN
chd-214	222	8	,	,	PUNCT
chd-214	222	9	chung	chung	PROPN
chd-214	222	10	,	,	PUNCT
chd-214	222	11	l.	l.	PROPN
chd-214	222	12	w.	w.	PROPN
chd-214	222	13	,	,	PUNCT
chd-214	222	14	zhau	zhau	NOUN
chd-214	222	15	,	,	PUNCT
chd-214	222	16	h.	h.	PROPN
chd-214	222	17	e.	e.	PROPN
chd-214	222	18	,	,	PUNCT
chd-214	222	19	and	and	CCONJ
chd-214	222	20	wang	wang	PROPN
chd-214	222	21	,	,	PUNCT
chd-214	222	22	r.	r.	PROPN
chd-214	222	23	(	(	PUNCT
chd-214	222	24	2010	2010	NUM
chd-214	222	25	)	)	PUNCT
chd-214	222	26	.	.	PUNCT
chd-214	223	1	tumor	tumor	NOUN
chd-214	223	2	-	-	PUNCT
chd-214	223	3	stroma	stroma	ADJ
chd-214	223	4	co	co	NOUN
chd-214	224	1	-	-	NOUN
chd-214	225	1	evolution	evolution	NOUN
chd-214	225	2	in	in	ADP
chd-214	225	3	prostate	prostate	NOUN
chd-214	225	4	cancer	cancer	NOUN
chd-214	225	5	progression	progression	NOUN
chd-214	225	6	and	and	CCONJ
chd-214	225	7	metastasis	metastasis	NOUN
chd-214	225	8	.	.	PUNCT
chd-214	226	1	seminars	seminar	NOUN
chd-214	226	2	in	in	ADP
chd-214	226	3	cell	cell	NOUN
chd-214	226	4	&	&	CCONJ
chd-214	226	5	developmental	developmental	ADJ
chd-214	226	6	biology	biology	NOUN
chd-214	226	7	,	,	PUNCT
chd-214	226	8	21(1	21(1	NUM
chd-214	226	9	)	)	PUNCT
chd-214	226	10	,	,	PUNCT
chd-214	226	11	26–32	26–32	NUM
chd-214	226	12	.	.	PUNCT
chd-214	227	1	https://doi.org/10.1016/j.semcdb.2009.11.016	https://doi.org/10.1016/j.semcdb.2009.11.016	PROPN
chd-214	227	2	18	18	NUM
chd-214	227	3	.	.	PUNCT
chd-214	227	4	wallace	wallace	PROPN
chd-214	227	5	,	,	PUNCT
chd-214	227	6	t.	t.	NOUN
chd-214	227	7	a.	a.	NOUN
chd-214	227	8	,	,	PUNCT
chd-214	227	9	prueitt	prueitt	VERB
chd-214	227	10	,	,	PUNCT
chd-214	227	11	r.	r.	PROPN
chd-214	227	12	l.	l.	PROPN
chd-214	227	13	,	,	PUNCT
chd-214	227	14	yi	yi	PROPN
chd-214	227	15	,	,	PUNCT
chd-214	227	16	m.	m.	NOUN
chd-214	227	17	,	,	PUNCT
chd-214	227	18	howe	howe	NOUN
chd-214	227	19	,	,	PUNCT
chd-214	227	20	t.	t.	NOUN
chd-214	227	21	m.	m.	NOUN
chd-214	227	22	,	,	PUNCT
chd-214	227	23	gillespie	gillespie	PROPN
chd-214	227	24	,	,	PUNCT
chd-214	227	25	j.	j.	PROPN
chd-214	227	26	w.	w.	PROPN
chd-214	227	27	,	,	PUNCT
chd-214	227	28	yfantis	yfantis	PROPN
chd-214	227	29	,	,	PUNCT
chd-214	227	30	h.	h.	PROPN
chd-214	227	31	g.	g.	PROPN
chd-214	227	32	,	,	PUNCT
chd-214	227	33	stephens	stephens	PROPN
chd-214	227	34	,	,	PUNCT
chd-214	227	35	r.	r.	PROPN
chd-214	227	36	m.	m.	PROPN
chd-214	227	37	,	,	PUNCT
chd-214	227	38	caporaso	caporaso	PROPN
chd-214	227	39	,	,	PUNCT
chd-214	227	40	n.	n.	PROPN
chd-214	227	41	e.	e.	PROPN
chd-214	227	42	,	,	PUNCT
chd-214	227	43	loffredo	loffredo	PROPN
chd-214	227	44	,	,	PUNCT
chd-214	227	45	c.	c.	PROPN
chd-214	227	46	a.	a.	PROPN
chd-214	227	47	,	,	PUNCT
chd-214	227	48	and	and	CCONJ
chd-214	227	49	ambs	amb	NOUN
chd-214	227	50	,	,	PUNCT
chd-214	227	51	s.	s.	PROPN
chd-214	227	52	(	(	PUNCT
chd-214	227	53	2008	2008	NUM
chd-214	227	54	)	)	PUNCT
chd-214	227	55	.	.	PUNCT
chd-214	228	1	tumor	tumor	NOUN
chd-214	228	2	immunobiological	immunobiological	ADJ
chd-214	228	3	differences	difference	NOUN
chd-214	228	4	in	in	ADP
chd-214	228	5	prostate	prostate	NOUN
chd-214	228	6	cancer	cancer	NOUN
chd-214	228	7	between	between	ADP
chd-214	228	8	african	african	ADJ
chd-214	228	9	-	-	PUNCT
chd-214	228	10	american	american	ADJ
chd-214	228	11	and	and	CCONJ
chd-214	228	12	european	european	ADJ
chd-214	228	13	-	-	PUNCT
chd-214	228	14	american	american	ADJ
chd-214	228	15	men	man	NOUN
chd-214	228	16	.	.	PUNCT
chd-214	229	1	cancer	cancer	NOUN
chd-214	229	2	research	research	PROPN
chd-214	229	3	,	,	PUNCT
chd-214	229	4	68(3	68(3	PROPN
chd-214	229	5	)	)	PUNCT
chd-214	229	6	,	,	PUNCT
chd-214	229	7	927–936	927–936	NUM
chd-214	229	8	.	.	PUNCT
chd-214	230	1	https://doi.org/10.1158/00085472.can-07-2608	https://doi.org/10.1158/00085472.can-07-2608	NOUN
chd-214	230	2	.	.	PUNCT
chd-214	231	1	19	19	NUM
chd-214	231	2	.	.	X
chd-214	232	1	gillard	gillard	PROPN
chd-214	232	2	,	,	PUNCT
chd-214	232	3	m.	m.	NOUN
chd-214	232	4	,	,	PUNCT
chd-214	232	5	javier	javier	PROPN
chd-214	232	6	,	,	PUNCT
chd-214	232	7	r.	r.	PROPN
chd-214	232	8	,	,	PUNCT
chd-214	232	9	ji	ji	PROPN
chd-214	232	10	,	,	PUNCT
chd-214	232	11	y.	y.	PROPN
chd-214	232	12	,	,	PUNCT
chd-214	232	13	zheng	zheng	PROPN
chd-214	232	14	,	,	PUNCT
chd-214	232	15	s.	s.	PROPN
chd-214	232	16	l.	l.	PROPN
chd-214	232	17	,	,	PUNCT
chd-214	232	18	xu	xu	PROPN
chd-214	232	19	,	,	PUNCT
chd-214	232	20	j.	j.	PROPN
chd-214	232	21	,	,	PUNCT
chd-214	232	22	brendler	brendler	NOUN
chd-214	232	23	,	,	PUNCT
chd-214	232	24	c.	c.	PROPN
chd-214	232	25	b.	b.	PROPN
chd-214	232	26	,	,	PUNCT
chd-214	232	27	crawford	crawford	PROPN
chd-214	232	28	,	,	PUNCT
chd-214	232	29	s.	s.	PROPN
chd-214	232	30	e.	e.	PROPN
chd-214	232	31	,	,	PUNCT
chd-214	232	32	pierce	pierce	PROPN
chd-214	232	33	,	,	PUNCT
chd-214	232	34	b.	b.	PROPN
chd-214	232	35	l.	l.	PROPN
chd-214	232	36	,	,	PUNCT
chd-214	232	37	griend	griend	PROPN
chd-214	232	38	,	,	PUNCT
chd-214	232	39	d.	d.	PROPN
chd-214	232	40	,	,	PUNCT
chd-214	232	41	and	and	CCONJ
chd-214	232	42	franco	franco	NOUN
chd-214	232	43	,	,	PUNCT
chd-214	232	44	o.	o.	PROPN
chd-214	232	45	e.	e.	PROPN
chd-214	232	46	(	(	PUNCT
chd-214	232	47	2018	2018	NUM
chd-214	232	48	)	)	PUNCT
chd-214	232	49	.	.	PUNCT
chd-214	233	1	elevation	elevation	NOUN
chd-214	233	2	of	of	ADP
chd-214	233	3	stromal	stromal	ADJ
chd-214	233	4	-	-	PUNCT
chd-214	233	5	derived	derive	VERB
chd-214	233	6	mediators	mediator	NOUN
chd-214	233	7	of	of	ADP
chd-214	233	8	inflammation	inflammation	NOUN
chd-214	233	9	promote	promote	VERB
chd-214	233	10	prostate	prostate	NOUN
chd-214	233	11	cancer	cancer	NOUN
chd-214	233	12	progression	progression	NOUN
chd-214	233	13	in	in	ADP
chd-214	233	14	african	african	ADJ
chd-214	233	15	-	-	PUNCT
chd-214	233	16	american	american	ADJ
chd-214	233	17	men	man	NOUN
chd-214	233	18	.	.	PUNCT
chd-214	234	1	cancer	cancer	NOUN
chd-214	234	2	research	research	NOUN
chd-214	234	3	,	,	PUNCT
chd-214	234	4	78(21	78(21	NUM
chd-214	234	5	)	)	PUNCT
chd-214	234	6	,	,	PUNCT
chd-214	234	7	6134	6134	NUM
chd-214	234	8	–	–	PUNCT
chd-214	234	9	6145	6145	NUM
chd-214	234	10	.	.	PUNCT
chd-214	235	1	https://doi.org/10.1158/0008-5472.can-17-3810	https://doi.org/10.1158/0008-5472.can-17-3810	NUM
chd-214	235	2	20	20	NUM
chd-214	235	3	.	.	PUNCT
chd-214	235	4	kinseth	kinseth	PROPN
chd-214	235	5	,	,	PUNCT
chd-214	235	6	m.	m.	NOUN
chd-214	235	7	a.	a.	PROPN
chd-214	235	8	,	,	PUNCT
chd-214	235	9	jia	jia	PROPN
chd-214	235	10	,	,	PUNCT
chd-214	235	11	z.	z.	PROPN
chd-214	235	12	,	,	PUNCT
chd-214	235	13	rahmatpanah	rahmatpanah	PROPN
chd-214	235	14	,	,	PUNCT
chd-214	235	15	f.	f.	PROPN
chd-214	235	16	,	,	PUNCT
chd-214	235	17	sawyers	sawyer	NOUN
chd-214	235	18	,	,	PUNCT
chd-214	235	19	a.	a.	PROPN
chd-214	235	20	,	,	PUNCT
chd-214	235	21	sutton	sutton	PROPN
chd-214	235	22	,	,	PUNCT
chd-214	235	23	m.	m.	NOUN
chd-214	235	24	,	,	PUNCT
chd-214	235	25	wang	wang	PROPN
chd-214	235	26	-	-	PUNCT
chd-214	235	27	rodriguez	rodriguez	PROPN
chd-214	235	28	,	,	PUNCT
chd-214	235	29	j.	j.	PROPN
chd-214	235	30	,	,	PUNCT
chd-214	235	31	mercola	mercola	PROPN
chd-214	235	32	,	,	PUNCT
chd-214	235	33	d.	d.	PROPN
chd-214	235	34	,	,	PUNCT
chd-214	235	35	and	and	CCONJ
chd-214	235	36	mcguire	mcguire	PROPN
chd-214	235	37	,	,	PUNCT
chd-214	235	38	k.	k.	PROPN
chd-214	235	39	l.	l.	PROPN
chd-214	235	40	(	(	PUNCT
chd-214	235	41	2014	2014	NUM
chd-214	235	42	)	)	PUNCT
chd-214	235	43	.	.	PUNCT
chd-214	236	1	expression	expression	NOUN
chd-214	236	2	differences	difference	NOUN
chd-214	236	3	between	between	ADP
chd-214	236	4	african	african	ADJ
chd-214	236	5	american	american	ADJ
chd-214	236	6	and	and	CCONJ
chd-214	236	7	caucasian	caucasian	ADJ
chd-214	236	8	prostate	prostate	NOUN
chd-214	236	9	cancer	cancer	NOUN
chd-214	236	10	tissue	tissue	NOUN
chd-214	236	11	reveals	reveal	VERB
chd-214	236	12	that	that	SCONJ
chd-214	236	13	stroma	stroma	ADJ
chd-214	236	14	https://doi.org/10.3390/cancers13112656	https://doi.org/10.3390/cancers13112656	NOUN
chd-214	236	15	https://doi.org/10.1002/pros.23923	https://doi.org/10.1002/pros.23923	PROPN
chd-214	236	16	https://doi.org/10.3389/fonc.2021.770500	https://doi.org/10.3389/fonc.2021.770500	PROPN
chd-214	236	17	https://doi.org/10.1177/1557988318798279	https://doi.org/10.1177/1557988318798279	NOUN
chd-214	236	18	https://doi.org/10.15585/mmwr.mm6941a1	https://doi.org/10.15585/mmwr.mm6941a1	NOUN
chd-214	236	19	https://doi.org/10.2741/4515	https://doi.org/10.2741/4515	X
chd-214	236	20	https://doi.org/10.1002/cncr.30687	https://doi.org/10.1002/cncr.30687	NOUN
chd-214	236	21	https://doi.org/10.1002/pros.10051	https://doi.org/10.1002/pros.10051	ADJ
chd-214	236	22	https://doi.org/10.1158/0008-5472.can-15-1787	https://doi.org/10.1158/0008-5472.can-15-1787	X
chd-214	236	23	https://doi.org/10.3390/ijms19041255	https://doi.org/10.3390/ijms19041255	ADJ
chd-214	236	24	https://doi.org/10.4103/1477-3163.83937	https://doi.org/10.4103/1477-3163.83937	NOUN
chd-214	236	25	https://doi.org/10.1097/01.ju.000007%209761.56154.e5	https://doi.org/10.1097/01.ju.000007%209761.56154.e5	VERB
chd-214	236	26	https://doi.org/10.1016/j.urology.2003.10.013	https://doi.org/10.1016/j.urology.2003.10.013	PROPN
chd-214	236	27	https://doi.org/10.1016/j.semcdb.2009.11.016	https://doi.org/10.1016/j.semcdb.2009.11.016	PROPN
chd-214	236	28	https://doi.org/10.1158/0008-5472.can-07-2608	https://doi.org/10.1158/0008-5472.can-07-2608	PROPN
chd-214	236	29	https://doi.org/10.1158/0008-5472.can-07-2608	https://doi.org/10.1158/0008-5472.can-07-2608	NOUN
chd-214	236	30	https://doi.org/10.1158/0008-5472.can-17-3810	https://doi.org/10.1158/0008-5472.can-17-3810	AUX
chd-214	236	31	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	NUM
chd-214	236	32	e11	e11	ADJ
chd-214	236	33	cancer	cancer	NOUN
chd-214	236	34	health	health	NOUN
chd-214	236	35	disparities	disparity	NOUN
chd-214	236	36	research	research	NOUN
chd-214	236	37	is	be	AUX
chd-214	236	38	the	the	DET
chd-214	236	39	site	site	NOUN
chd-214	236	40	of	of	ADP
chd-214	236	41	aggressive	aggressive	ADJ
chd-214	236	42	changes	change	NOUN
chd-214	236	43	.	.	PUNCT
chd-214	237	1	international	international	ADJ
chd-214	237	2	journal	journal	PROPN
chd-214	237	3	of	of	ADP
chd-214	237	4	cancer	cancer	NOUN
chd-214	237	5	,	,	PUNCT
chd-214	237	6	134(1	134(1	NUM
chd-214	237	7	)	)	PUNCT
chd-214	237	8	,	,	PUNCT
chd-214	237	9	81–91	81–91	NUM
chd-214	237	10	.	.	PUNCT
chd-214	238	1	https://doi.org/10.1002/ijc.28326	https://doi.org/10.1002/ijc.28326	NOUN
chd-214	238	2	21	21	NUM
chd-214	238	3	.	.	PUNCT
chd-214	239	1	aaron	aaron	PROPN
chd-214	239	2	,	,	PUNCT
chd-214	239	3	l.	l.	PROPN
chd-214	239	4	,	,	PUNCT
chd-214	239	5	franco	franco	PROPN
chd-214	239	6	,	,	PUNCT
chd-214	239	7	o.	o.	PROPN
chd-214	239	8	e.	e.	PROPN
chd-214	239	9	,	,	PUNCT
chd-214	239	10	and	and	CCONJ
chd-214	239	11	hayward	hayward	PROPN
chd-214	239	12	,	,	PUNCT
chd-214	239	13	s.	s.	PROPN
chd-214	239	14	w.	w.	PROPN
chd-214	239	15	(	(	PUNCT
chd-214	239	16	2016	2016	NUM
chd-214	239	17	)	)	PUNCT
chd-214	239	18	.	.	PUNCT
chd-214	240	1	review	review	NOUN
chd-214	240	2	of	of	ADP
chd-214	240	3	prostate	prostate	NOUN
chd-214	240	4	anatomy	anatomy	NOUN
chd-214	240	5	and	and	CCONJ
chd-214	240	6	embryology	embryology	NOUN
chd-214	240	7	and	and	CCONJ
chd-214	240	8	the	the	DET
chd-214	240	9	etiology	etiology	NOUN
chd-214	240	10	of	of	ADP
chd-214	240	11	benign	benign	ADJ
chd-214	240	12	prostatic	prostatic	ADJ
chd-214	240	13	hyperplasia	hyperplasia	NOUN
chd-214	240	14	.	.	PUNCT
chd-214	241	1	the	the	DET
chd-214	241	2	urologic	urologic	ADJ
chd-214	241	3	clinics	clinic	NOUN
chd-214	241	4	of	of	ADP
chd-214	241	5	north	north	PROPN
chd-214	241	6	america	america	PROPN
chd-214	241	7	,	,	PUNCT
chd-214	241	8	43(3	43(3	PROPN
chd-214	241	9	)	)	PUNCT
chd-214	241	10	,	,	PUNCT
chd-214	241	11	279–288	279–288	NUM
chd-214	241	12	.	.	PUNCT
chd-214	242	1	https://doi.org/10.1016/j.ucl.2016.04.012	https://doi.org/10.1016/j.ucl.2016.04.012	NOUN
chd-214	242	2	22	22	NUM
chd-214	242	3	.	.	PUNCT
chd-214	243	1	yu	yu	PROPN
chd-214	243	2	,	,	PUNCT
chd-214	243	3	j.	j.	PROPN
chd-214	243	4	,	,	PUNCT
chd-214	243	5	fulcher	fulcher	PROPN
chd-214	243	6	,	,	PUNCT
chd-214	243	7	a.	a.	PROPN
chd-214	243	8	s.	s.	PROPN
chd-214	243	9	,	,	PUNCT
chd-214	243	10	winks	wink	NOUN
chd-214	243	11	,	,	PUNCT
chd-214	243	12	s.	s.	PROPN
chd-214	243	13	g.	g.	PROPN
chd-214	243	14	,	,	PUNCT
chd-214	243	15	turner	turner	PROPN
chd-214	243	16	,	,	PUNCT
chd-214	243	17	m.	m.	NOUN
chd-214	243	18	a.	a.	PROPN
chd-214	243	19	,	,	PUNCT
chd-214	243	20	clayton	clayton	PROPN
chd-214	243	21	,	,	PUNCT
chd-214	243	22	r.	r.	PROPN
chd-214	243	23	d.	d.	PROPN
chd-214	243	24	,	,	PUNCT
chd-214	243	25	brooks	brooks	PROPN
chd-214	243	26	,	,	PUNCT
chd-214	243	27	m.	m.	NOUN
chd-214	243	28	,	,	PUNCT
chd-214	243	29	and	and	CCONJ
chd-214	243	30	li	li	PROPN
chd-214	243	31	,	,	PUNCT
chd-214	243	32	s.	s.	PROPN
chd-214	243	33	(	(	PUNCT
chd-214	243	34	2017	2017	NUM
chd-214	243	35	)	)	PUNCT
chd-214	243	36	.	.	PUNCT
chd-214	244	1	diagnosis	diagnosis	NOUN
chd-214	244	2	of	of	ADP
chd-214	244	3	typical	typical	ADJ
chd-214	244	4	and	and	CCONJ
chd-214	244	5	atypical	atypical	ADJ
chd-214	244	6	transition	transition	NOUN
chd-214	244	7	zone	zone	NOUN
chd-214	244	8	prostate	prostate	NOUN
chd-214	244	9	cancer	cancer	NOUN
chd-214	244	10	and	and	CCONJ
chd-214	244	11	its	its	PRON
chd-214	244	12	mimics	mimic	NOUN
chd-214	244	13	at	at	ADP
chd-214	244	14	multiparametric	multiparametric	ADJ
chd-214	244	15	prostate	prostate	NOUN
chd-214	244	16	mri	mri	NOUN
chd-214	244	17	.	.	PUNCT
chd-214	245	1	the	the	DET
chd-214	245	2	british	british	ADJ
chd-214	245	3	journal	journal	PROPN
chd-214	245	4	of	of	ADP
chd-214	245	5	radiology	radiology	NOUN
chd-214	245	6	,	,	PUNCT
chd-214	245	7	90(1073	90(1073	NUM
chd-214	245	8	)	)	PUNCT
chd-214	245	9	,	,	PUNCT
chd-214	245	10	20160693	20160693	NUM
chd-214	245	11	.	.	PUNCT
chd-214	246	1	https://doi.org/10.1259/bjr.20160693	https://doi.org/10.1259/bjr.20160693	PROPN
chd-214	246	2	23	23	NUM
chd-214	246	3	.	.	PUNCT
chd-214	247	1	datta	datta	PROPN
chd-214	247	2	,	,	PUNCT
chd-214	247	3	d.	d.	PROPN
chd-214	247	4	,	,	PUNCT
chd-214	247	5	aftabuddin	aftabuddin	PROPN
chd-214	247	6	,	,	PUNCT
chd-214	247	7	m.	m.	NOUN
chd-214	247	8	,	,	PUNCT
chd-214	247	9	gupta	gupta	PROPN
chd-214	247	10	,	,	PUNCT
chd-214	247	11	d.	d.	PROPN
chd-214	247	12	k.	k.	PROPN
chd-214	247	13	,	,	PUNCT
chd-214	247	14	raha	raha	PROPN
chd-214	247	15	,	,	PUNCT
chd-214	247	16	s.	s.	PROPN
chd-214	247	17	,	,	PUNCT
chd-214	247	18	and	and	CCONJ
chd-214	247	19	sen	sen	PROPN
chd-214	247	20	,	,	PUNCT
chd-214	247	21	p.	p.	NOUN
chd-214	247	22	(	(	PUNCT
chd-214	247	23	2016	2016	NUM
chd-214	247	24	)	)	PUNCT
chd-214	247	25	.	.	PUNCT
chd-214	248	1	human	human	ADJ
chd-214	248	2	prostate	prostate	NOUN
chd-214	248	3	cancer	cancer	NOUN
chd-214	248	4	hallmarks	hallmark	NOUN
chd-214	248	5	map	map	NOUN
chd-214	248	6	.	.	PUNCT
chd-214	249	1	scientific	scientific	ADJ
chd-214	249	2	reports	report	NOUN
chd-214	249	3	,	,	PUNCT
chd-214	249	4	6	6	NUM
chd-214	249	5	,	,	PUNCT
chd-214	249	6	30691	30691	NUM
chd-214	249	7	.	.	PUNCT
chd-214	250	1	https://doi.org/10.1038/srep30691	https://doi.org/10.1038/srep30691	PROPN
chd-214	250	2	24	24	NUM
chd-214	250	3	.	.	PUNCT
chd-214	250	4	shiao	shiao	PROPN
chd-214	250	5	,	,	PUNCT
chd-214	250	6	s.	s.	PROPN
chd-214	250	7	l.	l.	PROPN
chd-214	250	8	,	,	PUNCT
chd-214	250	9	chu	chu	PROPN
chd-214	250	10	,	,	PUNCT
chd-214	250	11	g.	g.	PROPN
chd-214	250	12	c.	c.	PROPN
chd-214	250	13	,	,	PUNCT
chd-214	250	14	&	&	CCONJ
chd-214	250	15	chung	chung	PROPN
chd-214	250	16	,	,	PUNCT
chd-214	250	17	l.	l.	PROPN
chd-214	250	18	w.	w.	PROPN
chd-214	250	19	(	(	PUNCT
chd-214	250	20	2016	2016	NUM
chd-214	250	21	)	)	PUNCT
chd-214	250	22	.	.	PUNCT
chd-214	251	1	regulation	regulation	NOUN
chd-214	251	2	of	of	ADP
chd-214	251	3	prostate	prostate	NOUN
chd-214	251	4	cancer	cancer	NOUN
chd-214	251	5	progression	progression	NOUN
chd-214	251	6	by	by	ADP
chd-214	251	7	the	the	DET
chd-214	251	8	tumor	tumor	NOUN
chd-214	251	9	microenvironment	microenvironment	NOUN
chd-214	251	10	.	.	PUNCT
chd-214	252	1	cancer	cancer	NOUN
chd-214	252	2	letters	letter	NOUN
chd-214	252	3	,	,	PUNCT
chd-214	252	4	380(1	380(1	NUM
chd-214	252	5	)	)	PUNCT
chd-214	252	6	,	,	PUNCT
chd-214	252	7	340–348	340–348	NUM
chd-214	252	8	.	.	PUNCT
chd-214	253	1	https://doi.org/10.1016/j.canlet.2015.12.022	https://doi.org/10.1016/j.canlet.2015.12.022	PROPN
chd-214	253	2	25	25	NUM
chd-214	253	3	.	.	PUNCT
chd-214	253	4	bonollo	bonollo	PROPN
chd-214	253	5	,	,	PUNCT
chd-214	253	6	f.	f.	PROPN
chd-214	253	7	,	,	PUNCT
chd-214	253	8	thalmann	thalmann	PROPN
chd-214	253	9	,	,	PUNCT
chd-214	253	10	g.	g.	PROPN
chd-214	253	11	n.	n.	PROPN
chd-214	253	12	,	,	PUNCT
chd-214	253	13	kruithof	kruithof	NOUN
chd-214	253	14	-	-	PUNCT
chd-214	253	15	de	de	X
chd-214	253	16	julio	julio	PROPN
chd-214	253	17	,	,	PUNCT
chd-214	253	18	m.	m.	NOUN
chd-214	253	19	,	,	PUNCT
chd-214	253	20	and	and	CCONJ
chd-214	253	21	karkampouna	karkampouna	PROPN
chd-214	253	22	,	,	PUNCT
chd-214	253	23	s.	s.	PROPN
chd-214	253	24	(	(	PUNCT
chd-214	253	25	2020	2020	NUM
chd-214	253	26	)	)	PUNCT
chd-214	253	27	.	.	PUNCT
chd-214	254	1	the	the	DET
chd-214	254	2	role	role	NOUN
chd-214	254	3	of	of	ADP
chd-214	254	4	cancer	cancer	NOUN
chd-214	254	5	-	-	PUNCT
chd-214	254	6	associated	associate	VERB
chd-214	254	7	fibroblasts	fibroblast	NOUN
chd-214	254	8	in	in	ADP
chd-214	254	9	prostate	prostate	NOUN
chd-214	254	10	cancer	cancer	NOUN
chd-214	254	11	tumorigenesis	tumorigenesis	NOUN
chd-214	254	12	.	.	PUNCT
chd-214	255	1	cancers	cancer	NOUN
chd-214	255	2	,	,	PUNCT
chd-214	255	3	12(7	12(7	NUM
chd-214	255	4	)	)	PUNCT
chd-214	255	5	,	,	PUNCT
chd-214	255	6	1887	1887	NUM
chd-214	255	7	.	.	PUNCT
chd-214	256	1	https://doi.org/10.3390/cancers12071887	https://doi.org/10.3390/cancers12071887	PROPN
chd-214	256	2	26	26	NUM
chd-214	256	3	.	.	PUNCT
chd-214	257	1	reams	ream	NOUN
chd-214	257	2	,	,	PUNCT
chd-214	257	3	r.	r.	PROPN
chd-214	257	4	r.	r.	PROPN
chd-214	257	5	,	,	PUNCT
chd-214	257	6	agrawal	agrawal	PROPN
chd-214	257	7	,	,	PUNCT
chd-214	257	8	d.	d.	PROPN
chd-214	257	9	,	,	PUNCT
chd-214	257	10	davis	davis	PROPN
chd-214	257	11	,	,	PUNCT
chd-214	257	12	m.	m.	PROPN
chd-214	257	13	b.	b.	PROPN
chd-214	257	14	,	,	PUNCT
chd-214	257	15	yoder	yoder	PROPN
chd-214	257	16	,	,	PUNCT
chd-214	257	17	s.	s.	PROPN
chd-214	257	18	,	,	PUNCT
chd-214	257	19	odedina	odedina	PROPN
chd-214	257	20	,	,	PUNCT
chd-214	257	21	f.	f.	PROPN
chd-214	257	22	t.	t.	PROPN
chd-214	257	23	,	,	PUNCT
chd-214	257	24	kumar	kumar	PROPN
chd-214	257	25	,	,	PUNCT
chd-214	257	26	n.	n.	PROPN
chd-214	257	27	,	,	PUNCT
chd-214	257	28	higginbotham	higginbotham	PROPN
chd-214	257	29	,	,	PUNCT
chd-214	257	30	j.	j.	PROPN
chd-214	257	31	m.	m.	PROPN
chd-214	257	32	,	,	PUNCT
chd-214	257	33	akinremi	akinremi	ADV
chd-214	257	34	,	,	PUNCT
chd-214	257	35	t.	t.	PROPN
chd-214	257	36	,	,	PUNCT
chd-214	257	37	suther	suther	ADV
chd-214	257	38	,	,	PUNCT
chd-214	257	39	s.	s.	PROPN
chd-214	257	40	,	,	PUNCT
chd-214	257	41	and	and	CCONJ
chd-214	257	42	soliman	soliman	NOUN
chd-214	257	43	,	,	PUNCT
chd-214	257	44	k.	k.	PROPN
chd-214	257	45	f.	f.	PROPN
chd-214	257	46	(	(	PUNCT
chd-214	257	47	2009	2009	NUM
chd-214	257	48	)	)	PUNCT
chd-214	257	49	.	.	PUNCT
chd-214	258	1	microarray	microarray	PROPN
chd-214	258	2	comparison	comparison	NOUN
chd-214	258	3	of	of	ADP
chd-214	258	4	prostate	prostate	NOUN
chd-214	258	5	tumor	tumor	NOUN
chd-214	258	6	gene	gene	NOUN
chd-214	258	7	expression	expression	NOUN
chd-214	258	8	in	in	ADP
chd-214	258	9	african	african	ADJ
chd-214	258	10	-	-	PUNCT
chd-214	258	11	american	american	ADJ
chd-214	258	12	and	and	CCONJ
chd-214	258	13	caucasian	caucasian	ADJ
chd-214	258	14	american	american	ADJ
chd-214	258	15	males	male	NOUN
chd-214	258	16	:	:	PUNCT
chd-214	258	17	a	a	DET
chd-214	258	18	pilot	pilot	NOUN
chd-214	258	19	project	project	NOUN
chd-214	258	20	study	study	NOUN
chd-214	258	21	.	.	PUNCT
chd-214	259	1	infectious	infectious	ADJ
chd-214	259	2	agents	agent	NOUN
chd-214	259	3	and	and	CCONJ
chd-214	259	4	cancer	cancer	NOUN
chd-214	259	5	,	,	PUNCT
chd-214	259	6	4	4	NUM
chd-214	259	7	suppl	suppl	NOUN
chd-214	259	8	1(suppl	1(suppl	NUM
chd-214	259	9	1	1	NUM
chd-214	259	10	)	)	PUNCT
chd-214	259	11	,	,	PUNCT
chd-214	259	12	s3	s3	PROPN
chd-214	259	13	.	.	PUNCT
chd-214	260	1	https://doi.org/10.1186/1750-9378-4-s1-s3	https://doi.org/10.1186/1750-9378-4-s1-s3	VERB
chd-214	260	2	27	27	NUM
chd-214	260	3	.	.	PUNCT
chd-214	261	1	yuan	yuan	PROPN
chd-214	261	2	,	,	PUNCT
chd-214	261	3	j.	j.	PROPN
chd-214	261	4	,	,	PUNCT
chd-214	261	5	kensler	kensler	PROPN
chd-214	261	6	,	,	PUNCT
chd-214	261	7	k.	k.	PROPN
chd-214	261	8	h.	h.	PROPN
chd-214	261	9	,	,	PUNCT
chd-214	261	10	hu	hu	PROPN
chd-214	261	11	,	,	PUNCT
chd-214	261	12	z.	z.	PROPN
chd-214	261	13	,	,	PUNCT
chd-214	261	14	zhang	zhang	PROPN
chd-214	261	15	,	,	PUNCT
chd-214	261	16	y.	y.	PROPN
chd-214	261	17	,	,	PUNCT
chd-214	261	18	zhang	zhang	PROPN
chd-214	261	19	,	,	PUNCT
chd-214	261	20	t.	t.	PROPN
chd-214	261	21	,	,	PUNCT
chd-214	261	22	jiang	jiang	PROPN
chd-214	261	23	,	,	PUNCT
chd-214	261	24	j.	j.	PROPN
chd-214	261	25	,	,	PUNCT
chd-214	261	26	xu	xu	PROPN
chd-214	261	27	,	,	PUNCT
chd-214	261	28	m.	m.	NOUN
chd-214	261	29	,	,	PUNCT
chd-214	261	30	pan	pan	PROPN
chd-214	261	31	,	,	PUNCT
chd-214	261	32	y.	y.	PROPN
chd-214	261	33	,	,	PUNCT
chd-214	261	34	long	long	ADV
chd-214	261	35	,	,	PUNCT
chd-214	261	36	m.	m.	NOUN
chd-214	261	37	,	,	PUNCT
chd-214	261	38	montone	montone	PROPN
chd-214	261	39	,	,	PUNCT
chd-214	261	40	k.	k.	PROPN
chd-214	261	41	t.	t.	PROPN
chd-214	261	42	,	,	PUNCT
chd-214	261	43	tanyi	tanyi	PROPN
chd-214	261	44	,	,	PUNCT
chd-214	261	45	j.	j.	PROPN
chd-214	261	46	l.	l.	PROPN
chd-214	261	47	,	,	PUNCT
chd-214	261	48	fan	fan	PROPN
chd-214	261	49	,	,	PUNCT
chd-214	261	50	y.	y.	PROPN
chd-214	261	51	,	,	PUNCT
chd-214	261	52	zhang	zhang	PROPN
chd-214	261	53	,	,	PUNCT
chd-214	261	54	r.	r.	PROPN
chd-214	261	55	,	,	PUNCT
chd-214	261	56	hu	hu	PROPN
chd-214	261	57	,	,	PUNCT
chd-214	261	58	x.	x.	PROPN
chd-214	261	59	,	,	PUNCT
chd-214	261	60	rebbeck	rebbeck	PROPN
chd-214	261	61	,	,	PUNCT
chd-214	261	62	t.	t.	PROPN
chd-214	261	63	r.	r.	PROPN
chd-214	261	64	,	,	PUNCT
chd-214	261	65	and	and	CCONJ
chd-214	261	66	zhang	zhang	PROPN
chd-214	261	67	,	,	PUNCT
chd-214	261	68	l.	l.	PROPN
chd-214	261	69	(	(	PUNCT
chd-214	261	70	2020	2020	NUM
chd-214	261	71	)	)	PUNCT
chd-214	261	72	.	.	PUNCT
chd-214	262	1	integrative	integrative	ADJ
chd-214	262	2	comparison	comparison	NOUN
chd-214	262	3	of	of	ADP
chd-214	262	4	the	the	DET
chd-214	262	5	genomic	genomic	NOUN
chd-214	262	6	and	and	CCONJ
chd-214	262	7	transcriptomic	transcriptomic	ADJ
chd-214	262	8	landscape	landscape	NOUN
chd-214	262	9	between	between	ADP
chd-214	262	10	prostate	prostate	NOUN
chd-214	262	11	cancer	cancer	NOUN
chd-214	262	12	patients	patient	NOUN
chd-214	262	13	of	of	ADP
chd-214	262	14	predominantly	predominantly	ADV
chd-214	262	15	african	african	ADJ
chd-214	262	16	or	or	CCONJ
chd-214	262	17	european	european	ADJ
chd-214	262	18	genetic	genetic	ADJ
chd-214	262	19	ancestry	ancestry	NOUN
chd-214	262	20	.	.	PUNCT
chd-214	263	1	plos	plos	PROPN
chd-214	263	2	genetics	genetics	PROPN
chd-214	263	3	,	,	PUNCT
chd-214	263	4	16(2	16(2	NUM
chd-214	263	5	)	)	PUNCT
chd-214	263	6	,	,	PUNCT
chd-214	263	7	e1008641	e1008641	PROPN
chd-214	263	8	.	.	PUNCT
chd-214	264	1	https://doi.org/10.1371/journal.pgen.1008641	https://doi.org/10.1371/journal.pgen.1008641	PROPN
chd-214	264	2	28	28	NUM
chd-214	264	3	.	.	PUNCT
chd-214	265	1	weiner	weiner	NOUN
chd-214	265	2	,	,	PUNCT
chd-214	265	3	a.	a.	PROPN
chd-214	265	4	b.	b.	PROPN
chd-214	265	5	,	,	PUNCT
chd-214	265	6	vidotto	vidotto	NOUN
chd-214	265	7	,	,	PUNCT
chd-214	265	8	t.	t.	PROPN
chd-214	265	9	,	,	PUNCT
chd-214	265	10	liu	liu	PROPN
chd-214	265	11	,	,	PUNCT
chd-214	265	12	y.	y.	PROPN
chd-214	265	13	,	,	PUNCT
chd-214	265	14	mendes	mende	NOUN
chd-214	265	15	,	,	PUNCT
chd-214	265	16	a.	a.	NOUN
chd-214	265	17	a.	a.	PROPN
chd-214	265	18	,	,	PUNCT
chd-214	265	19	salles	salles	PROPN
chd-214	265	20	,	,	PUNCT
chd-214	265	21	d.	d.	PROPN
chd-214	265	22	c.	c.	PROPN
chd-214	265	23	,	,	PUNCT
chd-214	265	24	faisal	faisal	PROPN
chd-214	265	25	,	,	PUNCT
chd-214	265	26	f.	f.	PROPN
chd-214	265	27	a.	a.	PROPN
chd-214	265	28	,	,	PUNCT
chd-214	265	29	murali	murali	PROPN
chd-214	265	30	,	,	PUNCT
chd-214	265	31	s.	s.	PROPN
chd-214	265	32	,	,	PUNCT
chd-214	265	33	mcfarlane	mcfarlane	PROPN
chd-214	265	34	,	,	PUNCT
chd-214	265	35	m.	m.	NOUN
chd-214	265	36	,	,	PUNCT
chd-214	265	37	imada	imada	PROPN
chd-214	265	38	,	,	PUNCT
chd-214	265	39	e.	e.	PROPN
chd-214	265	40	l.	l.	PROPN
chd-214	265	41	,	,	PUNCT
chd-214	265	42	zhao	zhao	PROPN
chd-214	265	43	,	,	PUNCT
chd-214	265	44	x.	x.	PROPN
chd-214	265	45	,	,	PUNCT
chd-214	265	46	li	li	PROPN
chd-214	265	47	,	,	PUNCT
chd-214	265	48	z.	z.	PROPN
chd-214	265	49	,	,	PUNCT
chd-214	265	50	davicioni	davicioni	PROPN
chd-214	265	51	,	,	PUNCT
chd-214	265	52	e.	e.	PROPN
chd-214	265	53	,	,	PUNCT
chd-214	265	54	marchionni	marchionni	PROPN
chd-214	265	55	,	,	PUNCT
chd-214	265	56	l.	l.	PROPN
chd-214	265	57	,	,	PUNCT
chd-214	265	58	chinnaiyan	chinnaiyan	PROPN
chd-214	265	59	,	,	PUNCT
chd-214	265	60	a.	a.	NOUN
chd-214	265	61	m.	m.	NOUN
chd-214	265	62	,	,	PUNCT
chd-214	265	63	freedland	freedland	PROPN
chd-214	265	64	,	,	PUNCT
chd-214	265	65	s.	s.	PROPN
chd-214	265	66	j.	j.	PROPN
chd-214	265	67	,	,	PUNCT
chd-214	265	68	spratt	spratt	PROPN
chd-214	265	69	,	,	PUNCT
chd-214	265	70	d.	d.	PROPN
chd-214	265	71	e.	e.	PROPN
chd-214	265	72	,	,	PUNCT
chd-214	265	73	wu	wu	PROPN
chd-214	265	74	,	,	PUNCT
chd-214	265	75	j.	j.	PROPN
chd-214	265	76	d.	d.	PROPN
chd-214	265	77	,	,	PUNCT
chd-214	265	78	lotan	lotan	PROPN
chd-214	265	79	,	,	PUNCT
chd-214	265	80	t.	t.	PROPN
chd-214	265	81	l.	l.	PROPN
chd-214	265	82	,	,	PUNCT
chd-214	265	83	and	and	CCONJ
chd-214	265	84	schaeffer	schaeffer	PROPN
chd-214	265	85	,	,	PUNCT
chd-214	265	86	e.	e.	PROPN
chd-214	265	87	m.	m.	PROPN
chd-214	265	88	(	(	PUNCT
chd-214	265	89	2021	2021	NUM
chd-214	265	90	)	)	PUNCT
chd-214	265	91	.	.	PUNCT
chd-214	266	1	plasma	plasma	NOUN
chd-214	266	2	cells	cell	NOUN
chd-214	266	3	are	be	AUX
chd-214	266	4	enriched	enrich	VERB
chd-214	266	5	in	in	ADP
chd-214	266	6	localized	localized	ADJ
chd-214	266	7	prostate	prostate	NOUN
chd-214	266	8	cancer	cancer	NOUN
chd-214	266	9	in	in	ADP
chd-214	266	10	black	black	ADJ
chd-214	266	11	men	man	NOUN
chd-214	266	12	and	and	CCONJ
chd-214	266	13	are	be	AUX
chd-214	266	14	associated	associate	VERB
chd-214	266	15	with	with	ADP
chd-214	266	16	improved	improved	ADJ
chd-214	266	17	outcomes	outcome	NOUN
chd-214	266	18	.	.	PUNCT
chd-214	267	1	nature	nature	NOUN
chd-214	267	2	communications	communication	NOUN
chd-214	267	3	,	,	PUNCT
chd-214	267	4	12(1	12(1	NUM
chd-214	267	5	)	)	PUNCT
chd-214	267	6	,	,	PUNCT
chd-214	267	7	935	935	NUM
chd-214	267	8	.	.	PUNCT
chd-214	268	1	https://doi.org/10.1038/s41467-021-21245-w	https://doi.org/10.1038/s41467-021-21245-w	PROPN
chd-214	268	2	.	.	PUNCT
chd-214	269	1	29	29	NUM
chd-214	269	2	.	.	PUNCT
chd-214	270	1	rahmatpanah	rahmatpanah	PROPN
chd-214	270	2	,	,	PUNCT
chd-214	270	3	f.	f.	PROPN
chd-214	270	4	,	,	PUNCT
chd-214	270	5	robles	robles	PROPN
chd-214	270	6	,	,	PUNCT
chd-214	270	7	g.	g.	PROPN
chd-214	270	8	,	,	PUNCT
chd-214	270	9	lilly	lilly	PROPN
chd-214	270	10	,	,	PUNCT
chd-214	270	11	m.	m.	NOUN
chd-214	270	12	,	,	PUNCT
chd-214	270	13	keane	keane	PROPN
chd-214	270	14	,	,	PUNCT
chd-214	270	15	t.	t.	PROPN
chd-214	270	16	,	,	PUNCT
chd-214	270	17	kumar	kumar	PROPN
chd-214	270	18	,	,	PUNCT
chd-214	270	19	v.	v.	PROPN
chd-214	270	20	,	,	PUNCT
chd-214	270	21	mercola	mercola	PROPN
chd-214	270	22	,	,	PUNCT
chd-214	270	23	d.	d.	PROPN
chd-214	270	24	,	,	PUNCT
chd-214	270	25	randhawa	randhawa	PROPN
chd-214	270	26	,	,	PUNCT
chd-214	270	27	p.	p.	NOUN
chd-214	270	28	,	,	PUNCT
chd-214	270	29	and	and	CCONJ
chd-214	270	30	mcclelland	mcclelland	NOUN
chd-214	270	31	,	,	PUNCT
chd-214	270	32	m.	m.	NOUN
chd-214	270	33	(	(	PUNCT
chd-214	270	34	2021	2021	NUM
chd-214	270	35	)	)	PUNCT
chd-214	270	36	.	.	PUNCT
chd-214	271	1	rna	rna	NOUN
chd-214	271	2	expression	expression	NOUN
chd-214	271	3	differences	difference	NOUN
chd-214	271	4	in	in	ADP
chd-214	271	5	prostate	prostate	NOUN
chd-214	271	6	tumors	tumor	NOUN
chd-214	271	7	and	and	CCONJ
chd-214	271	8	tumoradjacent	tumoradjacent	NOUN
chd-214	271	9	stroma	stroma	NOUN
chd-214	271	10	between	between	ADP
chd-214	271	11	black	black	ADJ
chd-214	271	12	and	and	CCONJ
chd-214	271	13	white	white	ADJ
chd-214	271	14	americans	americans	PROPN
chd-214	271	15	.	.	PUNCT
chd-214	272	1	oncotarget	oncotarget	NOUN
chd-214	272	2	,	,	PUNCT
chd-214	272	3	12(15	12(15	NUM
chd-214	272	4	)	)	PUNCT
chd-214	272	5	,	,	PUNCT
chd-214	272	6	1457–1469	1457–1469	NUM
chd-214	272	7	.	.	PUNCT
chd-214	273	1	https://	https://	PROPN
chd-214	273	2	doi.org/10.18632/oncotarget.28024	doi.org/10.18632/oncotarget.28024	PROPN
chd-214	273	3	30	30	NUM
chd-214	273	4	.	.	PUNCT
chd-214	274	1	franco	franco	PROPN
chd-214	274	2	,	,	PUNCT
chd-214	274	3	o.	o.	PROPN
chd-214	274	4	e.	e.	PROPN
chd-214	274	5	,	,	PUNCT
chd-214	274	6	shaw	shaw	PROPN
chd-214	274	7	,	,	PUNCT
chd-214	274	8	a.	a.	PROPN
chd-214	274	9	k.	k.	PROPN
chd-214	274	10	,	,	PUNCT
chd-214	274	11	strand	strand	PROPN
chd-214	274	12	,	,	PUNCT
chd-214	274	13	d.	d.	PROPN
chd-214	274	14	w.	w.	PROPN
chd-214	274	15	,	,	PUNCT
chd-214	274	16	and	and	CCONJ
chd-214	274	17	hayward	hayward	PROPN
chd-214	274	18	,	,	PUNCT
chd-214	274	19	s.	s.	PROPN
chd-214	274	20	w.	w.	PROPN
chd-214	274	21	(	(	PUNCT
chd-214	274	22	2010	2010	NUM
chd-214	274	23	)	)	PUNCT
chd-214	274	24	.	.	PUNCT
chd-214	275	1	cancer	cancer	NOUN
chd-214	275	2	associated	associate	VERB
chd-214	275	3	fibroblasts	fibroblast	NOUN
chd-214	275	4	in	in	ADP
chd-214	275	5	cancer	cancer	NOUN
chd-214	275	6	pathogenesis	pathogenesis	NOUN
chd-214	275	7	.	.	PUNCT
chd-214	276	1	seminars	seminar	NOUN
chd-214	276	2	in	in	ADP
chd-214	276	3	cell	cell	NOUN
chd-214	276	4	&	&	CCONJ
chd-214	276	5	developmental	developmental	ADJ
chd-214	276	6	biology	biology	NOUN
chd-214	276	7	,	,	PUNCT
chd-214	276	8	21(1	21(1	NUM
chd-214	276	9	)	)	PUNCT
chd-214	276	10	,	,	PUNCT
chd-214	276	11	33–39	33–39	NUM
chd-214	276	12	.	.	PUNCT
chd-214	277	1	https://doi.org/10.1016/j.semcdb.2009.10.010	https://doi.org/10.1016/j.semcdb.2009.10.010	NOUN
chd-214	277	2	31	31	NUM
chd-214	277	3	.	.	PUNCT
chd-214	278	1	chiarugi	chiarugi	NOUN
chd-214	278	2	,	,	PUNCT
chd-214	278	3	p.	p.	NOUN
chd-214	278	4	,	,	PUNCT
chd-214	278	5	paoli	paoli	PROPN
chd-214	278	6	,	,	PUNCT
chd-214	278	7	p.	p.	PROPN
chd-214	278	8	,	,	PUNCT
chd-214	278	9	&	&	CCONJ
chd-214	278	10	cirri	cirri	PROPN
chd-214	278	11	,	,	PUNCT
chd-214	278	12	p.	p.	NOUN
chd-214	278	13	(	(	PUNCT
chd-214	278	14	2014	2014	NUM
chd-214	278	15	)	)	PUNCT
chd-214	278	16	.	.	PUNCT
chd-214	279	1	tumor	tumor	NOUN
chd-214	279	2	microenvironment	microenvironment	NOUN
chd-214	279	3	and	and	CCONJ
chd-214	279	4	metabolism	metabolism	NOUN
chd-214	279	5	in	in	ADP
chd-214	279	6	prostate	prostate	NOUN
chd-214	279	7	cancer	cancer	NOUN
chd-214	279	8	.	.	PUNCT
chd-214	280	1	seminars	seminar	NOUN
chd-214	280	2	in	in	ADP
chd-214	280	3	oncology	oncology	NOUN
chd-214	280	4	,	,	PUNCT
chd-214	280	5	41(2	41(2	NUM
chd-214	280	6	)	)	PUNCT
chd-214	280	7	,	,	PUNCT
chd-214	280	8	267–280	267–280	NUM
chd-214	280	9	.	.	PUNCT
chd-214	281	1	https://doi.org/10.1053/	https://doi.org/10.1053/	PROPN
chd-214	281	2	j.seminoncol.2014.03.004	j.seminoncol.2014.03.004	PROPN
chd-214	281	3	32	32	NUM
chd-214	281	4	.	.	PUNCT
chd-214	281	5	ayala	ayala	PROPN
chd-214	281	6	,	,	PUNCT
chd-214	281	7	g.	g.	PROPN
chd-214	281	8	,	,	PUNCT
chd-214	281	9	morello	morello	PROPN
chd-214	281	10	,	,	PUNCT
chd-214	281	11	m.	m.	NOUN
chd-214	281	12	,	,	PUNCT
chd-214	281	13	frolov	frolov	PROPN
chd-214	281	14	,	,	PUNCT
chd-214	281	15	a.	a.	NOUN
chd-214	281	16	,	,	PUNCT
chd-214	281	17	you	you	PRON
chd-214	281	18	,	,	PUNCT
chd-214	281	19	s.	s.	PROPN
chd-214	281	20	,	,	PUNCT
chd-214	281	21	li	li	PROPN
chd-214	281	22	,	,	PUNCT
chd-214	281	23	r.	r.	PROPN
chd-214	281	24	,	,	PUNCT
chd-214	281	25	rosati	rosati	PROPN
chd-214	281	26	,	,	PUNCT
chd-214	281	27	f.	f.	PROPN
chd-214	281	28	,	,	PUNCT
chd-214	281	29	bartolucci	bartolucci	PROPN
chd-214	281	30	,	,	PUNCT
chd-214	281	31	g.	g.	PROPN
chd-214	281	32	,	,	PUNCT
chd-214	281	33	danza	danza	NOUN
chd-214	281	34	,	,	PUNCT
chd-214	281	35	g.	g.	PROPN
chd-214	281	36	,	,	PUNCT
chd-214	281	37	adam	adam	PROPN
chd-214	281	38	,	,	PUNCT
chd-214	281	39	r.	r.	PROPN
chd-214	281	40	m.	m.	PROPN
chd-214	281	41	,	,	PUNCT
chd-214	281	42	thompson	thompson	PROPN
chd-214	281	43	,	,	PUNCT
chd-214	281	44	t.	t.	PROPN
chd-214	281	45	c.	c.	PROPN
chd-214	281	46	,	,	PUNCT
chd-214	281	47	lisanti	lisanti	PROPN
chd-214	281	48	,	,	PUNCT
chd-214	281	49	m.	m.	NOUN
chd-214	281	50	p.	p.	PROPN
chd-214	281	51	,	,	PUNCT
chd-214	281	52	freeman	freeman	PROPN
chd-214	281	53	,	,	PUNCT
chd-214	281	54	m.	m.	NOUN
chd-214	281	55	r.	r.	PROPN
chd-214	281	56	,	,	PUNCT
chd-214	281	57	and	and	CCONJ
chd-214	281	58	vizio	vizio	PROPN
chd-214	281	59	,	,	PUNCT
chd-214	281	60	d.	d.	PROPN
chd-214	281	61	d.	d.	PROPN
chd-214	281	62	(	(	PUNCT
chd-214	281	63	2013	2013	NUM
chd-214	281	64	)	)	PUNCT
chd-214	281	65	.	.	PUNCT
chd-214	282	1	loss	loss	NOUN
chd-214	282	2	of	of	ADP
chd-214	282	3	caveolin-1	caveolin-1	NUM
chd-214	282	4	in	in	ADP
chd-214	282	5	prostate	prostate	NOUN
chd-214	282	6	cancer	cancer	NOUN
chd-214	282	7	stroma	stroma	NOUN
chd-214	282	8	correlates	correlate	VERB
chd-214	282	9	with	with	ADP
chd-214	282	10	reduced	reduced	ADJ
chd-214	282	11	relapse	relapse	NOUN
chd-214	282	12	-	-	PUNCT
chd-214	282	13	free	free	ADJ
chd-214	282	14	survival	survival	NOUN
chd-214	282	15	and	and	CCONJ
chd-214	282	16	is	be	AUX
chd-214	282	17	functionally	functionally	ADV
chd-214	282	18	relevant	relevant	ADJ
chd-214	282	19	to	to	ADP
chd-214	282	20	tumour	tumour	NOUN
chd-214	282	21	progression	progression	NOUN
chd-214	282	22	.	.	PUNCT
chd-214	283	1	the	the	DET
chd-214	283	2	journal	journal	PROPN
chd-214	283	3	of	of	ADP
chd-214	283	4	pathology	pathology	PROPN
chd-214	283	5	,	,	PUNCT
chd-214	283	6	231(1	231(1	NUM
chd-214	283	7	)	)	PUNCT
chd-214	283	8	,	,	PUNCT
chd-214	283	9	77–87	77–87	NUM
chd-214	283	10	.	.	PUNCT
chd-214	283	11	https://doi.org/10.1002/path.4217	https://doi.org/10.1002/path.4217	PROPN
chd-214	283	12	33	33	NUM
chd-214	283	13	.	.	PUNCT
chd-214	284	1	chen	chen	PROPN
chd-214	284	2	,	,	PUNCT
chd-214	284	3	d.	d.	PROPN
chd-214	284	4	,	,	PUNCT
chd-214	284	5	and	and	CCONJ
chd-214	284	6	che	che	PROPN
chd-214	284	7	,	,	PUNCT
chd-214	284	8	g.	g.	PROPN
chd-214	284	9	(	(	PUNCT
chd-214	284	10	2014	2014	NUM
chd-214	284	11	)	)	PUNCT
chd-214	284	12	.	.	PUNCT
chd-214	285	1	value	value	NOUN
chd-214	285	2	of	of	ADP
chd-214	285	3	caveolin-1	caveolin-1	NUM
chd-214	285	4	in	in	ADP
chd-214	285	5	cancer	cancer	NOUN
chd-214	285	6	progression	progression	NOUN
chd-214	285	7	and	and	CCONJ
chd-214	285	8	prognosis	prognosis	NOUN
chd-214	285	9	:	:	PUNCT
chd-214	285	10	emphasis	emphasis	NOUN
chd-214	285	11	on	on	ADP
chd-214	285	12	cancerassociated	cancerassociate	VERB
chd-214	285	13	fibroblasts	fibroblast	NOUN
chd-214	285	14	,	,	PUNCT
chd-214	285	15	human	human	ADJ
chd-214	285	16	cancer	cancer	NOUN
chd-214	285	17	cells	cell	NOUN
chd-214	285	18	and	and	CCONJ
chd-214	285	19	mechanism	mechanism	NOUN
chd-214	285	20	of	of	ADP
chd-214	285	21	caveolin-1	caveolin-1	NUM
chd-214	285	22	expression	expression	NOUN
chd-214	285	23	(	(	PUNCT
chd-214	285	24	review	review	NOUN
chd-214	285	25	)	)	PUNCT
chd-214	285	26	.	.	PUNCT
chd-214	286	1	oncology	oncology	NOUN
chd-214	286	2	letters	letter	NOUN
chd-214	286	3	,	,	PUNCT
chd-214	286	4	8(4	8(4	NUM
chd-214	286	5	)	)	PUNCT
chd-214	286	6	,	,	PUNCT
chd-214	286	7	1409–1421	1409–1421	NUM
chd-214	286	8	.	.	PUNCT
chd-214	287	1	https://doi.org/10.3892/	https://doi.org/10.3892/	PROPN
chd-214	287	2	ol.2014.2385	ol.2014.2385	VERB
chd-214	287	3	34	34	NUM
chd-214	287	4	.	.	PUNCT
chd-214	288	1	ni	ni	PROPN
chd-214	288	2	,	,	PUNCT
chd-214	288	3	w.	w.	PROPN
chd-214	288	4	d.	d.	PROPN
chd-214	288	5	,	,	PUNCT
chd-214	288	6	yang	yang	PROPN
chd-214	288	7	,	,	PUNCT
chd-214	288	8	z.	z.	PROPN
chd-214	288	9	t.	t.	PROPN
chd-214	288	10	,	,	PUNCT
chd-214	288	11	cui	cui	PROPN
chd-214	288	12	,	,	PUNCT
chd-214	288	13	c.	c.	PROPN
chd-214	288	14	a.	a.	PROPN
chd-214	288	15	,	,	PUNCT
chd-214	288	16	cui	cui	PROPN
chd-214	288	17	,	,	PUNCT
chd-214	288	18	y.	y.	PROPN
chd-214	288	19	,	,	PUNCT
chd-214	288	20	fang	fang	PROPN
chd-214	288	21	,	,	PUNCT
chd-214	288	22	l.	l.	PROPN
chd-214	288	23	y.	y.	PROPN
chd-214	288	24	,	,	PUNCT
chd-214	288	25	and	and	CCONJ
chd-214	288	26	xuan	xuan	PROPN
chd-214	288	27	,	,	PUNCT
chd-214	288	28	y.	y.	PROPN
chd-214	288	29	h.	h.	PROPN
chd-214	288	30	(	(	PUNCT
chd-214	288	31	2017	2017	NUM
chd-214	288	32	)	)	PUNCT
chd-214	288	33	.	.	PUNCT
chd-214	289	1	tenascin	tenascin	PROPN
chd-214	289	2	-	-	PUNCT
chd-214	289	3	c	c	PROPN
chd-214	289	4	is	be	AUX
chd-214	289	5	a	a	DET
chd-214	289	6	potential	potential	ADJ
chd-214	289	7	cancerassociated	cancerassociate	VERB
chd-214	289	8	fibroblasts	fibroblast	NOUN
chd-214	289	9	marker	marker	NOUN
chd-214	289	10	and	and	CCONJ
chd-214	289	11	predicts	predict	VERB
chd-214	289	12	poor	poor	ADJ
chd-214	289	13	prognosis	prognosis	NOUN
chd-214	289	14	in	in	ADP
chd-214	289	15	prostate	prostate	NOUN
chd-214	289	16	cancer	cancer	NOUN
chd-214	289	17	.	.	PUNCT
chd-214	290	1	biochemical	biochemical	ADJ
chd-214	290	2	and	and	CCONJ
chd-214	290	3	biophysical	biophysical	ADJ
chd-214	290	4	research	research	NOUN
chd-214	290	5	communications	communication	NOUN
chd-214	290	6	,	,	PUNCT
chd-214	290	7	486(3	486(3	NUM
chd-214	290	8	)	)	PUNCT
chd-214	290	9	,	,	PUNCT
chd-214	290	10	607–612	607–612	NUM
chd-214	290	11	.	.	PUNCT
chd-214	291	1	https://doi.org/10.1016/j.bbrc.2017.03.021	https://doi.org/10.1016/j.bbrc.2017.03.021	NOUN
chd-214	291	2	35	35	NUM
chd-214	291	3	.	.	PUNCT
chd-214	292	1	strasner	strasn	ADJ
chd-214	292	2	,	,	PUNCT
chd-214	292	3	a.	a.	NOUN
chd-214	292	4	,	,	PUNCT
chd-214	292	5	&	&	CCONJ
chd-214	292	6	karin	karin	PROPN
chd-214	292	7	,	,	PUNCT
chd-214	292	8	m.	m.	NOUN
chd-214	292	9	(	(	PUNCT
chd-214	292	10	2015	2015	NUM
chd-214	292	11	)	)	PUNCT
chd-214	292	12	.	.	PUNCT
chd-214	293	1	immune	immune	ADJ
chd-214	293	2	infiltration	infiltration	NOUN
chd-214	293	3	and	and	CCONJ
chd-214	293	4	prostate	prostate	NOUN
chd-214	293	5	cancer	cancer	NOUN
chd-214	293	6	.	.	PUNCT
chd-214	294	1	frontiers	frontier	NOUN
chd-214	294	2	in	in	ADP
chd-214	294	3	oncology	oncology	NOUN
chd-214	294	4	,	,	PUNCT
chd-214	294	5	5	5	NUM
chd-214	294	6	,	,	PUNCT
chd-214	294	7	128	128	NUM
chd-214	294	8	.	.	PUNCT
chd-214	295	1	https://doi.org/10.3389/fonc.2015.00128	https://doi.org/10.3389/fonc.2015.00128	PROPN
chd-214	295	2	.	.	PROPN
chd-214	296	1	36	36	NUM
chd-214	296	2	.	.	PUNCT
chd-214	297	1	king	king	PROPN
chd-214	297	2	thomas	thomas	PROPN
chd-214	297	3	,	,	PUNCT
chd-214	297	4	j.	j.	PROPN
chd-214	297	5	,	,	PUNCT
chd-214	297	6	mir	mir	PROPN
chd-214	297	7	,	,	PUNCT
chd-214	297	8	h.	h.	PROPN
chd-214	297	9	,	,	PUNCT
chd-214	297	10	kapur	kapur	PROPN
chd-214	297	11	,	,	PUNCT
chd-214	297	12	n.	n.	PROPN
chd-214	297	13	,	,	PUNCT
chd-214	297	14	&	&	CCONJ
chd-214	297	15	singh	singh	PROPN
chd-214	297	16	,	,	PUNCT
chd-214	297	17	s.	s.	PROPN
chd-214	297	18	(	(	PUNCT
chd-214	297	19	2019	2019	NUM
chd-214	297	20	)	)	PUNCT
chd-214	297	21	.	.	PUNCT
chd-214	298	1	racial	racial	ADJ
chd-214	298	2	differences	difference	NOUN
chd-214	298	3	in	in	ADP
chd-214	298	4	immunological	immunological	ADJ
chd-214	298	5	landscape	landscape	NOUN
chd-214	298	6	modifiers	modifier	NOUN
chd-214	298	7	contributing	contribute	VERB
chd-214	298	8	to	to	ADP
chd-214	298	9	disparity	disparity	NOUN
chd-214	298	10	in	in	ADP
chd-214	298	11	prostate	prostate	NOUN
chd-214	298	12	cancer	cancer	NOUN
chd-214	298	13	.	.	PUNCT
chd-214	299	1	cancers	cancer	NOUN
chd-214	299	2	,	,	PUNCT
chd-214	299	3	11(12	11(12	NUM
chd-214	299	4	)	)	PUNCT
chd-214	299	5	,	,	PUNCT
chd-214	299	6	1857	1857	NUM
chd-214	299	7	.	.	PUNCT
chd-214	300	1	https://doi.org/10.3390/cancers11121857	https://doi.org/10.3390/cancers11121857	PROPN
chd-214	300	2	37	37	NUM
chd-214	300	3	.	.	PUNCT
chd-214	301	1	sentana	sentana	NOUN
chd-214	301	2	-	-	PUNCT
chd-214	301	3	lledo	lledo	PROPN
chd-214	301	4	,	,	PUNCT
chd-214	301	5	d.	d.	PROPN
chd-214	301	6	,	,	PUNCT
chd-214	301	7	sartor	sartor	PROPN
chd-214	301	8	,	,	PUNCT
chd-214	301	9	o.	o.	NOUN
chd-214	301	10	,	,	PUNCT
chd-214	301	11	balk	balk	VERB
chd-214	301	12	,	,	PUNCT
chd-214	301	13	s.	s.	PROPN
chd-214	301	14	p.	p.	PROPN
chd-214	301	15	,	,	PUNCT
chd-214	301	16	&	&	CCONJ
chd-214	301	17	einstein	einstein	PROPN
chd-214	301	18	,	,	PUNCT
chd-214	301	19	d.	d.	PROPN
chd-214	301	20	j.	j.	PROPN
chd-214	301	21	(	(	PUNCT
chd-214	301	22	2022	2022	NUM
chd-214	301	23	)	)	PUNCT
chd-214	301	24	.	.	PUNCT
chd-214	302	1	immune	immune	ADJ
chd-214	302	2	mechanisms	mechanism	NOUN
chd-214	302	3	behind	behind	ADP
chd-214	302	4	prostate	prostate	NOUN
chd-214	302	5	cancer	cancer	NOUN
chd-214	302	6	in	in	ADP
chd-214	302	7	men	man	NOUN
chd-214	302	8	of	of	ADP
chd-214	302	9	african	african	ADJ
chd-214	302	10	ancestry	ancestry	NOUN
chd-214	302	11	:	:	PUNCT
chd-214	302	12	a	a	DET
chd-214	302	13	review	review	NOUN
chd-214	302	14	.	.	PUNCT
chd-214	303	1	the	the	DET
chd-214	303	2	prostate	prostate	NOUN
chd-214	303	3	,	,	PUNCT
chd-214	303	4	10.1002	10.1002	NUM
chd-214	303	5	/	/	SYM
chd-214	303	6	pros.24333	pros.24333	PROPN
chd-214	303	7	.	.	PUNCT
chd-214	303	8	advance	advance	VERB
chd-214	303	9	online	online	ADJ
chd-214	303	10	publication	publication	NOUN
chd-214	303	11	.	.	PUNCT
chd-214	304	1	https://doi.org/10.1002/pros.24333	https://doi.org/10.1002/pros.24333	ADJ
chd-214	304	2	38	38	NUM
chd-214	304	3	.	.	PUNCT
chd-214	305	1	awasthi	awasthi	PROPN
chd-214	305	2	,	,	PUNCT
chd-214	305	3	s.	s.	PROPN
chd-214	305	4	,	,	PUNCT
chd-214	305	5	berglund	berglund	PROPN
chd-214	305	6	,	,	PUNCT
chd-214	305	7	a.	a.	PROPN
chd-214	305	8	,	,	PUNCT
chd-214	305	9	abraham	abraham	PROPN
chd-214	305	10	-	-	PUNCT
chd-214	305	11	miranda	miranda	PROPN
chd-214	305	12	,	,	PUNCT
chd-214	305	13	j.	j.	PROPN
chd-214	305	14	,	,	PUNCT
chd-214	305	15	rounbehler	rounbehler	PROPN
chd-214	305	16	,	,	PUNCT
chd-214	305	17	r.	r.	PROPN
chd-214	305	18	j.	j.	PROPN
chd-214	305	19	,	,	PUNCT
chd-214	305	20	kensler	kensler	PROPN
chd-214	305	21	,	,	PUNCT
chd-214	305	22	k.	k.	PROPN
chd-214	305	23	,	,	PUNCT
chd-214	305	24	serna	serna	PROPN
chd-214	305	25	,	,	PUNCT
chd-214	305	26	a.	a.	NOUN
chd-214	305	27	,	,	PUNCT
chd-214	305	28	vidal	vidal	NOUN
chd-214	305	29	,	,	PUNCT
chd-214	305	30	a.	a.	NOUN
chd-214	305	31	,	,	PUNCT
chd-214	305	32	you	you	PRON
chd-214	305	33	,	,	PUNCT
chd-214	305	34	s.	s.	PROPN
chd-214	305	35	,	,	PUNCT
chd-214	305	36	freeman	freeman	PROPN
chd-214	305	37	,	,	PUNCT
chd-214	305	38	m.	m.	PROPN
chd-214	305	39	r.	r.	PROPN
chd-214	305	40	,	,	PUNCT
chd-214	305	41	davicioni	davicioni	PROPN
chd-214	305	42	,	,	PUNCT
chd-214	305	43	e.	e.	PROPN
chd-214	305	44	,	,	PUNCT
chd-214	305	45	liu	liu	PROPN
chd-214	305	46	,	,	PUNCT
chd-214	305	47	y.	y.	PROPN
chd-214	305	48	,	,	PUNCT
chd-214	305	49	karnes	karnes	PROPN
chd-214	305	50	,	,	PUNCT
chd-214	305	51	r.	r.	PROPN
chd-214	305	52	j.	j.	PROPN
chd-214	305	53	,	,	PUNCT
chd-214	305	54	klein	klein	PROPN
chd-214	305	55	,	,	PUNCT
chd-214	305	56	e.	e.	PROPN
chd-214	305	57	a.	a.	PROPN
chd-214	305	58	,	,	PUNCT
chd-214	305	59	den	den	PROPN
chd-214	305	60	,	,	PUNCT
chd-214	305	61	r.	r.	PROPN
chd-214	305	62	b.	b.	PROPN
chd-214	305	63	,	,	PUNCT
chd-214	305	64	trock	trock	NOUN
chd-214	305	65	,	,	PUNCT
chd-214	305	66	b.	b.	PROPN
chd-214	305	67	j.	j.	PROPN
chd-214	305	68	,	,	PUNCT
chd-214	305	69	campbell	campbell	PROPN
chd-214	305	70	,	,	PUNCT
chd-214	305	71	j.	j.	PROPN
chd-214	305	72	d.	d.	PROPN
chd-214	305	73	,	,	PUNCT
chd-214	305	74	einstein	einstein	PROPN
chd-214	305	75	,	,	PUNCT
chd-214	305	76	d.	d.	PROPN
chd-214	305	77	j.	j.	PROPN
chd-214	305	78	,	,	PUNCT
chd-214	305	79	gupta	gupta	PROPN
chd-214	305	80	,	,	PUNCT
chd-214	305	81	r.	r.	PROPN
chd-214	305	82	,	,	PUNCT
chd-214	305	83	balk	balk	VERB
chd-214	305	84	,	,	PUNCT
chd-214	305	85	s.	s.	PROPN
chd-214	305	86	,	,	PUNCT
chd-214	305	87	lal	lal	PROPN
chd-214	305	88	,	,	PUNCT
chd-214	305	89	p.	p.	PROPN
chd-214	305	90	,	,	PUNCT
chd-214	305	91	…	…	PUNCT
chd-214	305	92	yamoah	yamoah	NOUN
chd-214	305	93	,	,	PUNCT
chd-214	305	94	k.	k.	PROPN
chd-214	305	95	(	(	PUNCT
chd-214	305	96	2021	2021	NUM
chd-214	305	97	)	)	PUNCT
chd-214	305	98	.	.	PUNCT
chd-214	306	1	comparative	comparative	ADJ
chd-214	306	2	genomics	genomic	NOUN
chd-214	306	3	reveals	reveal	VERB
chd-214	306	4	distinct	distinct	ADJ
chd-214	306	5	immuneoncologic	immuneoncologic	ADJ
chd-214	306	6	pathways	pathway	NOUN
chd-214	306	7	in	in	ADP
chd-214	306	8	african	african	ADJ
chd-214	306	9	american	american	ADJ
chd-214	306	10	men	man	NOUN
chd-214	306	11	with	with	ADP
chd-214	306	12	prostate	prostate	NOUN
chd-214	306	13	cancer	cancer	NOUN
chd-214	306	14	.	.	PUNCT
chd-214	307	1	clinical	clinical	ADJ
chd-214	307	2	cancer	cancer	NOUN
chd-214	307	3	research	research	NOUN
chd-214	307	4	:	:	PUNCT
chd-214	307	5	an	an	DET
chd-214	307	6	official	official	ADJ
chd-214	307	7	journal	journal	NOUN
chd-214	307	8	of	of	ADP
chd-214	307	9	the	the	DET
chd-214	307	10	american	american	PROPN
chd-214	307	11	association	association	PROPN
chd-214	307	12	for	for	ADP
chd-214	307	13	cancer	cancer	NOUN
chd-214	307	14	https://doi.org/10.1002/ijc.28326	https://doi.org/10.1002/ijc.28326	PROPN
chd-214	307	15	https://doi.org/10.1016/j.ucl.2016.04.012	https://doi.org/10.1016/j.ucl.2016.04.012	NOUN
chd-214	307	16	https://doi.org/10.1259/bjr.20160693	https://doi.org/10.1259/bjr.20160693	PROPN
chd-214	307	17	https://doi.org/10.1038/srep30691	https://doi.org/10.1038/srep30691	PROPN
chd-214	307	18	https://doi.org/10.1016/j.canlet.2015.12.022	https://doi.org/10.1016/j.canlet.2015.12.022	PROPN
chd-214	307	19	https://doi.org/10.3390/cancers12071887	https://doi.org/10.3390/cancers12071887	NOUN
chd-214	307	20	https://doi.org/10.1371/journal.pgen.1008641	https://doi.org/10.1371/journal.pgen.1008641	PROPN
chd-214	307	21	https://doi.org/10.1016/j.semcdb.2009.10.010	https://doi.org/10.1016/j.semcdb.2009.10.010	NOUN
chd-214	307	22	https://doi.org/10.1053/%20j.seminoncol.2014.03.004	https://doi.org/10.1053/%20j.seminoncol.2014.03.004	PROPN
chd-214	307	23	https://doi.org/10.3892/%20ol.2014.2385	https://doi.org/10.3892/%20ol.2014.2385	PROPN
chd-214	307	24	https://doi.org/10.1016/j.bbrc.2017.03.021	https://doi.org/10.1016/j.bbrc.2017.03.021	NOUN
chd-214	307	25	https://doi.org/10.3390/cancers11121857	https://doi.org/10.3390/cancers11121857	NOUN
chd-214	307	26	https://doi.org/10.1002/pros.24333	https://doi.org/10.1002/pros.24333	NOUN
chd-214	307	27	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	NUM
chd-214	307	28	e12	e12	NOUN
chd-214	307	29	cancer	cancer	NOUN
chd-214	307	30	health	health	NOUN
chd-214	307	31	disparities	disparity	NOUN
chd-214	307	32	research	research	NOUN
chd-214	307	33	research	research	NOUN
chd-214	307	34	,	,	PUNCT
chd-214	307	35	27(1	27(1	NUM
chd-214	307	36	)	)	PUNCT
chd-214	307	37	,	,	PUNCT
chd-214	307	38	320–329	320–329	NUM
chd-214	307	39	.	.	PUNCT
chd-214	308	1	https://doi.org/10.1158/10780432.ccr-20-2925	https://doi.org/10.1158/10780432.ccr-20-2925	PROPN
chd-214	308	2	39	39	NUM
chd-214	308	3	.	.	PUNCT
chd-214	309	1	wu	wu	PROPN
chd-214	309	2	,	,	PUNCT
chd-214	309	3	c.	c.	PROPN
chd-214	309	4	t.	t.	PROPN
chd-214	309	5	,	,	PUNCT
chd-214	309	6	hsieh	hsieh	PROPN
chd-214	309	7	,	,	PUNCT
chd-214	309	8	c.	c.	PROPN
chd-214	309	9	c.	c.	PROPN
chd-214	309	10	,	,	PUNCT
chd-214	309	11	lin	lin	PROPN
chd-214	309	12	,	,	PUNCT
chd-214	309	13	c.	c.	PROPN
chd-214	309	14	c.	c.	PROPN
chd-214	309	15	,	,	PUNCT
chd-214	309	16	chen	chen	PROPN
chd-214	309	17	,	,	PUNCT
chd-214	309	18	w.	w.	PROPN
chd-214	309	19	c.	c.	PROPN
chd-214	309	20	,	,	PUNCT
chd-214	309	21	hong	hong	PROPN
chd-214	309	22	,	,	PUNCT
chd-214	309	23	j.	j.	PROPN
chd-214	309	24	h.	h.	PROPN
chd-214	309	25	,	,	PUNCT
chd-214	309	26	&	&	CCONJ
chd-214	309	27	chen	chen	PROPN
chd-214	309	28	,	,	PUNCT
chd-214	309	29	m.	m.	PROPN
chd-214	309	30	f.	f.	PROPN
chd-214	309	31	(	(	PUNCT
chd-214	309	32	2012	2012	NUM
chd-214	309	33	)	)	PUNCT
chd-214	309	34	.	.	PUNCT
chd-214	310	1	significance	significance	NOUN
chd-214	310	2	of	of	ADP
chd-214	310	3	il-6	il-6	NOUN
chd-214	310	4	in	in	ADP
chd-214	310	5	the	the	DET
chd-214	310	6	transition	transition	NOUN
chd-214	310	7	of	of	ADP
chd-214	310	8	hormone	hormone	NOUN
chd-214	310	9	-	-	PUNCT
chd-214	310	10	resistant	resistant	ADJ
chd-214	310	11	prostate	prostate	NOUN
chd-214	310	12	cancer	cancer	NOUN
chd-214	310	13	and	and	CCONJ
chd-214	310	14	the	the	DET
chd-214	310	15	induction	induction	NOUN
chd-214	310	16	of	of	ADP
chd-214	310	17	myeloid	myeloid	NOUN
chd-214	310	18	-	-	PUNCT
chd-214	310	19	derived	derive	VERB
chd-214	310	20	suppressor	suppressor	NOUN
chd-214	310	21	cells	cell	NOUN
chd-214	310	22	.	.	PUNCT
chd-214	311	1	journal	journal	NOUN
chd-214	311	2	of	of	ADP
chd-214	311	3	molecular	molecular	ADJ
chd-214	311	4	medicine	medicine	NOUN
chd-214	311	5	(	(	PUNCT
chd-214	311	6	berlin	berlin	PROPN
chd-214	311	7	,	,	PUNCT
chd-214	311	8	germany	germany	PROPN
chd-214	311	9	)	)	PUNCT
chd-214	311	10	,	,	PUNCT
chd-214	311	11	90(11	90(11	NUM
chd-214	311	12	)	)	PUNCT
chd-214	311	13	,	,	PUNCT
chd-214	311	14	1343–1355	1343–1355	NUM
chd-214	311	15	.	.	PUNCT
chd-214	312	1	https://doi.org/10.1007/s00109-012-0916-x	https://doi.org/10.1007/s00109-012-0916-x	NOUN
chd-214	312	2	40	40	NUM
chd-214	312	3	.	.	PUNCT
chd-214	312	4	maynard	maynard	PROPN
chd-214	312	5	,	,	PUNCT
chd-214	312	6	j.	j.	PROPN
chd-214	312	7	p.	p.	PROPN
chd-214	312	8	,	,	PUNCT
chd-214	312	9	ertunc	ertunc	VERB
chd-214	312	10	,	,	PUNCT
chd-214	312	11	o.	o.	PROPN
chd-214	312	12	,	,	PUNCT
chd-214	312	13	kulac	kulac	PROPN
chd-214	312	14	,	,	PUNCT
chd-214	312	15	i.	i.	PROPN
chd-214	312	16	,	,	PUNCT
chd-214	312	17	baena	baena	ADJ
chd-214	312	18	-	-	PUNCT
chd-214	312	19	del	del	X
chd-214	312	20	valle	valle	NOUN
chd-214	312	21	,	,	PUNCT
chd-214	312	22	j.	j.	PROPN
chd-214	312	23	a.	a.	PROPN
chd-214	312	24	,	,	PUNCT
chd-214	312	25	de	de	PROPN
chd-214	312	26	marzo	marzo	X
chd-214	312	27	,	,	PUNCT
chd-214	312	28	a.	a.	NOUN
chd-214	312	29	m.	m.	NOUN
chd-214	312	30	,	,	PUNCT
chd-214	312	31	&	&	CCONJ
chd-214	312	32	sfanos	sfanos	PROPN
chd-214	312	33	,	,	PUNCT
chd-214	312	34	k.	k.	PROPN
chd-214	312	35	s.	s.	PROPN
chd-214	312	36	(	(	PUNCT
chd-214	312	37	2020	2020	NUM
chd-214	312	38	)	)	PUNCT
chd-214	312	39	.	.	PUNCT
chd-214	313	1	il8	il8	PROPN
chd-214	313	2	expression	expression	NOUN
chd-214	313	3	is	be	AUX
chd-214	313	4	associated	associate	VERB
chd-214	313	5	with	with	ADP
chd-214	313	6	prostate	prostate	NOUN
chd-214	313	7	cancer	cancer	NOUN
chd-214	313	8	aggressiveness	aggressiveness	NOUN
chd-214	313	9	and	and	CCONJ
chd-214	313	10	androgen	androgen	NOUN
chd-214	313	11	receptor	receptor	NOUN
chd-214	313	12	loss	loss	NOUN
chd-214	313	13	in	in	ADP
chd-214	313	14	primary	primary	ADJ
chd-214	313	15	and	and	CCONJ
chd-214	313	16	metastatic	metastatic	ADJ
chd-214	313	17	prostate	prostate	NOUN
chd-214	313	18	cancer	cancer	NOUN
chd-214	313	19	.	.	PUNCT
chd-214	314	1	molecular	molecular	ADJ
chd-214	314	2	cancer	cancer	NOUN
chd-214	314	3	research	research	NOUN
chd-214	314	4	:	:	PUNCT
chd-214	314	5	mcr	mcr	ADJ
chd-214	314	6	,	,	PUNCT
chd-214	314	7	18(1	18(1	NUM
chd-214	314	8	)	)	PUNCT
chd-214	314	9	,	,	PUNCT
chd-214	314	10	153–165	153–165	NUM
chd-214	314	11	.	.	PUNCT
chd-214	315	1	https://doi.org/10.1158/1541-7786.mcr-19-0595	https://doi.org/10.1158/1541-7786.mcr-19-0595	PROPN
chd-214	315	2	41	41	NUM
chd-214	315	3	.	.	PUNCT
chd-214	316	1	kaur	kaur	PROPN
chd-214	316	2	,	,	PUNCT
chd-214	316	3	h.	h.	PROPN
chd-214	316	4	b.	b.	PROPN
chd-214	316	5	,	,	PUNCT
chd-214	316	6	guedes	guedes	PROPN
chd-214	316	7	,	,	PUNCT
chd-214	316	8	l.	l.	PROPN
chd-214	316	9	b.	b.	PROPN
chd-214	316	10	,	,	PUNCT
chd-214	316	11	lu	lu	PROPN
chd-214	316	12	,	,	PUNCT
chd-214	316	13	j.	j.	PROPN
chd-214	316	14	,	,	PUNCT
chd-214	316	15	maldonado	maldonado	PROPN
chd-214	316	16	,	,	PUNCT
chd-214	316	17	l.	l.	PROPN
chd-214	316	18	,	,	PUNCT
chd-214	316	19	reitz	reitz	PROPN
chd-214	316	20	,	,	PUNCT
chd-214	316	21	l.	l.	PROPN
chd-214	316	22	,	,	PUNCT
chd-214	316	23	barber	barber	PROPN
chd-214	316	24	,	,	PUNCT
chd-214	316	25	j.	j.	PROPN
chd-214	316	26	r.	r.	PROPN
chd-214	316	27	,	,	PUNCT
chd-214	316	28	de	de	PROPN
chd-214	316	29	marzo	marzo	X
chd-214	316	30	,	,	PUNCT
chd-214	316	31	a.	a.	NOUN
chd-214	316	32	m.	m.	NOUN
chd-214	316	33	,	,	PUNCT
chd-214	316	34	tosoian	tosoian	PROPN
chd-214	316	35	,	,	PUNCT
chd-214	316	36	j.	j.	PROPN
chd-214	316	37	j.	j.	PROPN
chd-214	316	38	,	,	PUNCT
chd-214	316	39	tomlins	tomlin	NOUN
chd-214	316	40	,	,	PUNCT
chd-214	316	41	s.	s.	PROPN
chd-214	316	42	a.	a.	PROPN
chd-214	316	43	,	,	PUNCT
chd-214	316	44	schaeffer	schaeffer	PROPN
chd-214	316	45	,	,	PUNCT
chd-214	316	46	e.	e.	PROPN
chd-214	316	47	m.	m.	PROPN
chd-214	316	48	,	,	PUNCT
chd-214	316	49	joshu	joshu	PROPN
chd-214	316	50	,	,	PUNCT
chd-214	316	51	c.	c.	PROPN
chd-214	316	52	e.	e.	PROPN
chd-214	316	53	,	,	PUNCT
chd-214	316	54	sfanos	sfanos	PROPN
chd-214	316	55	,	,	PUNCT
chd-214	316	56	k.	k.	PROPN
chd-214	316	57	s.	s.	PROPN
chd-214	316	58	,	,	PUNCT
chd-214	316	59	&	&	CCONJ
chd-214	316	60	lotan	lotan	ADJ
chd-214	316	61	,	,	PUNCT
chd-214	316	62	t.	t.	PROPN
chd-214	316	63	l.	l.	PROPN
chd-214	316	64	(	(	PUNCT
chd-214	316	65	2018	2018	NUM
chd-214	316	66	)	)	PUNCT
chd-214	316	67	.	.	PUNCT
chd-214	317	1	association	association	NOUN
chd-214	317	2	of	of	ADP
chd-214	317	3	tumor	tumor	NOUN
chd-214	317	4	-	-	PUNCT
chd-214	317	5	infiltrating	infiltrate	VERB
chd-214	317	6	t	t	NOUN
chd-214	317	7	-	-	PUNCT
chd-214	317	8	cell	cell	NOUN
chd-214	317	9	density	density	NOUN
chd-214	317	10	with	with	ADP
chd-214	317	11	molecular	molecular	ADJ
chd-214	317	12	subtype	subtype	NOUN
chd-214	317	13	,	,	PUNCT
chd-214	317	14	racial	racial	ADJ
chd-214	317	15	ancestry	ancestry	NOUN
chd-214	317	16	and	and	CCONJ
chd-214	317	17	clinical	clinical	ADJ
chd-214	317	18	outcomes	outcome	NOUN
chd-214	317	19	in	in	ADP
chd-214	317	20	prostate	prostate	NOUN
chd-214	317	21	cancer	cancer	NOUN
chd-214	317	22	.	.	PUNCT
chd-214	318	1	modern	modern	ADJ
chd-214	318	2	pathology	pathology	NOUN
chd-214	318	3	:	:	PUNCT
chd-214	318	4	an	an	DET
chd-214	318	5	official	official	ADJ
chd-214	318	6	journal	journal	NOUN
chd-214	318	7	of	of	ADP
chd-214	318	8	the	the	DET
chd-214	318	9	united	united	PROPN
chd-214	318	10	states	states	PROPN
chd-214	318	11	and	and	CCONJ
chd-214	318	12	canadian	canadian	PROPN
chd-214	318	13	academy	academy	PROPN
chd-214	318	14	of	of	ADP
chd-214	318	15	pathology	pathology	PROPN
chd-214	318	16	,	,	PUNCT
chd-214	318	17	inc	inc	PROPN
chd-214	318	18	,	,	PUNCT
chd-214	318	19	31(10	31(10	NUM
chd-214	318	20	)	)	PUNCT
chd-214	318	21	,	,	PUNCT
chd-214	318	22	1539–1552	1539–1552	NUM
chd-214	318	23	.	.	PUNCT
chd-214	319	1	https://doi.org/10.1038/s41379-0180083-x	https://doi.org/10.1038/s41379-0180083-x	PROPN
chd-214	319	2	42	42	NUM
chd-214	319	3	.	.	PUNCT
chd-214	320	1	vitkin	vitkin	PROPN
chd-214	320	2	,	,	PUNCT
chd-214	320	3	n.	n.	NOUN
chd-214	320	4	,	,	PUNCT
chd-214	320	5	nersesian	nersesian	NOUN
chd-214	320	6	,	,	PUNCT
chd-214	320	7	s.	s.	PROPN
chd-214	320	8	,	,	PUNCT
chd-214	320	9	siemens	siemens	PROPN
chd-214	320	10	,	,	PUNCT
chd-214	320	11	d.	d.	PROPN
chd-214	320	12	r.	r.	PROPN
chd-214	320	13	,	,	PUNCT
chd-214	320	14	&	&	CCONJ
chd-214	320	15	koti	koti	PROPN
chd-214	320	16	,	,	PUNCT
chd-214	320	17	m.	m.	NOUN
chd-214	320	18	(	(	PUNCT
chd-214	320	19	2019	2019	NUM
chd-214	320	20	)	)	PUNCT
chd-214	320	21	.	.	PUNCT
chd-214	321	1	the	the	DET
chd-214	321	2	tumor	tumor	NOUN
chd-214	321	3	immune	immune	ADJ
chd-214	321	4	contexture	contexture	NOUN
chd-214	321	5	of	of	ADP
chd-214	321	6	prostate	prostate	NOUN
chd-214	321	7	cancer	cancer	NOUN
chd-214	321	8	.	.	PUNCT
chd-214	322	1	frontiers	frontier	NOUN
chd-214	322	2	in	in	ADP
chd-214	322	3	immunology	immunology	NOUN
chd-214	322	4	,	,	PUNCT
chd-214	322	5	10	10	NUM
chd-214	322	6	,	,	PUNCT
chd-214	322	7	603	603	NUM
chd-214	322	8	.	.	PUNCT
chd-214	323	1	https://doi.org/10.3389/fimmu.2019.00603	https://doi.org/10.3389/fimmu.2019.00603	PROPN
chd-214	323	2	43	43	NUM
chd-214	323	3	.	.	PUNCT
chd-214	324	1	wang	wang	PROPN
chd-214	324	2	,	,	PUNCT
chd-214	324	3	y.	y.	PROPN
chd-214	324	4	,	,	PUNCT
chd-214	324	5	freedman	freedman	PROPN
chd-214	324	6	,	,	PUNCT
chd-214	324	7	j.	j.	PROPN
chd-214	324	8	a.	a.	PROPN
chd-214	324	9	,	,	PUNCT
chd-214	324	10	liu	liu	PROPN
chd-214	324	11	,	,	PUNCT
chd-214	324	12	h.	h.	PROPN
chd-214	324	13	,	,	PUNCT
chd-214	324	14	moorman	moorman	NOUN
chd-214	324	15	,	,	PUNCT
chd-214	324	16	p.	p.	PROPN
chd-214	324	17	g.	g.	PROPN
chd-214	324	18	,	,	PUNCT
chd-214	324	19	hyslop	hyslop	PROPN
chd-214	324	20	,	,	PUNCT
chd-214	324	21	t.	t.	PROPN
chd-214	324	22	,	,	PUNCT
chd-214	324	23	george	george	PROPN
chd-214	324	24	,	,	PUNCT
chd-214	324	25	d.	d.	PROPN
chd-214	324	26	j.	j.	PROPN
chd-214	324	27	,	,	PUNCT
chd-214	324	28	lee	lee	PROPN
chd-214	324	29	,	,	PUNCT
chd-214	324	30	n.	n.	PROPN
chd-214	324	31	h.	h.	PROPN
chd-214	324	32	,	,	PUNCT
chd-214	324	33	patierno	patierno	PROPN
chd-214	324	34	,	,	PUNCT
chd-214	324	35	s.	s.	PROPN
chd-214	324	36	r.	r.	PROPN
chd-214	324	37	,	,	PUNCT
chd-214	324	38	and	and	CCONJ
chd-214	324	39	wei	wei	PROPN
chd-214	324	40	,	,	PUNCT
chd-214	324	41	q.	q.	PROPN
chd-214	324	42	(	(	PUNCT
chd-214	324	43	2017	2017	NUM
chd-214	324	44	)	)	PUNCT
chd-214	324	45	.	.	PUNCT
chd-214	325	1	associations	association	NOUN
chd-214	325	2	between	between	ADP
chd-214	325	3	rna	rna	PROPN
chd-214	325	4	splicing	splicing	NOUN
chd-214	325	5	regulatory	regulatory	ADJ
chd-214	325	6	variants	variant	NOUN
chd-214	325	7	of	of	ADP
chd-214	325	8	stemness	stemness	NOUN
chd-214	325	9	-	-	PUNCT
chd-214	325	10	related	relate	VERB
chd-214	325	11	genes	gene	NOUN
chd-214	325	12	and	and	CCONJ
chd-214	325	13	racial	racial	ADJ
chd-214	325	14	disparities	disparity	NOUN
chd-214	325	15	in	in	ADP
chd-214	325	16	susceptibility	susceptibility	NOUN
chd-214	325	17	to	to	ADP
chd-214	325	18	prostate	prostate	NOUN
chd-214	325	19	cancer	cancer	NOUN
chd-214	325	20	.	.	PUNCT
chd-214	326	1	international	international	ADJ
chd-214	326	2	journal	journal	PROPN
chd-214	326	3	of	of	ADP
chd-214	326	4	cancer	cancer	NOUN
chd-214	326	5	,	,	PUNCT
chd-214	326	6	141(4	141(4	NUM
chd-214	326	7	)	)	PUNCT
chd-214	326	8	,	,	PUNCT
chd-214	326	9	731–743	731–743	NUM
chd-214	326	10	.	.	PUNCT
chd-214	327	1	https://doi.org/10.1002/	https://doi.org/10.1002/	PROPN
chd-214	327	2	ijc.30787	ijc.30787	PRON
chd-214	327	3	.	.	PUNCT
chd-214	328	1	44	44	NUM
chd-214	328	2	.	.	X
chd-214	328	3	rayford	rayford	PROPN
chd-214	328	4	,	,	PUNCT
chd-214	328	5	w.	w.	PROPN
chd-214	328	6	,	,	PUNCT
chd-214	328	7	beksac	beksac	NOUN
chd-214	328	8	,	,	PUNCT
chd-214	328	9	a.	a.	NOUN
chd-214	328	10	t.	t.	PROPN
chd-214	328	11	,	,	PUNCT
chd-214	328	12	alger	alger	PROPN
chd-214	328	13	,	,	PUNCT
chd-214	328	14	j.	j.	PROPN
chd-214	328	15	,	,	PUNCT
chd-214	328	16	alshalalfa	alshalalfa	PROPN
chd-214	328	17	,	,	PUNCT
chd-214	328	18	m.	m.	NOUN
chd-214	328	19	,	,	PUNCT
chd-214	328	20	ahmed	ahmed	PROPN
chd-214	328	21	,	,	PUNCT
chd-214	328	22	m.	m.	NOUN
chd-214	328	23	,	,	PUNCT
chd-214	328	24	khan	khan	PROPN
chd-214	328	25	,	,	PUNCT
chd-214	328	26	i.	i.	PROPN
chd-214	328	27	,	,	PUNCT
chd-214	328	28	falagario	falagario	PROPN
chd-214	328	29	,	,	PUNCT
chd-214	328	30	u.	u.	PROPN
chd-214	328	31	g.	g.	PROPN
chd-214	328	32	,	,	PUNCT
chd-214	328	33	liu	liu	PROPN
chd-214	328	34	,	,	PUNCT
chd-214	328	35	y.	y.	PROPN
chd-214	328	36	,	,	PUNCT
chd-214	328	37	davicioni	davicioni	PROPN
chd-214	328	38	,	,	PUNCT
chd-214	328	39	e.	e.	PROPN
chd-214	328	40	,	,	PUNCT
chd-214	328	41	spratt	spratt	PROPN
chd-214	328	42	,	,	PUNCT
chd-214	328	43	d.	d.	PROPN
chd-214	328	44	e.	e.	PROPN
chd-214	328	45	,	,	PUNCT
chd-214	328	46	schaeffer	schaeffer	PROPN
chd-214	328	47	,	,	PUNCT
chd-214	328	48	e.	e.	PROPN
chd-214	328	49	m.	m.	PROPN
chd-214	328	50	,	,	PUNCT
chd-214	328	51	feng	feng	PROPN
chd-214	328	52	,	,	PUNCT
chd-214	328	53	f.	f.	PROPN
chd-214	328	54	y.	y.	PROPN
chd-214	328	55	,	,	PUNCT
chd-214	328	56	mahal	mahal	PROPN
chd-214	328	57	,	,	PUNCT
chd-214	328	58	b.	b.	PROPN
chd-214	328	59	,	,	PUNCT
chd-214	328	60	nguyen	nguyen	PROPN
chd-214	328	61	,	,	PUNCT
chd-214	328	62	p.	p.	PROPN
chd-214	328	63	l.	l.	PROPN
chd-214	328	64	,	,	PUNCT
chd-214	328	65	den	den	PROPN
chd-214	328	66	,	,	PUNCT
chd-214	328	67	r.	r.	PROPN
chd-214	328	68	b.	b.	PROPN
chd-214	328	69	,	,	PUNCT
chd-214	328	70	greenberger	greenberger	PROPN
chd-214	328	71	,	,	PUNCT
chd-214	328	72	m.	m.	PROPN
chd-214	328	73	d.	d.	PROPN
chd-214	328	74	,	,	PUNCT
chd-214	328	75	bradley	bradley	PROPN
chd-214	328	76	,	,	PUNCT
chd-214	328	77	r.	r.	PROPN
chd-214	328	78	,	,	PUNCT
chd-214	328	79	watson	watson	PROPN
chd-214	328	80	,	,	PUNCT
chd-214	328	81	j.	j.	PROPN
chd-214	328	82	m.	m.	PROPN
chd-214	328	83	,	,	PUNCT
chd-214	328	84	beamer	beamer	PROPN
chd-214	328	85	,	,	PUNCT
chd-214	328	86	m.	m.	NOUN
chd-214	328	87	,	,	PUNCT
chd-214	328	88	stamatakis	stamatakis	PROPN
chd-214	328	89	,	,	PUNCT
chd-214	328	90	l.	l.	PROPN
chd-214	328	91	,	,	PUNCT
chd-214	328	92	…	…	PUNCT
chd-214	328	93	tewari	tewari	X
chd-214	328	94	,	,	PUNCT
chd-214	328	95	a.	a.	PROPN
chd-214	328	96	k.	k.	PROPN
chd-214	328	97	(	(	PUNCT
chd-214	328	98	2021	2021	NUM
chd-214	328	99	)	)	PUNCT
chd-214	328	100	.	.	PUNCT
chd-214	329	1	comparative	comparative	ADJ
chd-214	329	2	analysis	analysis	NOUN
chd-214	329	3	of	of	ADP
chd-214	329	4	1152	1152	NUM
chd-214	329	5	african	african	ADJ
chd-214	329	6	-	-	PUNCT
chd-214	329	7	american	american	ADJ
chd-214	329	8	and	and	CCONJ
chd-214	329	9	european	european	ADJ
chd-214	329	10	-	-	PUNCT
chd-214	329	11	american	american	ADJ
chd-214	329	12	men	man	NOUN
chd-214	329	13	with	with	ADP
chd-214	329	14	prostate	prostate	NOUN
chd-214	329	15	cancer	cancer	NOUN
chd-214	329	16	identifies	identify	VERB
chd-214	329	17	distinct	distinct	ADJ
chd-214	329	18	genomic	genomic	NOUN
chd-214	329	19	and	and	CCONJ
chd-214	329	20	immunological	immunological	ADJ
chd-214	329	21	differences	difference	NOUN
chd-214	329	22	.	.	PUNCT
chd-214	330	1	communications	communication	NOUN
chd-214	330	2	biology	biology	NOUN
chd-214	330	3	,	,	PUNCT
chd-214	330	4	4(1	4(1	NUM
chd-214	330	5	)	)	PUNCT
chd-214	330	6	,	,	PUNCT
chd-214	330	7	670	670	NUM
chd-214	330	8	.	.	PUNCT
chd-214	331	1	https://doi.org/10.1038/s42003-021-02140-y	https://doi.org/10.1038/s42003-021-02140-y	PROPN
chd-214	331	2	45	45	NUM
chd-214	331	3	.	.	PUNCT
chd-214	332	1	chen	chen	PROPN
chd-214	332	2	,	,	PUNCT
chd-214	332	3	y.	y.	PROPN
chd-214	332	4	,	,	PUNCT
chd-214	332	5	meng	meng	PROPN
chd-214	332	6	,	,	PUNCT
chd-214	332	7	z.	z.	PROPN
chd-214	332	8	,	,	PUNCT
chd-214	332	9	zhang	zhang	PROPN
chd-214	332	10	,	,	PUNCT
chd-214	332	11	l.	l.	PROPN
chd-214	332	12	,	,	PUNCT
chd-214	332	13	&	&	CCONJ
chd-214	332	14	liu	liu	PROPN
chd-214	332	15	,	,	PUNCT
chd-214	332	16	f.	f.	PROPN
chd-214	332	17	(	(	PUNCT
chd-214	332	18	2021	2021	NUM
chd-214	332	19	)	)	PUNCT
chd-214	332	20	.	.	PUNCT
chd-214	333	1	cd2	cd2	PROPN
chd-214	333	2	is	be	AUX
chd-214	333	3	a	a	DET
chd-214	333	4	novel	novel	ADJ
chd-214	333	5	immune	immune	NOUN
chd-214	333	6	-	-	PUNCT
chd-214	333	7	related	relate	VERB
chd-214	333	8	prognostic	prognostic	ADJ
chd-214	333	9	biomarker	biomarker	NOUN
chd-214	333	10	of	of	ADP
chd-214	333	11	invasive	invasive	ADJ
chd-214	333	12	breast	breast	NOUN
chd-214	333	13	carcinoma	carcinoma	NOUN
chd-214	333	14	that	that	PRON
chd-214	333	15	modulates	modulate	VERB
chd-214	333	16	the	the	DET
chd-214	333	17	tumor	tumor	NOUN
chd-214	333	18	microenvironment	microenvironment	NOUN
chd-214	333	19	.	.	PUNCT
chd-214	334	1	frontiers	frontier	NOUN
chd-214	334	2	in	in	ADP
chd-214	334	3	immunology	immunology	NOUN
chd-214	334	4	,	,	PUNCT
chd-214	334	5	12	12	NUM
chd-214	334	6	,	,	PUNCT
chd-214	334	7	664845	664845	NUM
chd-214	334	8	.	.	PUNCT
chd-214	335	1	https://doi.org/10.3389/fimmu.2021.664845	https://doi.org/10.3389/fimmu.2021.664845	PROPN
chd-214	335	2	46	46	NUM
chd-214	335	3	.	.	PUNCT
chd-214	335	4	bühler	bühler	NOUN
chd-214	335	5	,	,	PUNCT
chd-214	335	6	p.	p.	NOUN
chd-214	335	7	,	,	PUNCT
chd-214	335	8	wolf	wolf	PROPN
chd-214	335	9	,	,	PUNCT
chd-214	335	10	p.	p.	NOUN
chd-214	335	11	,	,	PUNCT
chd-214	335	12	gierschner	gierschner	NOUN
chd-214	335	13	,	,	PUNCT
chd-214	335	14	d.	d.	PROPN
chd-214	335	15	,	,	PUNCT
chd-214	335	16	schaber	schaber	PROPN
chd-214	335	17	,	,	PUNCT
chd-214	335	18	i.	i.	PROPN
chd-214	335	19	,	,	PUNCT
chd-214	335	20	katzenwadel	katzenwadel	PROPN
chd-214	335	21	,	,	PUNCT
chd-214	335	22	a.	a.	NOUN
chd-214	335	23	,	,	PUNCT
chd-214	335	24	schultze	schultze	NOUN
chd-214	335	25	-	-	PUNCT
chd-214	335	26	seemann	seemann	ADJ
chd-214	335	27	,	,	PUNCT
chd-214	335	28	w.	w.	PROPN
chd-214	335	29	,	,	PUNCT
chd-214	335	30	wetterauer	wetterauer	PROPN
chd-214	335	31	,	,	PUNCT
chd-214	335	32	u.	u.	PROPN
chd-214	335	33	,	,	PUNCT
chd-214	335	34	tacke	tacke	PROPN
chd-214	335	35	,	,	PUNCT
chd-214	335	36	m.	m.	NOUN
chd-214	335	37	,	,	PUNCT
chd-214	335	38	swamy	swamy	NOUN
chd-214	335	39	,	,	PUNCT
chd-214	335	40	m.	m.	NOUN
chd-214	335	41	,	,	PUNCT
chd-214	335	42	schamel	schamel	PROPN
chd-214	335	43	,	,	PUNCT
chd-214	335	44	w.	w.	PROPN
chd-214	335	45	w.	w.	PROPN
chd-214	335	46	,	,	PUNCT
chd-214	335	47	&	&	CCONJ
chd-214	335	48	elsässer	elsässer	NOUN
chd-214	335	49	-	-	PUNCT
chd-214	335	50	beile	beile	NOUN
chd-214	335	51	,	,	PUNCT
chd-214	335	52	u.	u.	NOUN
chd-214	335	53	(	(	PUNCT
chd-214	335	54	2008	2008	NUM
chd-214	335	55	)	)	PUNCT
chd-214	335	56	.	.	PUNCT
chd-214	336	1	a	a	DET
chd-214	336	2	bispecific	bispecific	NOUN
chd-214	336	3	diabody	diabody	NOUN
chd-214	336	4	directed	direct	VERB
chd-214	336	5	against	against	ADP
chd-214	336	6	prostatespecific	prostatespecific	ADJ
chd-214	336	7	membrane	membrane	NOUN
chd-214	336	8	antigen	antigen	NOUN
chd-214	336	9	and	and	CCONJ
chd-214	336	10	cd3	cd3	PROPN
chd-214	336	11	induces	induce	VERB
chd-214	336	12	t	t	PROPN
chd-214	336	13	-	-	PUNCT
chd-214	336	14	cell	cell	NOUN
chd-214	336	15	mediated	mediate	VERB
chd-214	336	16	lysis	lysis	NOUN
chd-214	336	17	of	of	ADP
chd-214	336	18	prostate	prostate	NOUN
chd-214	336	19	cancer	cancer	NOUN
chd-214	336	20	cells	cell	NOUN
chd-214	336	21	.	.	PUNCT
chd-214	337	1	cancer	cancer	NOUN
chd-214	337	2	immunology	immunology	NOUN
chd-214	337	3	,	,	PUNCT
chd-214	337	4	immunotherapy	immunotherapy	NOUN
chd-214	337	5	:	:	PUNCT
chd-214	337	6	cii	cii	PROPN
chd-214	337	7	,	,	PUNCT
chd-214	337	8	57(1	57(1	PROPN
chd-214	337	9	)	)	PUNCT
chd-214	337	10	,	,	PUNCT
chd-214	337	11	43–52	43–52	NUM
chd-214	337	12	.	.	PUNCT
chd-214	337	13	https://doi.org/10.1007/s00262-007-0348-6	https://doi.org/10.1007/s00262-007-0348-6	NUM
chd-214	337	14	47	47	NUM
chd-214	337	15	.	.	PUNCT
chd-214	338	1	miller	miller	PROPN
chd-214	338	2	,	,	PUNCT
chd-214	338	3	a.	a.	NOUN
chd-214	338	4	m.	m.	NOUN
chd-214	338	5	,	,	PUNCT
chd-214	338	6	lundberg	lundberg	PROPN
chd-214	338	7	,	,	PUNCT
chd-214	338	8	k.	k.	PROPN
chd-214	338	9	,	,	PUNCT
chd-214	338	10	ozenci	ozenci	PROPN
chd-214	338	11	,	,	PUNCT
chd-214	338	12	v.	v.	PROPN
chd-214	338	13	,	,	PUNCT
chd-214	338	14	banham	banham	NOUN
chd-214	338	15	,	,	PUNCT
chd-214	338	16	a.	a.	PROPN
chd-214	338	17	h.	h.	PROPN
chd-214	338	18	,	,	PUNCT
chd-214	338	19	hellström	hellström	NOUN
chd-214	338	20	,	,	PUNCT
chd-214	338	21	m.	m.	NOUN
chd-214	338	22	,	,	PUNCT
chd-214	338	23	egevad	egevad	NOUN
chd-214	338	24	,	,	PUNCT
chd-214	338	25	l.	l.	PROPN
chd-214	338	26	,	,	PUNCT
chd-214	338	27	&	&	CCONJ
chd-214	338	28	pisa	pisa	PROPN
chd-214	338	29	,	,	PUNCT
chd-214	338	30	p.	p.	NOUN
chd-214	338	31	(	(	PUNCT
chd-214	338	32	2006	2006	NUM
chd-214	338	33	)	)	PUNCT
chd-214	338	34	.	.	PUNCT
chd-214	339	1	cd4+cd25high	cd4+cd25high	PROPN
chd-214	339	2	t	t	PROPN
chd-214	339	3	cells	cell	NOUN
chd-214	339	4	are	be	AUX
chd-214	339	5	enriched	enrich	VERB
chd-214	339	6	in	in	ADP
chd-214	339	7	the	the	DET
chd-214	339	8	tumor	tumor	NOUN
chd-214	339	9	and	and	CCONJ
chd-214	339	10	peripheral	peripheral	ADJ
chd-214	339	11	blood	blood	NOUN
chd-214	339	12	of	of	ADP
chd-214	339	13	prostate	prostate	NOUN
chd-214	339	14	cancer	cancer	NOUN
chd-214	339	15	patients	patient	NOUN
chd-214	339	16	.	.	PUNCT
chd-214	340	1	journal	journal	NOUN
chd-214	340	2	of	of	ADP
chd-214	340	3	immunology	immunology	NOUN
chd-214	340	4	(	(	PUNCT
chd-214	340	5	baltimore	baltimore	PROPN
chd-214	340	6	,	,	PUNCT
chd-214	340	7	md	md	PROPN
chd-214	340	8	.	.	PUNCT
chd-214	340	9	:	:	PUNCT
chd-214	340	10	1950	1950	NUM
chd-214	340	11	)	)	PUNCT
chd-214	340	12	,	,	PUNCT
chd-214	340	13	177(10	177(10	NUM
chd-214	340	14	)	)	PUNCT
chd-214	340	15	,	,	PUNCT
chd-214	340	16	7398–7405	7398–7405	NUM
chd-214	340	17	.	.	PUNCT
chd-214	341	1	https://doi.org/10.4049/jimmunol.177.10.7398	https://doi.org/10.4049/jimmunol.177.10.7398	PROPN
chd-214	341	2	48	48	NUM
chd-214	341	3	.	.	PUNCT
chd-214	342	1	kwek	kwek	PROPN
chd-214	342	2	,	,	PUNCT
chd-214	342	3	s.	s.	PROPN
chd-214	342	4	s.	s.	PROPN
chd-214	342	5	,	,	PUNCT
chd-214	342	6	lewis	lewis	PROPN
chd-214	342	7	,	,	PUNCT
chd-214	342	8	j.	j.	PROPN
chd-214	342	9	,	,	PUNCT
chd-214	342	10	zhang	zhang	PROPN
chd-214	342	11	,	,	PUNCT
chd-214	342	12	l.	l.	PROPN
chd-214	342	13	,	,	PUNCT
chd-214	342	14	weinberg	weinberg	PROPN
chd-214	342	15	,	,	PUNCT
chd-214	342	16	v.	v.	PROPN
chd-214	342	17	,	,	PUNCT
chd-214	342	18	greaney	greaney	PROPN
chd-214	342	19	,	,	PUNCT
chd-214	342	20	s.	s.	PROPN
chd-214	342	21	k.	k.	PROPN
chd-214	342	22	,	,	PUNCT
chd-214	342	23	harzstark	harzstark	PROPN
chd-214	342	24	,	,	PUNCT
chd-214	342	25	a.	a.	PROPN
chd-214	342	26	l.	l.	PROPN
chd-214	342	27	,	,	PUNCT
chd-214	342	28	lin	lin	PROPN
chd-214	342	29	,	,	PUNCT
chd-214	342	30	a.	a.	NOUN
chd-214	342	31	m.	m.	NOUN
chd-214	342	32	,	,	PUNCT
chd-214	342	33	ryan	ryan	PROPN
chd-214	342	34	,	,	PUNCT
chd-214	342	35	c.	c.	PROPN
chd-214	342	36	j.	j.	PROPN
chd-214	342	37	,	,	PUNCT
chd-214	342	38	small	small	PROPN
chd-214	342	39	,	,	PUNCT
chd-214	342	40	e.	e.	PROPN
chd-214	342	41	j.	j.	PROPN
chd-214	342	42	,	,	PUNCT
chd-214	342	43	&	&	CCONJ
chd-214	342	44	fong	fong	PROPN
chd-214	342	45	,	,	PUNCT
chd-214	342	46	l.	l.	PROPN
chd-214	342	47	(	(	PUNCT
chd-214	342	48	2015	2015	NUM
chd-214	342	49	)	)	PUNCT
chd-214	342	50	.	.	PUNCT
chd-214	343	1	preexisting	preexist	VERB
chd-214	343	2	levels	level	NOUN
chd-214	343	3	of	of	ADP
chd-214	343	4	cd4	cd4	PROPN
chd-214	343	5	t	t	PROPN
chd-214	343	6	cells	cell	NOUN
chd-214	343	7	expressing	express	VERB
chd-214	343	8	pd-1	pd-1	ADV
chd-214	343	9	are	be	AUX
chd-214	343	10	related	relate	VERB
chd-214	343	11	to	to	ADP
chd-214	343	12	overall	overall	ADJ
chd-214	343	13	survival	survival	NOUN
chd-214	343	14	in	in	ADP
chd-214	343	15	prostate	prostate	NOUN
chd-214	343	16	cancer	cancer	NOUN
chd-214	343	17	patients	patient	NOUN
chd-214	343	18	treated	treat	VERB
chd-214	343	19	with	with	ADP
chd-214	343	20	ipilimumab	ipilimumab	NOUN
chd-214	343	21	.	.	PUNCT
chd-214	344	1	cancer	cancer	NOUN
chd-214	344	2	immunology	immunology	NOUN
chd-214	344	3	research	research	NOUN
chd-214	344	4	,	,	PUNCT
chd-214	344	5	3(9	3(9	NUM
chd-214	344	6	)	)	PUNCT
chd-214	344	7	,	,	PUNCT
chd-214	344	8	1008–1016	1008–1016	NUM
chd-214	344	9	.	.	PUNCT
chd-214	345	1	https://doi.org/10.1158/2326-6066.cir-14-0227	https://doi.org/10.1158/2326-6066.cir-14-0227	PROPN
chd-214	345	2	49	49	NUM
chd-214	345	3	.	.	PUNCT
chd-214	346	1	al	al	PROPN
chd-214	346	2	barashdi	barashdi	PROPN
chd-214	346	3	,	,	PUNCT
chd-214	346	4	m.	m.	NOUN
chd-214	346	5	a.	a.	PROPN
chd-214	346	6	,	,	PUNCT
chd-214	346	7	ali	ali	PROPN
chd-214	346	8	,	,	PUNCT
chd-214	346	9	a.	a.	PROPN
chd-214	346	10	,	,	PUNCT
chd-214	346	11	mcmullin	mcmullin	PROPN
chd-214	346	12	,	,	PUNCT
chd-214	346	13	m.	m.	NOUN
chd-214	346	14	f.	f.	PROPN
chd-214	346	15	,	,	PUNCT
chd-214	346	16	&	&	CCONJ
chd-214	346	17	mills	mill	NOUN
chd-214	346	18	,	,	PUNCT
chd-214	346	19	k.	k.	PROPN
chd-214	346	20	(	(	PUNCT
chd-214	346	21	2021	2021	NUM
chd-214	346	22	)	)	PUNCT
chd-214	346	23	.	.	PUNCT
chd-214	347	1	protein	protein	NOUN
chd-214	347	2	tyrosine	tyrosine	NOUN
chd-214	347	3	phosphatase	phosphatase	NOUN
chd-214	347	4	receptor	receptor	NOUN
chd-214	347	5	type	type	NOUN
chd-214	347	6	c	c	NOUN
chd-214	347	7	(	(	PUNCT
chd-214	347	8	ptprc	ptprc	NOUN
chd-214	347	9	or	or	CCONJ
chd-214	347	10	cd45	cd45	PROPN
chd-214	347	11	)	)	PUNCT
chd-214	347	12	.	.	PUNCT
chd-214	348	1	journal	journal	NOUN
chd-214	348	2	of	of	ADP
chd-214	348	3	clinical	clinical	ADJ
chd-214	348	4	pathology	pathology	NOUN
chd-214	348	5	,	,	PUNCT
chd-214	348	6	74(9	74(9	NUM
chd-214	348	7	)	)	PUNCT
chd-214	348	8	,	,	PUNCT
chd-214	348	9	548–552	548–552	NUM
chd-214	348	10	.	.	PUNCT
chd-214	349	1	https://doi.org/10.1136/jclinpath-2020-206927	https://doi.org/10.1136/jclinpath-2020-206927	PROPN
chd-214	349	2	50	50	NUM
chd-214	349	3	.	.	PUNCT
chd-214	350	1	mittal	mittal	PROPN
chd-214	350	2	,	,	PUNCT
chd-214	350	3	d.	d.	PROPN
chd-214	350	4	,	,	PUNCT
chd-214	350	5	lepletier	lepletier	NOUN
chd-214	350	6	,	,	PUNCT
chd-214	350	7	a.	a.	NOUN
chd-214	350	8	,	,	PUNCT
chd-214	350	9	madore	madore	NOUN
chd-214	350	10	,	,	PUNCT
chd-214	350	11	j.	j.	PROPN
chd-214	350	12	,	,	PUNCT
chd-214	350	13	aguilera	aguilera	PROPN
chd-214	350	14	,	,	PUNCT
chd-214	350	15	a.	a.	PROPN
chd-214	350	16	r.	r.	PROPN
chd-214	350	17	,	,	PUNCT
chd-214	350	18	stannard	stannard	PROPN
chd-214	350	19	,	,	PUNCT
chd-214	350	20	k.	k.	PROPN
chd-214	350	21	,	,	PUNCT
chd-214	350	22	blake	blake	PROPN
chd-214	350	23	,	,	PUNCT
chd-214	350	24	s.	s.	PROPN
chd-214	350	25	j.	j.	PROPN
chd-214	350	26	,	,	PUNCT
chd-214	350	27	whitehall	whitehall	PROPN
chd-214	350	28	,	,	PUNCT
chd-214	350	29	v.	v.	PROPN
chd-214	350	30	,	,	PUNCT
chd-214	350	31	liu	liu	PROPN
chd-214	350	32	,	,	PUNCT
chd-214	350	33	c.	c.	PROPN
chd-214	350	34	,	,	PUNCT
chd-214	350	35	bettington	bettington	NOUN
chd-214	350	36	,	,	PUNCT
chd-214	350	37	m.	m.	NOUN
chd-214	350	38	l.	l.	PROPN
chd-214	350	39	,	,	PUNCT
chd-214	350	40	takeda	takeda	PROPN
chd-214	350	41	,	,	PUNCT
chd-214	350	42	k.	k.	PROPN
chd-214	350	43	,	,	PUNCT
chd-214	350	44	long	long	ADV
chd-214	350	45	,	,	PUNCT
chd-214	350	46	g.	g.	PROPN
chd-214	350	47	v.	v.	PROPN
chd-214	350	48	,	,	PUNCT
chd-214	350	49	scolyer	scolyer	PROPN
chd-214	350	50	,	,	PUNCT
chd-214	350	51	r.	r.	PROPN
chd-214	350	52	a.	a.	PROPN
chd-214	350	53	,	,	PUNCT
chd-214	350	54	lan	lan	PROPN
chd-214	350	55	,	,	PUNCT
chd-214	350	56	r.	r.	PROPN
chd-214	350	57	,	,	PUNCT
chd-214	350	58	siemers	siemer	NOUN
chd-214	350	59	,	,	PUNCT
chd-214	350	60	n.	n.	NOUN
chd-214	350	61	,	,	PUNCT
chd-214	350	62	korman	korman	PROPN
chd-214	350	63	,	,	PUNCT
chd-214	350	64	a.	a.	PROPN
chd-214	350	65	,	,	PUNCT
chd-214	350	66	teng	teng	PROPN
chd-214	350	67	,	,	PUNCT
chd-214	350	68	m.	m.	NOUN
chd-214	350	69	,	,	PUNCT
chd-214	350	70	johnston	johnston	PROPN
chd-214	350	71	,	,	PUNCT
chd-214	350	72	r.	r.	PROPN
chd-214	350	73	j.	j.	PROPN
chd-214	350	74	,	,	PUNCT
chd-214	350	75	dougall	dougall	PROPN
chd-214	350	76	,	,	PUNCT
chd-214	350	77	w.	w.	PROPN
chd-214	350	78	c.	c.	PROPN
chd-214	350	79	,	,	PUNCT
chd-214	350	80	&	&	CCONJ
chd-214	350	81	smyth	smyth	PROPN
chd-214	350	82	,	,	PUNCT
chd-214	350	83	m.	m.	NOUN
chd-214	350	84	j.	j.	PROPN
chd-214	350	85	(	(	PUNCT
chd-214	350	86	2019	2019	NUM
chd-214	350	87	)	)	PUNCT
chd-214	350	88	.	.	PUNCT
chd-214	351	1	cd96	cd96	PROPN
chd-214	351	2	is	be	AUX
chd-214	351	3	an	an	DET
chd-214	351	4	immune	immune	ADJ
chd-214	351	5	checkpoint	checkpoint	NOUN
chd-214	351	6	that	that	PRON
chd-214	351	7	regulates	regulate	VERB
chd-214	351	8	cd8	cd8	PROPN
chd-214	351	9	+	+	PROPN
chd-214	351	10	t	t	PROPN
chd-214	351	11	-	-	PUNCT
chd-214	351	12	cell	cell	NOUN
chd-214	351	13	antitumor	antitumor	PROPN
chd-214	351	14	function	function	NOUN
chd-214	351	15	.	.	PUNCT
chd-214	352	1	cancer	cancer	NOUN
chd-214	352	2	immunology	immunology	NOUN
chd-214	352	3	research	research	NOUN
chd-214	352	4	,	,	PUNCT
chd-214	352	5	7(4	7(4	NUM
chd-214	352	6	)	)	PUNCT
chd-214	352	7	,	,	PUNCT
chd-214	352	8	559–571	559–571	NUM
chd-214	352	9	.	.	PUNCT
chd-214	353	1	https://doi.org/10.1158/2326-6066.cir-18-0637	https://doi.org/10.1158/2326-6066.cir-18-0637	NUM
chd-214	353	2	.	.	NOUN
chd-214	354	1	51	51	NUM
chd-214	354	2	.	.	PUNCT
chd-214	355	1	huang	huang	PROPN
chd-214	355	2	,	,	PUNCT
chd-214	355	3	r.	r.	PROPN
chd-214	355	4	,	,	PUNCT
chd-214	355	5	guo	guo	PROPN
chd-214	355	6	,	,	PUNCT
chd-214	355	7	l.	l.	PROPN
chd-214	355	8	,	,	PUNCT
chd-214	355	9	gao	gao	PROPN
chd-214	355	10	,	,	PUNCT
chd-214	355	11	m.	m.	NOUN
chd-214	355	12	,	,	PUNCT
chd-214	355	13	li	li	PROPN
chd-214	355	14	,	,	PUNCT
chd-214	355	15	j.	j.	PROPN
chd-214	355	16	,	,	PUNCT
chd-214	355	17	&	&	CCONJ
chd-214	355	18	xiang	xiang	PROPN
chd-214	355	19	,	,	PUNCT
chd-214	355	20	s.	s.	PROPN
chd-214	355	21	(	(	PUNCT
chd-214	355	22	2021	2021	NUM
chd-214	355	23	)	)	PUNCT
chd-214	355	24	.	.	PUNCT
chd-214	356	1	research	research	NOUN
chd-214	356	2	trends	trend	NOUN
chd-214	356	3	and	and	CCONJ
chd-214	356	4	regulation	regulation	NOUN
chd-214	356	5	of	of	ADP
chd-214	356	6	ccl5	ccl5	PROPN
chd-214	356	7	in	in	ADP
chd-214	356	8	prostate	prostate	NOUN
chd-214	356	9	cancer	cancer	NOUN
chd-214	356	10	.	.	PUNCT
chd-214	357	1	oncotargets	oncotarget	NOUN
chd-214	357	2	and	and	CCONJ
chd-214	357	3	therapy	therapy	NOUN
chd-214	357	4	,	,	PUNCT
chd-214	357	5	14	14	NUM
chd-214	357	6	,	,	PUNCT
chd-214	357	7	1417–1427	1417–1427	NUM
chd-214	357	8	.	.	PUNCT
chd-214	357	9	https://doi.org/10.2147/ott.s279189	https://doi.org/10.2147/ott.s279189	PROPN
chd-214	357	10	52	52	NUM
chd-214	357	11	.	.	PUNCT
chd-214	358	1	tan	tan	PROPN
chd-214	358	2	,	,	PUNCT
chd-214	358	3	s.	s.	PROPN
chd-214	358	4	,	,	PUNCT
chd-214	358	5	wang	wang	PROPN
chd-214	358	6	,	,	PUNCT
chd-214	358	7	k.	k.	PROPN
chd-214	358	8	,	,	PUNCT
chd-214	358	9	sun	sun	PROPN
chd-214	358	10	,	,	PUNCT
chd-214	358	11	f.	f.	PROPN
chd-214	358	12	,	,	PUNCT
chd-214	358	13	li	li	PROPN
chd-214	358	14	,	,	PUNCT
chd-214	358	15	y.	y.	PROPN
chd-214	358	16	,	,	PUNCT
chd-214	358	17	&	&	CCONJ
chd-214	358	18	gao	gao	PROPN
chd-214	358	19	,	,	PUNCT
chd-214	358	20	y.	y.	PROPN
chd-214	358	21	(	(	PUNCT
chd-214	358	22	2018	2018	NUM
chd-214	358	23	)	)	PUNCT
chd-214	358	24	.	.	PUNCT
chd-214	359	1	cxcl9	cxcl9	PROPN
chd-214	359	2	promotes	promote	VERB
chd-214	359	3	prostate	prostate	NOUN
chd-214	359	4	cancer	cancer	NOUN
chd-214	359	5	progression	progression	NOUN
chd-214	359	6	through	through	ADP
chd-214	359	7	inhibition	inhibition	NOUN
chd-214	359	8	of	of	ADP
chd-214	359	9	cytokines	cytokine	NOUN
chd-214	359	10	from	from	ADP
chd-214	359	11	t	t	NOUN
chd-214	359	12	cells	cell	NOUN
chd-214	359	13	.	.	PUNCT
chd-214	360	1	molecular	molecular	ADJ
chd-214	360	2	medicine	medicine	NOUN
chd-214	360	3	reports	report	NOUN
chd-214	360	4	,	,	PUNCT
chd-214	360	5	18	18	NUM
chd-214	360	6	,	,	PUNCT
chd-214	360	7	1305	1305	NUM
chd-214	360	8	-	-	SYM
chd-214	360	9	1310	1310	NUM
chd-214	360	10	.	.	PUNCT
chd-214	361	1	53	53	NUM
chd-214	361	2	.	.	PUNCT
chd-214	362	1	gwak	gwak	PROPN
chd-214	362	2	,	,	PUNCT
chd-214	362	3	j.	j.	PROPN
chd-214	362	4	,	,	PUNCT
chd-214	362	5	jeong	jeong	PROPN
chd-214	362	6	,	,	PUNCT
chd-214	362	7	h.	h.	PROPN
chd-214	362	8	,	,	PUNCT
chd-214	362	9	lee	lee	PROPN
chd-214	362	10	,	,	PUNCT
chd-214	362	11	k.	k.	PROPN
chd-214	362	12	,	,	PUNCT
chd-214	362	13	shin	shin	PROPN
chd-214	362	14	,	,	PUNCT
chd-214	362	15	j.	j.	PROPN
chd-214	362	16	y.	y.	PROPN
chd-214	362	17	,	,	PUNCT
chd-214	362	18	sim	sim	ADJ
chd-214	362	19	,	,	PUNCT
chd-214	362	20	t.	t.	PROPN
chd-214	362	21	,	,	PUNCT
chd-214	362	22	na	na	PROPN
chd-214	362	23	,	,	PUNCT
chd-214	362	24	j.	j.	PROPN
chd-214	362	25	,	,	PUNCT
chd-214	362	26	kim	kim	PROPN
chd-214	362	27	,	,	PUNCT
chd-214	362	28	j.	j.	PROPN
chd-214	362	29	,	,	PUNCT
chd-214	362	30	&	&	CCONJ
chd-214	362	31	ju	ju	PROPN
chd-214	362	32	,	,	PUNCT
chd-214	362	33	b.	b.	PROPN
chd-214	362	34	g.	g.	PROPN
chd-214	362	35	(	(	PUNCT
chd-214	362	36	2020	2020	NUM
chd-214	362	37	)	)	PUNCT
chd-214	362	38	.	.	PUNCT
chd-214	363	1	sfmbt2	sfmbt2	NOUN
chd-214	363	2	-	-	PUNCT
chd-214	363	3	mediated	mediate	VERB
chd-214	363	4	infiltration	infiltration	NOUN
chd-214	363	5	of	of	ADP
chd-214	363	6	preadipocytes	preadipocyte	NOUN
chd-214	363	7	and	and	CCONJ
chd-214	363	8	tams	tam	NOUN
chd-214	363	9	in	in	ADP
chd-214	363	10	prostate	prostate	NOUN
chd-214	363	11	cancer	cancer	NOUN
chd-214	363	12	.	.	PUNCT
chd-214	364	1	cancers	cancer	NOUN
chd-214	364	2	,	,	PUNCT
chd-214	364	3	12(9	12(9	NUM
chd-214	364	4	)	)	PUNCT
chd-214	364	5	,	,	PUNCT
chd-214	364	6	2718	2718	NUM
chd-214	364	7	.	.	PUNCT
chd-214	364	8	https://doi.org/10.3390/cancers12092718	https://doi.org/10.3390/cancers12092718	PROPN
chd-214	364	9	54	54	NUM
chd-214	364	10	.	.	PUNCT
chd-214	365	1	wang	wang	PROPN
chd-214	365	2	,	,	PUNCT
chd-214	365	3	y.	y.	PROPN
chd-214	365	4	,	,	PUNCT
chd-214	365	5	xu	xu	PROPN
chd-214	365	6	,	,	PUNCT
chd-214	365	7	h.	h.	PROPN
chd-214	365	8	,	,	PUNCT
chd-214	365	9	si	si	PROPN
chd-214	365	10	,	,	PUNCT
chd-214	365	11	l.	l.	PROPN
chd-214	365	12	,	,	PUNCT
chd-214	365	13	li	li	PROPN
chd-214	365	14	,	,	PUNCT
chd-214	365	15	q.	q.	PROPN
chd-214	365	16	,	,	PUNCT
chd-214	365	17	zhu	zhu	PROPN
chd-214	365	18	,	,	PUNCT
chd-214	365	19	x.	x.	PROPN
chd-214	365	20	,	,	PUNCT
chd-214	365	21	yu	yu	PROPN
chd-214	365	22	,	,	PUNCT
chd-214	365	23	t.	t.	PROPN
chd-214	365	24	,	,	PUNCT
chd-214	365	25	&	&	CCONJ
chd-214	365	26	gang	gang	PROPN
chd-214	365	27	,	,	PUNCT
chd-214	365	28	x.	x.	NOUN
chd-214	365	29	(	(	PUNCT
chd-214	365	30	2018	2018	NUM
chd-214	365	31	)	)	PUNCT
chd-214	365	32	.	.	PUNCT
chd-214	366	1	mir-206	mir-206	NOUN
chd-214	366	2	inhibits	inhibit	VERB
chd-214	366	3	proliferation	proliferation	NOUN
chd-214	366	4	and	and	CCONJ
chd-214	366	5	migration	migration	NOUN
chd-214	366	6	of	of	ADP
chd-214	366	7	prostate	prostate	NOUN
chd-214	366	8	cancer	cancer	NOUN
chd-214	366	9	cells	cell	NOUN
chd-214	366	10	by	by	ADP
chd-214	366	11	targeting	target	VERB
chd-214	366	12	cxcl11	cxcl11	NOUN
chd-214	366	13	.	.	PUNCT
chd-214	367	1	the	the	DET
chd-214	367	2	prostate	prostate	NOUN
chd-214	367	3	,	,	PUNCT
chd-214	367	4	78(7	78(7	NUM
chd-214	367	5	)	)	PUNCT
chd-214	367	6	,	,	PUNCT
chd-214	367	7	479–490	479–490	NUM
chd-214	367	8	.	.	PUNCT
chd-214	367	9	https://doi.org/10.1002/pros.23468	https://doi.org/10.1002/pros.23468	NOUN
chd-214	367	10	55	55	NUM
chd-214	367	11	.	.	PUNCT
chd-214	368	1	patterson	patterson	PROPN
chd-214	368	2	,	,	PUNCT
chd-214	368	3	s.	s.	PROPN
chd-214	368	4	g.	g.	PROPN
chd-214	368	5	,	,	PUNCT
chd-214	368	6	wei	wei	PROPN
chd-214	368	7	,	,	PUNCT
chd-214	368	8	s.	s.	PROPN
chd-214	368	9	,	,	PUNCT
chd-214	368	10	chen	chen	PROPN
chd-214	368	11	,	,	PUNCT
chd-214	368	12	x.	x.	PROPN
chd-214	368	13	,	,	PUNCT
chd-214	368	14	sallman	sallman	PROPN
chd-214	368	15	,	,	PUNCT
chd-214	368	16	d.	d.	PROPN
chd-214	368	17	a.	a.	PROPN
chd-214	368	18	,	,	PUNCT
chd-214	368	19	gilvary	gilvary	NOUN
chd-214	368	20	,	,	PUNCT
chd-214	368	21	d.	d.	PROPN
chd-214	368	22	l.	l.	PROPN
chd-214	368	23	,	,	PUNCT
chd-214	368	24	zhong	zhong	PROPN
chd-214	368	25	,	,	PUNCT
chd-214	368	26	b.	b.	PROPN
chd-214	368	27	,	,	PUNCT
chd-214	368	28	pow	pow	NOUN
chd-214	368	29	-	-	PUNCT
chd-214	368	30	sang	sang	PROPN
chd-214	368	31	,	,	PUNCT
chd-214	368	32	j.	j.	PROPN
chd-214	368	33	,	,	PUNCT
chd-214	368	34	yeatman	yeatman	PROPN
chd-214	368	35	,	,	PUNCT
chd-214	368	36	t.	t.	PROPN
chd-214	368	37	,	,	PUNCT
chd-214	368	38	&	&	CCONJ
chd-214	368	39	djeu	djeu	PROPN
chd-214	368	40	,	,	PUNCT
chd-214	368	41	j.	j.	PROPN
chd-214	368	42	y.	y.	PROPN
chd-214	368	43	(	(	PUNCT
chd-214	368	44	2006	2006	NUM
chd-214	368	45	)	)	PUNCT
chd-214	368	46	.	.	PUNCT
chd-214	369	1	novel	novel	ADJ
chd-214	369	2	role	role	NOUN
chd-214	369	3	of	of	ADP
chd-214	369	4	stat1	stat1	NOUN
chd-214	369	5	in	in	ADP
chd-214	369	6	the	the	DET
chd-214	369	7	development	development	NOUN
chd-214	369	8	of	of	ADP
chd-214	369	9	docetaxel	docetaxel	PROPN
chd-214	369	10	resistance	resistance	NOUN
chd-214	369	11	in	in	ADP
chd-214	369	12	prostate	prostate	NOUN
chd-214	369	13	tumor	tumor	NOUN
chd-214	369	14	cells	cell	NOUN
chd-214	369	15	.	.	PUNCT
chd-214	370	1	oncogene	oncogene	NOUN
chd-214	370	2	,	,	PUNCT
chd-214	370	3	25(45	25(45	NUM
chd-214	370	4	)	)	PUNCT
chd-214	370	5	,	,	PUNCT
chd-214	370	6	6113	6113	NUM
chd-214	370	7	–	–	PUNCT
chd-214	370	8	6122	6122	NUM
chd-214	370	9	.	.	PUNCT
chd-214	371	1	https://doi.org/10.1038/sj.onc.1209632	https://doi.org/10.1038/sj.onc.1209632	NOUN
chd-214	371	2	https://doi.org/10.1158/1078-0432.ccr-20-2925	https://doi.org/10.1158/1078-0432.ccr-20-2925	PUNCT
chd-214	371	3	https://doi.org/10.1158/1078-0432.ccr-20-2925	https://doi.org/10.1158/1078-0432.ccr-20-2925	PROPN
chd-214	371	4	https://doi.org/10.1007/s00109-012-0916-x	https://doi.org/10.1007/s00109-012-0916-x	PROPN
chd-214	371	5	https://doi.org/10.1158/1541-7786.mcr-19-0595	https://doi.org/10.1158/1541-7786.mcr-19-0595	PRON
chd-214	371	6	https://doi.org/10.1038/s41379-018-0083-x	https://doi.org/10.1038/s41379-018-0083-x	NOUN
chd-214	371	7	https://doi.org/10.1038/s41379-018-0083-x	https://doi.org/10.1038/s41379-018-0083-x	NOUN
chd-214	371	8	https://doi.org/10.3389/fimmu.2019.00603	https://doi.org/10.3389/fimmu.2019.00603	PROPN
chd-214	371	9	https://doi.org/10.1002/%20ijc.30787	https://doi.org/10.1002/%20ijc.30787	NOUN
chd-214	371	10	https://doi.org/10.1038/s42003-021-02140-y	https://doi.org/10.1038/s42003-021-02140-y	PROPN
chd-214	371	11	https://doi.org/10.3389/fimmu.2021.664845	https://doi.org/10.3389/fimmu.2021.664845	PROPN
chd-214	371	12	https://doi.org/10.1007/s00262-007-0348-6	https://doi.org/10.1007/s00262-007-0348-6	NUM
chd-214	371	13	https://doi.org/10.4049/jimmunol.177.10.7398	https://doi.org/10.4049/jimmunol.177.10.7398	PROPN
chd-214	371	14	https://doi.org/10.1158/2326-6066.cir-14-0227	https://doi.org/10.1158/2326-6066.cir-14-0227	PROPN
chd-214	371	15	https://doi.org/10.1136/jclinpath-2020-206927	https://doi.org/10.1136/jclinpath-2020-206927	PROPN
chd-214	371	16	https://doi.org/10.2147/ott.s279189	https://doi.org/10.2147/ott.s279189	PROPN
chd-214	371	17	https://doi.org/10.3390/cancers12092718	https://doi.org/10.3390/cancers12092718	NOUN
chd-214	371	18	https://doi.org/10.1002/pros.23468	https://doi.org/10.1002/pros.23468	NOUN
chd-214	371	19	https://doi.org/10.1038/sj.onc.1209632	https://doi.org/10.1038/sj.onc.1209632	NOUN
chd-214	371	20	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	NUM
chd-214	371	21	e13	e13	NOUN
chd-214	371	22	cancer	cancer	NOUN
chd-214	371	23	health	health	NOUN
chd-214	371	24	disparities	disparity	NOUN
chd-214	371	25	research	research	VERB
chd-214	371	26	56	56	NUM
chd-214	371	27	.	.	PUNCT
chd-214	372	1	nayak	nayak	PROPN
chd-214	372	2	-	-	PUNCT
chd-214	372	3	kapoor	kapoor	PROPN
chd-214	372	4	,	,	PUNCT
chd-214	372	5	a.	a.	PROPN
chd-214	372	6	,	,	PUNCT
chd-214	372	7	hao	hao	PROPN
chd-214	372	8	,	,	PUNCT
chd-214	372	9	z.	z.	PROPN
chd-214	372	10	,	,	PUNCT
chd-214	372	11	sadek	sadek	PROPN
chd-214	372	12	,	,	PUNCT
chd-214	372	13	r.	r.	PROPN
chd-214	372	14	,	,	PUNCT
chd-214	372	15	dobbins	dobbin	NOUN
chd-214	372	16	,	,	PUNCT
chd-214	372	17	r.	r.	PROPN
chd-214	372	18	,	,	PUNCT
chd-214	372	19	marshall	marshall	PROPN
chd-214	372	20	,	,	PUNCT
chd-214	372	21	l.	l.	PROPN
chd-214	372	22	,	,	PUNCT
chd-214	372	23	vahanian	vahanian	PROPN
chd-214	372	24	,	,	PUNCT
chd-214	372	25	n.	n.	PROPN
chd-214	372	26	n.	n.	PROPN
chd-214	372	27	,	,	PUNCT
chd-214	372	28	jay	jay	PROPN
chd-214	372	29	ramsey	ramsey	PROPN
chd-214	372	30	,	,	PUNCT
chd-214	372	31	w.	w.	PROPN
chd-214	372	32	,	,	PUNCT
chd-214	372	33	kennedy	kennedy	PROPN
chd-214	372	34	,	,	PUNCT
chd-214	372	35	e.	e.	PROPN
chd-214	372	36	,	,	PUNCT
chd-214	372	37	mautino	mautino	PROPN
chd-214	372	38	,	,	PUNCT
chd-214	372	39	m.	m.	NOUN
chd-214	372	40	r.	r.	PROPN
chd-214	372	41	,	,	PUNCT
chd-214	372	42	link	link	PROPN
chd-214	372	43	,	,	PUNCT
chd-214	372	44	c.	c.	PROPN
chd-214	372	45	j.	j.	PROPN
chd-214	372	46	,	,	PUNCT
chd-214	372	47	lin	lin	PROPN
chd-214	372	48	,	,	PUNCT
chd-214	372	49	r.	r.	PROPN
chd-214	372	50	s.	s.	PROPN
chd-214	372	51	,	,	PUNCT
chd-214	372	52	royer	royer	PROPN
chd-214	372	53	-	-	PUNCT
chd-214	372	54	joo	joo	PROPN
chd-214	372	55	,	,	PUNCT
chd-214	372	56	s.	s.	PROPN
chd-214	372	57	,	,	PUNCT
chd-214	372	58	liang	liang	PROPN
chd-214	372	59	,	,	PUNCT
chd-214	372	60	x.	x.	PROPN
chd-214	372	61	,	,	PUNCT
chd-214	372	62	salphati	salphati	PROPN
chd-214	372	63	,	,	PUNCT
chd-214	372	64	l.	l.	PROPN
chd-214	372	65	,	,	PUNCT
chd-214	372	66	morrissey	morrissey	PROPN
chd-214	372	67	,	,	PUNCT
chd-214	372	68	k.	k.	PROPN
chd-214	372	69	m.	m.	PROPN
chd-214	372	70	,	,	PUNCT
chd-214	372	71	mahrus	mahrus	PROPN
chd-214	372	72	,	,	PUNCT
chd-214	372	73	s.	s.	PROPN
chd-214	372	74	,	,	PUNCT
chd-214	372	75	mccall	mccall	PROPN
chd-214	372	76	,	,	PUNCT
chd-214	372	77	b.	b.	PROPN
chd-214	372	78	,	,	PUNCT
chd-214	372	79	pirzkall	pirzkall	PROPN
chd-214	372	80	,	,	PUNCT
chd-214	372	81	a.	a.	PROPN
chd-214	372	82	,	,	PUNCT
chd-214	372	83	munn	munn	PROPN
chd-214	372	84	,	,	PUNCT
chd-214	372	85	d.	d.	PROPN
chd-214	372	86	h.	h.	PROPN
chd-214	372	87	,	,	PUNCT
chd-214	372	88	janik	janik	ADV
chd-214	372	89	,	,	PUNCT
chd-214	372	90	j.	j.	PROPN
chd-214	372	91	e.	e.	PROPN
chd-214	372	92	,	,	PUNCT
chd-214	372	93	…	…	PUNCT
chd-214	372	94	khleif	khleif	NOUN
chd-214	372	95	,	,	PUNCT
chd-214	372	96	s.	s.	PROPN
chd-214	372	97	n.	n.	PROPN
chd-214	372	98	(	(	PUNCT
chd-214	372	99	2018	2018	NUM
chd-214	372	100	)	)	PUNCT
chd-214	372	101	.	.	PUNCT
chd-214	373	1	phase	phase	NOUN
chd-214	373	2	ia	ia	PROPN
chd-214	373	3	study	study	NOUN
chd-214	373	4	of	of	ADP
chd-214	373	5	the	the	DET
chd-214	373	6	indoleamine	indoleamine	ADJ
chd-214	373	7	2,3	2,3	NUM
chd-214	373	8	-	-	NOUN
chd-214	373	9	dioxygenase	dioxygenase	NOUN
chd-214	373	10	1	1	NUM
chd-214	373	11	(	(	PUNCT
chd-214	373	12	ido1	ido1	NOUN
chd-214	373	13	)	)	PUNCT
chd-214	373	14	inhibitor	inhibitor	NOUN
chd-214	373	15	navoximod	navoximod	NOUN
chd-214	373	16	(	(	PUNCT
chd-214	373	17	gdc-0919	gdc-0919	NOUN
chd-214	373	18	)	)	PUNCT
chd-214	373	19	in	in	ADP
chd-214	373	20	patients	patient	NOUN
chd-214	373	21	with	with	ADP
chd-214	373	22	recurrent	recurrent	ADJ
chd-214	373	23	advanced	advanced	ADJ
chd-214	373	24	solid	solid	ADJ
chd-214	373	25	tumors	tumor	NOUN
chd-214	373	26	.	.	PUNCT
chd-214	374	1	journal	journal	PROPN
chd-214	374	2	for	for	ADP
chd-214	374	3	immunotherapy	immunotherapy	NOUN
chd-214	374	4	of	of	ADP
chd-214	374	5	cancer	cancer	NOUN
chd-214	374	6	,	,	PUNCT
chd-214	374	7	6(1	6(1	NUM
chd-214	374	8	)	)	PUNCT
chd-214	374	9	,	,	PUNCT
chd-214	374	10	61	61	NUM
chd-214	374	11	.	.	PUNCT
chd-214	375	1	https://doi.org/10.1186/s40425-018-0351-9	https://doi.org/10.1186/s40425-018-0351-9	NUM
chd-214	375	2	57	57	NUM
chd-214	375	3	.	.	PUNCT
chd-214	376	1	larsson	larsson	PROPN
chd-214	376	2	,	,	PUNCT
chd-214	376	3	p.	p.	PROPN
chd-214	376	4	,	,	PUNCT
chd-214	376	5	syed	syed	PROPN
chd-214	376	6	khaja	khaja	PROPN
chd-214	376	7	,	,	PUNCT
chd-214	376	8	a.	a.	PROPN
chd-214	376	9	s.	s.	PROPN
chd-214	376	10	,	,	PUNCT
chd-214	376	11	semenas	semena	NOUN
chd-214	376	12	,	,	PUNCT
chd-214	376	13	j.	j.	PROPN
chd-214	376	14	,	,	PUNCT
chd-214	376	15	wang	wang	PROPN
chd-214	376	16	,	,	PUNCT
chd-214	376	17	t.	t.	PROPN
chd-214	376	18	,	,	PUNCT
chd-214	376	19	sarwar	sarwar	PROPN
chd-214	376	20	,	,	PUNCT
chd-214	376	21	m.	m.	NOUN
chd-214	376	22	,	,	PUNCT
chd-214	376	23	dizeyi	dizeyi	PROPN
chd-214	376	24	,	,	PUNCT
chd-214	376	25	n.	n.	NOUN
chd-214	376	26	,	,	PUNCT
chd-214	376	27	simoulis	simoulis	PROPN
chd-214	376	28	,	,	PUNCT
chd-214	376	29	a.	a.	NOUN
chd-214	376	30	,	,	PUNCT
chd-214	376	31	hedblom	hedblom	PROPN
chd-214	376	32	,	,	PUNCT
chd-214	376	33	a.	a.	PROPN
chd-214	376	34	,	,	PUNCT
chd-214	376	35	wai	wai	PROPN
chd-214	376	36	,	,	PUNCT
chd-214	376	37	s.	s.	PROPN
chd-214	376	38	n.	n.	PROPN
chd-214	376	39	,	,	PUNCT
chd-214	376	40	ødum	ødum	NOUN
chd-214	376	41	,	,	PUNCT
chd-214	376	42	n.	n.	NOUN
chd-214	376	43	,	,	PUNCT
chd-214	376	44	&	&	CCONJ
chd-214	376	45	persson	persson	PROPN
chd-214	376	46	,	,	PUNCT
chd-214	376	47	j.	j.	PROPN
chd-214	376	48	l.	l.	PROPN
chd-214	376	49	(	(	PUNCT
chd-214	376	50	2020	2020	NUM
chd-214	376	51	)	)	PUNCT
chd-214	376	52	.	.	PUNCT
chd-214	377	1	the	the	DET
chd-214	377	2	functional	functional	ADJ
chd-214	377	3	interlink	interlink	NOUN
chd-214	377	4	between	between	ADP
chd-214	377	5	ar	ar	PROPN
chd-214	377	6	and	and	CCONJ
chd-214	377	7	mmp9	mmp9	PROPN
chd-214	377	8	/	/	SYM
chd-214	377	9	vegf	vegf	PROPN
chd-214	377	10	signaling	signal	VERB
chd-214	377	11	axis	axis	NOUN
chd-214	377	12	is	be	AUX
chd-214	377	13	mediated	mediate	VERB
chd-214	377	14	through	through	ADP
chd-214	377	15	pip5k1α	pip5k1α	PROPN
chd-214	377	16	/	/	SYM
chd-214	377	17	pakt	pakt	NOUN
chd-214	377	18	in	in	ADP
chd-214	377	19	prostate	prostate	NOUN
chd-214	377	20	cancer	cancer	NOUN
chd-214	377	21	.	.	PUNCT
chd-214	378	1	international	international	ADJ
chd-214	378	2	journal	journal	PROPN
chd-214	378	3	of	of	ADP
chd-214	378	4	cancer	cancer	NOUN
chd-214	378	5	,	,	PUNCT
chd-214	378	6	146(6	146(6	NUM
chd-214	378	7	)	)	PUNCT
chd-214	378	8	,	,	PUNCT
chd-214	378	9	1686–1699	1686–1699	NUM
chd-214	378	10	.	.	PUNCT
chd-214	379	1	https://doi.org/10.1002/ijc.32607	https://doi.org/10.1002/ijc.32607	PROPN
chd-214	379	2	58	58	NUM
chd-214	379	3	.	.	PUNCT
chd-214	380	1	huang	huang	PROPN
chd-214	380	2	,	,	PUNCT
chd-214	380	3	b.	b.	PROPN
chd-214	380	4	,	,	PUNCT
chd-214	380	5	raz	raz	PROPN
chd-214	380	6	,	,	PUNCT
chd-214	380	7	a.	a.	NOUN
chd-214	380	8	(	(	PUNCT
chd-214	380	9	1995	1995	NUM
chd-214	380	10	)	)	PUNCT
chd-214	380	11	.	.	PUNCT
chd-214	381	1	differential	differential	ADJ
chd-214	381	2	expression	expression	NOUN
chd-214	381	3	of	of	ADP
chd-214	381	4	autocrine	autocrine	NOUN
chd-214	381	5	motility	motility	NOUN
chd-214	381	6	factor	factor	NOUN
chd-214	381	7	receptor	receptor	NOUN
chd-214	381	8	(	(	PUNCT
chd-214	381	9	amfr	amfr	PROPN
chd-214	381	10	)	)	PUNCT
chd-214	381	11	mrna	mrna	PROPN
chd-214	381	12	in	in	ADP
chd-214	381	13	normal	normal	ADJ
chd-214	381	14	and	and	CCONJ
chd-214	381	15	cancer	cancer	NOUN
chd-214	381	16	cells	cell	NOUN
chd-214	381	17	detected	detect	VERB
chd-214	381	18	by	by	ADP
chd-214	381	19	in	in	ADP
chd-214	381	20	situ	situ	ADJ
chd-214	381	21	hybridization	hybridization	NOUN
chd-214	381	22	.	.	PUNCT
chd-214	382	1	cell	cell	NOUN
chd-214	382	2	res	re	NOUN
chd-214	382	3	(	(	PUNCT
chd-214	382	4	5	5	NUM
chd-214	382	5	)	)	PUNCT
chd-214	382	6	,	,	PUNCT
chd-214	382	7	221–234	221–234	NUM
chd-214	382	8	.	.	PUNCT
chd-214	383	1	https://doi.org/10.1038/cr.1995.21	https://doi.org/10.1038/cr.1995.21	PROPN
chd-214	383	2	59	59	NUM
chd-214	383	3	.	.	PUNCT
chd-214	384	1	dovey	dovey	ADJ
chd-214	384	2	,	,	PUNCT
chd-214	384	3	z.	z.	PROPN
chd-214	384	4	s.	s.	PROPN
chd-214	384	5	,	,	PUNCT
chd-214	384	6	nair	nair	PROPN
chd-214	384	7	,	,	PUNCT
chd-214	384	8	s.	s.	PROPN
chd-214	384	9	s.	s.	PROPN
chd-214	384	10	,	,	PUNCT
chd-214	384	11	chakravarty	chakravarty	PROPN
chd-214	384	12	,	,	PUNCT
chd-214	384	13	d.	d.	PROPN
chd-214	384	14	,	,	PUNCT
chd-214	384	15	and	and	CCONJ
chd-214	384	16	tewari	tewari	PROPN
chd-214	384	17	,	,	PUNCT
chd-214	384	18	a.	a.	PROPN
chd-214	384	19	k.	k.	PROPN
chd-214	384	20	(	(	PUNCT
chd-214	384	21	2021	2021	NUM
chd-214	384	22	)	)	PUNCT
chd-214	384	23	.	.	PUNCT
chd-214	385	1	racial	racial	ADJ
chd-214	385	2	disparity	disparity	NOUN
chd-214	385	3	in	in	ADP
chd-214	385	4	prostate	prostate	NOUN
chd-214	385	5	cancer	cancer	NOUN
chd-214	385	6	in	in	ADP
chd-214	385	7	the	the	DET
chd-214	385	8	african	african	ADJ
chd-214	385	9	american	american	ADJ
chd-214	385	10	population	population	NOUN
chd-214	385	11	with	with	ADP
chd-214	385	12	actionable	actionable	ADJ
chd-214	385	13	ideas	idea	NOUN
chd-214	385	14	and	and	CCONJ
chd-214	385	15	novel	novel	ADJ
chd-214	385	16	immunotherapies	immunotherapy	NOUN
chd-214	385	17	.	.	PUNCT
chd-214	386	1	cancer	cancer	NOUN
chd-214	386	2	reports	report	NOUN
chd-214	386	3	(	(	PUNCT
chd-214	386	4	hoboken	hoboken	PROPN
chd-214	386	5	,	,	PUNCT
chd-214	386	6	n.j	n.j	PROPN
chd-214	386	7	.	.	PROPN
chd-214	386	8	)	)	PUNCT
chd-214	386	9	,	,	PUNCT
chd-214	386	10	4(5	4(5	PROPN
chd-214	386	11	)	)	PUNCT
chd-214	386	12	,	,	PUNCT
chd-214	386	13	e1340	e1340	NUM
chd-214	386	14	.	.	PUNCT
chd-214	387	1	https://doi.org/10.1002/cnr2.1340	https://doi.org/10.1002/cnr2.1340	NUM
chd-214	387	2	60	60	NUM
chd-214	387	3	.	.	PUNCT
chd-214	388	1	vidal	vidal	NOUN
chd-214	388	2	,	,	PUNCT
chd-214	388	3	a.	a.	PROPN
chd-214	388	4	c.	c.	PROPN
chd-214	388	5	,	,	PUNCT
chd-214	388	6	chen	chen	PROPN
chd-214	388	7	,	,	PUNCT
chd-214	388	8	z.	z.	PROPN
chd-214	388	9	,	,	PUNCT
chd-214	388	10	howard	howard	PROPN
chd-214	388	11	,	,	PUNCT
chd-214	388	12	l.	l.	PROPN
chd-214	388	13	e.	e.	PROPN
chd-214	388	14	,	,	PUNCT
chd-214	388	15	moreira	moreira	PROPN
chd-214	388	16	,	,	PUNCT
chd-214	388	17	d.	d.	PROPN
chd-214	388	18	m.	m.	PROPN
chd-214	388	19	,	,	PUNCT
chd-214	388	20	castrosantamaria	castrosantamaria	PROPN
chd-214	388	21	,	,	PUNCT
chd-214	388	22	r.	r.	PROPN
chd-214	388	23	,	,	PUNCT
chd-214	388	24	andriole	andriole	NOUN
chd-214	388	25	,	,	PUNCT
chd-214	388	26	g.	g.	PROPN
chd-214	388	27	l.	l.	PROPN
chd-214	388	28	,	,	PUNCT
chd-214	388	29	taioli	taioli	PROPN
chd-214	388	30	,	,	PUNCT
chd-214	388	31	e.	e.	PROPN
chd-214	388	32	,	,	PUNCT
chd-214	388	33	fowke	fowke	NOUN
chd-214	388	34	,	,	PUNCT
chd-214	388	35	j.	j.	PROPN
chd-214	388	36	h.	h.	PROPN
chd-214	388	37	,	,	PUNCT
chd-214	388	38	knudsen	knudsen	PROPN
chd-214	388	39	,	,	PUNCT
chd-214	388	40	b.	b.	PROPN
chd-214	388	41	,	,	PUNCT
chd-214	388	42	drake	drake	PROPN
chd-214	388	43	,	,	PUNCT
chd-214	388	44	c.	c.	PROPN
chd-214	388	45	g.	g.	PROPN
chd-214	388	46	,	,	PUNCT
chd-214	388	47	nickel	nickel	NOUN
chd-214	388	48	,	,	PUNCT
chd-214	388	49	j.	j.	PROPN
chd-214	388	50	c.	c.	PROPN
chd-214	388	51	,	,	PUNCT
chd-214	388	52	and	and	CCONJ
chd-214	388	53	freedland	freedland	PROPN
chd-214	388	54	,	,	PUNCT
chd-214	388	55	s.	s.	PROPN
chd-214	388	56	j.	j.	PROPN
chd-214	388	57	(	(	PUNCT
chd-214	388	58	2016	2016	NUM
chd-214	388	59	)	)	PUNCT
chd-214	388	60	.	.	PUNCT
chd-214	389	1	racial	racial	ADJ
chd-214	389	2	differences	difference	NOUN
chd-214	389	3	in	in	ADP
chd-214	389	4	prostate	prostate	NOUN
chd-214	389	5	inflammation	inflammation	NOUN
chd-214	389	6	:	:	PUNCT
chd-214	389	7	results	result	NOUN
chd-214	389	8	from	from	ADP
chd-214	389	9	the	the	DET
chd-214	389	10	reduce	reduce	NOUN
chd-214	389	11	study	study	NOUN
chd-214	389	12	.	.	PUNCT
chd-214	390	1	oncotarget	oncotarget	NOUN
chd-214	390	2	,	,	PUNCT
chd-214	390	3	8(42	8(42	NUM
chd-214	390	4	)	)	PUNCT
chd-214	390	5	,	,	PUNCT
chd-214	390	6	71393–71399	71393–71399	NUM
chd-214	390	7	.	.	PUNCT
chd-214	391	1	https://doi.org/10.18632/oncotarget.10690	https://doi.org/10.18632/oncotarget.10690	NOUN
chd-214	391	2	61	61	NUM
chd-214	391	3	.	.	PUNCT
chd-214	392	1	folkman	folkman	PROPN
chd-214	392	2	j.	j.	PROPN
chd-214	392	3	(	(	PUNCT
chd-214	392	4	1990	1990	NUM
chd-214	392	5	)	)	PUNCT
chd-214	392	6	.	.	PUNCT
chd-214	393	1	what	what	PRON
chd-214	393	2	is	be	AUX
chd-214	393	3	the	the	DET
chd-214	393	4	evidence	evidence	NOUN
chd-214	393	5	that	that	SCONJ
chd-214	393	6	tumors	tumor	NOUN
chd-214	393	7	are	be	AUX
chd-214	393	8	angiogenesis	angiogenesis	ADV
chd-214	393	9	dependent	dependent	ADJ
chd-214	393	10	?	?	PUNCT
chd-214	393	11	.	.	PUNCT
chd-214	394	1	journal	journal	PROPN
chd-214	394	2	of	of	ADP
chd-214	394	3	the	the	DET
chd-214	394	4	national	national	PROPN
chd-214	394	5	cancer	cancer	PROPN
chd-214	394	6	institute	institute	PROPN
chd-214	394	7	,	,	PUNCT
chd-214	394	8	82(1	82(1	NOUN
chd-214	394	9	)	)	PUNCT
chd-214	394	10	,	,	PUNCT
chd-214	394	11	4–6	4–6	PROPN
chd-214	394	12	.	.	PUNCT
chd-214	394	13	https://doi.org/10.1093/jnci/82.1.4	https://doi.org/10.1093/jnci/82.1.4	PROPN
chd-214	394	14	62	62	NUM
chd-214	394	15	.	.	PUNCT
chd-214	395	1	carmeliet	carmeliet	PROPN
chd-214	395	2	,	,	PUNCT
chd-214	395	3	p.	p.	NOUN
chd-214	395	4	,	,	PUNCT
chd-214	395	5	and	and	CCONJ
chd-214	395	6	jain	jain	PROPN
chd-214	395	7	,	,	PUNCT
chd-214	395	8	r.	r.	PROPN
chd-214	395	9	k.	k.	PROPN
chd-214	395	10	(	(	PUNCT
chd-214	395	11	2000	2000	NUM
chd-214	395	12	)	)	PUNCT
chd-214	395	13	.	.	PUNCT
chd-214	396	1	angiogenesis	angiogenesis	NOUN
chd-214	396	2	in	in	ADP
chd-214	396	3	cancer	cancer	NOUN
chd-214	396	4	and	and	CCONJ
chd-214	396	5	other	other	ADJ
chd-214	396	6	diseases	disease	NOUN
chd-214	396	7	.	.	PUNCT
chd-214	397	1	nature	nature	NOUN
chd-214	397	2	,	,	PUNCT
chd-214	397	3	407(6801	407(6801	NUM
chd-214	397	4	)	)	PUNCT
chd-214	397	5	,	,	PUNCT
chd-214	397	6	249–257	249–257	NUM
chd-214	397	7	.	.	PUNCT
chd-214	398	1	https://doi.org/10.1038/35025220	https://doi.org/10.1038/35025220	PROPN
chd-214	398	2	63	63	NUM
chd-214	398	3	.	.	PUNCT
chd-214	399	1	dvorak	dvorak	PROPN
chd-214	399	2	h.	h.	PROPN
chd-214	399	3	f.	f.	PROPN
chd-214	399	4	(	(	PUNCT
chd-214	399	5	2002	2002	NUM
chd-214	399	6	)	)	PUNCT
chd-214	399	7	.	.	PUNCT
chd-214	400	1	vascular	vascular	ADJ
chd-214	400	2	permeability	permeability	NOUN
chd-214	400	3	factor	factor	NOUN
chd-214	400	4	/	/	SYM
chd-214	400	5	vascular	vascular	ADJ
chd-214	400	6	endothelial	endothelial	ADJ
chd-214	400	7	growth	growth	NOUN
chd-214	400	8	factor	factor	NOUN
chd-214	400	9	:	:	PUNCT
chd-214	400	10	a	a	DET
chd-214	400	11	critical	critical	ADJ
chd-214	400	12	cytokine	cytokine	NOUN
chd-214	400	13	in	in	ADP
chd-214	400	14	tumor	tumor	NOUN
chd-214	400	15	angiogenesis	angiogenesis	NOUN
chd-214	400	16	and	and	CCONJ
chd-214	400	17	a	a	DET
chd-214	400	18	potential	potential	ADJ
chd-214	400	19	target	target	NOUN
chd-214	400	20	for	for	ADP
chd-214	400	21	diagnosis	diagnosis	NOUN
chd-214	400	22	and	and	CCONJ
chd-214	400	23	therapy	therapy	NOUN
chd-214	400	24	.	.	PUNCT
chd-214	401	1	journal	journal	PROPN
chd-214	401	2	of	of	ADP
chd-214	401	3	clinical	clinical	ADJ
chd-214	401	4	oncology	oncology	NOUN
chd-214	401	5	:	:	PUNCT
chd-214	401	6	official	official	ADJ
chd-214	401	7	journal	journal	NOUN
chd-214	401	8	of	of	ADP
chd-214	401	9	the	the	DET
chd-214	401	10	american	american	ADJ
chd-214	401	11	society	society	NOUN
chd-214	401	12	of	of	ADP
chd-214	401	13	clinical	clinical	ADJ
chd-214	401	14	oncology	oncology	NOUN
chd-214	401	15	,	,	PUNCT
chd-214	401	16	20(21	20(21	NUM
chd-214	401	17	)	)	PUNCT
chd-214	401	18	,	,	PUNCT
chd-214	401	19	4368–4380	4368–4380	NOUN
chd-214	401	20	.	.	PUNCT
chd-214	402	1	https://doi.org/10.1200/jco.2002.10.088	https://doi.org/10.1200/jco.2002.10.088	NUM
chd-214	402	2	64	64	NUM
chd-214	402	3	.	.	PUNCT
chd-214	402	4	ferrara	ferrara	NOUN
chd-214	402	5	,	,	PUNCT
chd-214	402	6	n.	n.	NOUN
chd-214	402	7	,	,	PUNCT
chd-214	402	8	gerber	gerber	PROPN
chd-214	402	9	,	,	PUNCT
chd-214	402	10	h.	h.	PROPN
chd-214	402	11	p.	p.	PROPN
chd-214	402	12	,	,	PUNCT
chd-214	402	13	and	and	CCONJ
chd-214	402	14	lecouter	lecouter	NOUN
chd-214	402	15	,	,	PUNCT
chd-214	402	16	j.	j.	PROPN
chd-214	402	17	(	(	PUNCT
chd-214	402	18	2003	2003	NUM
chd-214	402	19	)	)	PUNCT
chd-214	402	20	.	.	PUNCT
chd-214	403	1	the	the	DET
chd-214	403	2	biology	biology	NOUN
chd-214	403	3	of	of	ADP
chd-214	403	4	vegf	vegf	PROPN
chd-214	403	5	and	and	CCONJ
chd-214	403	6	its	its	PRON
chd-214	403	7	receptors	receptor	NOUN
chd-214	403	8	.	.	PUNCT
chd-214	404	1	nature	nature	NOUN
chd-214	404	2	medicine	medicine	NOUN
chd-214	404	3	,	,	PUNCT
chd-214	404	4	9(6	9(6	NUM
chd-214	404	5	)	)	PUNCT
chd-214	404	6	,	,	PUNCT
chd-214	404	7	669–676	669–676	NUM
chd-214	404	8	.	.	PUNCT
chd-214	404	9	https://doi.org/10.1038/nm0603-669	https://doi.org/10.1038/nm0603-669	NOUN
chd-214	404	10	65	65	NUM
chd-214	404	11	.	.	PUNCT
chd-214	405	1	sarkar	sarkar	PROPN
chd-214	405	2	,	,	PUNCT
chd-214	405	3	c.	c.	PROPN
chd-214	405	4	,	,	PUNCT
chd-214	405	5	goswami	goswami	PROPN
chd-214	405	6	,	,	PUNCT
chd-214	405	7	s.	s.	PROPN
chd-214	405	8	,	,	PUNCT
chd-214	405	9	basu	basu	PROPN
chd-214	405	10	,	,	PUNCT
chd-214	405	11	s.	s.	PROPN
chd-214	405	12	,	,	PUNCT
chd-214	405	13	and	and	CCONJ
chd-214	405	14	chakroborty	chakroborty	NOUN
chd-214	405	15	,	,	PUNCT
chd-214	405	16	d.	d.	PROPN
chd-214	405	17	(	(	PUNCT
chd-214	405	18	2020	2020	NUM
chd-214	405	19	)	)	PUNCT
chd-214	405	20	.	.	PUNCT
chd-214	406	1	angiogenesis	angiogenesis	NOUN
chd-214	406	2	inhibition	inhibition	NOUN
chd-214	406	3	in	in	ADP
chd-214	406	4	prostate	prostate	NOUN
chd-214	406	5	cancer	cancer	NOUN
chd-214	406	6	:	:	PUNCT
chd-214	406	7	an	an	DET
chd-214	406	8	update	update	NOUN
chd-214	406	9	.	.	PUNCT
chd-214	407	1	cancers	cancer	NOUN
chd-214	407	2	,	,	PUNCT
chd-214	407	3	12(9	12(9	NUM
chd-214	407	4	)	)	PUNCT
chd-214	407	5	,	,	PUNCT
chd-214	407	6	2382	2382	NUM
chd-214	407	7	.	.	PUNCT
chd-214	408	1	https://doi.org/10.3390/cancers	https://doi.org/10.3390/cancer	NOUN
chd-214	408	2	12092382	12092382	NUM
chd-214	408	3	66	66	NUM
chd-214	408	4	.	.	PUNCT
chd-214	409	1	chakroborty	chakroborty	PROPN
chd-214	409	2	,	,	PUNCT
chd-214	409	3	d.	d.	PROPN
chd-214	409	4	,	,	PUNCT
chd-214	409	5	sarkar	sarkar	PROPN
chd-214	409	6	,	,	PUNCT
chd-214	409	7	c.	c.	PROPN
chd-214	409	8	,	,	PUNCT
chd-214	409	9	basu	basu	PROPN
chd-214	409	10	,	,	PUNCT
chd-214	409	11	b.	b.	PROPN
chd-214	409	12	,	,	PUNCT
chd-214	409	13	dasgupta	dasgupta	PROPN
chd-214	409	14	,	,	PUNCT
chd-214	409	15	p.	p.	PROPN
chd-214	409	16	s.	s.	PROPN
chd-214	409	17	,	,	PUNCT
chd-214	409	18	and	and	CCONJ
chd-214	409	19	basu	basu	PROPN
chd-214	409	20	,	,	PUNCT
chd-214	409	21	s.	s.	PROPN
chd-214	409	22	(	(	PUNCT
chd-214	409	23	2009	2009	NUM
chd-214	409	24	)	)	PUNCT
chd-214	409	25	.	.	PUNCT
chd-214	410	1	catecholamines	catecholamine	NOUN
chd-214	410	2	regulate	regulate	VERB
chd-214	410	3	tumor	tumor	NOUN
chd-214	410	4	angiogenesis	angiogenesis	NOUN
chd-214	410	5	.	.	PUNCT
chd-214	411	1	cancer	cancer	NOUN
chd-214	411	2	research	research	NOUN
chd-214	411	3	,	,	PUNCT
chd-214	411	4	69(9	69(9	NOUN
chd-214	411	5	)	)	PUNCT
chd-214	411	6	,	,	PUNCT
chd-214	411	7	3727–3730	3727–3730	NUM
chd-214	411	8	.	.	PUNCT
chd-214	412	1	https://doi.org/10.1158/	https://doi.org/10.1158/	PROPN
chd-214	412	2	0008	0008	NUM
chd-214	412	3	-	-	SYM
chd-214	412	4	5472.can-08	5472.can-08	NUM
chd-214	412	5	-	-	PUNCT
chd-214	412	6	4289	4289	NUM
chd-214	412	7	67	67	NUM
chd-214	412	8	.	.	PUNCT
chd-214	412	9	sarkar	sarkar	PROPN
chd-214	412	10	,	,	PUNCT
chd-214	412	11	c.	c.	PROPN
chd-214	412	12	,	,	PUNCT
chd-214	412	13	chakroborty	chakroborty	PROPN
chd-214	412	14	,	,	PUNCT
chd-214	412	15	d.	d.	PROPN
chd-214	412	16	,	,	PUNCT
chd-214	412	17	and	and	CCONJ
chd-214	412	18	basu	basu	PROPN
chd-214	412	19	,	,	PUNCT
chd-214	412	20	s.	s.	PROPN
chd-214	412	21	(	(	PUNCT
chd-214	412	22	2013	2013	NUM
chd-214	412	23	)	)	PUNCT
chd-214	412	24	.	.	PUNCT
chd-214	413	1	neurotransmitters	neurotransmitter	NOUN
chd-214	413	2	as	as	ADP
chd-214	413	3	regulators	regulator	NOUN
chd-214	413	4	of	of	ADP
chd-214	413	5	tumor	tumor	NOUN
chd-214	413	6	angiogenesis	angiogenesis	NOUN
chd-214	413	7	and	and	CCONJ
chd-214	413	8	immunity	immunity	NOUN
chd-214	413	9	:	:	PUNCT
chd-214	413	10	the	the	DET
chd-214	413	11	role	role	NOUN
chd-214	413	12	of	of	ADP
chd-214	413	13	catecholamines	catecholamine	NOUN
chd-214	413	14	.	.	PUNCT
chd-214	414	1	journal	journal	NOUN
chd-214	414	2	of	of	ADP
chd-214	414	3	neuroimmune	neuroimmune	PROPN
chd-214	414	4	pharmacology	pharmacology	NOUN
chd-214	414	5	:	:	PUNCT
chd-214	414	6	the	the	DET
chd-214	414	7	official	official	ADJ
chd-214	414	8	journal	journal	NOUN
chd-214	414	9	of	of	ADP
chd-214	414	10	the	the	DET
chd-214	414	11	society	society	NOUN
chd-214	414	12	on	on	ADP
chd-214	414	13	neuroimmune	neuroimmune	PROPN
chd-214	414	14	pharmacology	pharmacology	NOUN
chd-214	414	15	,	,	PUNCT
chd-214	414	16	8(1	8(1	NOUN
chd-214	414	17	)	)	PUNCT
chd-214	414	18	,	,	PUNCT
chd-214	414	19	7–14	7–14	PROPN
chd-214	414	20	.	.	PUNCT
chd-214	414	21	https://doi.org/10.1007/s11481-012-9395-7	https://doi.org/10.1007/s11481-012-9395-7	NUM
chd-214	414	22	.	.	PUNCT
chd-214	415	1	68	68	NUM
chd-214	415	2	.	.	PUNCT
chd-214	415	3	picus	picus	PROPN
chd-214	415	4	,	,	PUNCT
chd-214	415	5	j.	j.	PROPN
chd-214	415	6	,	,	PUNCT
chd-214	415	7	halabi	halabi	PROPN
chd-214	415	8	,	,	PUNCT
chd-214	415	9	s.	s.	PROPN
chd-214	415	10	,	,	PUNCT
chd-214	415	11	rini	rini	PROPN
chd-214	415	12	,	,	PUNCT
chd-214	415	13	b.	b.	PROPN
chd-214	415	14	,	,	PUNCT
chd-214	415	15	vogelzang	vogelzang	PROPN
chd-214	415	16	,	,	PUNCT
chd-214	415	17	n.	n.	PROPN
chd-214	415	18	,	,	PUNCT
chd-214	415	19	whang	whang	PROPN
chd-214	415	20	,	,	PUNCT
chd-214	415	21	y.	y.	PROPN
chd-214	415	22	,	,	PUNCT
chd-214	415	23	kaplan	kaplan	PROPN
chd-214	415	24	,	,	PUNCT
chd-214	415	25	e.	e.	PROPN
chd-214	415	26	,	,	PUNCT
chd-214	415	27	kelly	kelly	PROPN
chd-214	415	28	,	,	PUNCT
chd-214	415	29	w.	w.	PROPN
chd-214	415	30	,	,	PUNCT
chd-214	415	31	and	and	CCONJ
chd-214	415	32	small	small	ADJ
chd-214	415	33	,	,	PUNCT
chd-214	415	34	e.	e.	PROPN
chd-214	415	35	(	(	PUNCT
chd-214	415	36	2003	2003	NUM
chd-214	415	37	)	)	PUNCT
chd-214	415	38	.	.	PUNCT
chd-214	416	1	the	the	DET
chd-214	416	2	use	use	NOUN
chd-214	416	3	of	of	ADP
chd-214	416	4	bevacizumab	bevacizumab	NOUN
chd-214	416	5	(	(	PUNCT
chd-214	416	6	b	b	NOUN
chd-214	416	7	)	)	PUNCT
chd-214	416	8	with	with	ADP
chd-214	416	9	docetaxel	docetaxel	PROPN
chd-214	416	10	(	(	PUNCT
chd-214	416	11	d	d	NOUN
chd-214	416	12	)	)	PUNCT
chd-214	416	13	and	and	CCONJ
chd-214	416	14	estramustine	estramustine	PROPN
chd-214	416	15	(	(	PUNCT
chd-214	416	16	e	e	NOUN
chd-214	416	17	)	)	PUNCT
chd-214	416	18	in	in	ADP
chd-214	416	19	hormone	hormone	NOUN
chd-214	416	20	refractory	refractory	NOUN
chd-214	416	21	prostate	prostate	NOUN
chd-214	416	22	cancer	cancer	NOUN
chd-214	416	23	(	(	PUNCT
chd-214	416	24	hrpc	hrpc	X
chd-214	416	25	):	):	PUNCT
chd-214	416	26	initial	initial	ADJ
chd-214	416	27	results	result	NOUN
chd-214	416	28	of	of	ADP
chd-214	416	29	calgb	calgb	PROPN
chd-214	416	30	90006	90006	NUM
chd-214	416	31	(	(	PUNCT
chd-214	416	32	abstract	abstract	ADJ
chd-214	416	33	1578	1578	NUM
chd-214	416	34	)	)	PUNCT
chd-214	416	35	.	.	PUNCT
chd-214	417	1	proc	proc	PROPN
chd-214	417	2	am	be	AUX
chd-214	417	3	soc	soc	NOUN
chd-214	417	4	oncol	oncol	ADJ
chd-214	417	5	.	.	PUNCT
chd-214	418	1	22	22	NUM
chd-214	418	2	:	:	PUNCT
chd-214	418	3	393	393	NUM
chd-214	418	4	.	.	PUNCT
chd-214	419	1	69	69	NUM
chd-214	419	2	.	.	PUNCT
chd-214	420	1	retter	retter	NOUN
chd-214	420	2	,	,	PUNCT
chd-214	420	3	a.	a.	PROPN
chd-214	420	4	s.	s.	PROPN
chd-214	420	5	,	,	PUNCT
chd-214	420	6	figg	figg	PROPN
chd-214	420	7	,	,	PUNCT
chd-214	420	8	w.	w.	PROPN
chd-214	420	9	d.	d.	PROPN
chd-214	420	10	,	,	PUNCT
chd-214	420	11	and	and	CCONJ
chd-214	420	12	dahut	dahut	VERB
chd-214	420	13	,	,	PUNCT
chd-214	420	14	w.	w.	PROPN
chd-214	420	15	l.	l.	PROPN
chd-214	420	16	(	(	PUNCT
chd-214	420	17	2003	2003	NUM
chd-214	420	18	)	)	PUNCT
chd-214	420	19	.	.	PUNCT
chd-214	421	1	the	the	DET
chd-214	421	2	combination	combination	NOUN
chd-214	421	3	of	of	ADP
chd-214	421	4	antiangiogenic	antiangiogenic	ADJ
chd-214	421	5	and	and	CCONJ
chd-214	421	6	cytotoxic	cytotoxic	ADJ
chd-214	421	7	agents	agent	NOUN
chd-214	421	8	in	in	ADP
chd-214	421	9	the	the	DET
chd-214	421	10	treatment	treatment	NOUN
chd-214	421	11	of	of	ADP
chd-214	421	12	prostate	prostate	NOUN
chd-214	421	13	cancer	cancer	NOUN
chd-214	421	14	.	.	PUNCT
chd-214	422	1	clinical	clinical	ADJ
chd-214	422	2	prostate	prostate	NOUN
chd-214	422	3	cancer	cancer	NOUN
chd-214	422	4	,	,	PUNCT
chd-214	422	5	2(3	2(3	NUM
chd-214	422	6	)	)	PUNCT
chd-214	422	7	,	,	PUNCT
chd-214	422	8	153–159	153–159	NUM
chd-214	422	9	.	.	PUNCT
chd-214	423	1	https://doi.org/10.3816/cgc.2003.n.023	https://doi.org/10.3816/cgc.2003.n.023	NOUN
chd-214	423	2	.	.	NOUN
chd-214	423	3	70	70	NUM
chd-214	423	4	.	.	PUNCT
chd-214	424	1	lara	lara	PROPN
chd-214	424	2	,	,	PUNCT
chd-214	424	3	p.	p.	PROPN
chd-214	424	4	n.	n.	PROPN
chd-214	424	5	,	,	PUNCT
chd-214	424	6	jr	jr	PROPN
chd-214	424	7	,	,	PUNCT
chd-214	424	8	twardowski	twardowski	NOUN
chd-214	424	9	,	,	PUNCT
chd-214	424	10	p.	p.	NOUN
chd-214	424	11	,	,	PUNCT
chd-214	424	12	and	and	CCONJ
chd-214	424	13	quinn	quinn	PROPN
chd-214	424	14	,	,	PUNCT
chd-214	424	15	d.	d.	PROPN
chd-214	424	16	i.	i.	PROPN
chd-214	424	17	(	(	PUNCT
chd-214	424	18	2004	2004	NUM
chd-214	424	19	)	)	PUNCT
chd-214	424	20	.	.	PUNCT
chd-214	425	1	angiogenesis	angiogenesis	NOUN
chd-214	425	2	-	-	PUNCT
chd-214	425	3	targeted	target	VERB
chd-214	425	4	therapies	therapy	NOUN
chd-214	425	5	in	in	ADP
chd-214	425	6	prostate	prostate	NOUN
chd-214	425	7	cancer	cancer	NOUN
chd-214	425	8	.	.	PUNCT
chd-214	426	1	clinical	clinical	ADJ
chd-214	426	2	prostate	prostate	NOUN
chd-214	426	3	cancer	cancer	NOUN
chd-214	426	4	,	,	PUNCT
chd-214	426	5	3(3	3(3	NUM
chd-214	426	6	)	)	PUNCT
chd-214	426	7	,	,	PUNCT
chd-214	426	8	165–173	165–173	NUM
chd-214	426	9	.	.	PUNCT
chd-214	427	1	https://doi.org/10.3816/	https://doi.org/10.3816/	PROPN
chd-214	427	2	cgc.2004.n.027	cgc.2004.n.027	PROPN
chd-214	427	3	.	.	PUNCT
chd-214	428	1	71	71	NUM
chd-214	428	2	.	.	PUNCT
chd-214	428	3	loblaw	loblaw	NOUN
chd-214	428	4	,	,	PUNCT
chd-214	428	5	d.	d.	PROPN
chd-214	428	6	a.	a.	PROPN
chd-214	428	7	,	,	PUNCT
chd-214	428	8	mendelson	mendelson	PROPN
chd-214	428	9	,	,	PUNCT
chd-214	428	10	d.	d.	PROPN
chd-214	428	11	s.	s.	PROPN
chd-214	428	12	,	,	PUNCT
chd-214	428	13	talcott	talcott	PROPN
chd-214	428	14	,	,	PUNCT
chd-214	428	15	j.	j.	PROPN
chd-214	428	16	a.	a.	PROPN
chd-214	428	17	,	,	PUNCT
chd-214	428	18	virgo	virgo	NOUN
chd-214	428	19	,	,	PUNCT
chd-214	428	20	k.	k.	PROPN
chd-214	428	21	s.	s.	PROPN
chd-214	428	22	,	,	PUNCT
chd-214	428	23	somerfield	somerfield	PROPN
chd-214	428	24	,	,	PUNCT
chd-214	428	25	m.	m.	PROPN
chd-214	428	26	r.	r.	PROPN
chd-214	428	27	,	,	PUNCT
chd-214	428	28	ben	ben	PROPN
chd-214	428	29	-	-	PUNCT
chd-214	428	30	josef	josef	PROPN
chd-214	428	31	,	,	PUNCT
chd-214	428	32	e.	e.	PROPN
chd-214	428	33	,	,	PUNCT
chd-214	428	34	middleton	middleton	PROPN
chd-214	428	35	,	,	PUNCT
chd-214	428	36	r.	r.	PROPN
chd-214	428	37	,	,	PUNCT
chd-214	428	38	porterfield	porterfield	PROPN
chd-214	428	39	,	,	PUNCT
chd-214	428	40	h.	h.	PROPN
chd-214	428	41	,	,	PUNCT
chd-214	428	42	sharp	sharp	ADJ
chd-214	428	43	,	,	PUNCT
chd-214	428	44	s.	s.	PROPN
chd-214	428	45	a.	a.	PROPN
chd-214	428	46	,	,	PUNCT
chd-214	428	47	smith	smith	PROPN
chd-214	428	48	,	,	PUNCT
chd-214	428	49	t.	t.	PROPN
chd-214	428	50	j.	j.	PROPN
chd-214	428	51	,	,	PUNCT
chd-214	428	52	taplin	taplin	PROPN
chd-214	428	53	,	,	PUNCT
chd-214	428	54	m.	m.	PROPN
chd-214	428	55	e.	e.	PROPN
chd-214	428	56	,	,	PUNCT
chd-214	428	57	vogelzang	vogelzang	PROPN
chd-214	428	58	,	,	PUNCT
chd-214	428	59	n.	n.	PROPN
chd-214	428	60	j.	j.	PROPN
chd-214	428	61	,	,	PUNCT
chd-214	428	62	wade	wade	PROPN
chd-214	428	63	,	,	PUNCT
chd-214	428	64	j.	j.	PROPN
chd-214	428	65	l.	l.	PROPN
chd-214	428	66	,	,	PUNCT
chd-214	428	67	jr	jr	PROPN
chd-214	428	68	,	,	PUNCT
chd-214	428	69	bennett	bennett	PROPN
chd-214	428	70	,	,	PUNCT
chd-214	428	71	c.	c.	PROPN
chd-214	428	72	l.	l.	PROPN
chd-214	428	73	,	,	PUNCT
chd-214	428	74	scher	scher	PROPN
chd-214	428	75	,	,	PUNCT
chd-214	428	76	h.	h.	PROPN
chd-214	428	77	i.	i.	PROPN
chd-214	428	78	,	,	PUNCT
chd-214	428	79	and	and	CCONJ
chd-214	428	80	american	american	ADJ
chd-214	428	81	society	society	NOUN
chd-214	428	82	of	of	ADP
chd-214	428	83	clinical	clinical	ADJ
chd-214	428	84	oncology	oncology	NOUN
chd-214	428	85	(	(	PUNCT
chd-214	428	86	2004	2004	NUM
chd-214	428	87	)	)	PUNCT
chd-214	428	88	.	.	PUNCT
chd-214	429	1	american	american	ADJ
chd-214	429	2	society	society	NOUN
chd-214	429	3	of	of	ADP
chd-214	429	4	clinical	clinical	ADJ
chd-214	429	5	oncology	oncology	NOUN
chd-214	429	6	recommendations	recommendation	NOUN
chd-214	429	7	for	for	ADP
chd-214	429	8	the	the	DET
chd-214	429	9	initial	initial	ADJ
chd-214	429	10	hormonal	hormonal	ADJ
chd-214	429	11	management	management	NOUN
chd-214	429	12	of	of	ADP
chd-214	429	13	androgen	androgen	NOUN
chd-214	429	14	-	-	PUNCT
chd-214	429	15	sensitive	sensitive	ADJ
chd-214	429	16	metastatic	metastatic	ADJ
chd-214	429	17	,	,	PUNCT
chd-214	429	18	recurrent	recurrent	ADJ
chd-214	429	19	,	,	PUNCT
chd-214	429	20	or	or	CCONJ
chd-214	429	21	progressive	progressive	ADJ
chd-214	429	22	prostate	prostate	NOUN
chd-214	429	23	cancer	cancer	NOUN
chd-214	429	24	.	.	PUNCT
chd-214	430	1	journal	journal	NOUN
chd-214	430	2	of	of	ADP
chd-214	430	3	clinical	clinical	ADJ
chd-214	430	4	oncology	oncology	NOUN
chd-214	430	5	:	:	PUNCT
chd-214	430	6	official	official	ADJ
chd-214	430	7	journal	journal	NOUN
chd-214	430	8	of	of	ADP
chd-214	430	9	the	the	DET
chd-214	430	10	american	american	ADJ
chd-214	430	11	society	society	NOUN
chd-214	430	12	of	of	ADP
chd-214	430	13	clinical	clinical	ADJ
chd-214	430	14	oncology	oncology	NOUN
chd-214	430	15	,	,	PUNCT
chd-214	430	16	22(14	22(14	PROPN
chd-214	430	17	)	)	PUNCT
chd-214	430	18	,	,	PUNCT
chd-214	430	19	2927–2941	2927–2941	NUM
chd-214	430	20	.	.	PUNCT
chd-214	431	1	https://doi.org/10.1200/jco.2004.04.579	https://doi.org/10.1200/jco.2004.04.579	NOUN
chd-214	431	2	.	.	PROPN
chd-214	432	1	72	72	NUM
chd-214	432	2	.	.	X
chd-214	433	1	nicholson	nicholson	PROPN
chd-214	433	2	,	,	PUNCT
chd-214	433	3	b.	b.	PROPN
chd-214	433	4	,	,	PUNCT
chd-214	433	5	gulding	gulding	NOUN
chd-214	433	6	,	,	PUNCT
chd-214	433	7	k.	k.	PROPN
chd-214	433	8	,	,	PUNCT
chd-214	433	9	conaway	conaway	PROPN
chd-214	433	10	,	,	PUNCT
chd-214	433	11	m.	m.	NOUN
chd-214	433	12	,	,	PUNCT
chd-214	433	13	wedge	wedge	NOUN
chd-214	433	14	,	,	PUNCT
chd-214	433	15	s.	s.	PROPN
chd-214	433	16	r.	r.	PROPN
chd-214	433	17	,	,	PUNCT
chd-214	433	18	and	and	CCONJ
chd-214	433	19	theodorescu	theodorescu	NOUN
chd-214	433	20	,	,	PUNCT
chd-214	433	21	d.	d.	PROPN
chd-214	433	22	(	(	PUNCT
chd-214	433	23	2004	2004	NUM
chd-214	433	24	)	)	PUNCT
chd-214	433	25	.	.	PUNCT
chd-214	434	1	combination	combination	NOUN
chd-214	434	2	antiangiogenic	antiangiogenic	NOUN
chd-214	434	3	and	and	CCONJ
chd-214	434	4	androgen	androgen	NOUN
chd-214	434	5	deprivation	deprivation	NOUN
chd-214	434	6	therapy	therapy	NOUN
chd-214	434	7	for	for	ADP
chd-214	434	8	prostate	prostate	NOUN
chd-214	434	9	cancer	cancer	NOUN
chd-214	434	10	:	:	PUNCT
chd-214	434	11	a	a	DET
chd-214	434	12	promising	promising	ADJ
chd-214	434	13	therapeutic	therapeutic	ADJ
chd-214	434	14	approach	approach	NOUN
chd-214	434	15	.	.	PUNCT
chd-214	435	1	clinical	clinical	ADJ
chd-214	435	2	cancer	cancer	NOUN
chd-214	435	3	research	research	NOUN
chd-214	435	4	:	:	PUNCT
chd-214	435	5	an	an	DET
chd-214	435	6	official	official	ADJ
chd-214	435	7	journal	journal	NOUN
chd-214	435	8	of	of	ADP
chd-214	435	9	the	the	DET
chd-214	435	10	american	american	PROPN
chd-214	435	11	association	association	PROPN
chd-214	435	12	for	for	ADP
chd-214	435	13	cancer	cancer	NOUN
chd-214	435	14	research	research	NOUN
chd-214	435	15	,	,	PUNCT
chd-214	435	16	10(24	10(24	NUM
chd-214	435	17	)	)	PUNCT
chd-214	435	18	,	,	PUNCT
chd-214	435	19	8728–8734	8728–8734	NUM
chd-214	435	20	.	.	PUNCT
chd-214	436	1	https://doi.org/10.1158/	https://doi.org/10.1158/	PROPN
chd-214	436	2	1078	1078	NUM
chd-214	436	3	-	-	PUNCT
chd-214	436	4	0432.ccr-04	0432.ccr-04	PROPN
chd-214	436	5	-	-	PUNCT
chd-214	436	6	0902	0902	NUM
chd-214	436	7	.	.	PUNCT
chd-214	437	1	73	73	NUM
chd-214	437	2	.	.	PUNCT
chd-214	438	1	melegh	melegh	PROPN
chd-214	438	2	,	,	PUNCT
chd-214	438	3	z.	z.	PROPN
chd-214	438	4	,	,	PUNCT
chd-214	438	5	and	and	CCONJ
chd-214	438	6	oltean	oltean	ADJ
chd-214	438	7	,	,	PUNCT
chd-214	438	8	s.	s.	PROPN
chd-214	438	9	(	(	PUNCT
chd-214	438	10	2019	2019	NUM
chd-214	438	11	)	)	PUNCT
chd-214	438	12	.	.	PUNCT
chd-214	439	1	targeting	target	VERB
chd-214	439	2	angiogenesis	angiogenesis	NOUN
chd-214	439	3	in	in	ADP
chd-214	439	4	prostate	prostate	NOUN
chd-214	439	5	cancer	cancer	NOUN
chd-214	439	6	.	.	PUNCT
chd-214	440	1	international	international	ADJ
chd-214	440	2	journal	journal	NOUN
chd-214	440	3	of	of	ADP
chd-214	440	4	molecular	molecular	ADJ
chd-214	440	5	sciences	science	NOUN
chd-214	440	6	,	,	PUNCT
chd-214	440	7	20(11	20(11	NUM
chd-214	440	8	)	)	PUNCT
chd-214	440	9	,	,	PUNCT
chd-214	440	10	2676	2676	NUM
chd-214	440	11	.	.	PUNCT
chd-214	441	1	https://doi.org/10.3390/ijms20112676	https://doi.org/10.3390/ijms20112676	PROPN
chd-214	441	2	.	.	PUNCT
chd-214	442	1	74	74	NUM
chd-214	442	2	.	.	PUNCT
chd-214	442	3	sartor	sartor	NOUN
chd-214	442	4	,	,	PUNCT
chd-214	442	5	o.	o.	PROPN
chd-214	442	6	,	,	PUNCT
chd-214	442	7	armstrong	armstrong	PROPN
chd-214	442	8	,	,	PUNCT
chd-214	442	9	a.	a.	PROPN
chd-214	442	10	j.	j.	PROPN
chd-214	442	11	,	,	PUNCT
chd-214	442	12	ahaghotu	ahaghotu	PROPN
chd-214	442	13	,	,	PUNCT
chd-214	442	14	c.	c.	PROPN
chd-214	442	15	,	,	PUNCT
chd-214	442	16	mcleod	mcleod	PROPN
chd-214	442	17	,	,	PUNCT
chd-214	442	18	d.	d.	PROPN
chd-214	442	19	g.	g.	PROPN
chd-214	442	20	,	,	PUNCT
chd-214	442	21	cooperberg	cooperberg	PROPN
chd-214	442	22	,	,	PUNCT
chd-214	442	23	m.	m.	PROPN
chd-214	442	24	r.	r.	PROPN
chd-214	442	25	,	,	PUNCT
chd-214	442	26	penson	penson	PROPN
chd-214	442	27	,	,	PUNCT
chd-214	442	28	d.	d.	PROPN
chd-214	442	29	f.	f.	PROPN
chd-214	442	30	,	,	PUNCT
chd-214	442	31	kantoff	kantoff	PROPN
chd-214	442	32	,	,	PUNCT
chd-214	442	33	p.	p.	PROPN
chd-214	442	34	w.	w.	PROPN
chd-214	442	35	,	,	PUNCT
chd-214	442	36	vogelzang	vogelzang	PROPN
chd-214	442	37	,	,	PUNCT
chd-214	442	38	n.	n.	PROPN
chd-214	442	39	j.	j.	PROPN
chd-214	442	40	,	,	PUNCT
chd-214	442	41	hussain	hussain	PROPN
chd-214	442	42	,	,	PUNCT
chd-214	442	43	a.	a.	NOUN
chd-214	442	44	,	,	PUNCT
chd-214	442	45	pieczonka	pieczonka	PROPN
chd-214	442	46	,	,	PUNCT
chd-214	442	47	c.	c.	PROPN
chd-214	442	48	m.	m.	PROPN
chd-214	442	49	,	,	PUNCT
chd-214	442	50	shore	shore	PROPN
chd-214	442	51	,	,	PUNCT
chd-214	442	52	n.	n.	PROPN
chd-214	442	53	d.	d.	PROPN
chd-214	442	54	,	,	PUNCT
chd-214	442	55	quinn	quinn	PROPN
chd-214	442	56	,	,	PUNCT
chd-214	442	57	d.	d.	PROPN
chd-214	442	58	i.	i.	PROPN
chd-214	442	59	,	,	PUNCT
chd-214	442	60	small	small	ADJ
chd-214	442	61	,	,	PUNCT
chd-214	442	62	e.	e.	PROPN
chd-214	442	63	j.	j.	PROPN
chd-214	442	64	,	,	PUNCT
chd-214	442	65	heath	heath	PROPN
chd-214	442	66	,	,	PUNCT
chd-214	442	67	e.	e.	PROPN
chd-214	442	68	i.	i.	PROPN
chd-214	442	69	,	,	PUNCT
chd-214	442	70	tutrone	tutrone	PROPN
chd-214	442	71	,	,	PUNCT
chd-214	442	72	r.	r.	PROPN
chd-214	442	73	f.	f.	PROPN
chd-214	442	74	,	,	PUNCT
chd-214	442	75	schellhammer	schellhammer	PROPN
chd-214	442	76	,	,	PUNCT
chd-214	442	77	p.	p.	PROPN
chd-214	442	78	f.	f.	PROPN
chd-214	442	79	,	,	PUNCT
chd-214	442	80	harmon	harmon	PROPN
chd-214	442	81	,	,	PUNCT
chd-214	442	82	m.	m.	NOUN
chd-214	442	83	,	,	PUNCT
chd-214	442	84	chang	chang	PROPN
chd-214	442	85	,	,	PUNCT
chd-214	442	86	n.	n.	PROPN
chd-214	442	87	n.	n.	PROPN
chd-214	442	88	,	,	PUNCT
chd-214	442	89	sheikh	sheikh	PROPN
chd-214	442	90	,	,	PUNCT
chd-214	442	91	n.	n.	PROPN
chd-214	442	92	https://doi.org/10.1186/s40425-018-0351-9	https://doi.org/10.1186/s40425-018-0351-9	CCONJ
chd-214	443	1	https://doi.org/10.1002/ijc.32607	https://doi.org/10.1002/ijc.32607	PROPN
chd-214	443	2	https://doi.org/10.1002/cnr2.1340	https://doi.org/10.1002/cnr2.1340	PROPN
chd-214	443	3	https://doi.org/10.18632/oncotarget.10690	https://doi.org/10.18632/oncotarget.10690	NOUN
chd-214	443	4	https://doi.org/10.1093/jnci/82.1.4	https://doi.org/10.1093/jnci/82.1.4	NOUN
chd-214	443	5	https://doi.org/10.1038/35025220	https://doi.org/10.1038/35025220	NOUN
chd-214	443	6	https://doi.org/10.1200/jco.2002.10.088	https://doi.org/10.1200/jco.2002.10.088	NUM
chd-214	443	7	https://doi.org/10.1038/nm0603-669	https://doi.org/10.1038/nm0603-669	NOUN
chd-214	443	8	https://doi.org/10.3390/cancers%2012092382	https://doi.org/10.3390/cancers%2012092382	NOUN
chd-214	443	9	https://doi.org/10.1158/%200008-5472.can-08-4289	https://doi.org/10.1158/%200008-5472.can-08-4289	PROPN
chd-214	443	10	https://doi.org/10.3816/	https://doi.org/10.3816/	PROPN
chd-214	443	11	https://doi.org/10.1200/jco.2004.04.579	https://doi.org/10.1200/jco.2004.04.579	ADJ
chd-214	443	12	https://doi.org/	https://doi.org/	ADJ
chd-214	443	13	https://doi.org/10.3390/ijms20112676	https://doi.org/10.3390/ijms20112676	PROPN
chd-214	443	14	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	PART
chd-214	443	15	e14	e14	PROPN
chd-214	443	16	cancer	cancer	NOUN
chd-214	443	17	health	health	NOUN
chd-214	443	18	disparities	disparity	NOUN
chd-214	443	19	research	research	NOUN
chd-214	443	20	a.	a.	PROPN
chd-214	443	21	,	,	PUNCT
chd-214	443	22	brown	brown	PROPN
chd-214	443	23	,	,	PUNCT
chd-214	443	24	b.	b.	PROPN
chd-214	443	25	,	,	PUNCT
chd-214	443	26	…	…	PUNCT
chd-214	443	27	higano	higano	NOUN
chd-214	443	28	,	,	PUNCT
chd-214	443	29	c.	c.	PROPN
chd-214	443	30	s.	s.	PROPN
chd-214	443	31	(	(	PUNCT
chd-214	443	32	2020	2020	NUM
chd-214	443	33	)	)	PUNCT
chd-214	443	34	.	.	PUNCT
chd-214	444	1	survival	survival	NOUN
chd-214	444	2	of	of	ADP
chd-214	444	3	africanamerican	africanamerican	PROPN
chd-214	444	4	and	and	CCONJ
chd-214	444	5	caucasian	caucasian	ADJ
chd-214	444	6	men	man	NOUN
chd-214	444	7	after	after	ADP
chd-214	444	8	sipuleucel	sipuleucel	NOUN
chd-214	444	9	-	-	PUNCT
chd-214	444	10	t	t	NOUN
chd-214	444	11	immunotherapy	immunotherapy	NOUN
chd-214	444	12	:	:	PUNCT
chd-214	444	13	outcomes	outcome	NOUN
chd-214	444	14	from	from	ADP
chd-214	444	15	the	the	DET
chd-214	444	16	proceed	proceed	ADJ
chd-214	444	17	registry	registry	NOUN
chd-214	444	18	.	.	PUNCT
chd-214	445	1	prostate	prostate	NOUN
chd-214	445	2	cancer	cancer	NOUN
chd-214	445	3	and	and	CCONJ
chd-214	445	4	prostatic	prostatic	ADJ
chd-214	445	5	diseases	disease	NOUN
chd-214	445	6	,	,	PUNCT
chd-214	445	7	23(3	23(3	NUM
chd-214	445	8	)	)	PUNCT
chd-214	445	9	,	,	PUNCT
chd-214	445	10	517–526	517–526	NUM
chd-214	445	11	.	.	PUNCT
chd-214	446	1	https://doi.org/10.1038/s41391-020-0213-7	https://doi.org/10.1038/s41391-020-0213-7	NUM
chd-214	446	2	75	75	NUM
chd-214	446	3	.	.	PUNCT
chd-214	447	1	smith	smith	PROPN
chd-214	447	2	,	,	PUNCT
chd-214	447	3	c.	c.	PROPN
chd-214	447	4	j.	j.	PROPN
chd-214	447	5	,	,	PUNCT
chd-214	447	6	dorsey	dorsey	PROPN
chd-214	447	7	,	,	PUNCT
chd-214	447	8	t.	t.	PROPN
chd-214	447	9	h.	h.	PROPN
chd-214	447	10	,	,	PUNCT
chd-214	447	11	tang	tang	PROPN
chd-214	447	12	,	,	PUNCT
chd-214	447	13	w.	w.	PROPN
chd-214	447	14	,	,	PUNCT
chd-214	447	15	jordan	jordan	PROPN
chd-214	447	16	,	,	PUNCT
chd-214	447	17	s.	s.	PROPN
chd-214	447	18	v.	v.	PROPN
chd-214	447	19	,	,	PUNCT
chd-214	447	20	loffredo	loffredo	PROPN
chd-214	447	21	,	,	PUNCT
chd-214	447	22	c.	c.	PROPN
chd-214	447	23	a.	a.	PROPN
chd-214	447	24	,	,	PUNCT
chd-214	447	25	&	&	CCONJ
chd-214	447	26	ambs	ambs	PROPN
chd-214	447	27	,	,	PUNCT
chd-214	447	28	s.	s.	PROPN
chd-214	447	29	(	(	PUNCT
chd-214	447	30	2017	2017	NUM
chd-214	447	31	)	)	PUNCT
chd-214	447	32	.	.	PUNCT
chd-214	448	1	aspirin	aspirin	NOUN
chd-214	448	2	use	use	NOUN
chd-214	448	3	reduces	reduce	VERB
chd-214	448	4	the	the	DET
chd-214	448	5	risk	risk	NOUN
chd-214	448	6	of	of	ADP
chd-214	448	7	aggressive	aggressive	ADJ
chd-214	448	8	prostate	prostate	NOUN
chd-214	448	9	cancer	cancer	NOUN
chd-214	448	10	and	and	CCONJ
chd-214	448	11	disease	disease	NOUN
chd-214	448	12	recurrence	recurrence	NOUN
chd-214	448	13	in	in	ADP
chd-214	448	14	african	african	ADJ
chd-214	448	15	-	-	PUNCT
chd-214	448	16	american	american	ADJ
chd-214	448	17	men	man	NOUN
chd-214	448	18	.	.	PUNCT
chd-214	449	1	cancer	cancer	NOUN
chd-214	449	2	epidemiology	epidemiology	NOUN
chd-214	449	3	,	,	PUNCT
chd-214	449	4	biomarkers	biomarker	NOUN
chd-214	449	5	&	&	CCONJ
chd-214	449	6	prevention	prevention	NOUN
chd-214	449	7	:	:	PUNCT
chd-214	449	8	a	a	DET
chd-214	449	9	publication	publication	NOUN
chd-214	449	10	of	of	ADP
chd-214	449	11	the	the	DET
chd-214	449	12	american	american	PROPN
chd-214	449	13	association	association	PROPN
chd-214	449	14	for	for	ADP
chd-214	449	15	cancer	cancer	NOUN
chd-214	449	16	research	research	NOUN
chd-214	449	17	,	,	PUNCT
chd-214	449	18	cosponsored	cosponsor	VERB
chd-214	449	19	by	by	ADP
chd-214	449	20	the	the	DET
chd-214	449	21	american	american	ADJ
chd-214	449	22	society	society	NOUN
chd-214	449	23	of	of	ADP
chd-214	449	24	preventive	preventive	ADJ
chd-214	449	25	oncology	oncology	NOUN
chd-214	449	26	,	,	PUNCT
chd-214	449	27	26(6	26(6	NUM
chd-214	449	28	)	)	PUNCT
chd-214	449	29	,	,	PUNCT
chd-214	449	30	845–853	845–853	NUM
chd-214	449	31	.	.	PUNCT
chd-214	450	1	https://doi.org/10.1158/1055-9965.epi-16-1027	https://doi.org/10.1158/1055-9965.epi-16-1027	NUM
chd-214	451	1	76	76	NUM
chd-214	451	2	.	.	PUNCT
chd-214	452	1	osborn	osborn	PROPN
chd-214	452	2	,	,	PUNCT
chd-214	452	3	v.	v.	PROPN
chd-214	452	4	w.	w.	PROPN
chd-214	452	5	,	,	PUNCT
chd-214	452	6	chen	chen	PROPN
chd-214	452	7	,	,	PUNCT
chd-214	452	8	s.	s.	PROPN
chd-214	452	9	c.	c.	PROPN
chd-214	452	10	,	,	PUNCT
chd-214	452	11	weiner	weiner	NOUN
chd-214	452	12	,	,	PUNCT
chd-214	452	13	j.	j.	PROPN
chd-214	452	14	,	,	PUNCT
chd-214	452	15	schwartz	schwartz	PROPN
chd-214	452	16	,	,	PUNCT
chd-214	452	17	d.	d.	PROPN
chd-214	452	18	,	,	PUNCT
chd-214	452	19	&	&	CCONJ
chd-214	452	20	schreiber	schreiber	PROPN
chd-214	452	21	,	,	PUNCT
chd-214	452	22	d.	d.	PROPN
chd-214	452	23	(	(	PUNCT
chd-214	452	24	2016	2016	NUM
chd-214	452	25	)	)	PUNCT
chd-214	452	26	.	.	PUNCT
chd-214	453	1	impact	impact	NOUN
chd-214	453	2	of	of	ADP
chd-214	453	3	aspirin	aspirin	NOUN
chd-214	453	4	on	on	ADP
chd-214	453	5	clinical	clinical	ADJ
chd-214	453	6	outcomes	outcome	NOUN
chd-214	453	7	for	for	ADP
chd-214	453	8	african	african	ADJ
chd-214	453	9	american	american	ADJ
chd-214	453	10	men	man	NOUN
chd-214	453	11	with	with	ADP
chd-214	453	12	prostate	prostate	NOUN
chd-214	453	13	cancer	cancer	NOUN
chd-214	453	14	undergoing	undergo	VERB
chd-214	453	15	radiation	radiation	NOUN
chd-214	453	16	.	.	PUNCT
chd-214	454	1	tumori	tumori	PROPN
chd-214	454	2	,	,	PUNCT
chd-214	454	3	102(1	102(1	NUM
chd-214	454	4	)	)	PUNCT
chd-214	454	5	,	,	PUNCT
chd-214	454	6	65–70	65–70	NUM
chd-214	454	7	.	.	PUNCT
chd-214	455	1	https://doi.org/10.5301/tj.5000424	https://doi.org/10.5301/tj.5000424	X
chd-214	456	1	77	77	NUM
chd-214	456	2	.	.	PUNCT
chd-214	457	1	lucotti	lucotti	PROPN
chd-214	457	2	,	,	PUNCT
chd-214	457	3	s.	s.	PROPN
chd-214	457	4	,	,	PUNCT
chd-214	457	5	cerutti	cerutti	PROPN
chd-214	457	6	,	,	PUNCT
chd-214	457	7	c.	c.	PROPN
chd-214	457	8	,	,	PUNCT
chd-214	457	9	soyer	soyer	PROPN
chd-214	457	10	,	,	PUNCT
chd-214	457	11	m.	m.	NOUN
chd-214	457	12	,	,	PUNCT
chd-214	457	13	gil	gil	PROPN
chd-214	457	14	-	-	PUNCT
chd-214	457	15	bernabé	bernabé	NOUN
chd-214	457	16	,	,	PUNCT
chd-214	457	17	a.	a.	NOUN
chd-214	457	18	m.	m.	NOUN
chd-214	457	19	,	,	PUNCT
chd-214	457	20	gomes	gome	NOUN
chd-214	457	21	,	,	PUNCT
chd-214	457	22	a.	a.	PROPN
chd-214	457	23	l.	l.	PROPN
chd-214	457	24	,	,	PUNCT
chd-214	457	25	allen	allen	PROPN
chd-214	457	26	,	,	PUNCT
chd-214	457	27	p.	p.	PROPN
chd-214	457	28	d.	d.	PROPN
chd-214	457	29	,	,	PUNCT
chd-214	457	30	smart	smart	ADJ
chd-214	457	31	,	,	PUNCT
chd-214	457	32	s.	s.	PROPN
chd-214	457	33	,	,	PUNCT
chd-214	457	34	markelc	markelc	PROPN
chd-214	457	35	,	,	PUNCT
chd-214	457	36	b.	b.	PROPN
chd-214	457	37	,	,	PUNCT
chd-214	457	38	watson	watson	PROPN
chd-214	457	39	,	,	PUNCT
chd-214	457	40	k.	k.	PROPN
chd-214	457	41	,	,	PUNCT
chd-214	457	42	armstrong	armstrong	PROPN
chd-214	457	43	,	,	PUNCT
chd-214	457	44	p.	p.	PROPN
chd-214	457	45	c.	c.	PROPN
chd-214	457	46	,	,	PUNCT
chd-214	457	47	mitchell	mitchell	PROPN
chd-214	457	48	,	,	PUNCT
chd-214	457	49	j.	j.	PROPN
chd-214	457	50	a.	a.	PROPN
chd-214	457	51	,	,	PUNCT
chd-214	457	52	warner	warner	PROPN
chd-214	457	53	,	,	PUNCT
chd-214	457	54	t.	t.	PROPN
chd-214	457	55	d.	d.	PROPN
chd-214	457	56	,	,	PUNCT
chd-214	457	57	ridley	ridley	PROPN
chd-214	457	58	,	,	PUNCT
chd-214	457	59	a.	a.	PROPN
chd-214	457	60	j.	j.	PROPN
chd-214	457	61	,	,	PUNCT
chd-214	457	62	&	&	CCONJ
chd-214	457	63	muschel	muschel	PROPN
chd-214	457	64	,	,	PUNCT
chd-214	457	65	r.	r.	PROPN
chd-214	457	66	j.	j.	PROPN
chd-214	457	67	(	(	PUNCT
chd-214	457	68	2019	2019	NUM
chd-214	457	69	)	)	PUNCT
chd-214	457	70	.	.	PUNCT
chd-214	458	1	aspirin	aspirin	NOUN
chd-214	458	2	blocks	block	VERB
chd-214	458	3	formation	formation	NOUN
chd-214	458	4	of	of	ADP
chd-214	458	5	metastatic	metastatic	ADJ
chd-214	458	6	intravascular	intravascular	ADJ
chd-214	458	7	niches	niche	NOUN
chd-214	458	8	by	by	ADP
chd-214	458	9	inhibiting	inhibit	VERB
chd-214	458	10	plateletderived	plateletderive	VERB
chd-214	458	11	cox-1	cox-1	NOUN
chd-214	458	12	/	/	SYM
chd-214	458	13	thromboxane	thromboxane	NOUN
chd-214	458	14	a2	a2	PROPN
chd-214	458	15	.	.	PUNCT
chd-214	459	1	the	the	DET
chd-214	459	2	journal	journal	NOUN
chd-214	459	3	of	of	ADP
chd-214	459	4	clinical	clinical	ADJ
chd-214	459	5	investigation	investigation	NOUN
chd-214	459	6	,	,	PUNCT
chd-214	459	7	129(5	129(5	NUM
chd-214	459	8	)	)	PUNCT
chd-214	459	9	,	,	PUNCT
chd-214	459	10	1845–1862	1845–1862	NUM
chd-214	459	11	.	.	PUNCT
chd-214	460	1	https://doi.org/10.1172/jci121985	https://doi.org/10.1172/jci121985	PROPN
chd-214	460	2	78	78	NUM
chd-214	460	3	.	.	PUNCT
chd-214	460	4	tang	tang	PROPN
chd-214	460	5	,	,	PUNCT
chd-214	460	6	w.	w.	NOUN
chd-214	460	7	,	,	PUNCT
chd-214	460	8	fowke	fowke	NOUN
chd-214	460	9	,	,	PUNCT
chd-214	460	10	j.	j.	PROPN
chd-214	460	11	h.	h.	PROPN
chd-214	460	12	,	,	PUNCT
chd-214	460	13	hurwitz	hurwitz	PROPN
chd-214	460	14	,	,	PUNCT
chd-214	460	15	l.	l.	PROPN
chd-214	460	16	m.	m.	PROPN
chd-214	460	17	,	,	PUNCT
chd-214	460	18	steinwandel	steinwandel	NOUN
chd-214	460	19	,	,	PUNCT
chd-214	460	20	m.	m.	NOUN
chd-214	460	21	,	,	PUNCT
chd-214	460	22	blot	blot	NOUN
chd-214	460	23	,	,	PUNCT
chd-214	460	24	w.	w.	PROPN
chd-214	460	25	j.	j.	PROPN
chd-214	460	26	,	,	PUNCT
chd-214	460	27	&	&	CCONJ
chd-214	460	28	ambs	ambs	PROPN
chd-214	460	29	,	,	PUNCT
chd-214	460	30	s.	s.	PROPN
chd-214	460	31	(	(	PUNCT
chd-214	460	32	2021	2021	NUM
chd-214	460	33	)	)	PUNCT
chd-214	460	34	.	.	PUNCT
chd-214	461	1	aspirin	aspirin	NOUN
chd-214	461	2	use	use	NOUN
chd-214	461	3	and	and	CCONJ
chd-214	461	4	prostate	prostate	NOUN
chd-214	461	5	cancer	cancer	NOUN
chd-214	461	6	among	among	ADP
chd-214	461	7	african	african	ADJ
chd-214	461	8	-	-	PUNCT
chd-214	461	9	american	american	ADJ
chd-214	461	10	men	man	NOUN
chd-214	461	11	in	in	ADP
chd-214	461	12	the	the	DET
chd-214	461	13	southern	southern	ADJ
chd-214	461	14	community	community	NOUN
chd-214	461	15	cohort	cohort	NOUN
chd-214	461	16	study	study	NOUN
chd-214	461	17	.	.	PUNCT
chd-214	462	1	cancer	cancer	NOUN
chd-214	462	2	epidemiology	epidemiology	NOUN
chd-214	462	3	,	,	PUNCT
chd-214	462	4	biomarkers	biomarker	NOUN
chd-214	462	5	&	&	CCONJ
chd-214	462	6	prevention	prevention	NOUN
chd-214	462	7	:	:	PUNCT
chd-214	462	8	a	a	DET
chd-214	462	9	publication	publication	NOUN
chd-214	462	10	of	of	ADP
chd-214	462	11	the	the	DET
chd-214	462	12	american	american	PROPN
chd-214	462	13	association	association	PROPN
chd-214	462	14	for	for	ADP
chd-214	462	15	cancer	cancer	NOUN
chd-214	462	16	research	research	NOUN
chd-214	462	17	,	,	PUNCT
chd-214	462	18	cosponsored	cosponsor	VERB
chd-214	462	19	by	by	ADP
chd-214	462	20	the	the	DET
chd-214	462	21	american	american	ADJ
chd-214	462	22	society	society	NOUN
chd-214	462	23	of	of	ADP
chd-214	462	24	preventive	preventive	ADJ
chd-214	462	25	oncology	oncology	NOUN
chd-214	462	26	,	,	PUNCT
chd-214	462	27	30(3	30(3	NUM
chd-214	462	28	)	)	PUNCT
chd-214	462	29	,	,	PUNCT
chd-214	462	30	539–544	539–544	NUM
chd-214	462	31	.	.	PUNCT
chd-214	463	1	https://doi.org/10.1158/1055-9965.epi-19-0792	https://doi.org/10.1158/1055-9965.epi-19-0792	X
chd-214	463	2	.	.	PROPN
chd-214	463	3	79	79	NUM
chd-214	463	4	.	.	PUNCT
chd-214	464	1	ayala	ayala	PROPN
chd-214	464	2	,	,	PUNCT
chd-214	464	3	g.	g.	PROPN
chd-214	464	4	,	,	PUNCT
chd-214	464	5	tuxhorn	tuxhorn	PROPN
chd-214	464	6	,	,	PUNCT
chd-214	464	7	j.	j.	PROPN
chd-214	464	8	a.	a.	PROPN
chd-214	464	9	,	,	PUNCT
chd-214	464	10	wheeler	wheeler	NOUN
chd-214	464	11	,	,	PUNCT
chd-214	464	12	t.	t.	NOUN
chd-214	464	13	m.	m.	NOUN
chd-214	464	14	,	,	PUNCT
chd-214	464	15	frolov	frolov	PROPN
chd-214	464	16	,	,	PUNCT
chd-214	464	17	a.	a.	NOUN
chd-214	464	18	,	,	PUNCT
chd-214	464	19	scardino	scardino	NOUN
chd-214	464	20	,	,	PUNCT
chd-214	464	21	p.	p.	PROPN
chd-214	464	22	t.	t.	PROPN
chd-214	464	23	,	,	PUNCT
chd-214	464	24	ohori	ohori	NOUN
chd-214	464	25	,	,	PUNCT
chd-214	464	26	m.	m.	NOUN
chd-214	464	27	,	,	PUNCT
chd-214	464	28	wheeler	wheeler	NOUN
chd-214	464	29	,	,	PUNCT
chd-214	464	30	m.	m.	NOUN
chd-214	464	31	,	,	PUNCT
chd-214	464	32	spitler	spitler	NOUN
chd-214	464	33	,	,	PUNCT
chd-214	464	34	j.	j.	PROPN
chd-214	464	35	,	,	PUNCT
chd-214	464	36	&	&	CCONJ
chd-214	464	37	rowley	rowley	PROPN
chd-214	464	38	,	,	PUNCT
chd-214	464	39	d.	d.	PROPN
chd-214	464	40	r.	r.	PROPN
chd-214	464	41	(	(	PUNCT
chd-214	464	42	2003	2003	NUM
chd-214	464	43	)	)	PUNCT
chd-214	464	44	.	.	PUNCT
chd-214	465	1	reactive	reactive	ADJ
chd-214	465	2	stroma	stroma	NOUN
chd-214	465	3	as	as	ADP
chd-214	465	4	a	a	DET
chd-214	465	5	predictor	predictor	NOUN
chd-214	465	6	of	of	ADP
chd-214	465	7	biochemical	biochemical	ADJ
chd-214	465	8	-	-	PUNCT
chd-214	465	9	free	free	ADJ
chd-214	465	10	recurrence	recurrence	NOUN
chd-214	465	11	in	in	ADP
chd-214	465	12	prostate	prostate	NOUN
chd-214	465	13	cancer	cancer	NOUN
chd-214	465	14	.	.	PUNCT
chd-214	466	1	clinical	clinical	ADJ
chd-214	466	2	cancer	cancer	NOUN
chd-214	466	3	research	research	NOUN
chd-214	466	4	:	:	PUNCT
chd-214	466	5	an	an	DET
chd-214	466	6	official	official	ADJ
chd-214	466	7	journal	journal	NOUN
chd-214	466	8	of	of	ADP
chd-214	466	9	the	the	DET
chd-214	466	10	american	american	PROPN
chd-214	466	11	association	association	PROPN
chd-214	466	12	for	for	ADP
chd-214	466	13	cancer	cancer	NOUN
chd-214	466	14	research	research	NOUN
chd-214	466	15	,	,	PUNCT
chd-214	466	16	9(13	9(13	NUM
chd-214	466	17	)	)	PUNCT
chd-214	466	18	,	,	PUNCT
chd-214	466	19	4792–4801	4792–4801	NUM
chd-214	466	20	.	.	NOUN
chd-214	466	21	80	80	NUM
chd-214	466	22	.	.	PUNCT
chd-214	467	1	fiori	fiori	NOUN
chd-214	467	2	,	,	PUNCT
chd-214	467	3	m.	m.	PROPN
chd-214	467	4	e.	e.	PROPN
chd-214	467	5	,	,	PUNCT
chd-214	467	6	di	di	PROPN
chd-214	467	7	franco	franco	PROPN
chd-214	467	8	,	,	PUNCT
chd-214	467	9	s.	s.	PROPN
chd-214	467	10	,	,	PUNCT
chd-214	467	11	villanova	villanova	PROPN
chd-214	467	12	,	,	PUNCT
chd-214	467	13	l.	l.	PROPN
chd-214	467	14	,	,	PUNCT
chd-214	467	15	bianca	bianca	PROPN
chd-214	467	16	,	,	PUNCT
chd-214	467	17	p.	p.	NOUN
chd-214	467	18	,	,	PUNCT
chd-214	467	19	stassi	stassi	ADJ
chd-214	467	20	,	,	PUNCT
chd-214	467	21	g.	g.	PROPN
chd-214	467	22	,	,	PUNCT
chd-214	467	23	&	&	CCONJ
chd-214	467	24	de	de	X
chd-214	467	25	maria	maria	PROPN
chd-214	467	26	,	,	PUNCT
chd-214	467	27	r.	r.	PROPN
chd-214	467	28	(	(	PUNCT
chd-214	467	29	2019	2019	NUM
chd-214	467	30	)	)	PUNCT
chd-214	467	31	.	.	PUNCT
chd-214	468	1	cancer	cancer	NOUN
chd-214	468	2	-	-	PUNCT
chd-214	468	3	associated	associate	VERB
chd-214	468	4	fibroblasts	fibroblast	NOUN
chd-214	468	5	as	as	ADP
chd-214	468	6	abettors	abettor	NOUN
chd-214	468	7	of	of	ADP
chd-214	468	8	tumor	tumor	NOUN
chd-214	468	9	progression	progression	NOUN
chd-214	468	10	at	at	ADP
chd-214	468	11	the	the	DET
chd-214	468	12	crossroads	crossroad	NOUN
chd-214	468	13	of	of	ADP
chd-214	468	14	emt	emt	NOUN
chd-214	468	15	and	and	CCONJ
chd-214	468	16	therapy	therapy	NOUN
chd-214	468	17	resistance	resistance	NOUN
chd-214	468	18	.	.	PUNCT
chd-214	469	1	molecular	molecular	ADJ
chd-214	469	2	cancer	cancer	NOUN
chd-214	469	3	,	,	PUNCT
chd-214	469	4	18(1	18(1	NOUN
chd-214	469	5	)	)	PUNCT
chd-214	469	6	,	,	PUNCT
chd-214	469	7	70	70	NUM
chd-214	469	8	.	.	PUNCT
chd-214	469	9	https://doi.org/10.1186/s12943-019-0994-2	https://doi.org/10.1186/s12943-019-0994-2	PROPN
chd-214	469	10	81	81	NUM
chd-214	469	11	.	.	PUNCT
chd-214	470	1	huang	huang	PROPN
chd-214	470	2	,	,	PUNCT
chd-214	470	3	h.	h.	PROPN
chd-214	470	4	,	,	PUNCT
chd-214	470	5	wang	wang	PROPN
chd-214	470	6	,	,	PUNCT
chd-214	470	7	c.	c.	PROPN
chd-214	470	8	,	,	PUNCT
chd-214	470	9	liu	liu	PROPN
chd-214	470	10	,	,	PUNCT
chd-214	470	11	f.	f.	PROPN
chd-214	470	12	,	,	PUNCT
chd-214	470	13	li	li	PROPN
chd-214	470	14	,	,	PUNCT
chd-214	470	15	h.	h.	PROPN
chd-214	470	16	z.	z.	PROPN
chd-214	470	17	,	,	PUNCT
chd-214	470	18	peng	peng	PROPN
chd-214	470	19	,	,	PUNCT
chd-214	470	20	g.	g.	PROPN
chd-214	470	21	,	,	PUNCT
chd-214	470	22	gao	gao	PROPN
chd-214	470	23	,	,	PUNCT
chd-214	470	24	x.	x.	PROPN
chd-214	470	25	,	,	PUNCT
chd-214	470	26	dong	dong	PROPN
chd-214	470	27	,	,	PUNCT
chd-214	470	28	k.	k.	PROPN
chd-214	470	29	q.	q.	PROPN
chd-214	470	30	,	,	PUNCT
chd-214	470	31	wang	wang	PROPN
chd-214	470	32	,	,	PUNCT
chd-214	470	33	h.	h.	PROPN
chd-214	470	34	r.	r.	PROPN
chd-214	470	35	,	,	PUNCT
chd-214	470	36	kong	kong	PROPN
chd-214	470	37	,	,	PUNCT
chd-214	470	38	d.	d.	PROPN
chd-214	470	39	p.	p.	PROPN
chd-214	470	40	,	,	PUNCT
chd-214	470	41	qu	qu	PROPN
chd-214	470	42	,	,	PUNCT
chd-214	470	43	m.	m.	NOUN
chd-214	470	44	,	,	PUNCT
chd-214	470	45	dai	dai	PROPN
chd-214	470	46	,	,	PUNCT
chd-214	470	47	l.	l.	PROPN
chd-214	470	48	h.	h.	PROPN
chd-214	470	49	,	,	PUNCT
chd-214	470	50	wang	wang	PROPN
chd-214	470	51	,	,	PUNCT
chd-214	470	52	k.	k.	PROPN
chd-214	470	53	j.	j.	PROPN
chd-214	470	54	,	,	PUNCT
chd-214	470	55	zhou	zhou	PROPN
chd-214	470	56	,	,	PUNCT
chd-214	470	57	z.	z.	PROPN
chd-214	470	58	,	,	PUNCT
chd-214	470	59	yang	yang	PROPN
chd-214	470	60	,	,	PUNCT
chd-214	470	61	j.	j.	PROPN
chd-214	470	62	,	,	PUNCT
chd-214	470	63	yang	yang	PROPN
chd-214	470	64	,	,	PUNCT
chd-214	470	65	z.	z.	PROPN
chd-214	470	66	y.	y.	PROPN
chd-214	470	67	,	,	PUNCT
chd-214	470	68	cheng	cheng	PROPN
chd-214	470	69	,	,	PUNCT
chd-214	470	70	y.	y.	PROPN
chd-214	470	71	q.	q.	PROPN
chd-214	470	72	,	,	PUNCT
chd-214	470	73	tian	tian	PROPN
chd-214	470	74	,	,	PUNCT
chd-214	470	75	q.	q.	PROPN
chd-214	470	76	q.	q.	PROPN
chd-214	470	77	,	,	PUNCT
chd-214	470	78	liu	liu	PROPN
chd-214	470	79	,	,	PUNCT
chd-214	470	80	d.	d.	PROPN
chd-214	470	81	,	,	PUNCT
chd-214	470	82	xu	xu	PROPN
chd-214	470	83	,	,	PUNCT
chd-214	470	84	c.	c.	PROPN
chd-214	470	85	l.	l.	PROPN
chd-214	470	86	,	,	PUNCT
chd-214	470	87	xu	xu	PROPN
chd-214	470	88	,	,	PUNCT
chd-214	470	89	d.	d.	PROPN
chd-214	470	90	f.	f.	PROPN
chd-214	470	91	,	,	PUNCT
chd-214	470	92	…	…	PUNCT
chd-214	470	93	sun	sun	NOUN
chd-214	470	94	,	,	PUNCT
chd-214	470	95	y.	y.	PROPN
chd-214	470	96	h.	h.	PROPN
chd-214	470	97	(	(	PUNCT
chd-214	470	98	2018	2018	NUM
chd-214	470	99	)	)	PUNCT
chd-214	470	100	.	.	PUNCT
chd-214	471	1	reciprocal	reciprocal	ADJ
chd-214	471	2	network	network	NOUN
chd-214	471	3	between	between	ADP
chd-214	471	4	cancer	cancer	NOUN
chd-214	471	5	stem	stem	NOUN
chd-214	471	6	-	-	PUNCT
chd-214	471	7	like	like	ADJ
chd-214	471	8	cells	cell	NOUN
chd-214	471	9	and	and	CCONJ
chd-214	471	10	macrophages	macrophage	NOUN
chd-214	471	11	facilitates	facilitate	VERB
chd-214	471	12	the	the	DET
chd-214	471	13	progression	progression	NOUN
chd-214	471	14	and	and	CCONJ
chd-214	471	15	androgen	androgen	NOUN
chd-214	471	16	deprivation	deprivation	NOUN
chd-214	471	17	therapy	therapy	NOUN
chd-214	471	18	resistance	resistance	NOUN
chd-214	471	19	of	of	ADP
chd-214	471	20	prostate	prostate	NOUN
chd-214	471	21	cancer	cancer	NOUN
chd-214	471	22	.	.	PUNCT
chd-214	472	1	clinical	clinical	ADJ
chd-214	472	2	cancer	cancer	NOUN
chd-214	472	3	research	research	NOUN
chd-214	472	4	:	:	PUNCT
chd-214	472	5	an	an	DET
chd-214	472	6	official	official	ADJ
chd-214	472	7	journal	journal	NOUN
chd-214	472	8	of	of	ADP
chd-214	472	9	the	the	DET
chd-214	472	10	american	american	PROPN
chd-214	472	11	association	association	PROPN
chd-214	472	12	for	for	ADP
chd-214	472	13	cancer	cancer	NOUN
chd-214	472	14	research	research	NOUN
chd-214	472	15	,	,	PUNCT
chd-214	472	16	24(18	24(18	NUM
chd-214	472	17	)	)	PUNCT
chd-214	472	18	,	,	PUNCT
chd-214	472	19	4612–4626	4612–4626	NUM
chd-214	472	20	.	.	PUNCT
chd-214	473	1	https://doi.org/10.1158/1078-0432.ccr-18-0461	https://doi.org/10.1158/1078-0432.ccr-18-0461	ADV
chd-214	473	2	82	82	NUM
chd-214	473	3	.	.	PUNCT
chd-214	474	1	ahmed	ahmed	PROPN
chd-214	474	2	,	,	PUNCT
chd-214	474	3	r.	r.	PROPN
chd-214	474	4	,	,	PUNCT
chd-214	474	5	zaman	zaman	NOUN
chd-214	474	6	,	,	PUNCT
chd-214	474	7	t.	t.	PROPN
chd-214	474	8	,	,	PUNCT
chd-214	474	9	chowdhury	chowdhury	PROPN
chd-214	474	10	,	,	PUNCT
chd-214	474	11	f.	f.	PROPN
chd-214	474	12	,	,	PUNCT
chd-214	474	13	mraiche	mraiche	PROPN
chd-214	474	14	,	,	PUNCT
chd-214	474	15	f.	f.	PROPN
chd-214	474	16	,	,	PUNCT
chd-214	474	17	tariq	tariq	PROPN
chd-214	474	18	,	,	PUNCT
chd-214	474	19	m.	m.	NOUN
chd-214	474	20	,	,	PUNCT
chd-214	474	21	ahmad	ahmad	PROPN
chd-214	474	22	,	,	PUNCT
chd-214	474	23	i.	i.	PROPN
chd-214	474	24	s.	s.	PROPN
chd-214	474	25	,	,	PUNCT
chd-214	474	26	&	&	CCONJ
chd-214	474	27	hasan	hasan	PROPN
chd-214	474	28	,	,	PUNCT
chd-214	474	29	a.	a.	NOUN
chd-214	474	30	(	(	PUNCT
chd-214	474	31	2022	2022	NUM
chd-214	474	32	)	)	PUNCT
chd-214	474	33	.	.	PUNCT
chd-214	475	1	single	single	ADJ
chd-214	475	2	-	-	PUNCT
chd-214	475	3	cell	cell	NOUN
chd-214	475	4	rna	rna	NOUN
chd-214	475	5	sequencing	sequence	VERB
chd-214	475	6	with	with	ADP
chd-214	475	7	spatial	spatial	ADJ
chd-214	475	8	transcriptomics	transcriptomic	NOUN
chd-214	475	9	of	of	ADP
chd-214	475	10	cancer	cancer	NOUN
chd-214	475	11	tissues	tissue	NOUN
chd-214	475	12	.	.	PUNCT
chd-214	476	1	international	international	ADJ
chd-214	476	2	journal	journal	NOUN
chd-214	476	3	of	of	ADP
chd-214	476	4	molecular	molecular	ADJ
chd-214	476	5	sciences	science	NOUN
chd-214	476	6	,	,	PUNCT
chd-214	476	7	23(6	23(6	NUM
chd-214	476	8	)	)	PUNCT
chd-214	476	9	,	,	PUNCT
chd-214	476	10	3042	3042	NUM
chd-214	476	11	.	.	PUNCT
chd-214	477	1	https://doi.org/10.3390/ijms23063042	https://doi.org/10.3390/ijms23063042	NOUN
chd-214	477	2	83	83	NUM
chd-214	477	3	.	.	PUNCT
chd-214	478	1	mangiola	mangiola	PROPN
chd-214	478	2	,	,	PUNCT
chd-214	478	3	s.	s.	PROPN
chd-214	478	4	,	,	PUNCT
chd-214	478	5	mccoy	mccoy	PROPN
chd-214	478	6	,	,	PUNCT
chd-214	478	7	p.	p.	PROPN
chd-214	478	8	,	,	PUNCT
chd-214	478	9	modrak	modrak	NOUN
chd-214	478	10	,	,	PUNCT
chd-214	478	11	m.	m.	NOUN
chd-214	478	12	,	,	PUNCT
chd-214	478	13	souza	souza	NOUN
chd-214	478	14	-	-	PUNCT
chd-214	478	15	fonsecaguimaraes	fonsecaguimaraes	PROPN
chd-214	478	16	,	,	PUNCT
chd-214	478	17	f.	f.	PROPN
chd-214	478	18	,	,	PUNCT
chd-214	478	19	blashki	blashki	PROPN
chd-214	478	20	,	,	PUNCT
chd-214	478	21	d.	d.	PROPN
chd-214	478	22	,	,	PUNCT
chd-214	478	23	stuchbery	stuchbery	PROPN
chd-214	478	24	,	,	PUNCT
chd-214	478	25	r.	r.	PROPN
chd-214	478	26	,	,	PUNCT
chd-214	478	27	keam	keam	PROPN
chd-214	478	28	,	,	PUNCT
chd-214	478	29	s.	s.	PROPN
chd-214	478	30	p.	p.	PROPN
chd-214	478	31	,	,	PUNCT
chd-214	478	32	kerger	kerger	NOUN
chd-214	478	33	,	,	PUNCT
chd-214	478	34	m.	m.	NOUN
chd-214	478	35	,	,	PUNCT
chd-214	478	36	chow	chow	PROPN
chd-214	478	37	,	,	PUNCT
chd-214	478	38	k.	k.	PROPN
chd-214	478	39	,	,	PUNCT
chd-214	478	40	nasa	nasa	PROPN
chd-214	478	41	,	,	PUNCT
chd-214	478	42	c.	c.	PROPN
chd-214	478	43	,	,	PUNCT
chd-214	478	44	le	le	PROPN
chd-214	478	45	page	page	NOUN
chd-214	478	46	,	,	PUNCT
chd-214	478	47	m.	m.	NOUN
chd-214	478	48	,	,	PUNCT
chd-214	478	49	lister	lister	PROPN
chd-214	478	50	,	,	PUNCT
chd-214	478	51	n.	n.	NOUN
chd-214	478	52	,	,	PUNCT
chd-214	478	53	monard	monard	NOUN
chd-214	478	54	,	,	PUNCT
chd-214	478	55	s.	s.	PROPN
chd-214	478	56	,	,	PUNCT
chd-214	478	57	peters	peters	PROPN
chd-214	478	58	,	,	PUNCT
chd-214	478	59	j.	j.	PROPN
chd-214	478	60	,	,	PUNCT
chd-214	478	61	dundee	dundee	PROPN
chd-214	478	62	,	,	PUNCT
chd-214	478	63	p.	p.	PROPN
chd-214	478	64	,	,	PUNCT
chd-214	478	65	williams	williams	PROPN
chd-214	478	66	,	,	PUNCT
chd-214	478	67	s.	s.	PROPN
chd-214	478	68	g.	g.	PROPN
chd-214	478	69	,	,	PUNCT
chd-214	478	70	costello	costello	PROPN
chd-214	478	71	,	,	PUNCT
chd-214	478	72	a.	a.	PROPN
chd-214	478	73	j.	j.	PROPN
chd-214	478	74	,	,	PUNCT
chd-214	478	75	neeson	neeson	PROPN
chd-214	478	76	,	,	PUNCT
chd-214	478	77	p.	p.	PROPN
chd-214	478	78	j.	j.	PROPN
chd-214	478	79	,	,	PUNCT
chd-214	478	80	pal	pal	PROPN
chd-214	478	81	,	,	PUNCT
chd-214	478	82	b.	b.	PROPN
chd-214	478	83	,	,	PUNCT
chd-214	478	84	huntington	huntington	PROPN
chd-214	478	85	,	,	PUNCT
chd-214	478	86	n.	n.	PROPN
chd-214	478	87	d.	d.	PROPN
chd-214	478	88	,	,	PUNCT
chd-214	478	89	…	…	PUNCT
chd-214	478	90	hovens	hovens	PROPN
chd-214	478	91	,	,	PUNCT
chd-214	478	92	c.	c.	PROPN
chd-214	478	93	m.	m.	NOUN
chd-214	478	94	(	(	PUNCT
chd-214	478	95	2021	2021	NUM
chd-214	478	96	)	)	PUNCT
chd-214	478	97	.	.	PUNCT
chd-214	479	1	transcriptome	transcriptome	ADJ
chd-214	479	2	sequencing	sequencing	NOUN
chd-214	479	3	and	and	CCONJ
chd-214	479	4	multi	multi	ADJ
chd-214	479	5	-	-	ADJ
chd-214	479	6	plex	plex	ADJ
chd-214	479	7	imaging	imaging	NOUN
chd-214	479	8	of	of	ADP
chd-214	479	9	prostate	prostate	NOUN
chd-214	479	10	cancer	cancer	NOUN
chd-214	479	11	microenvironment	microenvironment	NOUN
chd-214	479	12	reveals	reveal	VERB
chd-214	479	13	a	a	DET
chd-214	479	14	dominant	dominant	ADJ
chd-214	479	15	role	role	NOUN
chd-214	479	16	for	for	ADP
chd-214	479	17	monocytic	monocytic	ADJ
chd-214	479	18	cells	cell	NOUN
chd-214	479	19	in	in	ADP
chd-214	479	20	progression	progression	NOUN
chd-214	479	21	.	.	PUNCT
chd-214	480	1	bmc	bmc	ADJ
chd-214	480	2	cancer	cancer	NOUN
chd-214	480	3	,	,	PUNCT
chd-214	480	4	21(1	21(1	NUM
chd-214	480	5	)	)	PUNCT
chd-214	480	6	,	,	PUNCT
chd-214	480	7	846	846	NUM
chd-214	480	8	.	.	PUNCT
chd-214	481	1	https://doi.org/10.1186/s12885-02108529-6	https://doi.org/10.1186/s12885-02108529-6	ADJ
chd-214	481	2	84	84	NUM
chd-214	481	3	.	.	PUNCT
chd-214	482	1	zhu	zhu	PROPN
chd-214	482	2	,	,	PUNCT
chd-214	482	3	s.	s.	PROPN
chd-214	482	4	,	,	PUNCT
chd-214	482	5	qing	qing	NOUN
chd-214	482	6	,	,	PUNCT
chd-214	482	7	t.	t.	PROPN
chd-214	482	8	,	,	PUNCT
chd-214	482	9	zheng	zheng	PROPN
chd-214	482	10	,	,	PUNCT
chd-214	482	11	y.	y.	PROPN
chd-214	482	12	,	,	PUNCT
chd-214	482	13	jin	jin	PROPN
chd-214	482	14	,	,	PUNCT
chd-214	482	15	l.	l.	PROPN
chd-214	482	16	,	,	PUNCT
chd-214	482	17	&	&	CCONJ
chd-214	482	18	shi	shi	PROPN
chd-214	482	19	,	,	PUNCT
chd-214	482	20	l.	l.	PROPN
chd-214	482	21	(	(	PUNCT
chd-214	482	22	2017	2017	NUM
chd-214	482	23	)	)	PUNCT
chd-214	482	24	.	.	PUNCT
chd-214	483	1	advances	advance	NOUN
chd-214	483	2	in	in	ADP
chd-214	483	3	single	single	ADJ
chd-214	483	4	-	-	PUNCT
chd-214	483	5	cell	cell	NOUN
chd-214	483	6	rna	rna	NOUN
chd-214	483	7	sequencing	sequencing	NOUN
chd-214	483	8	and	and	CCONJ
chd-214	483	9	its	its	PRON
chd-214	483	10	applications	application	NOUN
chd-214	483	11	in	in	ADP
chd-214	483	12	cancer	cancer	NOUN
chd-214	483	13	research	research	NOUN
chd-214	483	14	.	.	PUNCT
chd-214	484	1	oncotarget	oncotarget	NOUN
chd-214	484	2	,	,	PUNCT
chd-214	484	3	8(32	8(32	NUM
chd-214	484	4	)	)	PUNCT
chd-214	484	5	,	,	PUNCT
chd-214	484	6	53763	53763	NUM
chd-214	484	7	–	–	PUNCT
chd-214	484	8	53779	53779	NUM
chd-214	484	9	.	.	PUNCT
chd-214	485	1	https://doi.org/10.18632/oncotarget.17893	https://doi.org/10.18632/oncotarget.17893	NOUN
chd-214	485	2	85	85	NUM
chd-214	485	3	.	.	PUNCT
chd-214	486	1	hernandez	hernandez	PROPN
chd-214	486	2	,	,	PUNCT
chd-214	486	3	s.	s.	PROPN
chd-214	486	4	,	,	PUNCT
chd-214	486	5	rojas	rojas	PROPN
chd-214	486	6	,	,	PUNCT
chd-214	486	7	f.	f.	PROPN
chd-214	486	8	,	,	PUNCT
chd-214	486	9	laberiano	laberiano	PROPN
chd-214	486	10	,	,	PUNCT
chd-214	486	11	c.	c.	PROPN
chd-214	486	12	,	,	PUNCT
chd-214	486	13	lazcano	lazcano	PROPN
chd-214	486	14	,	,	PUNCT
chd-214	486	15	r.	r.	PROPN
chd-214	486	16	,	,	PUNCT
chd-214	486	17	wistuba	wistuba	PROPN
chd-214	486	18	,	,	PUNCT
chd-214	486	19	i.	i.	PROPN
chd-214	486	20	,	,	PUNCT
chd-214	486	21	&	&	CCONJ
chd-214	486	22	parra	parra	PROPN
chd-214	486	23	,	,	PUNCT
chd-214	486	24	e.	e.	PROPN
chd-214	486	25	r.	r.	PROPN
chd-214	486	26	(	(	PUNCT
chd-214	486	27	2021	2021	NUM
chd-214	486	28	)	)	PUNCT
chd-214	486	29	.	.	PUNCT
chd-214	487	1	multiplex	multiplex	PROPN
chd-214	487	2	immunofluorescence	immunofluorescence	PROPN
chd-214	487	3	tyramide	tyramide	NOUN
chd-214	487	4	signal	signal	NOUN
chd-214	487	5	amplification	amplification	NOUN
chd-214	487	6	for	for	ADP
chd-214	487	7	immune	immune	ADJ
chd-214	487	8	cell	cell	NOUN
chd-214	487	9	profiling	profiling	NOUN
chd-214	487	10	of	of	ADP
chd-214	487	11	paraffin	paraffin	NOUN
chd-214	487	12	-	-	PUNCT
chd-214	487	13	embedded	embed	VERB
chd-214	487	14	tumor	tumor	NOUN
chd-214	487	15	tissues	tissue	NOUN
chd-214	487	16	.	.	PUNCT
chd-214	488	1	frontiers	frontier	NOUN
chd-214	488	2	in	in	ADP
chd-214	488	3	molecular	molecular	ADJ
chd-214	488	4	biosciences	bioscience	NOUN
chd-214	488	5	,	,	PUNCT
chd-214	488	6	8	8	NUM
chd-214	488	7	,	,	PUNCT
chd-214	488	8	667067	667067	NUM
chd-214	488	9	.	.	PUNCT
chd-214	489	1	https://doi.org/10.3389/fmolb.2021.667067	https://doi.org/10.3389/fmolb.2021.667067	PROPN
chd-214	489	2	https://doi.org/10.1158/1055-9965.epi-19-0792	https://doi.org/10.1158/1055-9965.epi-19-0792	PROPN
chd-214	489	3	https://doi.org/10.3390/ijms23063042	https://doi.org/10.3390/ijms23063042	NOUN
chd-214	489	4	https://doi.org/10.1186/s12885-021-08529-6	https://doi.org/10.1186/s12885-021-08529-6	NUM
chd-214	489	5	https://doi.org/10.1186/s12885-021-08529-6	https://doi.org/10.1186/s12885-021-08529-6	NUM
chd-214	489	6	https://doi.org/10.18632/oncotarget.17893	https://doi.org/10.18632/oncotarget.17893	NOUN
chd-214	489	7	https://doi.org/10.3389/fmolb.2021.667067	https://doi.org/10.3389/fmolb.2021.667067	PROPN
chd-214	489	8	1.0	1.0	NUM
chd-214	489	9	.	.	PUNCT
chd-214	490	1	introduction	introduction	NOUN
chd-214	490	2	2.0	2.0	NUM
chd-214	490	3	.	.	PUNCT
chd-214	491	1	prostate	prostate	NOUN
chd-214	491	2	cancer	cancer	NOUN
chd-214	491	3	microenvironment	microenvironment	NOUN
chd-214	491	4	2.1	2.1	NUM
chd-214	491	5	.	.	PUNCT
chd-214	492	1	fibroblasts	fibroblast	VERB
chd-214	492	2	2.2	2.2	NUM
chd-214	492	3	.	.	PUNCT
chd-214	492	4	immune	immune	ADJ
chd-214	492	5	cells	cell	NOUN
chd-214	492	6	2.3	2.3	NUM
chd-214	492	7	.	.	PUNCT
chd-214	493	1	endothelial	endothelial	ADJ
chd-214	493	2	cells	cell	NOUN
chd-214	493	3	3.0	3.0	NUM
chd-214	493	4	.	.	PUNCT
chd-214	494	1	clinical	clinical	ADJ
chd-214	494	2	implications	implication	NOUN
chd-214	494	3	of	of	ADP
chd-214	494	4	the	the	DET
chd-214	494	5	racially	racially	ADV
chd-214	494	6	different	different	ADJ
chd-214	494	7	tumor	tumor	NOUN
chd-214	494	8	microenvironment	microenvironment	ADJ
chd-214	494	9	composition	composition	NOUN
chd-214	494	10	in	in	ADP
chd-214	494	11	prostate	prostate	NOUN
chd-214	494	12	cancer	cancer	NOUN
chd-214	494	13	4.0	4.0	NUM
chd-214	494	14	.	.	PUNCT
chd-214	495	1	conclusion	conclusion	NOUN
chd-214	495	2	and	and	CCONJ
chd-214	495	3	future	future	ADJ
chd-214	495	4	perspective	perspective	ADJ
chd-214	495	5	acknowledgments	acknowledgment	NOUN
chd-214	495	6	conflicts	conflict	NOUN
chd-214	495	7	of	of	ADP
chd-214	495	8	interest	interest	NOUN
chd-214	495	9	authors	author	NOUN
chd-214	495	10	’	’	PART
chd-214	495	11	contributions	contribution	NOUN